CN101219215A - 用于治疗及诊断衣原体感染的化合物和方法 - Google Patents
用于治疗及诊断衣原体感染的化合物和方法 Download PDFInfo
- Publication number
- CN101219215A CN101219215A CNA2007101933449A CN200710193344A CN101219215A CN 101219215 A CN101219215 A CN 101219215A CN A2007101933449 A CNA2007101933449 A CN A2007101933449A CN 200710193344 A CN200710193344 A CN 200710193344A CN 101219215 A CN101219215 A CN 101219215A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- polypeptide
- chlamydia
- chlamydia trachomatis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061041 Chlamydial infection Diseases 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title abstract description 122
- 150000001875 compounds Chemical class 0.000 title abstract description 23
- 238000003745 diagnosis Methods 0.000 title abstract description 8
- 201000000902 chlamydia Diseases 0.000 title abstract description 7
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 title abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 451
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 298
- 229920001184 polypeptide Polymers 0.000 claims abstract description 289
- 229960005486 vaccine Drugs 0.000 claims abstract description 68
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 245
- 102000040430 polynucleotide Human genes 0.000 claims description 130
- 108091033319 polynucleotide Proteins 0.000 claims description 130
- 239000002157 polynucleotide Substances 0.000 claims description 130
- 230000005847 immunogenicity Effects 0.000 claims description 59
- 230000004927 fusion Effects 0.000 claims description 49
- 238000002360 preparation method Methods 0.000 claims description 32
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 27
- 239000002671 adjuvant Substances 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 229960001438 immunostimulant agent Drugs 0.000 claims description 22
- 239000003022 immunostimulating agent Substances 0.000 claims description 22
- 230000003308 immunostimulating effect Effects 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 179
- 241000606161 Chlamydia Species 0.000 abstract description 164
- 239000000427 antigen Substances 0.000 abstract description 123
- 108091007433 antigens Proteins 0.000 abstract description 123
- 102000036639 antigens Human genes 0.000 abstract description 123
- 238000001514 detection method Methods 0.000 abstract description 33
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 32
- 239000012472 biological sample Substances 0.000 abstract description 29
- 230000000890 antigenic effect Effects 0.000 abstract description 16
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 10
- 241000606153 Chlamydia trachomatis Species 0.000 description 348
- 229940038705 chlamydia trachomatis Drugs 0.000 description 348
- 108090000623 proteins and genes Proteins 0.000 description 153
- 210000001744 T-lymphocyte Anatomy 0.000 description 142
- 210000004027 cell Anatomy 0.000 description 137
- 108020004414 DNA Proteins 0.000 description 117
- 241001647372 Chlamydia pneumoniae Species 0.000 description 107
- 102000004169 proteins and genes Human genes 0.000 description 90
- 108700026244 Open Reading Frames Proteins 0.000 description 83
- 235000018102 proteins Nutrition 0.000 description 83
- 239000013615 primer Substances 0.000 description 79
- 239000012634 fragment Substances 0.000 description 78
- 239000000523 sample Substances 0.000 description 68
- 101150077194 CAP1 gene Proteins 0.000 description 59
- 238000003780 insertion Methods 0.000 description 49
- 230000037431 insertion Effects 0.000 description 49
- 230000000875 corresponding effect Effects 0.000 description 46
- 210000004443 dendritic cell Anatomy 0.000 description 46
- 208000015181 infectious disease Diseases 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 44
- 238000005516 engineering process Methods 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 41
- 208000007190 Chlamydia Infections Diseases 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 38
- 229940024606 amino acid Drugs 0.000 description 38
- 150000001413 amino acids Chemical class 0.000 description 38
- 239000002773 nucleotide Substances 0.000 description 37
- 125000003729 nucleotide group Chemical group 0.000 description 37
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 35
- 102100035954 Choline transporter-like protein 2 Human genes 0.000 description 33
- 101000948115 Homo sapiens Choline transporter-like protein 2 Proteins 0.000 description 33
- 238000011534 incubation Methods 0.000 description 33
- 230000036039 immunity Effects 0.000 description 31
- 210000000612 antigen-presenting cell Anatomy 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- 238000012360 testing method Methods 0.000 description 28
- 102100037850 Interferon gamma Human genes 0.000 description 26
- 108010074328 Interferon-gamma Proteins 0.000 description 26
- 230000000295 complement effect Effects 0.000 description 25
- 241000588724 Escherichia coli Species 0.000 description 24
- 230000003321 amplification Effects 0.000 description 24
- 238000009396 hybridization Methods 0.000 description 24
- 238000003199 nucleic acid amplification method Methods 0.000 description 24
- 238000003752 polymerase chain reaction Methods 0.000 description 24
- 238000002965 ELISA Methods 0.000 description 22
- 230000008521 reorganization Effects 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 22
- 101150061263 tct-1 gene Proteins 0.000 description 22
- 102100034763 Peroxiredoxin-2 Human genes 0.000 description 21
- 239000002299 complementary DNA Substances 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 101150050161 pmpC gene Proteins 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- 238000011160 research Methods 0.000 description 21
- 230000008878 coupling Effects 0.000 description 19
- 238000010168 coupling process Methods 0.000 description 19
- 238000005859 coupling reaction Methods 0.000 description 19
- 101100027987 Chlamydia trachomatis omcB gene Proteins 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 210000001616 monocyte Anatomy 0.000 description 17
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 17
- 238000001890 transfection Methods 0.000 description 17
- 125000006853 reporter group Chemical group 0.000 description 16
- 101150059608 pmpE gene Proteins 0.000 description 15
- 210000004988 splenocyte Anatomy 0.000 description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 description 14
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 14
- 230000028993 immune response Effects 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 108010068880 Chlamydia trachomatis polymorphic membrane protein D Proteins 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000013256 coordination polymer Substances 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 101150106828 pmpD gene Proteins 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 238000012408 PCR amplification Methods 0.000 description 12
- 230000005867 T cell response Effects 0.000 description 12
- 230000002776 aggregation Effects 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 238000011081 inoculation Methods 0.000 description 12
- 210000003101 oviduct Anatomy 0.000 description 12
- 239000003155 DNA primer Substances 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 108700017066 Chlamydia trachomatis PmpG Proteins 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 10
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 239000002751 oligonucleotide probe Substances 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 101100462201 Mus musculus Opn4 gene Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 239000007767 bonding agent Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000005336 cracking Methods 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 239000004005 microsphere Substances 0.000 description 9
- 101150033274 pmpI gene Proteins 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 108091081024 Start codon Proteins 0.000 description 8
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 238000013507 mapping Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 229940104230 thymidine Drugs 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 7
- 238000011735 C3H mouse Methods 0.000 description 7
- 230000006052 T cell proliferation Effects 0.000 description 7
- -1 acetyl- Chemical group 0.000 description 7
- 238000001042 affinity chromatography Methods 0.000 description 7
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 101150052825 dnaK gene Proteins 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 101150003321 lpdA gene Proteins 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 206010044325 trachoma Diseases 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 6
- 102000009016 Cholera Toxin Human genes 0.000 description 6
- 108010049048 Cholera Toxin Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000008676 import Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 229910052722 tritium Inorganic materials 0.000 description 6
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 5
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 5
- 241001647378 Chlamydia psittaci Species 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000001516 cell proliferation assay Methods 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 230000009260 cross reactivity Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 210000004976 peripheral blood cell Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 101150067195 pmpB gene Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 4
- 101710153593 Albumin A Proteins 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108091060211 Expressed sequence tag Proteins 0.000 description 4
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 4
- DGTOKVBDZXJHNZ-WZLNRYEVSA-N Ile-Thr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N DGTOKVBDZXJHNZ-WZLNRYEVSA-N 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 241000880493 Leptailurus serval Species 0.000 description 4
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 4
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 4
- PHKBGZKVOJCIMZ-SRVKXCTJSA-N Met-Pro-Arg Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PHKBGZKVOJCIMZ-SRVKXCTJSA-N 0.000 description 4
- 101100278084 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) dnaK1 gene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108090000792 Ribosomal protein L1 Proteins 0.000 description 4
- 101100428373 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) POR1 gene Proteins 0.000 description 4
- 208000007893 Salpingitis Diseases 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 101100117145 Synechocystis sp. (strain PCC 6803 / Kazusa) dnaK2 gene Proteins 0.000 description 4
- 108020005038 Terminator Codon Proteins 0.000 description 4
- 101710183681 Uncharacterized protein 7 Proteins 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 108010038633 aspartylglutamate Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001400 expression cloning Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 108010064235 lysylglycine Proteins 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 101150087557 omcB gene Proteins 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 230000010148 water-pollination Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 3
- CELPEWWLSXMVPH-CIUDSAMLSA-N Asp-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O CELPEWWLSXMVPH-CIUDSAMLSA-N 0.000 description 3
- 101100439426 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) groEL4 gene Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 101100188655 Chlamydia pneumoniae omcB gene Proteins 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- YNMQUIVKEFRCPH-QSFUFRPTSA-N Ile-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)O)N YNMQUIVKEFRCPH-QSFUFRPTSA-N 0.000 description 3
- CSQNHSGHAPRGPQ-YTFOTSKYSA-N Ile-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)O)N CSQNHSGHAPRGPQ-YTFOTSKYSA-N 0.000 description 3
- GVNNAHIRSDRIII-AJNGGQMLSA-N Ile-Lys-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N GVNNAHIRSDRIII-AJNGGQMLSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- MPOHDJKRBLVGCT-CIUDSAMLSA-N Lys-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N MPOHDJKRBLVGCT-CIUDSAMLSA-N 0.000 description 3
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 3
- KBTQZYASLSUFJR-KKUMJFAQSA-N Met-Phe-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N KBTQZYASLSUFJR-KKUMJFAQSA-N 0.000 description 3
- IHRFZLQEQVHXFA-RHYQMDGZSA-N Met-Thr-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCCN IHRFZLQEQVHXFA-RHYQMDGZSA-N 0.000 description 3
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 3
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- AQGUSRZKDZYGGV-GMOBBJLQSA-N Pro-Ile-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O AQGUSRZKDZYGGV-GMOBBJLQSA-N 0.000 description 3
- WHNJMTHJGCEKGA-ULQDDVLXSA-N Pro-Phe-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WHNJMTHJGCEKGA-ULQDDVLXSA-N 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000002278 Ribosomal Proteins Human genes 0.000 description 3
- 108010000605 Ribosomal Proteins Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 230000005859 cell recognition Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000039 congener Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 108010090037 glycyl-alanyl-isoleucine Proteins 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 101150077981 groEL gene Proteins 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 108010034529 leucyl-lysine Proteins 0.000 description 3
- 108010054155 lysyllysine Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- 208000005963 oophoritis Diseases 0.000 description 3
- 101150053615 pmpG gene Proteins 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 210000005000 reproductive tract Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 2
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 2
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 2
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 2
- LYILPUNCKACNGF-NAKRPEOUSA-N Ala-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N LYILPUNCKACNGF-NAKRPEOUSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- QPOARHANPULOTM-GMOBBJLQSA-N Arg-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N QPOARHANPULOTM-GMOBBJLQSA-N 0.000 description 2
- UHFUZWSZQKMDSX-DCAQKATOSA-N Arg-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UHFUZWSZQKMDSX-DCAQKATOSA-N 0.000 description 2
- PTSDPWIHOYMRGR-UGYAYLCHSA-N Asn-Ile-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O PTSDPWIHOYMRGR-UGYAYLCHSA-N 0.000 description 2
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 2
- ALHMNHZJBYBYHS-DCAQKATOSA-N Asn-Lys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ALHMNHZJBYBYHS-DCAQKATOSA-N 0.000 description 2
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 2
- VOGCFWDZYYTEOY-DCAQKATOSA-N Asn-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N VOGCFWDZYYTEOY-DCAQKATOSA-N 0.000 description 2
- OOXUBGLNDRGOKT-FXQIFTODSA-N Asn-Ser-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OOXUBGLNDRGOKT-FXQIFTODSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229920002160 Celluloid Polymers 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 241000498849 Chlamydiales Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- HJXSYJVCMUOUNY-SRVKXCTJSA-N Cys-Ser-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N HJXSYJVCMUOUNY-SRVKXCTJSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- RGRMOYQUIJVQQD-SRVKXCTJSA-N Gln-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N RGRMOYQUIJVQQD-SRVKXCTJSA-N 0.000 description 2
- HQTDNEZTGZUWSY-XVKPBYJWSA-N Glu-Val-Gly Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)NCC(O)=O HQTDNEZTGZUWSY-XVKPBYJWSA-N 0.000 description 2
- DTRUBYPMMVPQPD-YUMQZZPRSA-N Gly-Gln-Arg Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DTRUBYPMMVPQPD-YUMQZZPRSA-N 0.000 description 2
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 2
- OCPPBNKYGYSLOE-IUCAKERBSA-N Gly-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN OCPPBNKYGYSLOE-IUCAKERBSA-N 0.000 description 2
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- WJUYPBBCSSLVJE-CIUDSAMLSA-N His-Asn-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N WJUYPBBCSSLVJE-CIUDSAMLSA-N 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- DMHGKBGOUAJRHU-RVMXOQNASA-N Ile-Arg-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N DMHGKBGOUAJRHU-RVMXOQNASA-N 0.000 description 2
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 2
- UKTUOMWSJPXODT-GUDRVLHUSA-N Ile-Asn-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N UKTUOMWSJPXODT-GUDRVLHUSA-N 0.000 description 2
- BGZIJZJBXRVBGJ-SXTJYALSSA-N Ile-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N BGZIJZJBXRVBGJ-SXTJYALSSA-N 0.000 description 2
- PELCGFMHLZXWBQ-BJDJZHNGSA-N Ile-Ser-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)N PELCGFMHLZXWBQ-BJDJZHNGSA-N 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101710149059 Large cysteine-rich periplasmic protein OmcB Proteins 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- FYPWFNKQVVEELI-ULQDDVLXSA-N Leu-Phe-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 FYPWFNKQVVEELI-ULQDDVLXSA-N 0.000 description 2
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 2
- ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 2
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 2
- ZQCVMVCVPFYXHZ-SRVKXCTJSA-N Lys-Asn-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN ZQCVMVCVPFYXHZ-SRVKXCTJSA-N 0.000 description 2
- MYZMQWHPDAYKIE-SRVKXCTJSA-N Lys-Leu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O MYZMQWHPDAYKIE-SRVKXCTJSA-N 0.000 description 2
- QQPSCXKFDSORFT-IHRRRGAJSA-N Lys-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN QQPSCXKFDSORFT-IHRRRGAJSA-N 0.000 description 2
- VSTNAUBHKQPVJX-IHRRRGAJSA-N Lys-Met-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O VSTNAUBHKQPVJX-IHRRRGAJSA-N 0.000 description 2
- TXTZMVNJIRZABH-ULQDDVLXSA-N Lys-Val-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TXTZMVNJIRZABH-ULQDDVLXSA-N 0.000 description 2
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- ZDJICAUBMUKVEJ-CIUDSAMLSA-N Met-Ser-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O ZDJICAUBMUKVEJ-CIUDSAMLSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- YEEFZOKPYOUXMX-KKUMJFAQSA-N Phe-Gln-Met Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O YEEFZOKPYOUXMX-KKUMJFAQSA-N 0.000 description 2
- QTVUPXHPSXZJKH-ULQDDVLXSA-N Phe-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N QTVUPXHPSXZJKH-ULQDDVLXSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- FYQSMXKJYTZYRP-DCAQKATOSA-N Pro-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FYQSMXKJYTZYRP-DCAQKATOSA-N 0.000 description 2
- ZSKJPKFTPQCPIH-RCWTZXSCSA-N Pro-Arg-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSKJPKFTPQCPIH-RCWTZXSCSA-N 0.000 description 2
- UTAUEDINXUMHLG-FXQIFTODSA-N Pro-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 UTAUEDINXUMHLG-FXQIFTODSA-N 0.000 description 2
- ILMLVTGTUJPQFP-FXQIFTODSA-N Pro-Asp-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ILMLVTGTUJPQFP-FXQIFTODSA-N 0.000 description 2
- WWXNZNWZNZPDIF-SRVKXCTJSA-N Pro-Val-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 WWXNZNWZNZPDIF-SRVKXCTJSA-N 0.000 description 2
- ZAUHSLVPDLNTRZ-QXEWZRGKSA-N Pro-Val-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZAUHSLVPDLNTRZ-QXEWZRGKSA-N 0.000 description 2
- 101710197985 Probable protein Rev Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710188053 Protein D Proteins 0.000 description 2
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 2
- 101710132893 Resolvase Proteins 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 102000004191 Ribosomal protein L1 Human genes 0.000 description 2
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 2
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101150109085 TSA gene Proteins 0.000 description 2
- NAXBBCLCEOTAIG-RHYQMDGZSA-N Thr-Arg-Lys Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O NAXBBCLCEOTAIG-RHYQMDGZSA-N 0.000 description 2
- UDQBCBUXAQIZAK-GLLZPBPUSA-N Thr-Glu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDQBCBUXAQIZAK-GLLZPBPUSA-N 0.000 description 2
- JMGJDTNUMAZNLX-RWRJDSDZSA-N Thr-Glu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JMGJDTNUMAZNLX-RWRJDSDZSA-N 0.000 description 2
- JWQNAFHCXKVZKZ-UVOCVTCTSA-N Thr-Lys-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWQNAFHCXKVZKZ-UVOCVTCTSA-N 0.000 description 2
- RPECVQBNONKZAT-WZLNRYEVSA-N Thr-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H]([C@@H](C)O)N RPECVQBNONKZAT-WZLNRYEVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- AKXBNSZMYAOGLS-STQMWFEESA-N Tyr-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AKXBNSZMYAOGLS-STQMWFEESA-N 0.000 description 2
- FNWGDMZVYBVAGJ-XEGUGMAKSA-N Tyr-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N FNWGDMZVYBVAGJ-XEGUGMAKSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 2
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 description 2
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 2
- UKEVLVBHRKWECS-LSJOCFKGSA-N Val-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N UKEVLVBHRKWECS-LSJOCFKGSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 159000000013 aluminium salts Chemical class 0.000 description 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000001358 anti-chlamydial effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 101150096566 clpX gene Proteins 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000012637 gene transfection Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 108010008237 glutamyl-valyl-glycine Proteins 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 108010028295 histidylhistidine Proteins 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108010030617 leucyl-phenylalanyl-valine Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 108010005942 methionylglycine Proteins 0.000 description 2
- 108010068488 methionylphenylalanine Proteins 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 101150095517 pmpH gene Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 102220144047 rs7667001 Human genes 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101150033033 28K gene Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- LGQPPBQRUBVTIF-JBDRJPRFSA-N Ala-Ala-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LGQPPBQRUBVTIF-JBDRJPRFSA-N 0.000 description 1
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- SSSROGPPPVTHLX-FXQIFTODSA-N Ala-Arg-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSROGPPPVTHLX-FXQIFTODSA-N 0.000 description 1
- HGRBNYQIMKTUNT-XVYDVKMFSA-N Ala-Asn-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HGRBNYQIMKTUNT-XVYDVKMFSA-N 0.000 description 1
- STACJSVFHSEZJV-GHCJXIJMSA-N Ala-Asn-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STACJSVFHSEZJV-GHCJXIJMSA-N 0.000 description 1
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
- YSMPVONNIWLJML-FXQIFTODSA-N Ala-Asp-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(O)=O YSMPVONNIWLJML-FXQIFTODSA-N 0.000 description 1
- IKKVASZHTMKJIR-ZKWXMUAHSA-N Ala-Asp-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IKKVASZHTMKJIR-ZKWXMUAHSA-N 0.000 description 1
- WCBVQNZTOKJWJS-ACZMJKKPSA-N Ala-Cys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O WCBVQNZTOKJWJS-ACZMJKKPSA-N 0.000 description 1
- MVBWLRJESQOQTM-ACZMJKKPSA-N Ala-Gln-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O MVBWLRJESQOQTM-ACZMJKKPSA-N 0.000 description 1
- BEMGNWZECGIJOI-WDSKDSINSA-N Ala-Gly-Glu Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O BEMGNWZECGIJOI-WDSKDSINSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 1
- JEPNLGMEZMCFEX-QSFUFRPTSA-N Ala-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)N JEPNLGMEZMCFEX-QSFUFRPTSA-N 0.000 description 1
- DVJSJDDYCYSMFR-ZKWXMUAHSA-N Ala-Ile-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O DVJSJDDYCYSMFR-ZKWXMUAHSA-N 0.000 description 1
- CFPQUJZTLUQUTJ-HTFCKZLJSA-N Ala-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C)N CFPQUJZTLUQUTJ-HTFCKZLJSA-N 0.000 description 1
- YHKANGMVQWRMAP-DCAQKATOSA-N Ala-Leu-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YHKANGMVQWRMAP-DCAQKATOSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 1
- CHFFHQUVXHEGBY-GARJFASQSA-N Ala-Lys-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CHFFHQUVXHEGBY-GARJFASQSA-N 0.000 description 1
- MSWSRLGNLKHDEI-ACZMJKKPSA-N Ala-Ser-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O MSWSRLGNLKHDEI-ACZMJKKPSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 1
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 1
- NLYYHIKRBRMAJV-AEJSXWLSSA-N Ala-Val-Pro Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N NLYYHIKRBRMAJV-AEJSXWLSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- KWKQGHSSNHPGOW-BQBZGAKWSA-N Arg-Ala-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(O)=O KWKQGHSSNHPGOW-BQBZGAKWSA-N 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 1
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 1
- DQNLFLGFZAUIOW-FXQIFTODSA-N Arg-Cys-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O DQNLFLGFZAUIOW-FXQIFTODSA-N 0.000 description 1
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 1
- QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 description 1
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 1
- OGUPCHKBOKJFMA-SRVKXCTJSA-N Arg-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N OGUPCHKBOKJFMA-SRVKXCTJSA-N 0.000 description 1
- UBCPNBUIQNMDNH-NAKRPEOUSA-N Arg-Ile-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O UBCPNBUIQNMDNH-NAKRPEOUSA-N 0.000 description 1
- OOIMKQRCPJBGPD-XUXIUFHCSA-N Arg-Ile-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O OOIMKQRCPJBGPD-XUXIUFHCSA-N 0.000 description 1
- YBZMTKUDWXZLIX-UWVGGRQHSA-N Arg-Leu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YBZMTKUDWXZLIX-UWVGGRQHSA-N 0.000 description 1
- GRRXPUAICOGISM-RWMBFGLXSA-N Arg-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O GRRXPUAICOGISM-RWMBFGLXSA-N 0.000 description 1
- MNBHKGYCLBUIBC-UFYCRDLUSA-N Arg-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MNBHKGYCLBUIBC-UFYCRDLUSA-N 0.000 description 1
- LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 1
- ADPACBMPYWJJCE-FXQIFTODSA-N Arg-Ser-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O ADPACBMPYWJJCE-FXQIFTODSA-N 0.000 description 1
- PSUXEQYPYZLNER-QXEWZRGKSA-N Arg-Val-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PSUXEQYPYZLNER-QXEWZRGKSA-N 0.000 description 1
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- QQEWINYJRFBLNN-DLOVCJGASA-N Asn-Ala-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QQEWINYJRFBLNN-DLOVCJGASA-N 0.000 description 1
- NLCDVZJDEXIDDL-BIIVOSGPSA-N Asn-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O NLCDVZJDEXIDDL-BIIVOSGPSA-N 0.000 description 1
- CTQIOCMSIJATNX-WHFBIAKZSA-N Asn-Gly-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O CTQIOCMSIJATNX-WHFBIAKZSA-N 0.000 description 1
- VXLBDJWTONZHJN-YUMQZZPRSA-N Asn-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N VXLBDJWTONZHJN-YUMQZZPRSA-N 0.000 description 1
- GQRDIVQPSMPQME-ZPFDUUQYSA-N Asn-Ile-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O GQRDIVQPSMPQME-ZPFDUUQYSA-N 0.000 description 1
- JQBCANGGAVVERB-CFMVVWHZSA-N Asn-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N JQBCANGGAVVERB-CFMVVWHZSA-N 0.000 description 1
- MDDXKBHIMYYJLW-FXQIFTODSA-N Asn-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N MDDXKBHIMYYJLW-FXQIFTODSA-N 0.000 description 1
- YUOXLJYVSZYPBJ-CIUDSAMLSA-N Asn-Pro-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O YUOXLJYVSZYPBJ-CIUDSAMLSA-N 0.000 description 1
- XTMZYFMTYJNABC-ZLUOBGJFSA-N Asn-Ser-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N XTMZYFMTYJNABC-ZLUOBGJFSA-N 0.000 description 1
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 1
- GHWWTICYPDKPTE-NGZCFLSTSA-N Asn-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N GHWWTICYPDKPTE-NGZCFLSTSA-N 0.000 description 1
- KVMPVNGOKHTUHZ-GCJQMDKQSA-N Asp-Ala-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KVMPVNGOKHTUHZ-GCJQMDKQSA-N 0.000 description 1
- UQBGYPFHWFZMCD-ZLUOBGJFSA-N Asp-Asn-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UQBGYPFHWFZMCD-ZLUOBGJFSA-N 0.000 description 1
- UWOPETAWXDZUJR-ACZMJKKPSA-N Asp-Cys-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O UWOPETAWXDZUJR-ACZMJKKPSA-N 0.000 description 1
- SNAWMGHSCHKSDK-GUBZILKMSA-N Asp-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N SNAWMGHSCHKSDK-GUBZILKMSA-N 0.000 description 1
- KLYPOCBLKMPBIQ-GHCJXIJMSA-N Asp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N KLYPOCBLKMPBIQ-GHCJXIJMSA-N 0.000 description 1
- IVPNEDNYYYFAGI-GARJFASQSA-N Asp-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N IVPNEDNYYYFAGI-GARJFASQSA-N 0.000 description 1
- RXBGWGRSWXOBGK-KKUMJFAQSA-N Asp-Lys-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RXBGWGRSWXOBGK-KKUMJFAQSA-N 0.000 description 1
- LIJXJYGRSRWLCJ-IHRRRGAJSA-N Asp-Phe-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LIJXJYGRSRWLCJ-IHRRRGAJSA-N 0.000 description 1
- MVRGBQGZSDJBSM-GMOBBJLQSA-N Asp-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)O)N MVRGBQGZSDJBSM-GMOBBJLQSA-N 0.000 description 1
- RVMXMLSYBTXCAV-VEVYYDQMSA-N Asp-Pro-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMXMLSYBTXCAV-VEVYYDQMSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- VNXQRBXEQXLERQ-CIUDSAMLSA-N Asp-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N VNXQRBXEQXLERQ-CIUDSAMLSA-N 0.000 description 1
- OTKUAVXGMREHRX-CFMVVWHZSA-N Asp-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 OTKUAVXGMREHRX-CFMVVWHZSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 101000609456 Beet necrotic yellow vein virus (isolate Japan/S) Protein P26 Proteins 0.000 description 1
- QLIUPRCQJURPNG-UHFFFAOYSA-N C(CCCCCC)(=O)O.NNC(NN)=O Chemical compound C(CCCCCC)(=O)O.NNC(NN)=O QLIUPRCQJURPNG-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 101100474216 Chlamydia pneumoniae rpsM gene Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- AMRLSQGGERHDHJ-FXQIFTODSA-N Cys-Ala-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMRLSQGGERHDHJ-FXQIFTODSA-N 0.000 description 1
- GHUVBPIYQYXXEF-SRVKXCTJSA-N Cys-Cys-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 GHUVBPIYQYXXEF-SRVKXCTJSA-N 0.000 description 1
- UYYZZJXUVIZTMH-AVGNSLFASA-N Cys-Glu-Phe Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O UYYZZJXUVIZTMH-AVGNSLFASA-N 0.000 description 1
- KXUKWRVYDYIPSQ-CIUDSAMLSA-N Cys-Leu-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O KXUKWRVYDYIPSQ-CIUDSAMLSA-N 0.000 description 1
- VPQZSNQICFCCSO-BJDJZHNGSA-N Cys-Leu-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VPQZSNQICFCCSO-BJDJZHNGSA-N 0.000 description 1
- WVLZTXGTNGHPBO-SRVKXCTJSA-N Cys-Leu-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O WVLZTXGTNGHPBO-SRVKXCTJSA-N 0.000 description 1
- JTEGHEWKBCTIAL-IXOXFDKPSA-N Cys-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CS)N)O JTEGHEWKBCTIAL-IXOXFDKPSA-N 0.000 description 1
- XKDHARKYRGHLKO-QEJZJMRPSA-N Cys-Trp-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N XKDHARKYRGHLKO-QEJZJMRPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- RKAQZCDMSUQTSS-FXQIFTODSA-N Gln-Asp-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N RKAQZCDMSUQTSS-FXQIFTODSA-N 0.000 description 1
- JFSNBQJNDMXMQF-XHNCKOQMSA-N Gln-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O JFSNBQJNDMXMQF-XHNCKOQMSA-N 0.000 description 1
- NROSLUJMIQGFKS-IUCAKERBSA-N Gln-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N NROSLUJMIQGFKS-IUCAKERBSA-N 0.000 description 1
- IWUFOVSLWADEJC-AVGNSLFASA-N Gln-His-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O IWUFOVSLWADEJC-AVGNSLFASA-N 0.000 description 1
- WEAVZFWWIPIANL-SRVKXCTJSA-N Gln-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N WEAVZFWWIPIANL-SRVKXCTJSA-N 0.000 description 1
- RWQCWSGOOOEGPB-FXQIFTODSA-N Gln-Ser-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O RWQCWSGOOOEGPB-FXQIFTODSA-N 0.000 description 1
- KVQOVQVGVKDZNW-GUBZILKMSA-N Gln-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N KVQOVQVGVKDZNW-GUBZILKMSA-N 0.000 description 1
- NVHJGTGTUGEWCG-ZVZYQTTQSA-N Gln-Trp-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O NVHJGTGTUGEWCG-ZVZYQTTQSA-N 0.000 description 1
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 1
- FHPXTPQBODWBIY-CIUDSAMLSA-N Glu-Ala-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FHPXTPQBODWBIY-CIUDSAMLSA-N 0.000 description 1
- MXOODARRORARSU-ACZMJKKPSA-N Glu-Ala-Ser Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N MXOODARRORARSU-ACZMJKKPSA-N 0.000 description 1
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 1
- NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 1
- IGKGSULCWCKNCA-SRVKXCTJSA-N Glu-Arg-Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(CNC([C@H](CCCNC(N)=N)NC([C@H](CCC(O)=O)N)=O)=O)=O IGKGSULCWCKNCA-SRVKXCTJSA-N 0.000 description 1
- AFODTOLGSZQDSL-PEFMBERDSA-N Glu-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N AFODTOLGSZQDSL-PEFMBERDSA-N 0.000 description 1
- FKGNJUCQKXQNRA-NRPADANISA-N Glu-Cys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O FKGNJUCQKXQNRA-NRPADANISA-N 0.000 description 1
- QQLBPVKLJBAXBS-FXQIFTODSA-N Glu-Glu-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QQLBPVKLJBAXBS-FXQIFTODSA-N 0.000 description 1
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- BUAKRRKDHSSIKK-IHRRRGAJSA-N Glu-Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BUAKRRKDHSSIKK-IHRRRGAJSA-N 0.000 description 1
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 1
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 1
- HILMIYALTUQTRC-XVKPBYJWSA-N Glu-Gly-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HILMIYALTUQTRC-XVKPBYJWSA-N 0.000 description 1
- QLPYYTDOUQNJGQ-AVGNSLFASA-N Glu-His-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N QLPYYTDOUQNJGQ-AVGNSLFASA-N 0.000 description 1
- GXMXPCXXKVWOSM-KQXIARHKSA-N Glu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N GXMXPCXXKVWOSM-KQXIARHKSA-N 0.000 description 1
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 1
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
- NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 1
- FMBWLLMUPXTXFC-SDDRHHMPSA-N Glu-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)N)C(=O)O FMBWLLMUPXTXFC-SDDRHHMPSA-N 0.000 description 1
- KXRORHJIRAOQPG-SOUVJXGZSA-N Glu-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O KXRORHJIRAOQPG-SOUVJXGZSA-N 0.000 description 1
- RMWAOBGCZZSJHE-UMNHJUIQSA-N Glu-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N RMWAOBGCZZSJHE-UMNHJUIQSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
- UXJHNZODTMHWRD-WHFBIAKZSA-N Gly-Asn-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O UXJHNZODTMHWRD-WHFBIAKZSA-N 0.000 description 1
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 1
- KQDMENMTYNBWMR-WHFBIAKZSA-N Gly-Asp-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O KQDMENMTYNBWMR-WHFBIAKZSA-N 0.000 description 1
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 1
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 1
- TZOVVRJYUDETQG-RCOVLWMOSA-N Gly-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN TZOVVRJYUDETQG-RCOVLWMOSA-N 0.000 description 1
- CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical group [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 1
- PDAWDNVHMUKWJR-ZETCQYMHSA-N Gly-Gly-His Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 PDAWDNVHMUKWJR-ZETCQYMHSA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 description 1
- OJNZVYSGVYLQIN-BQBZGAKWSA-N Gly-Met-Asp Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O OJNZVYSGVYLQIN-BQBZGAKWSA-N 0.000 description 1
- FEUPVVCGQLNXNP-IRXDYDNUSA-N Gly-Phe-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FEUPVVCGQLNXNP-IRXDYDNUSA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- FGPLUIQCSKGLTI-WDSKDSINSA-N Gly-Ser-Glu Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O FGPLUIQCSKGLTI-WDSKDSINSA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- DBUNZBWUWCIELX-JHEQGTHGSA-N Gly-Thr-Glu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DBUNZBWUWCIELX-JHEQGTHGSA-N 0.000 description 1
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- DZMVESFTHXSSPZ-XVYDVKMFSA-N His-Ala-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DZMVESFTHXSSPZ-XVYDVKMFSA-N 0.000 description 1
- WMKXFMUJRCEGRP-SRVKXCTJSA-N His-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N WMKXFMUJRCEGRP-SRVKXCTJSA-N 0.000 description 1
- HVCRQRQPIIRNLY-IUCAKERBSA-N His-Gln-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N HVCRQRQPIIRNLY-IUCAKERBSA-N 0.000 description 1
- YADRBUZBKHHDAO-XPUUQOCRSA-N His-Gly-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C)C(O)=O YADRBUZBKHHDAO-XPUUQOCRSA-N 0.000 description 1
- NTXIJPDAHXSHNL-ONGXEEELSA-N His-Gly-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NTXIJPDAHXSHNL-ONGXEEELSA-N 0.000 description 1
- GHAFKUCRIVBLDJ-IHRRRGAJSA-N His-His-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CN=CN2)N GHAFKUCRIVBLDJ-IHRRRGAJSA-N 0.000 description 1
- IWXMHXYOACDSIA-PYJNHQTQSA-N His-Ile-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O IWXMHXYOACDSIA-PYJNHQTQSA-N 0.000 description 1
- UROVZOUMHNXPLZ-AVGNSLFASA-N His-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 UROVZOUMHNXPLZ-AVGNSLFASA-N 0.000 description 1
- YYOCMTFVGKDNQP-IHRRRGAJSA-N His-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N YYOCMTFVGKDNQP-IHRRRGAJSA-N 0.000 description 1
- CGAMSLMBYJHMDY-ONGXEEELSA-N His-Val-Gly Chemical compound CC(C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N CGAMSLMBYJHMDY-ONGXEEELSA-N 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000983292 Homo sapiens N-fatty-acyl-amino acid synthase/hydrolase PM20D1 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 description 1
- LVQDUPQUJZWKSU-PYJNHQTQSA-N Ile-Arg-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LVQDUPQUJZWKSU-PYJNHQTQSA-N 0.000 description 1
- UAVQIQOOBXFKRC-BYULHYEWSA-N Ile-Asn-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O UAVQIQOOBXFKRC-BYULHYEWSA-N 0.000 description 1
- QSPLUJGYOPZINY-ZPFDUUQYSA-N Ile-Asp-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QSPLUJGYOPZINY-ZPFDUUQYSA-N 0.000 description 1
- CCHSQWLCOOZREA-GMOBBJLQSA-N Ile-Asp-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N CCHSQWLCOOZREA-GMOBBJLQSA-N 0.000 description 1
- AQTWDZDISVGCAC-CFMVVWHZSA-N Ile-Asp-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N AQTWDZDISVGCAC-CFMVVWHZSA-N 0.000 description 1
- CTHAJJYOHOBUDY-GHCJXIJMSA-N Ile-Cys-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N CTHAJJYOHOBUDY-GHCJXIJMSA-N 0.000 description 1
- PFTFEWHJSAXGED-ZKWXMUAHSA-N Ile-Cys-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N PFTFEWHJSAXGED-ZKWXMUAHSA-N 0.000 description 1
- WZDCVAWMBUNDDY-KBIXCLLPSA-N Ile-Glu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)O)N WZDCVAWMBUNDDY-KBIXCLLPSA-N 0.000 description 1
- KIMHKBDJQQYLHU-PEFMBERDSA-N Ile-Glu-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KIMHKBDJQQYLHU-PEFMBERDSA-N 0.000 description 1
- MTFVYKQRLXYAQN-LAEOZQHASA-N Ile-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O MTFVYKQRLXYAQN-LAEOZQHASA-N 0.000 description 1
- PNDMHTTXXPUQJH-RWRJDSDZSA-N Ile-Glu-Thr Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@H](O)C)C(=O)O PNDMHTTXXPUQJH-RWRJDSDZSA-N 0.000 description 1
- NYEYYMLUABXDMC-NHCYSSNCSA-N Ile-Gly-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)N NYEYYMLUABXDMC-NHCYSSNCSA-N 0.000 description 1
- JLWLMGADIQFKRD-QSFUFRPTSA-N Ile-His-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CN=CN1 JLWLMGADIQFKRD-QSFUFRPTSA-N 0.000 description 1
- KEKTTYCXKGBAAL-VGDYDELISA-N Ile-His-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N KEKTTYCXKGBAAL-VGDYDELISA-N 0.000 description 1
- UWLHDGMRWXHFFY-HPCHECBXSA-N Ile-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@@H]1C(=O)O)N UWLHDGMRWXHFFY-HPCHECBXSA-N 0.000 description 1
- KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 1
- ADDYYRVQQZFIMW-MNXVOIDGSA-N Ile-Lys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ADDYYRVQQZFIMW-MNXVOIDGSA-N 0.000 description 1
- MASWXTFJVNRZPT-NAKRPEOUSA-N Ile-Met-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)O)N MASWXTFJVNRZPT-NAKRPEOUSA-N 0.000 description 1
- IIWQTXMUALXGOV-PCBIJLKTSA-N Ile-Phe-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N IIWQTXMUALXGOV-PCBIJLKTSA-N 0.000 description 1
- XQLGNKLSPYCRMZ-HJWJTTGWSA-N Ile-Phe-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)O)N XQLGNKLSPYCRMZ-HJWJTTGWSA-N 0.000 description 1
- YKZAMJXNJUWFIK-JBDRJPRFSA-N Ile-Ser-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)O)N YKZAMJXNJUWFIK-JBDRJPRFSA-N 0.000 description 1
- JODPUDMBQBIWCK-GHCJXIJMSA-N Ile-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O JODPUDMBQBIWCK-GHCJXIJMSA-N 0.000 description 1
- ZNOBVZFCHNHKHA-KBIXCLLPSA-N Ile-Ser-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZNOBVZFCHNHKHA-KBIXCLLPSA-N 0.000 description 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 1
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 1
- HZVRQFKRALAMQS-SLBDDTMCSA-N Ile-Trp-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZVRQFKRALAMQS-SLBDDTMCSA-N 0.000 description 1
- KXUKTDGKLAOCQK-LSJOCFKGSA-N Ile-Val-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O KXUKTDGKLAOCQK-LSJOCFKGSA-N 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 101150025881 Itk gene Proteins 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000773 L-serino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 101100521429 Lactococcus lactis subsp. lactis (strain IL1403) prsA gene Proteins 0.000 description 1
- CZCSUZMIRKFFFA-CIUDSAMLSA-N Leu-Ala-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O CZCSUZMIRKFFFA-CIUDSAMLSA-N 0.000 description 1
- MJOZZTKJZQFKDK-GUBZILKMSA-N Leu-Ala-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(N)=O MJOZZTKJZQFKDK-GUBZILKMSA-N 0.000 description 1
- PBCHMHROGNUXMK-DLOVCJGASA-N Leu-Ala-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 PBCHMHROGNUXMK-DLOVCJGASA-N 0.000 description 1
- FJUKMPUELVROGK-IHRRRGAJSA-N Leu-Arg-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N FJUKMPUELVROGK-IHRRRGAJSA-N 0.000 description 1
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 1
- FIJMQLGQLBLBOL-HJGDQZAQSA-N Leu-Asn-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FIJMQLGQLBLBOL-HJGDQZAQSA-N 0.000 description 1
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
- MMEDVBWCMGRKKC-GARJFASQSA-N Leu-Asp-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N MMEDVBWCMGRKKC-GARJFASQSA-N 0.000 description 1
- WCTCIIAGNMFYAO-DCAQKATOSA-N Leu-Cys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O WCTCIIAGNMFYAO-DCAQKATOSA-N 0.000 description 1
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 1
- DPWGZWUMUUJQDT-IUCAKERBSA-N Leu-Gln-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O DPWGZWUMUUJQDT-IUCAKERBSA-N 0.000 description 1
- CIVKXGPFXDIQBV-WDCWCFNPSA-N Leu-Gln-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CIVKXGPFXDIQBV-WDCWCFNPSA-N 0.000 description 1
- KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 description 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 1
- BABSVXFGKFLIGW-UWVGGRQHSA-N Leu-Gly-Arg Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N BABSVXFGKFLIGW-UWVGGRQHSA-N 0.000 description 1
- PBGDOSARRIJMEV-DLOVCJGASA-N Leu-His-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O PBGDOSARRIJMEV-DLOVCJGASA-N 0.000 description 1
- DBSLVQBXKVKDKJ-BJDJZHNGSA-N Leu-Ile-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DBSLVQBXKVKDKJ-BJDJZHNGSA-N 0.000 description 1
- AUBMZAMQCOYSIC-MNXVOIDGSA-N Leu-Ile-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O AUBMZAMQCOYSIC-MNXVOIDGSA-N 0.000 description 1
- LIINDKYIGYTDLG-PPCPHDFISA-N Leu-Ile-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LIINDKYIGYTDLG-PPCPHDFISA-N 0.000 description 1
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- UBZGNBKMIJHOHL-BZSNNMDCSA-N Leu-Leu-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 UBZGNBKMIJHOHL-BZSNNMDCSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 description 1
- ZGUMORRUBUCXEH-AVGNSLFASA-N Leu-Lys-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZGUMORRUBUCXEH-AVGNSLFASA-N 0.000 description 1
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- YRRCOJOXAJNSAX-IHRRRGAJSA-N Leu-Pro-Lys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N YRRCOJOXAJNSAX-IHRRRGAJSA-N 0.000 description 1
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- CGHXMODRYJISSK-NHCYSSNCSA-N Leu-Val-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O CGHXMODRYJISSK-NHCYSSNCSA-N 0.000 description 1
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 1
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 1
- YIBOAHAOAWACDK-QEJZJMRPSA-N Lys-Ala-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YIBOAHAOAWACDK-QEJZJMRPSA-N 0.000 description 1
- QIJVAFLRMVBHMU-KKUMJFAQSA-N Lys-Asp-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QIJVAFLRMVBHMU-KKUMJFAQSA-N 0.000 description 1
- ZXEUFAVXODIPHC-GUBZILKMSA-N Lys-Glu-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZXEUFAVXODIPHC-GUBZILKMSA-N 0.000 description 1
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 1
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 1
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 description 1
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 1
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 1
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 1
- RIJCHEVHFWMDKD-SRVKXCTJSA-N Lys-Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RIJCHEVHFWMDKD-SRVKXCTJSA-N 0.000 description 1
- PYFNONMJYNJENN-AVGNSLFASA-N Lys-Lys-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N PYFNONMJYNJENN-AVGNSLFASA-N 0.000 description 1
- GAHJXEMYXKLZRQ-AJNGGQMLSA-N Lys-Lys-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GAHJXEMYXKLZRQ-AJNGGQMLSA-N 0.000 description 1
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 1
- URGPVYGVWLIRGT-DCAQKATOSA-N Lys-Met-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O URGPVYGVWLIRGT-DCAQKATOSA-N 0.000 description 1
- ZZHPLPSLBVBWOA-WDSOQIARSA-N Lys-Met-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N ZZHPLPSLBVBWOA-WDSOQIARSA-N 0.000 description 1
- LNMKRJJLEFASGA-BZSNNMDCSA-N Lys-Phe-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LNMKRJJLEFASGA-BZSNNMDCSA-N 0.000 description 1
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 1
- UWHCKWNPWKTMBM-WDCWCFNPSA-N Lys-Thr-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O UWHCKWNPWKTMBM-WDCWCFNPSA-N 0.000 description 1
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- WAAZECNCPVGPIV-RHYQMDGZSA-N Lys-Thr-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O WAAZECNCPVGPIV-RHYQMDGZSA-N 0.000 description 1
- OEYKVQKYCHATHO-SZMVWBNQSA-N Lys-Trp-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N OEYKVQKYCHATHO-SZMVWBNQSA-N 0.000 description 1
- VVURYEVJJTXWNE-ULQDDVLXSA-N Lys-Tyr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O VVURYEVJJTXWNE-ULQDDVLXSA-N 0.000 description 1
- VWPJQIHBBOJWDN-DCAQKATOSA-N Lys-Val-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O VWPJQIHBBOJWDN-DCAQKATOSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 description 1
- DSWOTZCVCBEPOU-IUCAKERBSA-N Met-Arg-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCNC(N)=N DSWOTZCVCBEPOU-IUCAKERBSA-N 0.000 description 1
- NKDSBBBPGIVWEI-RCWTZXSCSA-N Met-Arg-Thr Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NKDSBBBPGIVWEI-RCWTZXSCSA-N 0.000 description 1
- CRGKLOXHKICQOL-GARJFASQSA-N Met-Gln-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N CRGKLOXHKICQOL-GARJFASQSA-N 0.000 description 1
- LRALLISKBZNSKN-BQBZGAKWSA-N Met-Gly-Ser Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LRALLISKBZNSKN-BQBZGAKWSA-N 0.000 description 1
- RXWPLVRJQNWXRQ-IHRRRGAJSA-N Met-His-His Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CNC=N1 RXWPLVRJQNWXRQ-IHRRRGAJSA-N 0.000 description 1
- BKIFWLQFOOKUCA-DCAQKATOSA-N Met-His-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N BKIFWLQFOOKUCA-DCAQKATOSA-N 0.000 description 1
- SODXFJOPSCXOHE-IHRRRGAJSA-N Met-Leu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O SODXFJOPSCXOHE-IHRRRGAJSA-N 0.000 description 1
- XOFDBXYPKZUAAM-GUBZILKMSA-N Met-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N XOFDBXYPKZUAAM-GUBZILKMSA-N 0.000 description 1
- MFDDVIJCQYOOES-GUBZILKMSA-N Met-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCSC)N MFDDVIJCQYOOES-GUBZILKMSA-N 0.000 description 1
- LBSWWNKMVPAXOI-GUBZILKMSA-N Met-Val-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O LBSWWNKMVPAXOI-GUBZILKMSA-N 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
- 102100026873 N-fatty-acyl-amino acid synthase/hydrolase PM20D1 Human genes 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 101800000512 Non-structural protein 1 Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 102000035028 Nucleic proteins Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 235000012364 Peperomia pellucida Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- WIVCOAKLPICYGY-KKUMJFAQSA-N Phe-Asp-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N WIVCOAKLPICYGY-KKUMJFAQSA-N 0.000 description 1
- LXUJDHOKVUYHRC-KKUMJFAQSA-N Phe-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N LXUJDHOKVUYHRC-KKUMJFAQSA-N 0.000 description 1
- SXJGROGVINAYSH-AVGNSLFASA-N Phe-Gln-Asp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N SXJGROGVINAYSH-AVGNSLFASA-N 0.000 description 1
- IILUKIJNFMUBNF-IHRRRGAJSA-N Phe-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O IILUKIJNFMUBNF-IHRRRGAJSA-N 0.000 description 1
- KYYMILWEGJYPQZ-IHRRRGAJSA-N Phe-Glu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KYYMILWEGJYPQZ-IHRRRGAJSA-N 0.000 description 1
- QPVFUAUFEBPIPT-CDMKHQONSA-N Phe-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QPVFUAUFEBPIPT-CDMKHQONSA-N 0.000 description 1
- BVHFFNYBKRTSIU-MEYUZBJRSA-N Phe-His-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BVHFFNYBKRTSIU-MEYUZBJRSA-N 0.000 description 1
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 1
- DOXQMJCSSYZSNM-BZSNNMDCSA-N Phe-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O DOXQMJCSSYZSNM-BZSNNMDCSA-N 0.000 description 1
- RYQWALWYQWBUKN-FHWLQOOXSA-N Phe-Phe-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RYQWALWYQWBUKN-FHWLQOOXSA-N 0.000 description 1
- GPLWGAYGROGDEN-BZSNNMDCSA-N Phe-Phe-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O GPLWGAYGROGDEN-BZSNNMDCSA-N 0.000 description 1
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 1
- LTAWNJXSRUCFAN-UNQGMJICSA-N Phe-Thr-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LTAWNJXSRUCFAN-UNQGMJICSA-N 0.000 description 1
- BSTPNLNKHKBONJ-HTUGSXCWSA-N Phe-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O BSTPNLNKHKBONJ-HTUGSXCWSA-N 0.000 description 1
- BPIMVBKDLSBKIJ-FCLVOEFKSA-N Phe-Thr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BPIMVBKDLSBKIJ-FCLVOEFKSA-N 0.000 description 1
- NJONQBYLTANINY-IHPCNDPISA-N Phe-Trp-Asn Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(O)=O NJONQBYLTANINY-IHPCNDPISA-N 0.000 description 1
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 1
- GLUYKHMBGKQBHE-JYJNAYRXSA-N Phe-Val-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 GLUYKHMBGKQBHE-JYJNAYRXSA-N 0.000 description 1
- JTKGCYOOJLUETJ-ULQDDVLXSA-N Phe-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JTKGCYOOJLUETJ-ULQDDVLXSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- DBALDZKOTNSBFM-FXQIFTODSA-N Pro-Ala-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DBALDZKOTNSBFM-FXQIFTODSA-N 0.000 description 1
- WWAQEUOYCYMGHB-FXQIFTODSA-N Pro-Asn-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 WWAQEUOYCYMGHB-FXQIFTODSA-N 0.000 description 1
- HXOLCSYHGRNXJJ-IHRRRGAJSA-N Pro-Asp-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HXOLCSYHGRNXJJ-IHRRRGAJSA-N 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- KLSOMAFWRISSNI-OSUNSFLBSA-N Pro-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 KLSOMAFWRISSNI-OSUNSFLBSA-N 0.000 description 1
- XYSXOCIWCPFOCG-IHRRRGAJSA-N Pro-Leu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XYSXOCIWCPFOCG-IHRRRGAJSA-N 0.000 description 1
- IWIANZLCJVYEFX-RYUDHWBXSA-N Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 IWIANZLCJVYEFX-RYUDHWBXSA-N 0.000 description 1
- SEZGGSHLMROBFX-CIUDSAMLSA-N Pro-Ser-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O SEZGGSHLMROBFX-CIUDSAMLSA-N 0.000 description 1
- WVXQQUWOKUZIEG-VEVYYDQMSA-N Pro-Thr-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O WVXQQUWOKUZIEG-VEVYYDQMSA-N 0.000 description 1
- IURWWZYKYPEANQ-HJGDQZAQSA-N Pro-Thr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IURWWZYKYPEANQ-HJGDQZAQSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 1
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010064250 RNA polymerase beta subunit Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 101710137010 Retinol-binding protein 3 Proteins 0.000 description 1
- 102100038247 Retinol-binding protein 3 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- SRTCFKGBYBZRHA-ACZMJKKPSA-N Ser-Ala-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SRTCFKGBYBZRHA-ACZMJKKPSA-N 0.000 description 1
- IDQFQFVEWMWRQQ-DLOVCJGASA-N Ser-Ala-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O IDQFQFVEWMWRQQ-DLOVCJGASA-N 0.000 description 1
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 1
- VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 description 1
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 1
- HZWAHWQZPSXNCB-BPUTZDHNSA-N Ser-Arg-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HZWAHWQZPSXNCB-BPUTZDHNSA-N 0.000 description 1
- WXUBSIDKNMFAGS-IHRRRGAJSA-N Ser-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WXUBSIDKNMFAGS-IHRRRGAJSA-N 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 1
- WTPKKLMBNBCCNL-ACZMJKKPSA-N Ser-Cys-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N WTPKKLMBNBCCNL-ACZMJKKPSA-N 0.000 description 1
- IXUGADGDCQDLSA-FXQIFTODSA-N Ser-Gln-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N IXUGADGDCQDLSA-FXQIFTODSA-N 0.000 description 1
- DGHFNYXVIXNNMC-GUBZILKMSA-N Ser-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N DGHFNYXVIXNNMC-GUBZILKMSA-N 0.000 description 1
- VMVNCJDKFOQOHM-GUBZILKMSA-N Ser-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N VMVNCJDKFOQOHM-GUBZILKMSA-N 0.000 description 1
- KJMOINFQVCCSDX-XKBZYTNZSA-N Ser-Gln-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KJMOINFQVCCSDX-XKBZYTNZSA-N 0.000 description 1
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 description 1
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- BKZYBLLIBOBOOW-GHCJXIJMSA-N Ser-Ile-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O BKZYBLLIBOBOOW-GHCJXIJMSA-N 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- JLPMFVAIQHCBDC-CIUDSAMLSA-N Ser-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N JLPMFVAIQHCBDC-CIUDSAMLSA-N 0.000 description 1
- XVWDJUROVRQKAE-KKUMJFAQSA-N Ser-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 XVWDJUROVRQKAE-KKUMJFAQSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 1
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 1
- IAOHCSQDQDWRQU-GUBZILKMSA-N Ser-Val-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IAOHCSQDQDWRQU-GUBZILKMSA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 101000741271 Sorghum bicolor Phosphoenolpyruvate carboxylase 1 Proteins 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101100310092 Thauera selenatis serD gene Proteins 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 1
- JTEICXDKGWKRRV-HJGDQZAQSA-N Thr-Asn-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O JTEICXDKGWKRRV-HJGDQZAQSA-N 0.000 description 1
- DHPPWTOLRWYIDS-XKBZYTNZSA-N Thr-Cys-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O DHPPWTOLRWYIDS-XKBZYTNZSA-N 0.000 description 1
- HJOSVGCWOTYJFG-WDCWCFNPSA-N Thr-Glu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O HJOSVGCWOTYJFG-WDCWCFNPSA-N 0.000 description 1
- XOWKUMFHEZLKLT-CIQUZCHMSA-N Thr-Ile-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O XOWKUMFHEZLKLT-CIQUZCHMSA-N 0.000 description 1
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 1
- DCRHJDRLCFMEBI-RHYQMDGZSA-N Thr-Lys-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O DCRHJDRLCFMEBI-RHYQMDGZSA-N 0.000 description 1
- YJVJPJPHHFOVMG-VEVYYDQMSA-N Thr-Met-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O YJVJPJPHHFOVMG-VEVYYDQMSA-N 0.000 description 1
- IQPWNQRRAJHOKV-KATARQTJSA-N Thr-Ser-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN IQPWNQRRAJHOKV-KATARQTJSA-N 0.000 description 1
- KVEWWQRTAVMOFT-KJEVXHAQSA-N Thr-Tyr-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O KVEWWQRTAVMOFT-KJEVXHAQSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- KPMIQCXJDVKWKO-IFFSRLJSSA-N Thr-Val-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KPMIQCXJDVKWKO-IFFSRLJSSA-N 0.000 description 1
- VYVBSMCZNHOZGD-RCWTZXSCSA-N Thr-Val-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O VYVBSMCZNHOZGD-RCWTZXSCSA-N 0.000 description 1
- 101710154778 Thymidylate synthase 1 Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- TWJDQTTXXZDJKV-BPUTZDHNSA-N Trp-Arg-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O TWJDQTTXXZDJKV-BPUTZDHNSA-N 0.000 description 1
- OFCKFBGRYHOKFP-IHPCNDPISA-N Trp-Asp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N OFCKFBGRYHOKFP-IHPCNDPISA-N 0.000 description 1
- MZDJYWGXAIEYEP-BPUTZDHNSA-N Trp-Cys-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N MZDJYWGXAIEYEP-BPUTZDHNSA-N 0.000 description 1
- HXNVJPQADLRHGR-JBACZVJFSA-N Trp-Glu-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N HXNVJPQADLRHGR-JBACZVJFSA-N 0.000 description 1
- WKQNLTQSCYXKQK-VFAJRCTISA-N Trp-Lys-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WKQNLTQSCYXKQK-VFAJRCTISA-N 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- FDKDGFGTHGJKNV-FHWLQOOXSA-N Tyr-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FDKDGFGTHGJKNV-FHWLQOOXSA-N 0.000 description 1
- HZWPGKAKGYJWCI-ULQDDVLXSA-N Tyr-Val-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(C)C)C(O)=O HZWPGKAKGYJWCI-ULQDDVLXSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- JYVKKBDANPZIAW-AVGNSLFASA-N Val-Arg-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N JYVKKBDANPZIAW-AVGNSLFASA-N 0.000 description 1
- DBOXBUDEAJVKRE-LSJOCFKGSA-N Val-Asn-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N DBOXBUDEAJVKRE-LSJOCFKGSA-N 0.000 description 1
- HZYOWMGWKKRMBZ-BYULHYEWSA-N Val-Asp-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZYOWMGWKKRMBZ-BYULHYEWSA-N 0.000 description 1
- PWRITNSESKQTPW-NRPADANISA-N Val-Gln-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N PWRITNSESKQTPW-NRPADANISA-N 0.000 description 1
- SYOMXKPPFZRELL-ONGXEEELSA-N Val-Gly-Lys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N SYOMXKPPFZRELL-ONGXEEELSA-N 0.000 description 1
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 1
- JZWZACGUZVCQPS-RNJOBUHISA-N Val-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N JZWZACGUZVCQPS-RNJOBUHISA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- ZZGPVSZDZQRJQY-ULQDDVLXSA-N Val-Leu-Phe Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O ZZGPVSZDZQRJQY-ULQDDVLXSA-N 0.000 description 1
- YMTOEGGOCHVGEH-IHRRRGAJSA-N Val-Lys-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O YMTOEGGOCHVGEH-IHRRRGAJSA-N 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 1
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 1
- HWNYVQMOLCYHEA-IHRRRGAJSA-N Val-Ser-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N HWNYVQMOLCYHEA-IHRRRGAJSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- UFCHCOKFAGOQSF-BQFCYCMXSA-N Val-Trp-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N UFCHCOKFAGOQSF-BQFCYCMXSA-N 0.000 description 1
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 description 1
- ZHWZDZFWBXWPDW-GUBZILKMSA-N Val-Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O ZHWZDZFWBXWPDW-GUBZILKMSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- HIGRAKVNKLCVCA-UHFFFAOYSA-N alumine Chemical compound C1=CC=[Al]C=C1 HIGRAKVNKLCVCA-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 238000005844 autocatalytic reaction Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 150000004054 benzoquinones Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 101150043719 clpP1 gene Proteins 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108010009297 diglycyl-histidine Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229950006286 pentrinitrol Drugs 0.000 description 1
- BRBAEHHXGZRCBK-UHFFFAOYSA-N pentrinitrol Chemical compound [O-][N+](=O)OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O BRBAEHHXGZRCBK-UHFFFAOYSA-N 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 101150010607 pmpA gene Proteins 0.000 description 1
- 101150116202 pmpF gene Proteins 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical group 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Abstract
本发明公开了用于诊断和治疗衣原体感染的化合物方法。提供的化合物包括含有衣原体抗原的至少一个抗原部分的多肽以及编码这种多肽的DNA序列。还提供了含有这种多肽或DNA序列的药物组合物及疫苗,以及针对这种多肽的抗体。含有这种多肽或DNA序列以及适当检测试剂的诊断试剂盒可以用于检测患者和生物学样本中衣原体感染。
Description
本申请是申请日为1999年12月8日、发明名称为“用于治疗及诊断衣原体感染的化合物和方法”的中国发明专利申请99815723.6的分案申请。
技术领域
本发明普遍涉及衣原体感染的检测与治疗。特别是,本发明涉及含有衣原体抗原的多肽,这些多肽在衣原体感染的血清学诊断和治疗中的应用。
发明背景
衣原体是引起多种重要的人类及动物感染的胞内细菌病原体。沙眼衣原体(Chlamydia trachomatis)是最常见的性传播疾病的病原体之一,能引起骨盆炎症疾病(PID),导致输卵管梗阻和不育。沙眼衣原体也可能在男性不育中起作用。1990年,美国治疗PID的费用估计为40亿美元。由于眼睛感染沙眼衣原体引起的沙眼是世界范围内可预防的失明的主要病因。肺炎衣原体(Chamydia pneumonia)是人类急性呼吸道感染的主要原因,也认为其在动脉粥样硬化特别是冠状心脏病的发病机理中起作用。含有高效价肺炎衣原体抗体的个体患冠状心脏病的可能性比血清阴性个体至少高两倍。因此衣原体感染在美国和世界范围内都是一个重要的健康问题。
衣原体感染通常是无症状的。例如,到妇女对PID引起医学注意时,可能已发生不可逆的损伤,导致不育。因此在本领域中需要改进的疫苗和药用组合物来预防和治疗衣原体感染。本发明满足了这一需要,并进一步具有其他相关优点。
发明概述
本发明提供用于诊断和治疗衣原体感染的组合物和方法。一方面,本发明提供含有衣原体抗原的免疫原性部分的多肽,或这种抗原的变体。某些部分和其他变体有免疫原性,使得该变体与抗原特异性抗血清反应的能力基本上不减弱。在某些实施方案中,这种多肽含有一种由选自下列的多核苷酸序列编码的氨基酸序列:(a)SEQ ID NO:1,15,21-25,44-64,66-76,79-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-290的序列;(b)这些序列的互补序列;和(c)在中度严格条件下可与(a)或(b)的序列杂交的序列。在特定实施方案中,本发明的多肽含有至少一部分衣原体蛋白,其包含选自SEQ ID NO:5-14,17-20,26,28,30-32,34,39-43,65,89-109,138-158,167,168,224-262,246,247,254-256,292所列序列的氨基酸序列,及其变体。
本发明进一步提供编码如上所述的多肽的多核苷酸,或其部分(如编码衣原体蛋白至少15个氨基酸残基的部分),含有这些多核苷酸的表达载体,和用这些表达载体转化或转染的宿主细胞。
在有关方面,也提供了编码以上多肽的多核苷酸序列,含有一种或多种这些多核苷酸序列的重组表达载体,和用这些表达载体转化或转染的宿主细胞。
另一方面,本发明提供了含有本发明的多肽、或含有本发明的多肽和已知衣原体抗原的融合蛋白,以及编码这些融合蛋白的多核苷酸,与生理学可接受的载体或免疫刺激物一起用作药用组合物和疫苗。
本发明进一步提供含有下列成分的药用组合物:(a)一种可与衣原体蛋白特异结合的多克隆或单克隆抗体,或其抗原结合片段;和(b)生理学可接受的载体。在其他方面中,本发明提供含有此处公开的一种或多种衣原体多肽,或编码这种多肽的多核苷酸分子,和生理学可接受的载体的药用组合物。本发明也提供用于预防和治疗目的的疫苗,其含有一种或多种此处所述的多肽和免疫刺激物,以及含有一种或多种编码这些多肽的多核苷酸序列和免疫刺激物的疫苗。
另一方面,提供了在患者中诱导保护性免疫的方法,其包括对患者施用一种有效量的一种或多种上述药用组合物或疫苗。
再另一方面,提供了治疗患者的衣原体感染的方法,该方法包括从患者中获得外周血单核细胞(PBMC),将PBMC与本发明的多肽(或编码这种多肽的多核苷酸)温育,产生温育的T细胞,并对患者施用这种温育的T细胞。本发明还提供治疗衣原体感染的方法,包括将抗原递呈细胞与本发明的多肽(或编码这种多肽的多核苷酸)温育,产生温育的抗原递呈细胞,并对患者施用这种温育的抗原递呈细胞。增殖的细胞在对患者施用前可以但不必克隆。在某些实施方案中,抗原递呈细胞选自树突细胞、巨噬细胞、单核细胞、B细胞和成纤维细胞。也提供了用于治疗衣原体感染的组合物,其含有已与本发明的多肽或多核苷酸一起温育的T细胞或抗原递呈细胞。在有关方面中,提供了包含下列成分的疫苗:(a)一种表达如上所述的多肽的抗原递呈细胞,和(b)一种免疫刺激物。
在其他方面,本发明还提供从生物样品中除去衣原体感染的细胞的方法,其包括使生物样品接触可与衣原体蛋白特异反应的T细胞,其中在足以从样品中除去表达该蛋白的细胞的条件下和时间内进行此接触步骤。
在相关方面,提供了抑制患者衣原体感染发展的方法,包括对患者施用如上所述处理的生物样品。在本发明的其他方面中,提供了检测患者衣原体感染的方法和诊断试剂盒。在一个实施方案中,该方法包括:(a)使生物样品接触此处公开的至少一种多肽或融合蛋白;和(b)检测样品中可与该多肽或融合蛋白结合的结合剂的存在,从而检测生物样品中的衣原体感染。合适的生物样品包括全血、痰、血清、血浆、唾液、脑脊液和尿。在一个实施方案中,诊断试剂盒含有此处公开的一种或多种多肽或融合蛋白,以及检测试剂。在另一个实施方案中,诊断试剂盒含有一种可与本发明的多肽结合的单克隆抗体或多克隆抗体。
本发明也提供了检测衣原体感染的方法,包括:(a)从患者中获得生物样品;(b)在聚合酶链反应中使样品接触至少两种寡核苷酸引物,至少一种寡核苷酸引物对于此处公开的多核苷酸序列是特异的;和(c)检测样品中在寡核苷酸引物存在下扩增的多核苷酸序列。在一个实施方案中,寡核苷酸引物含有此处公开的多核苷酸序列或可与之杂交的序列的至少约10个连续核苷酸。
另一方面,本发明提供了检测患者衣原体感染的方法,包括:(a)从患者中获得生物样品;(b)使样品接触一种对于此处公开的多核苷酸序列特异的寡核苷酸探针;和(c)检测样品中可与该寡核苷酸探针杂交的多核苷酸序列。在一个实施方案中,寡核苷酸探针含有此处公开的多核苷酸序列的至少约15个连续核苷酸,或可与之杂交的序列。
在参考以下的详细叙述后,本发明的这些及其他方面将是显然的。此处公开的所有参考文献均在此完全引用作为参考。
序列标识
SEQ ID NO:1是沙眼衣原体克隆1-B1-66的确定的DNA序列。
SEQ ID NO:2是沙眼衣原体克隆4-D7-28的确定的DNA序列。
SEQ ID NO:3是沙眼衣原体克隆3-G3-10的确定的DNA序列。
SEQ ID NO:4是沙眼衣原体克隆10-C10-31的确定的DNA序列。
SEQ ID NO:5是1-B1-66的预测的氨基酸序列。
SEQ ID NO:6是4-D7-28的预测的氨基酸序列。
SEQ ID NO:7是3-G3-10的第一种预测的氨基酸序列。
SEQ ID NO:8是3-G3-10的第二种预测的氨基酸序列。
SEQ ID NO:9是3-G3-10的第三种预测的氨基酸序列。
SEQ ID NO:10是3-G3-10的第四种预测的氨基酸序列。
SEQ ID NO:11是3-G3-10的第五种预测的氨基酸序列。
SEQ ID NO:12是10-C10-31的预测的氨基酸序列。
SEQ ID NO:13是合成肽1-B1-66/48-67的氨基酸序列。
SEQ ID NO:14是合成肽1-B1-66/58-77的氨基酸序列。
SEQ ID NO:15是沙眼衣原体血清变型LGV II克隆2C7-8的确定的DNA序列。
SEQ ID NO:16是沙眼衣原体血清变型D的第一个推断开放阅读框的确定的DNA序列。
SEQ ID NO:17是由沙眼衣原体血清变型D的第一个推断开放阅读框编码的预测的氨基酸序列。
SEQ ID NO:18是合成肽CtC7.8-12的氨基酸序列。
SEQ ID NO:19是合成肽CtC7.8-13的氨基酸序列。
SEQ ID NO:20是由沙眼衣原体血清变型D的第二个推断开放阅读框编码的预测的氨基酸序列。
SEQ ID NO:21是沙眼衣原体LGV II克隆4C9-18的确定的DNA序列。
SEQ ID NO:22是与沙眼衣原体LGV II的硫辛酰胺脱氢酶同源的确定的DNA序列。
SEQ ID NO:23是与沙眼衣原体LGV II的假拟蛋白同源的确定的DNA序列。
SEQ ID NO:24是与沙眼衣原体LGV II的泛醌甲基转移酶同源的确定的DNA序列。
SEQ ID NO:25是沙眼衣原体LGV II的克隆4C9-18#2 BL21 pLysS的确定的DNA序列。
SEQ ID NO:26是沙眼衣原体LGV II的4C9-18#2的预测的氨基酸序列。
SEQ ID NO:27是肺炎衣原体TWAR株的Cp-SWIB的确定的DNA序列。
SEQ ID NO:28是肺炎衣原体TWAR株的Cp-SWIB的预测的氨基酸序列。
SEQ ID NO:29是肺炎衣原体TWAR株的Cp-S13的确定的DNA序列。
SEQ ID NO:30是肺炎衣原体TWAR株的Cp-S13的预测的氨基酸序列。
SEQ ID NO:31是CtC7.8-12和CtC7.8-13的10mer共有肽的氨基酸序列。
SEQ ID NO:32是沙眼衣原体LGV II的克隆2C7-8的预测的氨基酸序列。
SEQ ID NO:33是显示与克隆2C7-8同源性的沙眼衣原体血清变型D的一个克隆的确定的DNA序列。
SEQ ID NO:34是SEQ ID NO:33的序列所编码的预测的氨基酸序列。
SEQ ID NO:35是肺炎衣原体的C.p.SWIB Nde(5’引物)的DNA序列。
SEQ ID NO:36是肺炎衣原体的C.p.SWIB EcoRI(3’引物)的DNA序列。
SEQ ID NO:37是肺炎衣原体的C.p.S13 Nde(5’引物)的DNA序列。
SEQ ID NO:38是肺炎衣原体的C.p.S13 EcoRI(3’引物)的DNA序列。
SEQ ID NO:39是来源于沙眼衣原体LGV II的CtSwib 52-67肽的氨基酸序列。
SEQ ID NO:40是来源于肺炎衣原体LGV II的CtSwib 53-68肽的氨基酸序列。
SEQ ID NO:41是来源于人SWI域的HuSwib 288-302肽的氨基酸序列。
SEQ ID NO:42是来源于沙眼衣原体拓扑异构酶-SWIB融合体的CpSWI-T 822-837肽的氨基酸序列。
SEQ ID NO:43是来源于肺炎衣原体拓扑异构酶-SWIB融合体的CpSWI-T828-842肽的氨基酸序列。
SEQ ID NO:44是沙眼衣原体LGV II克隆19783.3,jen.seq(1>509)CTL2#11-3’的第一个确定的DNA序列,代表3’端。
SEQ ID NO:45是沙眼衣原体LGV II克隆19783.4,jen.seq(1>481)CTL2#11-5’的第二个确定的DNA序列,代表5’端。
SEQ ID NO:46是沙眼衣原体LGV II克隆19784CTL2_12consensus.seq(1>427)CTL2#12的确定的DNA序列。
SEQ ID NO:47是沙眼衣原体LGV II克隆19785.4,jen.seq(1>600)CTL2#16-5’的确定的DNA序列,代表5’端。
SEQ ID NO:48是沙眼衣原体LGV II克隆19786.3,jen.seq(1>600)CTL2#18-3’的第一个确定的DNA序列,代表3’端。
SEQ ID NO:49是沙眼衣原体LGV II克隆19786.4,jen.seq(1>600)CTL2#18-5’的第二种确定的DNA序列,代表5’端。
SEQ ID NO:50是沙眼衣原体LGV II克隆19788CTL2_21consensus.seq(1>406)CTL2#21的确定的DNA序列。
SEQ ID NO:51是沙眼衣原体LGV II克隆19790CTL2_23consensus.seq(1>602)CTL2#23的确定的DNA序列。
SEQ ID NO:52是沙眼衣原体LGV II克隆19791CTL2_24consensus.seq(1>145)CTL2#24的确定的DNA序列。
SEQ ID NO:53是沙眼衣原体LGV II克隆CTL2#4的确定的DNA序列。
SEQ ID NO:54是沙眼衣原体LGV II克隆CTL2#8b的确定的DNA序列。
SEQ ID NO:55是沙眼衣原体LGV II克隆15-G1-89的确定的DNA序列,它与硫辛酰胺脱氢酶基因CT557有同源性。
SEQ ID NO:56是沙眼衣原体LGV II克隆14-H1-4的确定的DNA序列,它与硫醇特异的抗氧化剂基因CT603有同源性。
SEQ ID NO:57是沙眼衣原体LGV II克隆12-G3-83的确定的DNA序列,它与假拟蛋白CT622有同源性。
SEQ ID NO:58是沙眼衣原体LGV II克隆12-B3-95的确定的DNA序列,它与硫辛酰胺脱氢酶基因CT557有同源性。
SEQ ID NO:59是沙眼衣原体LGV II克隆11-H4-28的确定的DNA序列,它与dnaK基因CT396有同源性。
SEQ ID NO:60是沙眼衣原体LGV II克隆11-H3-68的确定的DNA序列,它与PGP6-D毒性蛋白和L1核糖体基因CT318有部分同源性。
SEQ ID NO:61是沙眼衣原体LGV II克隆11-G1-34的确定的DNA序列,它与苹果酸脱氢酶基因CT376和糖原水解酶基因CT042有部分同源性。
SEQ ID NO:62是沙眼衣原体LGV II克隆11-G10-46的确定的DNA序列,它与假拟蛋白CT610有同源性。
SEQ ID NO:63是沙眼衣原体LGV II克隆11-C12-91的确定的DNA序列,它与OMP2基因CT443有同源性。
SEQ ID NO:64是沙眼衣原体LGV II克隆11-A3-93的确定的DNA序列,它与HAD超家族基因CT103有同源性。
SEQ ID NO:65是沙眼衣原体LGV II克隆14-H1-4的确定的氨基酸序列,它与硫醇特异的抗氧化剂基因CT603有同源性。
SEQ ID NO:66是沙眼衣原体LGV II克隆CtL2#9的确定的DNA序列。
SEQ ID NO:67是沙眼衣原体LGV II克隆CtL2#7的确定的DNA序列。
SEQ ID NO:68是沙眼衣原体LGV II克隆CtL2#6的确定的DNA序列。
SEQ ID NO:69是沙眼衣原体LGV II克隆CtL2#5的确定的DNA序列。
SEQ ID NO:70是沙眼衣原体LGV II克隆CtL2#2的确定的DNA序列。
SEQ ID NO:71是沙眼衣原体LGV II克隆CtL2#1的确定的DNA序列。
SEQ ID NO:72是沙眼衣原体LGV II克隆23509.2CtL2#3-5’的第一种确定的DNA序列,代表5’端。
SEQ ID NO:73是沙眼衣原体LGV II克隆23509.1CtL2#3-3’的第二种确定的DNA序列,代表3’端。
SEQ ID NO:74是沙眼衣原体LGV II克隆22121.2CtL2#10-5’的第一种确定的DNA序列,代表5’端。
SEQ ID NO:75是沙眼衣原体LGV II克隆22121.1CtL2#10-3’的第二种确定的DNA序列,代表3’端。
SEQ ID NO:76是确定的沙眼衣原体LGV II克隆19787-6CtL2#19-5’的确定的DNA序列,代表5’端。
SEQ ID NO:77是肺炎衣原体LGV II克隆CpS13-His的确定的DNA序列。
SEQ ID NO:78是肺炎衣原体LGV II克隆Cp_SWIB-His的确定的DNA序列。
SEQ ID NO:79是沙眼衣原体LGV II克隆23-G7-68的确定的DNA序列,它与L11、L10和L1核糖体蛋白有部分同源性。
SEQ ID NO:80是沙眼衣原体LGV II克隆22-F8-91的确定的DNA序列,它与pmpC基因有同源性。
SEQ ID NO:81是沙眼衣原体LGV II克隆21-E8-95的确定的DNA序列,它与CT610-CT613基因有同源性。
SEQ ID NO:82是沙眼衣原体LGV II克隆19-F12-57的确定的DNA序列,它与CT858和recA基因有同源性。
SEQ ID NO:83是沙眼衣原体LGV II克隆19-F12-53的确定的DNA序列,它与编码谷氨酰tRNA合成酶的CT445基因有同源性。
SEQ ID NO:84是沙眼衣原体LGV II克隆19-A5-54的确定的DNA序列,它与隐蔽性质粒基因有同源性。
SEQ ID NO:85是沙眼衣原体LGV II克隆17-E11-72的确定的DNA序列,它与OppC_2和pmpD基因有部分同源性。
SEQ ID NO:86是沙眼衣原体LGV II克隆17-C1-77的确定的DNA序列,它与CT857和CT858开放阅读框有部分同源性。
SEQ ID NO:87是沙眼衣原体LGV II克隆15-H2-76的确定的DNA序列,它与pmpD和SycE基因及CT089 ORF有部分同源性。
SEQ ID NO:88是沙眼衣原体LGV II克隆15-A3-26的确定的DNA序列,它与CT858 ORF有同源性。
SEQ ID NO:89是肺炎衣原体克隆Cp_SWIB-His的确定的氨基酸序列。
SEQ ID NO:90是沙眼衣原体LGV II克隆CtL2_LPDA_FL的确定的氨基酸序列。
SEQ ID NO:91是肺炎衣原体克隆CpS13-His的确定的氨基酸序列。
SEQ ID NO:92是沙眼衣原体克隆CtL2_TSA_FL的确定的氨基酸序列。
SEQ ID NO:93是沙眼衣原体LGV II的Ct-Swib 43-61肽的氨基酸序列。
SEQ ID NO:94是沙眼衣原体LGV II的Ct-Swib 48-67肽的氨基酸序列。
SEQ ID NO:95是沙眼衣原体LGV II的Ct-Swib 52-71肽的氨基酸序列。
SEQ ID NO:96是沙眼衣原体LGV II的Ct-Swib 58-77肽的氨基酸序列。
SEQ ID NO:97是沙眼衣原体LGV II的Ct-Swib 63-82肽的氨基酸序列。
SEQ ID NO:98是沙眼衣原体LGV II的Ct-Swib 51-66肽的氨基酸序列。
SEQ ID NO:99是肺炎衣原体LGV II的Cp-Swib 52-67肽的氨基酸序列。
SEQ ID NO:100是肺炎衣原体LGV II的Cp-Swib 37-51肽的氨基酸序列。
SEQ ID NO:101是肺炎衣原体LGV II的Cp-Swib 32-51肽的氨基酸序列。
SEQ ID NO:102是肺炎衣原体LGV II的Cp-Swib 37-56肽的氨基酸序列。
SEQ ID NO:103是沙眼衣原体LGV II的Ct-Swib 36-50肽的氨基酸序列。
SEQ ID NO:104是沙眼衣原体的Ct-S13 46-65肽的氨基酸序列。
SEQ ID NO:105是沙眼衣原体的Ct-S13 60-80肽的氨基酸序列。
SEQ ID NO:106是沙眼衣原体的Ct-S13 1-20肽的氨基酸序列。
SEQ ID NO:107是沙眼衣原体的Ct-S13 46-65肽的氨基酸序列。
SEQ ID NO:108是沙眼衣原体的Ct-S13 56-75肽的氨基酸序列。
SEQ ID NO:109是肺炎衣原体的Cp-S13 56-75肽的氨基酸序列。
SEQ ID NO:110是沙眼衣原体LGV II克隆21-G12-60的确定的DNA序列,其含有假拟蛋白CT875、CT229和CT228的部分开放阅读框。
SEQ ID NO:111是沙眼衣原体LGV II克隆22-B3-53的确定的DNA序列,它与GroEL的CT110 ORF有同源性。
SEQ ID NO:112是沙眼衣原体LGV II克隆22-A1-49的确定的DNA序列,它与CT660和CT659 ORF有部分同源性。
SEQ ID NO:113是沙眼衣原体LGV II克隆17-E2-9的确定的DNA序列,它与CT611和CT610 ORF有部分同源性。
SEQ ID NO:114是沙眼衣原体LGV II克隆17-C10-31的确定的DNA序列,它与CT858 ORF有部分同源性。
SEQ ID NO:115是沙眼衣原体LGV II克隆21-C7-66的确定的DNA序列,它与dnaK样基因有同源性。
SEQ ID NO:116是沙眼衣原体LGV II克隆20-G3-45的确定的DNA序列,其含有pmpB基因CT413的部分。
SEQ ID NO:117是沙眼衣原体LGV II克隆18-C5-2的确定的DNA序列,它与S1核糖体蛋白ORF有同源性。
SEQ ID NO:118是沙眼衣原体LGV II克隆17-C5-19的确定的DNA序列,其含有CT431和CT430 ORF的部分。
SEQ ID NO:119是沙眼衣原体LGV II克隆16-D4-22的确定的DNA序列,其含有在哺乳动物细胞内生长的质粒的ORF3和ORF4的部分序列。
SEQ ID NO:120是沙眼衣原体血清变型LGV II Cap1基因CT529的全长确定的DNA序列。
SEQ ID NO:121是沙眼衣原体血清变型LGV II Cap1基因CT529的预测的全长氨基酸序列。
SEQ ID NO:122是沙眼衣原体血清变型E Cap1基因CT529的全长确定的DNA序列。
SEQ ID NO:123是沙眼衣原体血清变型E Cap1基因CT529的预测的全长氨基酸序列。
SEQ ID NO:124是沙眼衣原体血清变型1A Cap1基因CT529的全长确定的DNA序列。
SEQ ID NO:125是沙眼衣原体血清变型1A Cap1基因CT529的预测的全长氨基酸序列。
SEQ ID NO:126是沙眼衣原体血清变型G Cap1基因CT529的确定的全长DNA序列。
SEQ ID NO:127是沙眼衣原体血清变型G Cap1基因CT529的预测的全长氨基酸序列。
SEQ ID NO:128是沙眼衣原体血清变型F1 NII Cap1基因CT529的确定的全长DNA序列。
SEQ ID NO:129是沙眼衣原体血清变型F1 NII Cap1基因CT529的预测的全长氨基酸序列。
SEQ ID NO:130是沙眼衣原体血清变型L1 Cap1基因CT529的确定的全长DNA序列。
SEQ ID NO:131是沙眼衣原体血清变型L1 Cap1基因CT529的预测的全长氨基酸序列。
SEQ ID NO:132是沙眼衣原体血清变型L3 Cap1基因CT529的确定的全长DNA序列。
SEQ ID NO:133是沙眼衣原体血清变型L3 Cap1基因CT529的预测的全长氨基酸序列。
SEQ ID NO:134是沙眼衣原体血清变型Ba Cap1基因CT529的确定的全长DNA序列。
SEQ ID NO:135是沙眼衣原体血清变型Ba Cap1基因CT529的预测的全长氨基酸序列。
SEQ ID NO:136是沙眼衣原体血清变型MOPN Cap1基因CT529的确定的全长DNA序列。
SEQ ID NO:137是沙眼衣原体血清变型MOPN Cap1基因CT529的预测的全长氨基酸序列。
SEQ ID NO:138是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#124-139的确定的氨基酸序列。
SEQ ID NO:139是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#132-147的确定的氨基酸序列。
SEQ ID NO:140是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#138-155的确定的氨基酸序列。
SEQ ID NO:141是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#146-163的确定的氨基酸序列。
SEQ ID NO:142是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#154-171的确定的氨基酸序列。
SEQ ID NO:143是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#162-178的确定的氨基酸序列。
SEQ ID NO:144是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#138-147的确定的氨基酸序列。
SEQ ID NO:145是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#139-147的确定的氨基酸序列。
SEQ ID NO:146是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#140-147的确定的氨基酸序列。
SEQ ID NO:147是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#138-146的确定的氨基酸序列。
SEQ ID NO:148是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#138-145的确定的氨基酸序列。
SEQ ID NO:149是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽#F140->I的确定的氨基酸序列。
SEQ ID NO:150是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽##S139>Ga的确定的氨基酸序列。
SEQ ID NO:151是沙眼衣原体血清变型L2的Cap1 CT529 ORF肽##S139>Gb的确定的氨基酸序列。
SEQ ID NO:152是沙眼衣原体血清变型L2的216aa ORF的肽#2C7.8-6的确定的氨基酸序列。
SEQ ID NO:153是沙眼衣原体血清变型L2的216aa ORF的肽#2C7.8-7的确定的氨基酸序列。
SEQ ID NO:154是沙眼衣原体血清变型L2的216aa ORF的肽#2C7.8-8的确定的氨基酸序列。
SEQ ID NO:155是沙眼衣原体血清变型L2的216aa ORF的肽#2C7.8-9的确定的氨基酸序列。
SEQ ID NO:156是沙眼衣原体血清变型L2的216aa ORF的肽#2C7.8-10的确定的氨基酸序列。
SEQ ID NO:157是沙眼衣原体血清变型L2的克隆2C7.8内216aaORF的53个氨基酸残基肽的确定的氨基酸序列。
SEQ ID NO:158是沙眼衣原体血清变型L2的克隆2C7.8内CT529ORF的53个氨基酸残基肽的确定的氨基酸序列。
SEQ ID NO:159是用于克隆全长CT529血清变型L2的5’(正向)引物的确定的DNA序列。
SEQ ID NO:160是用于克隆全长CT529血清变型L2的5’(反向)引物的确定的DNA序列。
SEQ ID NO:161是用于克隆除L2和MOPN外的全长CT529血清变型的5’(正向)引物的确定的DNA序列。
SEQ ID NO:162是用于克隆除L2和MOPN外的全长CT529血清变型的5’(反向)引物的确定的DNA序列。
SEQ ID NO:163是用于克隆全长CT529血清变型MOPN的5’(正向)引物的确定的DNA序列。
SEQ ID NO:164是用于克隆全长CT529血清变型MOPN的5’(反向)引物的确定的DNA序列。
SEQ ID NO:165是用于pBIB-KS的5’(正向)引物的确定的DNA序列。
SEQ ID NO:166是用于pBIB-KS的5’(反向)引物的确定的DNA序列。
SEQID NO:167是血清变型L2的9-mer表位肽Cap1#139-147的确定的氨基酸序列。
SEQ ID NO:168是血清变型D的9-mer表位肽Cap1#139-147的确定的氨基酸序列。
SEQ ID NO:169是沙眼衣原体pmpI基因的确定的全长DNA序列。
SEQ ID NO:170是沙眼衣原体pmpG基因的确定的全长DNA序列。。
SEQ ID NO:171是沙眼衣原体pmpE基因的确定的全长DNA序列。
SEQ ID NO:172是沙眼衣原体pmpD基因的确定的全长DNA序列。。
SEQ ID NO:173是沙眼衣原体pmpC基因的确定的全长DNA序列。
SEQ ID NO:174是沙眼衣原体pmpB基因的确定的全长DNA序列。。
SEQ ID NO:175是沙眼衣原体pmpI基因的预测的全长氨基酸序列。
SEQ ID NO:176是沙眼衣原体pmpG基因的预测的全长氨基酸序列。
SEQ ID NO:177是沙眼衣原体pmpE基因的预测的全长氨基酸序列。
SEQ ID NO:178是沙眼衣原体pmpD基因的预测的全长氨基酸序列。
SEQ ID NO:179是沙眼衣原体pmpC基因的预测的全长氨基酸序列。
SEQ ID NO:180是沙眼衣原体pmpB基因的预测的全长氨基酸序列。
SEQ ID NO:181是沙眼衣原体pmpI基因的确定的DNA序列减信号序列。
SEQ ID NO:182是沙眼衣原体pmpG基因的随后确定的全长DNA序列。
SEQ ID NO:183是沙眼衣原体pmpE基因的确定的DNA序列减信号序列。
SEQ ID NO:184是代表沙眼衣原体pmpD基因羧基端的第一种确定的DNA序列。
SEQ ID NO:185是代表沙眼衣原体pmpD基因氨基端的第二种确定的DNA序列。
SEQ ID NO:186是代表沙眼衣原体pmpC基因羧基端的第一种确定的DNA序列。
SEQ ID NO:187是代表沙眼衣原体pmpC基因氨基端减信号序列的第二种确定的DNA序列。
SEQ ID NO:188是在与Ra12的融合分子中代表肺炎衣原体血清变型MOMPS pmp基因的确定的DNA序列。
SEQ ID NO:189是沙眼衣原体pmpI基因的预测的氨基酸序列减信号序列。
SEQ ID NO:190是随后预测的沙眼衣原体pmpG基因的氨基酸序列。
SEQ ID NO:191是沙眼衣原体pmpE基因的预测的氨基酸序列减信号序列。
SEQ ID NO:192是代表沙眼衣原体pmpD基因羧基端的第一种预测的氨基酸序列。
SEQ ID NO:193是代表沙眼衣原体pmpD基因氨基端的第二种预测的氨基酸序列减信号序列。
SEQ ID NO:194是代表沙眼衣原体pmpC基因羧基端的第一种预测的氨基酸序列。
SEQ ID NO:195是代表沙眼衣原体pmpC基因氨基端的第二种预测的氨基酸序列。
SEQ ID NO:196是在与Ra12的融合分子中代表肺炎衣原体血清变型MOMPS pmp基因的预测的氨基酸序列。
SEQ ID NO:197是用于在SKB疫苗载体中克隆沙眼衣原体pmpC基因的5’oligo引物的确定的DNA序列。
SEQ ID NO:198是用于在SKB疫苗载体中克隆沙眼衣原体pmpC基因的3’oligo引物的确定的DNA序列。
SEQ ID NO:199是用于在SKB疫苗载体中克隆沙眼衣原体pmpC基因的插入序列的确定的DNA序列。
SEQ ID NO:200是用于在SKB疫苗载体中克隆沙眼衣原体pmpD基因的5’oligo引物的确定的DNA序列。
SEQ ID NO:201是用于在SKB疫苗载体中克隆沙眼衣原体pmpD基因的3’oligo引物的确定的DNA序列。
SEQ ID NO:202是用于在SKB疫苗载体中克隆沙眼衣原体pmpD基因的插入序列的确定的DNA序列。
SEQ ID NO:203是用于在SKB疫苗载体中克隆沙眼衣原体pmpE基因的5’oligo引物的确定的DNA序列。
SEQ ID NO:204是用于在SKB疫苗载体中克隆沙眼衣原体pmpE基因的3’oligo引物的确定的DNA序列。
SEQ ID NO:205是用于在SKB疫苗载体中克隆沙眼衣原体pmpG基因的5’oligo引物的确定的DNA序列。
SEQ ID NO:206是用于在SKB疫苗载体中克隆沙眼衣原体pmpG基因的3’oligo引物的确定的DNA序列。
SEQ ID NO:207是用于在pET17b载体中克隆沙眼衣原体pmpC基因氨基端部分的5’oligo引物的确定的DNA序列。
SEQ ID NO:208是用于在pET17b载体中克隆沙眼衣原体pmpC基因氨基端部分的3’oligo引物的确定的DNA序列。
SEQ ID NO:209是用于在pET17b载体中克隆沙眼衣原体pmpC基因羧基端部分的5’oligo引物的确定的DNA序列。
SEQ ID NO:210是用于在pET17b载体中克隆沙眼衣原体pmpC基因羧基端部分的3’oligo引物的确定的DNA序列。
SEQ ID NO:211是用于在pET17b载体中克隆沙眼衣原体pmpD基因氨基端部分的5’oligo引物的确定的DNA序列。
SEQ ID NO:212是用于在pET17b载体中克隆沙眼衣原体pmpD基因氨基端部分的3’oligo引物的确定的DNA序列。
SEQ ID NO:213是用于在pET17b载体中克隆沙眼衣原体pmpD基因羧基端部分的5’oligo引物的确定的DNA序列。
SEQ ID NO:214是用于在pET17b载体中克隆沙眼衣原体pmpD基因羧基端部分的3’oligo引物的确定的DNA序列。
SEQ ID NO:215是用于在pET17b载体中克隆沙眼衣原体pmpE基因的5’oligo引物的确定的DNA序列。
SEQ ID NO:216是用于在pET17b载体中克隆沙眼衣原体pmpE基因的3’oligo引物的确定的DNA序列。
SEQ ID NO:217是用于在pET17b载体中克隆沙眼衣原体pmpE基因的插入序列的确定的DNA序列。
SEQ ID NO:218是用于在pET17b载体中克隆沙眼衣原体pmpE基因的插入序列的氨基酸序列。
SEQ ID NO:219是用于在pET17b载体中克隆沙眼衣原体pmpG基因的5’oligo引物的确定的DNA序列。
SEQ ID NO:220是用于在pET17b载体中克隆沙眼衣原体pmpG基因的3’oligo引物的确定的DNA序列。
SEQ ID NO:221是用于在pET17b载体中克隆沙眼衣原体pmpG基因的插入序列的氨基酸序列。
SEQ ID NO:222是用于在pET17b载体中克隆沙眼衣原体pmpI基因的5’oligo引物的确定的DNA序列。
SEQ ID NO:223是用于在pET17b载体中克隆沙眼衣原体pmpI基因的3’oligo引物的确定的DNA序列。
SEQ ID NO:224是肺炎衣原体Swib肽1-20的确定的氨基酸序列。
SEQ ID NO:225是肺炎衣原体Swib肽6-25的确定的氨基酸序列。
SEQ ID NO:226是肺炎衣原体Swib肽12-31的确定的氨基酸序列。
SEQ ID NO:227是肺炎衣原体Swib肽17-36的确定的氨基酸序列。
SEQ ID NO:228是肺炎衣原体Swib肽22-41的确定的氨基酸序列。
SEQ ID NO:229是肺炎衣原体Swib肽27-46的确定的氨基酸序列。
SEQ ID NO:230是肺炎衣原体Swib肽42-61的确定的氨基酸序列。
SEQ ID NO:231是肺炎衣原体Swib肽46-65的确定的氨基酸序列。
SEQ ID NO:232是肺炎衣原体Swib肽51-70的确定的氨基酸序列。
SEQ ID NO:233是肺炎衣原体Swib肽56-75的确定的氨基酸序列。
SEQ ID NO:234是肺炎衣原体Swib肽61-80的确定的氨基酸序列。
SEQ ID NO:235是肺炎衣原体Swib肽66-87的确定的氨基酸序列。
SEQ ID NO:236是沙眼衣原体OMCB肽103-122的确定的氨基酸序列。
SEQ ID NO:237是沙眼衣原体OMCB肽108-127的确定的氨基酸序列。
SEQ ID NO:238是沙眼衣原体OMCB肽113-132的确定的氨基酸序列。
SEQ ID NO:239是沙眼衣原体OMCB肽118-137的确定的氨基酸序列。
SEQ ID NO:240是沙眼衣原体OMCB肽123-143的确定的氨基酸序列。
SEQ ID NO:241是沙眼衣原体OMCB肽128-147的确定的氨基酸序列。
SEQ ID NO:242是沙眼衣原体OMCB肽133-152的确定的氨基酸序列。
SEQ ID NO:243是沙眼衣原体OMCB肽137-156的确定的氨基酸序列。
SEQ ID NO:244是沙眼衣原体OMCB肽142-161的确定的氨基酸序列。
SEQ ID NO:245是沙眼衣原体OMCB肽147-166的确定的氨基酸序列。
SEQ ID NO:246是沙眼衣原体OMCB肽152-171的确定的氨基酸序列。
SEQ ID NO:247是沙眼衣原体OMCB肽157-176的确定的氨基酸序列。
SEQ ID NO:248是沙眼衣原体OMCB肽162-181的确定的氨基酸序列。
SEQ ID NO:249是沙眼衣原体OMCB肽167-186的确定的氨基酸序列。
SEQ ID NO:250是沙眼衣原体OMCB肽171-190的确定的氨基酸序列。
SEQ ID NO:251是沙眼衣原体OMCB肽171-186的确定的氨基酸序列。
SEQ ID NO:252是沙眼衣原体OMCB肽175-186的确定的氨基酸序列。
SEQ ID NO:253是肺炎衣原体OMCB肽185-198的确定的氨基酸序列。
SEQ ID NO:254是沙眼衣原体TSA肽96-115的确定的氨基酸序列。
SEQ ID NO:255是沙眼衣原体TSA肽101-120的确定的氨基酸序列。
SEQ ID NO:256是沙眼衣原体TSA肽106-125的确定的氨基酸序列。
SEQ ID NO:257是沙眼衣原体TSA肽111-130的确定的氨基酸序列。
SEQ ID NO:258是沙眼衣原体TSA肽116-135的确定的氨基酸序列。
SEQ ID NO:259是沙眼衣原体TSA肽121-140的确定的氨基酸序列。
SEQ ID NO:260是沙眼衣原体TSA肽126-145的确定的氨基酸序列。
SEQ ID NO:261是沙眼衣原体TSA肽131-150的确定的氨基酸序列。
SEQ ID NO:262是沙眼衣原体TSA肽136-155的确定的氨基酸序列。
SEQ ID NO:263是沙眼衣原体CT529/Cap1基因血清变型I的确定的全长DNA序列。
SEQ ID NO:264是沙眼衣原体CT529/Cap1基因血清变型I的预测的全长氨基酸序列。
SEQ ID NO:265是沙眼衣原体CT529/Cap1基因血清变型K的确定的全长DNA序列。
SEQ ID NO:266是沙眼衣原体CT529/Cap1基因血清变型K的预测的全长氨基酸序列。
SEQ ID NO:267是沙眼衣原体克隆17-G4-36的确定的DNA序列,它与serD中DNA引导的RNA聚合酶β亚基-CT315的ORF部分有同源性。
SEQ ID NO:268是克隆2E10中沙眼衣原体CT016基因部分序列的确定的DNA序列。
SEQ ID NO:269是克隆2E10中沙眼衣原体tRNA合酶基因部分序列的确定的DNA序列。
SEQ ID NO:270是克隆2E10中沙眼衣原体clpX基因部分序列的确定的DNA序列。
SEQ ID NO:271是沙眼衣原体克隆CtL2gam-30的第一种确定的DNA序列,其代表5’端。
SEQ ID NO:272是沙眼衣原体克隆CtL2gam-30的第二种确定的DNA序列,其代表3’端。
SEQ ID NO:273是沙眼衣原体克隆CtL2gam-28的确定的DNA序列。
SEQ ID NO:274是沙眼衣原体克隆CtL2gam-27的确定的DNA序列。
SEQ ID NO:275是沙眼衣原体克隆CtL2gam-26的确定的DNA序列。
SEQ ID NO:276是沙眼衣原体克隆CtL2gam-24的确定的DNA序列。
SEQ ID NO:277是沙眼衣原体克隆CtL2gam-23的确定的DNA序列。
SEQ ID NO:278是沙眼衣原体克隆CtL2gam-21的确定的DNA序列。
SEQ ID NO:279是沙眼衣原体克隆CtL2gam-18的确定的DNA序列。
SEQ ID NO:280是沙眼衣原体克隆CtL2gam-17的确定的DNA序列。
SEQ ID NO:281是沙眼衣原体克隆CtL2gam-15的第一种确定的DNA序列,其代表5’端。
SEQ ID NO:282是沙眼衣原体克隆CtL2gam-15的第二种确定的DNA序列,其代表3’端。
SEQ ID NO:283是沙眼衣原体克隆CtL2gam-13的确定的DNA序列。
SEQ ID NO:284是沙眼衣原体克隆CtL2gam-10的确定的DNA序列。
SEQ ID NO:285是沙眼衣原体克隆CtL2gam-8的确定的DNA序列。
SEQ ID NO:286是沙眼衣原体克隆CtL2gam-6的第一种确定的DNA序列,其代表5’端。
SEQ ID NO:287是沙眼衣原体克隆CtL2gam-6的第二种确定的DNA序列,其代表3’端。
SEQ ID NO:288是沙眼衣原体克隆CtL2gam-5的确定的DNA序列。
SEQ ID NO:289是沙眼衣原体克隆CtL2gam-2的确定的DNA序列。
SEQ ID NO:290是沙眼衣原体克隆CtL2gam-1的确定的DNA序列。
SEQ ID NO:291是CT529基因的肺炎衣原体同源物的确定的确定的全长DNA序列。
SEQ ID NO:292是CT529基因的肺炎衣原体同源物的预测的全长氨基酸序列。
SEQ ID NO:293是用于在SKB疫苗载体中克隆沙眼衣原体pmpG基因的插入序列的确定的DNA序列。
附图描述
图1说明表达克隆4C9-18#2的靶细胞激活的衣原体特异性T细胞系的INF-γ的诱导。
图2说明修饰后含有一个Kosak翻译起始位点和终止密码子的反转录病毒载体pBIB-KS1,2,3。
图3显示在铬释放测定中用衣原体肽CtC7.8-12(SEQ ID NO:18)和CtC7.8-13(SEQ ID NO:19)脉冲的P815细胞的特异裂解。
图4显示用沙眼衣原体SWIB蛋白免疫的C57Bl/6小鼠中的抗体同种型滴度。
图5显示用衣原体SWIB蛋白免疫的C3H小鼠的脾细胞中衣原体特异的T细胞增殖反应。
图6说明根据肺炎衣原体设计的5’和3’引物序列,其用来从肺炎衣原体中分离SWIB和S13基因。
图7A和图7B显示,在用表达衣原体蛋白的单核细胞衍生的树突细胞激活后,能与沙眼衣原体和肺炎衣原体交叉反应的人抗衣原体T细胞系(TCL-8)的INF-γ诱导。
图8显示用T细胞系TCL8EB/DC对衣原体核糖体S13蛋白中T细胞表位的鉴定。
图9说明针对肺炎衣原体感染的树突细胞产生的CP-21T细胞对重组肺炎衣原体-SEIB蛋白、而不是对沙眼衣原体SWIB蛋白的增殖反应。
图10显示来源于无症状供体的初级T细胞系(TCT-10EB)的沙眼衣原体特异性SWIB增殖反应。
图11说明用抗原特异性T细胞系(TCL-10EB)对沙眼衣原体SWIB中T细胞表位的鉴定。
发明详述
如上所述,本发明普遍涉及用于诊断和治疗衣原体感染的组合物和方法。一方面,本发明的组合物包括至少含有衣原体抗原的一种免疫原性部分的多肽,或其变体。
在特定实施方案中,本发明公开了含有衣原体抗原的免疫原性部分的多肽,其中该衣原体抗原含有一种由多核苷酸分子编码的氨基酸序列,其包括选自下列的序列:(a)SEQ ID NO:1,15,21-25,44-64,66-76,79-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-290的核苷酸序列,(b)这些核苷酸序列的互补序列,和(c)这些序列的变体。
在此使用时,术语“多肽”包括任何长度的氨基酸链,包括全长的蛋白质(即抗原),其中氨基酸残基通过共价肽键连接。因此,含有本发明抗原之一的免疫原性部分的多肽可完全由该免疫原性部分组成,或可含有其他序列。其他序列可来源于天然衣原体抗原,或者可以是异源的,这些序列可以(但不需要)有免疫原性。
当在此使用时,术语“多核苷酸”是指脱氧核糖核苷酸或核糖核苷酸碱基的单链或双链聚合物,包括DNA和相应的RNA分子,包括HnRNA和mRNA分子,有义链和反义链,并包括全部cDNA、基因组DNA和重组DNA,以及完全或部分合成的多核苷酸。HnRNA分子含有内含子,一般以一对一的方式对应于DNA分子。mRNA分子对应于已从中切下内含子的HnRNA和DNA分子。多核苷酸可由完整基因或其任何部分组成。可操作的反义多核苷酸可含有相应多核苷酸的片段,因此“多核苷酸”的定义包括所有这些可操作的反义片段。
抗原的“免疫原性部分”是能与从衣原体感染的个体中获得的血清反应的部分(即,在此处所述的典型ELISA中,用感染个体的血清产生吸光度读数,其至少比用未感染个体的血清获得的吸光度高三个标准差)。这些免疫原性部分一般含有至少约5个氢基酸残基,更优选地至少约10个,最优选地至少约20个氨基酸残基。制备和鉴定已知序列的抗原的免疫原性部分的方法在本领域中周知,包括在Paul,《基础免疫学》(Fundamental Immunology),第3版,Raven出版社,1993,243-247和此处引用的参考文献中概述的方法。这些技术包括根据与抗原特异性抗体、抗血清和/或T细胞系或克隆反应的能力筛查多肽。在此使用时,如果抗血清和抗体能与抗原特异结合(即,它们在ELISA或其他免疫测定中能与该蛋白质反应,但与不相关的蛋白质无可检测到的反应),则它们是“抗原特异的”。这些抗血清和抗体可如此处所述制备,和用众所周知的技术制备。天然衣原体蛋白的免疫原性部分是可与这些抗血清和/或T细胞以大大低于全长多肽反应性(例如在ELISA和/或T细胞反应性测定中)的水平反应的部分。这些免疫原性部分可在这些测定中以类似于或高于全长多肽的水平反应。这些筛查一般可用本领域技术人员周知的方法进行,如Harlow和Lane,《抗体:实验室手册》,冷泉港实验室,1988所述。例如,多肽可固定于固体载体上,并与患者的血清接触,以使血清中的抗体与固定的多肽结合。然后可除去未结合的血清,并用例如125I-标记的蛋白A检测结合的抗体。
本发明涉及的抗原免疫原性部分的例子包括,例如,SEQ ID NO:9,10,18,19,31,39,93-96,98,100-102,106,108,138-140,158,167,168,246,247和254-256所示的T细胞刺激表位。通常可单独或联合使用含有此处所述一种或多种衣原体抗原的至少一种免疫原性部分的多肽,来检测患者的衣原体感染。
本发明的组合物和方法也包括上述多肽和多核苷酸分子的变体。这些变体包括但不限于,本发明序列的天然发生的等位变体。特别是,变体包括其他衣原体血清变型,如血清变型D、E和F,以及与此处所述的本发明的多肽和多核苷酸分子同源的几种LGV血清变型。优选地,血清变型同源物显示与此处所述的相应多肽序列有95-99%的同源性。
在此使用时,多肽“变体”是只是由于保守置换和/或修饰而不同于所列多肽的多肽,使得多肽的抗原性保留。在一个优选的实施方案中,变异多肽由于5个或更少氨基酸的置换、缺失或添加而不同于鉴定的序列。这些变体一般可通过修饰上述多肽序列之一并用如此处所述的典型方法评估修饰多肽的抗原性而鉴别。换句话说,变体与抗原特异性抗血清反应的能力相对于天然蛋白质可增强或不变,或者可相对于天然蛋白质减少不到50%,优选地不到20%。这些变体一般可通过修饰上述多肽序列之一并用此处所述的抗原特异性抗体或抗血清评估修饰多肽的反应性而鉴别。优选的变体包括已去除一个或多个部分,如N端前导序列或跨膜区的变体。其他优选的变体包括已从成熟蛋白质的N端和/或C端除去一小部分(例如,1-30个氨基酸,优选地5-15个氨基酸)的变体。多肽变体优选地显示与鉴定的多肽有至少约70%,更优选地至少约90%,最优选地至少约95%的同一性(如下所述测定)。
在此使用时,“保守置换”是将氨基酸置换为具有类似性质的另一种氨基酸的置换,这样,肽化学领域的技术人员能预料到多肽的二级结构和亲水性基本不变。氨基酸置换一般可根据残基极性、电荷、溶解度、疏水性、亲水性和/或两性性质的相似性进行。例如,带负电的氨基酸包括天冬氨酸和谷氨酸;带正电的氨基酸包括赖氨酸和精氨酸;含具有类似亲水性值的不带电极性头基团的氨基酸包括亮氨酸、异亮氨酸和缬氨酸;甘氨酸和丙氨酸;天冬酰胺和谷氨酰胺;丝氨酸、苏氨酸、苯丙氨酸和酪氨酸。可表现保守改变的其他组氨基酸包括:(1)ala、pro、gly、glu、asp、gln、asn、ser、thr;(2)cys、ser、tyr、thr;(3)val、ile、leu、met、ala、phe;(4)lys、arg、his;和(5)phe、tyr、trp、his。或者另外,变体也可含有非保守性改变。在一个优选的实施方案中,变体多肽由于5个或更少氨基酸的置换、缺失或添加而不同于天然序列。也可(或另外)通过例如缺失或添加对多肽的免疫原性、二级结构和亲水性有最小影响的氨基酸修饰变体。变体也可或另外含有其他修饰,包括对多肽的抗原性、二级结构和亲水性有最小影响的氨基酸的缺失或添加。例如,一种多肽可在蛋白质的N端与信号(或前导)序列偶联,该信号在翻译时或翻译后引导蛋白质的转移。多肽也可与接头或其他序列偶联,以便于多肽(例如聚-His)的合成、纯化或鉴定,或增强该多肽与固体载体的结合。例如,多肽可与免疫球蛋白Fc区偶联。
多核苷酸“变体”是一种由于含有一个或多个核苷酸缺失、置换或添加而不同于所列核苷酸序列的序列,使得所编码多肽的免疫原性相对于天然蛋白质不降低。对编码多肽的免疫原性的作用一般可如此处所述评估。利用标准诱变技术,如Adelman等人(DNA,2:183,1983)所述的寡核苷酸引导的位点特异性诱变,可容易地引入这些修饰。核苷酸变体可以是如下所述的天然发生的等位变体,或非天然发生的变体。变异核苷酸序列优选地显示与所列序列有至少约70%,更优选地至少约80%,最优选地至少约90%的同一性(如下所述测定)。
本发明提供的多肽包括与一种或多种此处所列多核苷酸序列基本同源的多核苷酸序列所编码的变体。在此使用时,“基本同源”是指在中度严格条件下能杂交的多核苷酸序列。合适的中度严格条件包括:用5×SSC、0.5%SDS、1.0mM EDTA(pH8.0)溶液预洗;于50-65℃下在5×SSC中杂交过夜,或者,如果有交叉种同源性,于45℃下在0.5×SSC中杂交过夜;随后用含0.1%SDS的2×、0.5×和0.2×SSC的每一种在65℃下洗涤两次20分钟。这些杂交多核苷酸序列也在本发明的范围之内,由于密码简并性而编码与本发明多肽相同的多肽的核苷酸序列也是如此。
在如下所述根据最大一致性对比时,如果两种序列中核苷酸或氨基酸残基的序列相同,则认为两种核苷酸或多肽序列“相同”。两种序列之间的对比一般通过在对比窗口上比较序列而进行,以鉴定并比较序列相似性的局部区域。在此使用时,“对比窗口”是指至少约20个、通常30至约75个、40至约50个连续位点的片段,其中可在最佳对比两种序列后将该序列与相同数量连续位点的参照序列对比。
用于对比的序列最佳排列可用生物信息学软件Lasergene suite(DNASTAR,Inc.,Madison,WI)中的Megalign程序进行,使用缺省参数。该程序包含在下列参考文献中叙述的几种对比方案:Dayhoff,M.O.(1978),蛋白质进行改变的模型--检测远亲关系的矩阵。Dayhoff,M.O.(编)《蛋白质序列和结构图集》,国家生物医学研究基金会,华盛顿,第5卷,增3,345-358;Hein J.(1990)对比和系统发生的统一方法,626-645,《酶学方法》,第183卷,Academic Press,Inc.,San Diego,CA;Higgins,D.G.和Sharp,P.M.(1989)利用微型计算机的快速且灵敏的多元序列对比CABIOS 5:151-153;Myers,E.W.和Muller,W.(1988)线性空间的最佳对比CABIOS 4:11-17;Robinson,E.D.(1971)Comb.Theor11:105;Santou,N.Nes,M.(1987)邻接法。一种重建系统发生树的新方法分子生物学进展(Mol.Biol.Evol.)4:406-425;Sneath,P.H.A.和Sokal,R.R.(1973)《数字分类学--数字分类学的原则和实践》,FreemanPress,San Francisco,CA;Wilbur,W.J.和Lipman,D.J.(1983)核酸与蛋白质数据库的快速相似性检索,美国国家科学院院报80:726-730。
优选地,通过在至少20个位点的对比窗口上比较两种最佳排列的序列测定“序列同一性百分比”,其中与用于最佳排列两种序列的参照序列(不含添加或缺失)相比,对比窗口中多核苷酸序列的部分可包含20%或更低、通常5-15%%或10-12%的添加或缺失(即缺口)。此百分数的计算方法是,测定在两种序列中存在相同核酸碱基或氨基酸残基的位点数,得到匹配的位点数,匹配位点数除以参照序列中的位点总数(即窗口大小),结果乘以100,得到序列同一性百分数。
本发明范围中也包括编码此处所述核苷酸序列的基因的等位基因。在此使用时,“等位基因”或“等位基因序列”是由核酸序列中至少一种突变引起的另一种形式的基因。等位基因可导致改变的mRNA或多肽,其结构或功能可能或可能不改变。任何给定的基因可能没有、有一个或有多个等位基因形式。产生等位基因的常见突变一般归于天然核苷酸的缺失、添加或置换。这些改变类型的每一种可单独发生或与其他类型同时发生,在给定序列中发生一次或多次。在特定实施方案中,本发明公开了至少含有衣原体抗原(或这种抗原的变体)的免疫原性部分的多肽,其包含由下列序列编码的一种或多种氨基酸序列:(a)选自SEQ IDNO:1-4,15,21-25,44-64,66-76和79-88的多核苷酸序列;(b)这些DNA序列的互补序列;和(c)与(a)或(b)的序列基本同源的DNA序列。如以下实施例所述,此处公开的几种衣原体抗原可识别一种T细胞系,该T细胞系可识别沙眼衣原体和肺炎衣原体感染的单核细胞衍生的树突细胞,表明它们可能存在沙眼衣原体和肺炎衣原体所共有的免疫反应性表位。因此在疫苗中可使用这些抗原,用于沙眼衣原体生殖道感染和肺炎衣原体感染。实施例6提供了为确定交叉反应性程度而对沙眼衣原体和肺炎衣原体的衣原体抗原的进一步表征。另外,实施例4描述了从沙眼衣原体中分离的cDNA片段(SEQ ID NO:15,16和33),其编码能刺激衣原体特异的鼠CD8+T细胞系的蛋白质(SEQ ID NO:17-19和32)。
总之,可用多种方法制备衣原体抗原和编码这些抗原的多核苷酸序列。例如,如下所述用衣原体特异的T细胞系筛查,可从衣原体基因组或cDNA表达文库中分离编码衣原体抗原的多核苷酸分子,并用本领域周知的技术测序。另外,如以下详述的,通过筛查用于衣原体相关表达(即,用此处所述典型测定法所测定的,在衣原体感染的细胞中至少两倍于对照的表达)的cDNA微阵列可鉴定多核苷酸。可用Synteni微阵列(Palo Alto,CA)按照使用说明书(基本如Schena等人,美国国家科学院院报93:10614-10619,1996和Heller等人,美国国家科学院院报94:2150-2155,1997所述)进行这些筛查。另外,也可从用表达此处所述蛋白质的细胞制备的cDNA中扩增多肽。这些多核苷酸可通过聚合酶链反应(PCR)扩增。为此,可根据此处提供的序列设计序列特异的引物,也可购买或合成。
抗原可如下所述重组产生,方法是向表达载体中插入编码该抗原的多核苷酸序列,并在合适的宿主中表达该抗原。可评估抗原的希望的性质,如与此处所述衣原体感染个体的血清反应的能力,并可用如传统Edman化学法测序。参见Edman和Berg,欧洲生物化学杂志(Eur.J.Biochem.)80:116-132,1967。
编码抗原的多核苷酸序列也可如下获得:为可与分离抗原的部分氨基酸序列衍生的简并寡核苷酸杂交的多核苷酸序列,筛查合适的衣原体cDNA或基因组DNA文库。在这种筛查中使用的简并寡核苷酸序列可以设计和合成,筛查可如Sambrook等人,《分子克隆:实验室指南》,冷泉港实验室,冷泉港,NY(和此处引用的参考文献)所述进行。也可使用聚合酶链反应(PCR),在本领域周知的方法中使用上述寡核苷酸,以从cDNA或基因组文库中分离核酸探针。然后可用分离的探针进行文库筛查。
可通过众所周知的技术用扩增的部分从合适的文库(例如衣原体cDNA文库)中分离全长基因。在这些技术中,用适于扩增的一种或多种多核苷酸探针或引物筛查(cDNA或基因组)文库。优选地,大小选择一种文库使之包含更大的分子。也可为了鉴定基因的5’和上游区优选随机引物文库。为了获得内含子并延伸5’序列而优选基因组文库。
对于杂交技术,部分序列可用众所周知的技术标记(例如,切口平移或用32p末端标记)。然后用标记探针杂交含变性细菌集落的滤膜(或含有噬斑的筛子)筛查细菌或噬菌体文库(参见,Sambrook等人,《分子克隆:实验室指南》,冷泉港实验室,冷泉港,NY,1989)。选择杂交的集落或噬斑并扩充,分离DNA进一步分析。例如,使用来源于部分序列的引物和来源于载体的引物,通过PCR可分析cDNA克隆,确定其他序列的量。可产生限制酶切图谱和部分序列来鉴定一种或多种重叠克隆。然后可用标准技术测定完整序列,其中可包括产生一系列缺失克隆。然后将得到的重叠序列装配为一个连续序列。用众所周知的技术通过连接合适的片段能产生全长cDNA分子。
此外,有大量扩增技术可用于由部分cDNA序列获得全长编码序列。在这些技术中,一般通过PCR进行扩增。可用多种可购得的试剂盒进行这一扩增步骤。引物可用本领域周知的技术设计(参见,例如,Mullis等人,Cold Spring Harbor Symp.Quant.Biol.51:263,1987;Erlich编,《PCR技术》,Stockton出版社,NY,1989),也可使用本领域周知的软件。引物优选地长22-30个核苷酸,具有至少50%的GC含量,并可在约68℃-72℃时与靶序列退火。扩增区域可如上所述测序,重叠序列装配为连续序列。
一种这样的扩增技术是反向PCR(参见,Triglia等人,核酸研究16:8186,1988),它使用限制酶在已知基因区中产生一条片段。然后通过分子内连接环化该片段,在使用来源于已知区的趋异引物的PCR中用作模板。在一种备择方法中,可通过用连接序列的引物和对已知区域特异的引物扩增而重新得到与部分序列相邻的序列。通常用相同的接头引物和对已知区域特异的第二条引物,对扩增的序列进行第二轮扩增。WO96/38591中描述了该方法的一种变化,其使用以相反方向从已知序列开始延伸的两条引物。其他技术包括捕获PCR(Lagerstrom等人,PCR方法应用(PCR Methods Applic.)1:111-19,1991)和步移PCR(Parker等人,核酸研究19:3055-60,1991)。转录介导的扩增或TMA是可用于扩增DNA、rRNA或mRNA的另一种方法,如专利号PCT/US91/03184所述。这一基于自身催化和等温非PCR的方法使用两条引物和两种酶:RNA聚合酶和反转录酶。一条引物含有RNA聚合酶的启动子序列。在第一次扩增中,启动子-引物与靶rRNA在特定位点杂交。反转录酶通过从启动子-引物3’端延伸产生靶rRNA的一个DNA拷贝。降解得到的复合体中的RNA,第二条引物与该DNA拷贝结合。反转录酶从引物末端合成一条新的DNA链,产生双链DNA。RNA聚合酶识别DNA模板中的启动子序列并起始转录。每一新合成的RNA扩增子再次进入TMA过程,用作新一轮复制的模板,导致RNA扩增子的指数扩增。也可使用利用扩增的其他方法获得全长cDNA序列。
在某些情况中,通过分析表达序列标记(EST)数据库如GenBank数据库中提供的序列能获得全长cDNA序列。检索重叠EST一般可用众所周知的程序(例如,NCBI BLAST检索)进行,这些EST可用来产生连续的全长序列。全长cDNA序列也可通过基因组片段的分析获得。
多核苷酸变体一般可用本领域所知的任何方法制备,包括化学合成,如固相亚磷酰胺化学合成。也可用标准诱变技术引入核苷酸序列的修饰,如寡核苷酸引导的位点专一诱变(参见Adelman等人,DNA 2:183,1983)。此外,假如编码衣原体蛋白的DNA掺入具有适当RNA聚合酶启动子(如T7或SP6)的载体中,也可通过体外或体内转录该DNA序列或其部分产生RNA分子。可用某些部分制备如此处所述的编码多肽。另外,也可对患者施用一种部分,使编码多肽在体内产生(例如,用编码衣原体多肽的cDNA构建体转染抗原递呈细胞如树突细胞,并对患者施用转染的细胞)。
与编码序列互补的序列部分(即反义多核苷酸)也可用作探针,或用来调节基因表达。也可向组织细胞中导入能转录为反义RNA的cDNA构建体,以利于反义RNA的产生。如此所述,可使用反义多核苷酸,抑制衣原体蛋白的表达。能用反义技术通过三股螺旋形成控制基因表达,这减弱了双螺旋为了结合聚合酶、转录因子或调节分子而充分打开的能力(参见Gee等人,Huber和Carr,《分子与免疫学方法》,FuturaPublishing Co.(Mt.Kisco,NY;1994))。此外,可设计一种反义分子与基因的控制区(例如,启动子、增强子或转录起始位点)杂交,并阻断基因转录;或通过抑制转录物与核糖体的结合阻断翻译。
也可设计一部分编码序列或互补序列作为探针或引物检测基因表达。探针可用多种报道基团标记,如放射性核素和酶,长度优选地至少为10个核苷酸,更优选地至少20个核苷酸,更优选地至少30个核苷酸。如上所述的引物优选地为22-30个核苷酸长。
可进一步修饰任何多核苷酸,以提高体内稳定性。可能的修饰包括但不限于:在5’和/或3’末端添加侧翼序列;在主链中使用硫代磷酸酯或2’O-甲基而不是磷酸二酯酶连接;和/或含有非传统碱基,如肌苷、queosine和wybutosine,以及乙酰-、甲基-、硫代-和其他修饰形式的腺嘌呤、胞嘧啶、鸟嘌呤、胸腺嘧啶和尿嘧啶。
可用已建立的重组DNA技术将如此处所述的核苷酸序列与多种其他核苷酸序列连接。例如,一种多核苷酸可克隆到多种克隆载体之一中,包括质粒、噬菌粒、λ噬菌体衍生物和粘粒。特定用途的载体包括表达载体、复制载体、探针产生载体和测序载体。通常,一种载体含有一个至少在一种生物中起作用的复制起点、常规限制性核酸内切酶位点和一种或多种选择性标记。其他元件取决于希望的用途,对于本领域技术人员是显然的。
用本领域周知的技术可产生包含少于约100个氨基酸、一般少于约50个氨基酸的合成多肽。例如,这些多肽可用商品化的固相技术合成,如Merrifield固相合成法,其中连续添加氨基酸形成氨基酸链。参见Merrifield,美国化学学会杂志(J.Am.Chem.Soc.)85:2149-2146,1963。自动合成多肽的装置购自供应商,如Perkin Elmer/Applied BioSystemsDivision,Foster City,CA,并可按照使用说明书操作。
如上所述,可用众所周知的技术制备和鉴定衣原体抗原的免疫原性部分,如Paul,《基础免疫学》,第3版,Raven Press,1993,243-247和此处引用的参考文献所总结的方法。这些技术包括针对免疫原性筛查天然抗原的多肽部分。在这些筛查中一般可使用此处所述的典型ELISA。多肽的免疫原性部分是在这些典型测定中产生一种信号的部分,在这些测定中该信号基本类似于全长抗原所产生的信号。换言之,衣原体抗原的免疫原性部分在此处所述的模式ELISA中产生全长抗原所诱导信号的至少20%、优选地约100%的信号。
衣原体抗原的部分和其他变体可用合成或重组方法产生。天然抗原的变体一般可用标准诱变技术制备,如寡核苷酸引导的位点专一诱变。也可用标准技术除去多核苷酸序列的部分而制备截短的多肽。
含天然抗原的部分和/或变体的重组多肽可用本领域技术人员周知的多种技术由编码该多肽的多核苷酸序列制备。例如,首先可用商品滤膜浓缩向培养基中分泌重组蛋白的适当宿主/载体系统的上清液。浓缩后,将浓缩液加到合适的纯化基质如亲和基质或离子交换树脂上。最后,用一种或多种反相HPLC步骤进一步纯化重组蛋白。
可用本领域技术人员所知的多种表达载体表达此处所述的重组多肽。可在含编码该重组多肽的多核苷酸分子的表达载体所转化或转染的适当宿主细胞中实现表达。合适的宿主细胞包括原核、酵母和高等真核细胞。优选地,使用的宿主细胞是大肠杆菌、酵母或哺乳动物细胞系,如COS或CHO。以这种方式表达的DNA序列可编码天然存在的抗原、天然存在的抗原的部分,或其其他变体。
一般而言,无论制备方法如何,以分离的、极纯的形式制备此处公开的多肽。优选地,多肽纯度至少约80%、更优选地至少约90%、最优选地至少约99%。
在某些特殊实施方案中,多肽可以是一种融合蛋白,其含有此处所述的多种多肽,或含有至少一种此处所述的多肽和一种不相关的序列,如已知的衣原体蛋白。例如,融合配偶体(partner)可参与提供T辅助表位(一种免疫融合配偶体),优选地可被人识别的T辅助表位,或可参与以高于天然重组蛋白的产量表达蛋白质(表达增强子)。某些优选的融合配偶体既是免疫的又是增强表达的融合配偶体。可选择其他融合配偶体,以提高蛋白质的溶解度,或使蛋白质导向希望的胞内区室。其他融合配偶体包括有利于蛋白质纯化的亲和标记。编码本发明的融合蛋白的DNA序列可用已知的重组DNA技术构建,以将如编码第一种和第二种多肽的各DNA序列装配为合适的表达载体。用或不用肽接头,将编码第一种多肽的DNA序列的3’端与编码第二种多肽的DNA序列的5’端连接,使序列的阅读框同步,而使两种DNA序列mRNA翻译为一种保留了第一种和第二种多肽的生物活性的融合蛋白。
可使用一种肽接头序列将第一种和第二种多肽分开一段距离,以充分确保每种多肽折叠为二级和三级结构。用本领域周知的标准技术将这种肽接头序列引入融合蛋白中。可根据下列因素选择合适的肽接头序列:(1)其采取灵活延伸构象的能力;(2)其不能采取与第一种和第二种多肽上的功能表位相互作用的二级结构的性质;和(3)可与多肽功能表位相互作用的疏水性或带电残基的缺乏。优选的肽接头序列含有Gly、Asn和Ser残基。在接头序列中也可使用其他接近中性的氨基酸,如Thr和Ala。可用作接头的氨基酸序列包括Maratea等人,基因40:39-46,1985;Murphy等人,美国国家科学院院报83:8258-8562,1986;美国专利号4,935,233和美国专利号4,751,180中公开的序列。接头序列长度可为1个到约50个氨基酸。肽接头序列的另一种应用是(当希望时),能使用第一种和第二种多肽上的非必需N端氨基酸区(当存在时)分开功能域,并阻止空间障碍。
连接的DNA序列与合适的转录或翻译调节元件有效连接。负责DNA表达的调节元件只位于编码第一种多肽的DNA序列的5’。类似地,末端翻译所需的终止密码子和转录终止信号只存在于编码第二种多肽的DNA序列的3’。
也提供了包含本发明的多肽和一种不相关的免疫原性蛋白质的融合蛋白。优选地,该免疫原性蛋白质能引发一种回忆反应。这些蛋白质的例子包括破伤风、结核和肝炎蛋白(参见,例如,Stoute等人,新英格兰医学杂志(New Engl.J.Med.)336:86-91,1997)。
在优选的实施方案中,免疫原性融合配偶体来源于蛋白D-革兰氏阴性菌B型流感嗜血菌的一种表面蛋白(WO 91/18926)。优选地,蛋白D衍生物包含该蛋白质的约三分之一(例如,N端前100-110个氨基酸),蛋白D衍生物可脂化。在某些优选实施方案中,N端含有脂蛋白D融合配偶体的前109个残基,产生含有其他外源T细胞表位的多肽,并增强在大肠杆菌中的表达水平(从而作为表达增强子)。脂尾确保抗原向抗原递呈细胞的最佳递呈。其他融合蛋白包括来源于流感病毒的非结构蛋白NS1(血球凝集素)。一般使用N端81个氨基酸,但也可使用含有T辅助表位的不同片段。
在另一个实施方案中,免疫融合配偶体是称作LYTA的蛋白质或其部分(优选地C端部分)。LYTA来源于肺炎链球菌(Streptococcuspneumoniae),该菌合成一种N-乙酰-L-丙氨酸酰胺酶,称作酰胺酶LYTA(由LytA基因编码;基因43:265-292,1986)。LYTA是一种自溶素,可特异降解肽聚糖主链中的某些键。LYTA蛋白的C端区域负责与胆碱或某些胆碱类似物如DEAE的亲和力。这种性质已用作发展用于融合蛋白表达的大肠杆菌C-LYTA表达质粒。在氨基端含C-LYTA片段的杂种蛋白的纯化已有描述(参见,生物技术(Biotechnology)10:795-798,1992)。在一个优选的实施方案中,LYTA的重复部分可掺入融合蛋白中。在开始于残基178的C端区中发现重复部分。一种特别优选的重复部分含有残基188-305。另外,融合蛋白Ra12可与本发明的多核苷酸连接,促进蛋白质表达。
另一方面,本发明提供使用一种或多种上述多肽或融合蛋白(或编码这些多肽或融合蛋白的多核苷酸)在患者中诱导针对衣原体感染的保护性免疫的方法。在此使用时,“患者”是指任何温血动物,优选的是人。患者可患有一种疾病,或者可能没有可检测的疾病和/或感染。换言之,可诱导保护性免疫,来预防或治疗衣原体感染。
在该方面,在药用组合物或疫苗中一般含有多肽、融合蛋白或多核苷酸分子。药用组合物可含有一种或多种多肽,其每一种可含有一种或多种上述序列(或其变体)和生理学可接受的载体。疫苗可含有一种或多种上述多肽和免疫刺激剂,如佐剂或脂质体(其中掺有多肽)。这些药用组合物和疫苗也可含有或掺入组合多肽中或存在于各自多肽中的其他衣原体抗原。
此外,疫苗可含有编码一种或多种上述多肽或融合蛋白的多核苷酸,使该多肽原位产生。在这些疫苗中,多核苷酸可存在于本领域技术人员周知的多种输送系统之一中,包括核酸表达系统、细菌和病毒表达系统。合适的核酸表达系统含有在患者中表达所必要的多核苷酸序列(如合适的启动子和终止信号)。细菌输送系统包括施用在细胞表面表达多肽免疫原性部分的表达细菌(如卡介苗)。在一个优选的实施方案中,可用病毒表达系统(例如,痘苗或其他痘病毒,反转录病毒或腺病毒)导入多核苷酸,这可能包括非致病性(缺陷)病毒的使用。向这些表达系统中掺入多核苷酸的技术为本领域技术人员所周知。多核苷酸也可作为“裸露的”质粒载体施用,如Ulmer等人,科学259:1745-1749,1993所述,Cohen,科学259:1691-1692,1993综述。向这些载体中掺入DNA的技术为本领域技术人员所周知。反转录病毒载体另外还可转移或掺入一种选择性标记基因(帮助鉴定或筛选转导的细胞)和/或导向部分,如编码特异靶细胞上受体的配体的基因,而使载体导向特异。也可通过本领域技术人员周知的方法用抗体实现导向。
其他治疗用制剂包括胶态分散系统,如大分子复合物、毫微囊剂、微球体、珠滴,和基于脂质的系统,包括水包油乳剂、胶囊、混合胶囊和脂质体。用作体外和体内输送载体的一种优选的胶态系统是脂质体(即,人工膜载体)。向可生物降解液滴中掺入多核苷酸可增强裸露多核苷酸的摄取,它们能有效地输送到细胞中。这些系统的制备和应用在本领域中周知。
在一个有关的方面,如上所述的多核苷酸疫苗可与本发明的多肽或已知的衣原体抗原同时施用或连续施用。例如,施用“裸露的”或在上述输送系统中的编码本发明的多肽的多核苷酸后,可施用抗原来提高疫苗的保护性免疫作用。
此处公开的多肽和多核苷酸也可在过继免疫治疗中使用以治疗衣原体感染。过继免疫治疗可泛泛地分类为主动或被动的免疫治疗。在主动免疫治疗中,治疗依赖于施用免疫应答调节剂(例如,疫苗、细菌佐剂和/或细胞因子)对内源宿主免疫系统的体内刺激。
在被动免疫治疗中,治疗包括施用具有明确的免疫反应性的生物试剂(如效应细胞或抗体),它们能直接或间接地介导抗衣原体作用,而不必依赖于完整的宿主免疫系统。效应细胞的例子包括T淋巴细胞(例如CD8+细胞毒性T淋巴细胞、CD4+T辅助细胞)、杀伤细胞(如自然杀伤细胞、淋巴因子活化的杀伤细胞)、B细胞或表达此处公开的抗原的抗原递呈细胞(如树突细胞和巨噬细胞)。也可用此处公开的多肽产生抗体或抗独特型抗体(如美国专利号4,918,164),用于被动免疫治疗。
为过继免疫治疗获得适量T细胞的主要方法是在体外培养免疫T细胞。使单个抗原特异性T细胞扩充为几十亿个保留体内抗原识别的T细胞的培养条件在本领域中周知。这些体外培养条件一般在细胞因子如IL-2和不分裂的饲养细胞存在下用抗原断续刺激。如上所述,此处所述的免疫反应性多肽可用来快速扩充抗原特异性T细胞培养物,以产生足量的细胞进行免疫治疗。特别是,抗原递呈细胞如树突细胞、巨噬细胞、单核细胞、成纤维细胞或B细胞可用免疫反应性多肽脉冲,或可用本领域周知的多种标准技术将多核苷酸序列导入抗原递呈细胞中。例如,抗原递呈细胞可用多核苷酸序列转染或转导,其中该序列含有适于增强表达的启动子区,并能表达为重组病毒或其他表达系统的部分。可用几种病毒载体转导抗原递呈细胞,包括痘病毒、痘苗病毒和腺病毒;也可通过多种方法用此处公开的多核苷酸序列转染抗原递呈细胞,包括基因枪技术、脂质介导的输送、电穿孔、渗压休克和颗粒输送机制,经本领域技术人员测定,可导致有效且可接受的表达水平。为了培养的T细胞在治疗中有效,培养的T细胞必须能生长并广泛分布,并能在体内长期存活。研究证明,培养的T细胞能被诱导在体内生长,通过用补充有IL-2的抗原重复刺激能大量地长期存活(参见,例如,Cheever,M.等人,“用培养的T细胞治疗:再论原则”,免疫学综述(Immunological Reviews)157:177,1997)。
此处公开的多肽也可用来产生和/或分离衣原体反应性T细胞,然后可向患者施用。一种技术,用对应于公开多肽的免疫原性部分的短肽体内免疫,可产生抗原特异的T细胞系。可从患者中分离产生的抗原特异性CD8+或CD4+T细胞克隆,用标准组织培养技术扩充,并回输患者。
此外,如Chang等人(肿瘤学与血液学评述(Crit.Rev.Oncol.Hematol.)22(3),213,1996)所述,通过选择性体外刺激并扩充自体T细胞,也可用对应于多肽免疫原性部分的肽产生衣原体反应性T细胞亚组,提供随后可向患者施用的抗原特异性T细胞。用可购得的细胞分离系统,如购自Nexell Therapeutics,Inc.Irvine,CA的IsolexTM系统,可从患者的外周血中分离免疫系统细胞,如T细胞。用输送载体如微球体中所含的一种或多种免疫反应性多肽刺激分离的细胞,产生抗原特异性T细胞。然后用标准技术扩充抗原特异性T细胞群体,并将这些细胞回输患者。
在其他实施方案中,能克隆、扩充对于此处公开的多肽特异的T细胞和/或抗体受体,并转移到其他载体或效应细胞中在过继免疫治疗中使用。特别是,可用合适的基因转染T细胞,表达衣原体特异的单克隆抗体的可变区,作为胞外识别元件,并与T细胞受体信号链连接,引起T细胞激活、特异裂解和细胞因子释放。这使T细胞能以不依赖MHC的方式重定向其特异性。参见,例如,Eshhar,Z.,癌症免疫学与免疫治疗(Cancer Immunol Immunother)45(3-4):131-6,1997和Hwu,P.等人,癌症研究55(15):3369-73,1995。另一个实施方案可包括衣原体抗原特异的α和βT细胞受体链向另一种T细胞中的转染,如Cole,DJ,等人,癌症研究55(4):748-52,1995。
在另一个实施方案中,同源或自体树突细胞可用对应于此处公开的多肽的至少一种免疫原性部分的肽脉冲。得到的抗原特异性树突细胞可转移给患者,或用来刺激T细胞,产生抗原特异性T细胞,随后可向患者施用。肽脉冲的树突细胞产生抗原特异性T细胞的应用,及随后这些抗原特异性T细胞消除鼠模型中疾病的应用,被Cheever等人,免疫学综述,157:177,1997证明。另外,表达公开的多核苷酸的载体可导入采自患者的干细胞中,并在体外无性繁殖,用于自体移植回同一患者。
在某些方面,此处公开的多肽、多核苷酸、T细胞和/或结合剂可掺入药用组合物或免疫原性组合物(即疫苗)中。药用组合物含有一种或多种这样的化合物和一种生理学可接受的载体。疫苗可含有一种或多种这样的化合物和一种免疫刺激剂。免疫刺激剂可以是提高或加强对外源抗原免疫应答的任何物质。免疫刺激剂的例子包括佐剂、可生物降解的微球体(例如,polylactic galactide)和脂质体(其中掺入化合物;参见,例如,Fullerton,美国专利号4,235,877)。例如,M.F.Powell和M.J.Newman编的《疫苗设计(亚基和佐剂方法)》,Plenum出版社(NY,1995)中概述了疫苗制剂。本发明范围内的药用组合物和疫苗也可含有其他化合物,它们可有生物活性或无活性。例如,组合物或疫苗中可含有掺入融合多肽中或作为单独化合物的其他衣原体抗原的一种或多种免疫原性部分。
药用组合物或疫苗可含有编码上述一种或多种多肽的DNA,使得多肽原位产生。如上所述,该DNA可存在于本领域技术人员所知的多种输送系统之一中,包括核酸表达系统、细菌和病毒表达系统。多种基因输送技术在本领域中周知,如Rolland,治疗药物载体系统评述(Crit.Rev.Therap.Drug Carrier Systems)15:143-198,1998和此处引用的参考文献所述。合适的核酸表达系统含有在患者中表达所需的DNA序列(如合适的启动子和终止信号)。细菌输送系统包括施用在细胞表面表达多肽免疫原性部分或分泌这种表位的细菌(如卡介苗)。在一个优选的实施方案中,可用病毒表达系统(例如痘苗或其他痘病毒、反转录病毒或腺病毒)导入DNA,可包括使用非致病性(缺陷的)可复制病毒。合适的系统在下列文献中公开,例如:Fisher-Hoch等人,美国国家科学院院报86:317-321,1989;Flexner等人,纽约科学院年报(Ann.N.Y.Acad.Sci.)569:86-103,1989;Flexner等人,疫苗(Vaccine)8:17-21,1990;美国专利号4,603,112、4,769,330和5,017,487;WO 89/01973;美国专利号4,777,127;GB2,200,651;EP0,345,242;WO 91/02805;Berkner,生物技术(Biotechniques)6:616-627,1988;Rosenfeld等人,科学252:431-434,1991;Kolls等人,美国国家科学院院报91:215-219,1994;Kass-Eisler等人,美国国家科学院院报90:11498-11502,1993;Guzman等人,循环(Circulation)88:2838-2848,1993;和Guzman等人,循环研究(Cir.Res.)73:1202-1207,1993。向这些表达系统中掺入DNA的技术为本领域技术人员所周知。DNA也可以是“裸露的”,如Ulmer等人,科学259:1745-1749,1993所述,Cohen,科学259:1691-1692,1993所综述。将DNA包被于能有效输送到细胞中的可生物降解的珠上可提高裸露DNA的摄取。
在本发明的药用组合物中可使用本领域技术人员所知的适当载体,但载体类型随施用模式而不同。可为任何适当的施用方式配制本发明的组合物,包括,例如,局部、口服、鼻、静脉内、颅骨内、腹膜内、皮下或肌内施用。至于肠胃外施用,如皮下注射,载体优选地含有水、盐水、 醇、脂肪、蜡或缓冲液。至于口服,可使用上述任何载体或固体载体,如甘露醇、乳糖、淀粉、硬脂酸镁、糖精钠、滑石粉、纤维素、葡萄糖、蔗糖和碳酸镁。也可用可生物降解的微球体(例如polylactatepolyglycolate)作为本发明的药用组合物的载体。例如,美国专利号4,897,268和5,075,109中公开了合适的可生物降解微球体。
这些组合物也可含有缓冲液(例如,中性缓冲盐水或磷酸缓冲盐溶液)、碳水化合物(例如葡萄糖、甘露糖、蔗糖或葡聚糖)、甘露醇、蛋白质、多肽或氨基酸如甘氨酸、抗氧化剂、螯合剂如EDTA或谷胱甘肽、佐剂(例如氢氧化铝)和/或防腐剂。此外,本发明的组合物可制为冻干品。也可用众所周知的方法将化合物包被于脂质体中。
在本发明的疫苗中可以使用多种免疫刺激剂。例如,可包含一种佐剂。大多数佐剂含有一种用来保护抗原免于快速分解代谢的物质,如氢氧化铝或矿物油,和免疫应答刺激物,如类脂A、Bortadella pertussis或结核杆菌(Mycobacterium tuberculosis)衍生的蛋白质。合适的佐剂可购得,如弗氏不完全佐剂和完全佐剂(Difco Laboratories,Dtroit,MI);Merck佐剂65(Merck Company,Inc.,Rahway,NJ);铝盐如氢氧化铝胶体(明矾)或磷酸铝;钙、铁或锌盐;酰化酪氨酸的不溶性悬液;酰化糖;阳离子或阴离子衍生的多糖;聚磷腈;可生物降解的微球体;单磷酰脂类A和quil A。细胞因子如GM-CSF或白细胞介素-2、-7或-12也可用作佐剂。
在此处提供的疫苗内,在选择条件下,佐剂组合物可用来诱导主要是Th1型或Th2型的免疫应答。高水平的Th1型细胞因子(例如IFN-γ、TNFα、IL-2和IL-12)倾向于诱导对施用抗原的细胞介导的免疫应答。相反,高水平的Th2型细胞因子(例如,IL-4、IL5、IL-6和IL-10)倾向于诱导体液免疫应答。施用此处提供的疫苗后,患者将支持包括Th1型和Th2型应答的免疫应答。在一个优选实施方案中,其中应答主要是Th1型的,Th1型细胞因子的水平将提高到比Th2型细胞因子水平更高的程度。这些细胞因子的水平可用标准测定法容易地评估。细胞因子家族的综述参见Mosmann和Coffman,免疫学年述(Ann.Rev.Immunol.)7:145-173,1989。
用于引发Th1型应答的优选的佐剂包括,例如,单磷酰脂类A优选地3-去-O-酰化单磷酰脂类A(3D-MPL)与铝盐的组合。MPL佐剂可从Ribi ImmunoChem Research Inc.(Hanilton,MT)获得(参见美国专利号4,436,727;4,877,611;4,866,034和4,912,094)。含CpG的寡核苷酸(其中CpG二核苷酸未甲基化)也主要诱导Th1应答。这些寡核苷酸众所周知,例如在WO96/02555有述。另一种优选的佐剂是皂角苷,优选地QS21,它可单独使用或与其他佐剂一起使用。例如,一种增强的系统包括单磷酰脂类A和皂角苷衍生物的组合,如QS21和3D-MPL的组合,如WO96/00153所述,或QS21与胆固醇断开的低反应原性组合物,如WO96/33739所述。其他优选的制剂包括水包油乳剂和生育酚。在WO95/17210中描述了在水包油乳剂中包含QS21、3D-MPL和生育酚的一种特别有效的佐剂制剂。此处提供的任何疫苗可用众所周知的方法制备,导致抗原、免疫应答增强剂和适当载体或赋形剂的组合。
此处所述的组合物可作为缓释制剂的一部分施用(即,施用后实现化合物缓释的制剂,如胶囊、海绵或胶体(例如由多糖组成))。这些制剂一般可用众所周知的技术制备,并通过如口服、直肠或皮下植入或植入希望的靶部分而施用。缓释制剂可含有分散于载体基质中和/或在速度控制膜所围成的容器中所含的多肽、多核苷酸或抗体。在这些制剂中使用的载体是生物适合的,也可以是可生物降解的;优选地该制剂提供相对恒定水平的活性化合物释放。缓释制剂所含活性化合物的量取决于植入的大小、释放的速度和预期的持续时间,和治疗或预防的病情。
在药用组合物和疫苗中可使用多种输送载体中的任一种,以利于针对衣原体感染的细胞的抗原特异性免疫应答的产生。输送载体包括抗原递呈细胞(APC),如树突细胞、巨噬细胞、B细胞、单核细胞和可改造为有效APC的其他细胞。这些细胞可以但不需要遗传修饰来提高递呈抗原的能力,促进T细胞应答的激活和/或保持,本身具有抗衣原体作用,和/或与受体免疫学相容(即匹配的HLA单体型)。APC一般可从多种生物液体和器官中分离,可以是自体、异体、同源或异源的细胞。
本发明的某些优选实施方案使用树突细胞或其祖细胞作为抗原递呈细胞。树突细胞是十分有效的APC(Banchereau和Steinman,自然392:245-251,1998),作为生理佐剂可有效地用于引发预防或治疗性免疫(参见Timmerman和Levy,医学年述(Ann.Rev.Med.)50:507-529,1999)。通常,树突细胞可根据其典型形状(原位星形在体外可见的明显的胞质加工(树突))、高效吸收、加工和递呈抗原的能力及其激活幼稚T细胞应答的能力鉴定。当然可改造树突细胞,使之表达在体内或来自体内的树突细胞上不常见的特异性细胞表面受体或配体,本发明设想这些修饰的树突细胞。作为树突细胞的一个选择,分泌的载有囊抗原的树突细胞(称为外来体)可在疫苗中使用(参见Zitvogel等人,自然医学(NatureMed.)4:594-600,1998)。
树突细胞及祖细胞可从外周血、骨髓、淋巴结、脾脏、皮肤、脐带血或其他任何合适的组织或液体中获得。例如,向从外周血中收集的单核细胞的培养物中加入细胞因子如GM-CSF、IL-4、IL-13和/或TNFα的组合物,树突细胞可以来自体内地分化。此外,通过向培养基中加入GM-CSF、IL-3、TNFα、CD40配体、LPS、flt3配体和/或可诱导树突细胞分化、成熟和增殖的其他化合物,从外周血、脐带血或骨髓中收集的CD34阳性细胞可分化为树突细胞。
树突细胞常规分类为“未成熟”和“成熟”细胞,这是区别两种明确表征的表型的一种简单方法。然而,该命名法不应看作排除分化中所有可能的中间阶段。未成熟树突细胞特征是具有高抗原摄取和加工能力的APC,与Fcγ受体和甘露糖受体的高表达有关。成熟表型的特征一般在于这些标记的较低表达,负责T细胞激活的细胞表面分子如I类和II类MHC、粘附分子(例如,CD54和CD11)和共刺激分子(例如CD40、CD80、CD86和4-1BB)的高表达。
APC一般可用编码衣原体蛋白(或其部分或其他变体)的多核苷酸转染,使得衣原体多肽或其免疫原性部分在细胞表面表达。这种转染可来自体内地发生,含有这些转染的细胞的组合物或疫苗然后可如此处所述用于治疗目的。此外,也可向患者施用导向树突或其他抗原递呈细胞的基因输送载体,引起体内发生的转染。树突细胞的体内和来自体内的转染一般可用本领域所知的任何方法进行,如WO97/24447所述方法,或Mahvi等人,免疫学与细胞生物学(Immunology and Cell Biology)75:456-460,1997所述的基因枪法。树突细胞的抗原负载的实现方法可以是,将树突细胞或祖细胞与衣原体多肽、(裸露的或质粒载体内的)DNA或RNA或与表达抗原的重组细菌或病毒(例如,牛痘、禽痘、腺病毒或慢病毒载体)温育。在负载前,多肽可与提供T细胞帮助的免疫配偶体(即载体分子)共价结合。此外,树突细胞可用未结合的免疫配偶体在多肽存在下或单独脉冲。
药用组合物和疫苗的施用途径和频率以及剂量因个体而不同。通常,药用组合物和疫苗可通过注射(例如,皮内、肌内、静脉内或皮下)、鼻内(例如吸入)或口服施用。1-36周中可施用1~3剂。优选地,以3~4个月的间隔施用3剂,之后可定期进行加强接种。替代方法可适于个体患者。一种合适的剂量是,当如上所述施用时,能在免疫的患者中引起足以在至少1~2年内保护患者免于衣原体感染的免疫应答的多肽或DNA量。药剂中存在的(或药剂中DNA原位产生的)多肽量约为每kg宿主1pg~1μg,一般为约10pg~1mg,优选地约100pg~1μg。合适的剂量因患者大小而不同,但一般为约0.1mL~5mL。
在本发明的药用组合物中可使用本领域技术人员周知的任何适当载体,载体的类型取决于施用模式。对于肠胃外施用,如皮下注射,载体优选地含有水、盐水、醇、脂肪、蜡或缓冲液。对于口服,可使用上述任何载体或固体载体,如甘露醇、乳糖、淀粉、硬脂酸镁、糖精钠、滑石粉、纤维素、葡萄糖、蔗糖和碳酸镁。可生物降解的微球体(例如polylacticgalactide)也可用作本发明的药用组合物的载体。例如,美国专利号4,897,268和5,075,109中公开了合适的可生物降解的微球体。
合适的剂量和治疗方案一般以足以产生治疗和/或预防益处的量提供活性化合物。通过在有关患者中建立比之未治疗的患者提高的临床结果,能监测这种反应。预先存在的对衣原体蛋白免疫应答的增强一般与提高的临床结果有关。这些免疫应答一般可用标准增殖、细胞毒性或细胞因子测定法评估,可用治疗前和治疗后从患者中获得的样品进行。
另一方面,本发明提供用上述多肽诊断衣原体感染的方法。在这一方面,提供了单独或组合使用一种或多种上述多肽检测生物样品中衣原体感染的方法。为清楚起见,当描述本发明诊断方法的具体实施方案时使用术语“多肽”。然而,本领域技术人员应当清楚,也可在这些方法中使用本发明的融合蛋白。
在此使用时,“生物样品”是从患者中获得的任何含抗体样品。优选地,样品是全血、痰、血清或血浆、唾液、脑脊液或尿。更优选地,样品是从患者中获得的血液、血清或血浆样品。如下所述,在测定中使用这些多肽,测定相对于预定的阈值,样品中多肽抗体的存在与否。这些抗体的存在表明以前对可表现衣原体感染的衣原体抗原的致敏。
在使用一种以上多肽的实施方案中,使用的多肽优选地是互补的(即,一种组成多肽能检测样品中的感染,其中另一种组成多肽无法检测该感染)。互补多肽一般可用每种多肽单独鉴定,以评价从已知感染衣原体的一系列患者中获得的血清样品。用每种多肽测定何种样品为阳性(如下所述)后,可配制两种或多种多肽的组合,它们能检测大多数或全部待测样品中的感染。
本领域技术人员已知多种测定法,使用一种或多种多肽检测样品中的抗体。参见,例如,Harlow和Lane,《抗体:实验室手册》,冷泉港实验室,1988,在此引用作为参考。在一个优选的实施方案中,测定包括用固定于固体载体上的多肽结合并从样品中去除抗体。然后可用一种含有报道基团的检测试剂检测结合的抗体。合适的检测试剂包括可与抗体/多肽复合物结合的抗体和用报道基团标记的游离多肽(例如在半竞争性测定中)。此外也可使用竞争性测定,其中可与多肽结合的抗体用一种报道基团标记,并使之在抗原与样品温育后能结合固定的抗原。样品成分抑制标记抗体与多肽结合的程度表明样品与固定多肽的反应性。
固体支持物可以是本领域技术人员所知的、抗原可附着的任何固体材料。例如,固体支持物可以是微量平板中的检测孔,或硝酸纤维素或其他合适的膜。此外,支持物也可以是珠或盘,如玻璃、玻璃纤维、乳胶或塑料材料如聚苯乙烯或聚氯乙烯。支持物也可以是磁粉或光纤传感器,如美国专利号5,359,681所公开的。
可用本领域技术人员所知的多种技术使多肽与固体支持物结合。在本发明说明书中,术语“结合”是指非共价结合如吸附和共价结合(可以是抗原与支持物上功能基团之间的直接连接,或者可以是利用交联剂的连接)。通过吸附于微量平板中的孔或膜的结合是优选的。在这些情况中,可通过使适当缓冲液中的多肽与固体支持物接触适当时间实现这种吸附。接触时间因温度而不同,但一般为约1小时至1天。使塑料微量平板的孔(如聚苯乙烯或聚氯乙烯)与约10ng~1μg的一定量多肽接触通常足以结合足量的抗原。
多肽与固体支持物共价结合的方法一般为,首先使支持物与可与支持物和多肽的功能基团如羟基或氨基反应的双功能试剂反应。例如,多肽可与含用苯醌包被的适当聚合物的支持物结合,或通过支持物上醛基与多肽的氨和活性氢缩合(参见,例如,Pierce免疫技术目录和手册,1991,A12-A13)。
在某些实施方案中,测定是酶联免疫吸附测定(ELISA)。该测定的进行方法可以是,首先使已固定于固体载体通常是微量平板孔上的多肽抗原接触样品,使样品中的多肽抗体能与固定的多肽结合。然后从固定的多肽上去除未结合的样品,并加入能结合固定的抗体-多肽复合物的检测试剂。然后用适于特定检测试剂的方法测定结合于固体支持物上的检测试剂的量。
更具体而言,多肽如上所述固定于支持物上后,支持物上保留的蛋白质结合位点一般被封闭。可使用本领域技术人员所知的任何合适的封闭剂,如牛血清白蛋白(BSA)或吐温20TM(Sigma Chemical Co.,St.Louis,MO)。固定的多肽然后与样品温育,使抗体与抗原结合。在温育前样品可用合适的稀释剂如磷酸缓冲液(PBS)稀释。合适的接触时间(即温育时间)一般为足以检测HGE-感染样品中抗体存在的时间。优选地,接触时间足以实现一定水平的结合,至少为结合与未结合抗体间达到的平衡的95%。本领域技术人员应认识到,通过测定一段时间后发生的结合水平可轻易地确定达到平衡所需的时间。在室温下,约30分钟的温育时间一般足够。
然后可通过用适当缓冲液如含0.1%吐温20TM的PBS洗涤固体支持物,去除未结合的样品。然后可向固体支持物上加入检测试剂。合适的检测试剂是可与固定的抗体-多肽复合物结合,并能用本领域所知的多种方法检测的任何化合物。优选地,检测试剂含有与报道基团偶联的结合剂(如蛋白A、蛋白G、免疫球蛋白、凝集素或游离抗原)。优选的报道基团包括酶(如辣根过氧化物酶)、底物、辅因子、抑制剂、染料、放射性核素、发光基团、荧光基团和生物素。结合剂与报道基团的偶联可用本领域技术人员周知的标准方法实现。也可从许多商业来源(例如ZymedLaboratories,San Francisco,CA和Pierce,Rockford,IL)购买与多种报道基团偶联的常见结合剂。
然后将检测试剂与固定的抗体-多肽复合物温育足以检测到结合抗体的一段时间。适当的时间长度一般可根据使用说明书确定,或通过测定一段时间后发生的结合水平确定。然后去除未结合的检测试剂,并用报道基团检测结合的检测试剂。用于检测报道基团的方法取决于报道基团的性质。对于放射性基团,闪烁计数或放射自显影法一般是合适的。分光法可用来检测染料、发光基团和荧光基团。生物素可用与不同报道基团(通常是放射性或荧光基团或酶)偶联的亲和素检测。酶报道基团一般可通过加入底物(一般经过特定的一段时间),随后通过反应产物的分光或其他分析来检测。
为了测定样品中抗衣原体抗体的存在与否,一般将仍与固体支持物结合的报道基团的检测信号与相应于预定的阈值的信号相比较。在一个优选实施方案中,阈值是固定抗原与采自未感染患者的样品温育后获得的平均信号。通常,产生比预定阈值高三个标准差的信号的样品被认为是衣原体感染阳性。在另一个优选实施方案中,根据Sackett等人,《临床流行病学:临床医学基础科学》,Little Brown and Co.,1985,106-107的方法,用接收操纵(Receiver Dperator)曲线测定阈值。简言之,在该实施方案中,可从对应于每一可能阈值的真阳性率(即敏感度)和假阳性率(100%特异性)对与诊断检测结果的坐标图上测定阈值。图上最接近上部左角的阈值(即,包围最大区域的值)是最精确的阈值,产生的信号高于用该方法所测得的阈值的样品被认为是阳性。此外,阈值可沿曲线转移到左侧,使假阳性率最低,或移到右侧,使假阴性率最低。产生的信号高于用该方法所测得的阈值的样品通常被认为是衣原体感染阳性。
在一个相关实施方案中,以快速流通或条形试验形式进行测定,其中抗原固定于膜上如硝酸纤维素。在流通检测中,当样品通过膜时,样品中的抗体与固定的多肽结合。然后当含检测试剂的溶液流经膜时,检测试剂(例如,蛋白A-胶态金)与抗体-多肽复合物结合。然后可如上所述进行结合的检测试剂的检测。在条形试验中,膜的多肽结合的一端浸于含样品的溶液中。样品沿膜通过含检测试剂的区域迁移到固定多肽区。多肽处检测试剂的浓度表明样品中抗衣原体抗体的存在。一般而言,该部分的检测试剂浓度产生一种模式,如可见的一条线。没有这种模式表明为阴性结果。一般选择固定于膜上的多肽量,使得当生物样品含有足以在ELISA中产生阳性信号的一定水平的抗体时,如上所述,能产生可目视辨别的模式。优选地,固定于膜上的多肽量为约25ng~1μg,更优选地为约50ng~500ng。这些试验一般能用极少量(如一滴)的患者血清或血液进行。
当然,有大量其他的测定方法适用于本发明的多肽。以上的叙述只是旨在举例。可在这些方法中使用的其他测定法的一个例子是Western印迹,其中在接触结合剂之前凝胶分离生物样品中的蛋白质。这些技术为本领域技术人员所周知。
本发明进一步提供试剂如可特异结合衣原体蛋白的抗体及其抗原结合片段。在此使用时,如果抗体或其抗原结合片段与衣原体蛋白以可检测的水平反应(例如ELISA),而在类似条件下不与无关蛋白可检测地反应,则认为其可“特异结合”衣原体蛋白。在此使用时,“结合”是指两种不同分子非共价结合形成复合体。例如通过测定复合体形成的结合常数能估计结合能力。结合常数是复合物浓度除以成分浓度之积所得的值。一般而言,在本发明说明书中,当复合物形成的结合常数超过约103L/mol时,称这两种化合物“结合”。结合常数可用本领域周知的方法测定。
还能用此处提供的代表性测定法用结合剂区分患或未患衣原体感染的患者。换言之,能结合衣原体蛋白的抗体或其他结合剂在至少约20%疾病患者中将产生表明存在衣原体感染的信号,在至少约90%的未感染个体中产生表明无病的阴性信号。为了确定一种结合剂是否满足这一要求,可如此处所述测定患或无衣原体感染的患者(用标准临床试验确定)的生物样品(例如血液、血清、痰、尿和/或组织活检)中是否存在能与该结合剂结合的多肽。显然应当测定统计学显著数量的有或无疾病的样品。每种结合剂都应满足以上标准;然而,本领域技术人员应当认识到,可组合使用结合剂以提高敏感度。
满足以上需要的任何试剂都可以是结合剂。例如,结合剂可以是有或无肽成分的核糖体,RNA分子或多肽。在一个优选的实施方案中,结合剂是一种抗体或其抗原结合片段。抗体可用本领域技术人员所知的多种技术制备。参见,例如,Harlow和Lane,《抗体:实验室手册》,冷泉港实验室,1988。通常可用细胞培养技术产生抗体,包括此处所述的单克隆抗体的产生,或通过抗体基因转染合适的细菌和哺乳动物细胞宿主,以产生重组抗体。在一种技术中,开始将含多肽的免疫原注射到多种哺乳动物(例如小鼠、大鼠、兔、绵羊或山羊)的任一种中。该步骤中,本发明的多肽可用作未加修饰的免疫原。此外,特别是对于相对较短的多肽,如果多肽与载体蛋白如牛血清白蛋白或匙孔戚血蓝蛋白连接,则可引发较强的免疫应答。将免疫原注射到动物宿主中,优选地根据包括一次或多次加强免疫的预定方案,定期对动物采血。然后通过如使用与适当固体载体偶联的多肽的亲和层析法,从这些抗血清中纯化对于多肽特异的多克隆抗体。
对于目的抗原性多肽特异的单克隆抗体可用如Kohler和Milstein,欧洲免疫学杂志6:511-519,1976的技术及其改进技术制备。简言之,这些方法包括制备能产生具有希望特异性(即与目的多肽的反应性)的抗体的无限增殖细胞系。可如上所述从获自免疫的动物的脾细胞中产生这些细胞系。然后例如通过融合优选地与免疫动物同源的骨髓瘤细胞融合配偶体,使脾细胞无限增殖化。可使用多种融合技术。例如,脾细胞和骨髓瘤细胞可与非离子去污剂结合几分钟,然后以低密度接种于支持杂种细胞生长但不支持骨髓瘤细胞生长的选择性培养基中。一种优选的筛选技术使用HAT(次黄嘌呤、氨喋呤、胸苷)筛选。经足够的时间后,通常1至2周,观察到杂种集落。选择单集落,检测其培养上清液对多肽的结合活性。优选具有高反应性和特异性的杂交瘤。
可从生长杂交瘤集落的上清液中分离单克隆抗体。另外,可用多种技术提高产量,如向合适的脊椎动物宿主如小鼠的腹膜腔中注射杂交瘤细胞系。然后可从腹水或血液中收集单克隆抗体。可通过常规技术如层析法、凝胶过滤、沉淀和抽提法从抗体中除去污染物。本发明的多肽可在纯化方法如亲和层析步骤中使用。
在某些实施方案中,可优选使用抗体的抗原结合片段。这些片段包括可用标准技术制备的Fab片段。简言之,可通过蛋白A珠柱亲和层析从兔血清中纯化免疫球蛋白(Harlow和Lane,《抗体:实验室手册》,冷泉港实验室,1988),并用木瓜蛋白酶消化产生Fab和Fc片段。Fab和Fc片段可通过蛋白A珠柱亲和层析分离。
本发明的单克隆抗体可与一种或多种治疗剂偶联。就此而言,合适的治疗剂包括放射性核素、分化诱导剂、药物、毒素及其衍生物。优选的放射性核素包括90Y、123I、125I、131I、186Re、188Re、211At和212Bi。优选的药物包括氨甲蝶呤和嘧啶和嘌呤类似物。优选的分化诱导剂包括佛波醇酯和丁酸。优选的毒素包括篦麻毒素、相思豆毒素、白喉毒素、霍乱毒素、gelonin、假单胞菌内毒素、志贺氏毒素和美洲商陆抗病毒蛋白。
治疗剂可与合适的单克隆抗体直接或间接(例如通过接头)偶联。当治疗剂与抗体均具有能彼此反应的取代基时,它们之间的直接反应是可能的。例如,其中一种的亲核基团如氨基或巯基能与另一种的含羰基团如酐或酰基卤反应,或与其他的含离去基团(如卤化物)的烷基反应。
此外,希望通过接头偶联治疗剂与抗体。接头能作为使抗体远离治疗剂的间隔区,以避免结合力干扰。接头也能用来提高治疗剂或抗体上取代基的化学反应性,从而提高偶联效率。化学反应性的提高也可利于治疗剂的使用,或否则不可能的治疗剂官能团的使用。
本领域技术人员应当明白,多种相同及不同功能的双功能或多功能试剂(如Pirece Chemical Co.,Rockford,IL目录所述)可用作接头。例如,通过氨基、羧基、巯基或氧化的糖残基可实现偶联。有大量参考文献描述了这些方法,如授予Rodwell等人的美国专利号4,671,958。
当不含本发明的免疫偶联物的抗体部分时治疗剂更有效的情况下,希望使用在向细胞内化期间或之后能切割的接头。已描述了大量可切割的不同接头。治疗剂从这些接头上胞内释放的机制包括,通过二硫键还原(例如,授予Spitler的美国专利号4,489,710)、通过光不稳定键照射(例如,授予Senter等人的美国专利号4,625,014)、通过衍生氨基侧链的水解(例如,授予Kohn等人的美国专利号4,638,045)、通过血清补体介导的水解(例如,授予Rodwell等人的美国专利号4,671,958)和酸催化的水解(参见,授予Blattler等人的美国专利号4,569,789)切割。
希望将一种以上的试剂与一种抗体偶联。在一个实施方案中,一种试剂的多个分子与一种抗体分子偶联。在另一个实施方案中,一种以上的试剂可与一种抗体偶联。无论特定实施方案如何,可用多种方法制备含一种以上试剂的免疫偶联物。例如,一种以上的试剂可直接与一种抗体分子偶联,或能使用提供多个连接位点的接头。此外也能使用载体。
载体可以以多种方式携带试剂,包括直接或通过接头共价键合。合适的载体包括蛋白质如白蛋白(例如,授予Kato等人的美国专利号4,507,234)、肽和多糖如氨基葡聚糖(例如,授予Shih等人的美国专利号4,699,784)。载体也可通过非共价结合或通过包裹于如脂质体囊中而携带试剂(例如,美国专利号4,429,008和4,873,088)。对于放射性核素试剂特异的载体包括放射性卤化小分子和螯合剂。例如,美国专利号4,735,792公开了典型的放射性卤化小分子及其合成。放射性核素螯合物可由螯合剂形成,包括含有氮及硫原子作为供电子原子用于结合金属或金属氧化物、放射性核素的螯合剂。例如,授予Davison等人的美国专利号4,673,562公开了典型的螯合剂及其合成。
抗体和免疫偶联物可使用多种施用途径。施用一般是静脉内、肌内、皮下的,或用适当方法在部分特异的区域。显然抗体/免疫偶联物的精确剂量将随所用的抗体、抗原密度和抗体清除率而不同。
在诊断检测中可使用抗体,用类似于以上详述的测定法或本领域技术人员周知的其他技术检测衣原体抗原的存在,从而提供一种检测患者衣原体感染的方法。
本发明的诊断试剂也可含有编码一种或多种上述多肽的DNA序列或其一种或多种部分。例如,在基于聚合酶链反应(PCR)的测定中至少使用两条寡核苷酸引物扩增生物样品中衣原体特异的cDNA,其中至少一条寡核苷酸引物对于编码本发明的多肽的DNA分子是特异的。然后用本领域周知的技术如凝胶电泳检测扩增的cDNA的存在。类似地,在杂交测定中可使用对于编码本发明的多肽的DNA分子特异的寡核苷酸探针,检测生物样品中本发明的多肽的存在。
在此使用时,术语“对于DNA分子特异的寡核苷酸引物/控针”是指与所述DNA分子有至少约80%、优选地至少约90%、更优选地至少约95%的同一性的寡核苷酸序列。本发明的诊断方法中可用的寡核苷酸引物和/或探针优选地含有至少约10-40个核苷酸。在一个优选实施方案中,寡核苷酸引物含有编码此处公开的多肽之一的DNA分子的至少约10个连续核苷酸。优选地,在本发明的诊断方法中使用的寡核苷酸探针含有编码此处公开的多肽之一的DNA分子的至少约15个连续寡核苷酸。基于PCR的测定和杂交测定技术在本领域周知(参见,例 Mullis等人,同上;Ehrlich,同上)。于是可用引物或探针检测生物样品中衣原体特异的序列。含有上述寡核苷酸序列的DNA探针或引物可单独或互相组合使用。
下列实施例是为了说明而提供,绝非意在限制。
实施例1
编码衣原体抗原的DNA序列的分离
本发明的衣原体抗原基本如Sanderson等人(实验医学杂志(J.Exp.Med.)1995,182:1751-1757)所述通过沙眼衣原体LGV II基因组DNA文库的表达克隆来分离,并显示诱导PBMC增殖和免疫反应性T细胞系中的IFN-γ。
通过用沙眼衣原体LGV II的原生小体刺激无衣原体生殖道感染史的正常供体的PBMC,产生衣原体特异的T细胞系。发现该T细胞系,称为TCL-8,能识别沙眼衣原体和肺炎衣原体感染的单核细胞衍生的树突细胞。
在λZAP(Stratagene,La Jolla,CA)中构建随机剪切的沙眼衣原体LGV II基因组文库,将扩增的文库加以30个克隆/孔的密度涂板于96孔微量滴定板中。在2mM IPTG存在下诱导细胞3小时使之表达重组蛋白,然后沉淀并重悬浮于200μl RPMI 10%FBS中。将10μl诱导的细胞悬液转移到含有自体单核细胞衍生的树突细胞的96孔板中。温育2小时后,洗涤树突细胞除去游离的大肠杆菌,并加入衣原体特异的T细胞。通过测定由集合体引起的IFN-γ产生和T细胞增殖鉴定阳性大肠杆菌集合体。
鉴定出4个阳性集合体,它们分解产生4种纯克隆(被称为1-B1-66、4-D7-28、3-G3-10和10-C10-31),插入片段大小分别为481bp、183bp、110bp和1400bp。SEQ ID NO:1-4分别列出了1-B1-66、4-D7-28、3-G3-10和10-C10-31的确定的DNA序列。克隆1-B1-66大致位于沙眼衣原体基因组的536690区中(NCBI沙眼衣原体数据库)。克隆1-B1-66中,鉴定了一个编码以前鉴定的9kDa蛋白质(Stephens等人,Genbank保藏号AE001320)的开放阅读框(ORF)(核苷酸115-375),其序列由SEQ IDNO:5列出。克隆4-D7-28是同一ORF的较小区(1-B1-66的氨基酸22-82)。克隆3-G3-10大致位于沙眼衣原体基因组的74559区中。插入片段以相对于基因组方向的反义方向克隆。克隆10-C10-31含有一个对应于以前公布的沙眼衣原体S13核糖体蛋白序列的开放阅读框(Gu,L.等人,细菌学杂志177:2594-2601,1995)。SEQ ID NO:6和12分别列出了4-D7-28和10-C10-31的预测的蛋白质序列。SEQ ID NO:7-11列出了3-G3-10的预测的蛋白质序列。
在相关的一系列筛查研究中,用另一种T细胞系筛查上述沙眼衣原体LGV II的基因组DNA文库。一种衣原体特异的T细胞系(TCT-1)来源于一名患衣原体生殖道感染的患者,方法是用沙眼衣原体LGV II原生小体感染的自体单核细胞衍生的树突细胞刺激患者的PBMC。一个克隆,4C9-18(SEQ ID NO:21),含有1256bp插入片段,经标准增殖测定法测定,可引发由衣原体特异的T细胞系TCT-1引起的特异性免疫应答。随后的分析揭示该克隆含有3种已知序列:硫辛酰胺脱氢酶(Genbank保藏号AE001326),在SEQ ID NO:22中公开;假拟蛋白CT429(Genbank保藏号AE001316),在SEQ ID NO:23中公开;泛醌甲基转移酶CT428的开放阅读框的部分(Genbank保藏号AE001316),在SEQ ID NO:24中公开。
在关于克隆4C9-18(SEQ ID NO:21)的其他研究中,在如SEQ IDNO:90所公开的克隆CtL2-LPDA-FL中表达沙眼衣原体(LGV II)的硫辛酰胺脱氢酶的全长氨基酸序列(SEQ ID NO:22)。
为了进一步表征含有T细胞刺激表位的开放阅读框,含克隆4C9-18的核苷酸1-695与编码氨基端6X-组氨酸标记的cDNA序列的cDNA片段亚克隆到pET17b载体(Novagen,Madison,WI)的NdeI/EcoRI位点,称为克隆4C9-18#2 BL21 pLysS(SEQ ID NO:25,相应的氨基酸序列列于SEQ ID NO:26中),并转化大肠杆菌。用2mM IPTG选择性诱导转化的大肠杆菌3小时导致从克隆4C9-18#2 BL21 pLysS中表达26kDa蛋白质,这通过标准考马斯染色的SDS-PAGE得到证实。为了测定克隆4C9-18#2 BL21 pLysS编码的蛋白质的免疫原性,向1×104单核细胞衍生的树突细胞上滴定表达26kDa蛋白质的大肠杆菌,温育2小时。洗涤树突细胞培养物,加入2.5×104个T细胞(TCT-1),再温育72小时,然后通过ELISA测定培养上清液中IFN-γ的水平。如图1所示,通过IFN-γ测定,发现T细胞系TCT-1可对诱导的培养物起反应,表明了对硫辛酰胺脱氢酶序列的衣原体特异的T细胞应答。类似地,标准增殖测定显示克隆4C9-18#2 BL21pLysS编码的蛋白质能刺激TCT-1 T细胞系。
随后用上述CD4+T细胞表达克隆技术鉴定其他沙眼衣原体抗原的研究产生了另外一些克隆。用TCT-1和TCL-8衣原体特异的T细胞系及TCP-21 T细胞系筛查沙眼衣原体LGV II基因组文库。TCP-21 T细胞系来源于一名对肺炎衣原体有体液免疫应答的患者。TCT-1细胞系鉴定出37个阳性集合体,TCT-3细胞系鉴定出41个阳性集合体,TCP-21细胞系鉴定出2个阳性集合体。下列克隆来源于这些阳性集合体中的10个。用TCP-21细胞系鉴定的克隆11-A3-93(SEQ ID NO:64)是与HAD超家族(CT103)有同源性的1339bp基因组片段。同一克隆中的第二个插入片段与互补链上存在的fab I基因(CT104)有同源性。用TCP-21细胞系鉴定的克隆11-C12-91(SEQ ID NO:63)含有为OMP2基因(CT443)部分的269bp插入片段,与肺炎衣原体的富含半胱氨酸的60kDa外膜蛋白有同源性。
用TCT-3细胞系鉴定的克隆11-G10-46(SEQ ID NO:62)含有与假拟蛋白CT610有同源性的688bp插入片段。用TCT-3细胞系鉴定的克隆11-G1-34(SEQ ID NO:61)具有两个含1215bp大小插入片段的部分开放阅读框(ORF)。一个ORF与苹果酸脱氢酶基因(CT376)有同源性,另一个ORF与糖原水解酶基因(CT042)有同源性。用TCT-3细胞系鉴定的克隆11-H3-68(SEQ ID NO:60)含有两个总插入大小为1180bp的ORF。一个部分ORF编码质粒编码的PGP6-D毒性蛋白,而第二个ORF是L1核糖体基因(CT318)的完整ORF。用TCT-3细胞系鉴定的克隆11-H4-28(SEQ ID NO:59)含有一个大小为552bp的插入片段,是dnaK基因(CT396)的ORF的部分。用TCT-1细胞系鉴定的克隆12-B3-95(SEQ ID NO:58)含有大小为463bp的插入片段,是硫辛酰胺脱氢酶基因(CT557)的ORF的一部分。用TCT-1细胞系鉴定的克隆15-G1-89和12-B3-95相同(分别为SEQ ID NO:55和58),含有一个大小为463bp的插入片段,是硫辛酰胺脱氢酶基因(CT557)的ORF的一部分。用TCT-1细胞系鉴定的克隆12-G3-83(SEQ ID NO:57)含有大小为1537bp的插入片段,含有假拟蛋白CT622的ORF的一部分。
用TCT-3细胞系鉴定的克隆23-G7-68(SEQ ID NO:79)含有950bp的插入片段,并含有一小部分L11核糖体ORF,L1核糖体蛋白的完整ORF和L10核糖体蛋白的一部分ORF。用TCT-1细胞系鉴定的克隆22-F8-91(SEQ ID NO:80)含有395bp的插入片段,该插入片段在克隆的互补链上含有pmp C ORF的一部分。用TCT-3细胞系鉴定的克隆21-E8-95(SEQ ID NO:81)含有2085bp的插入片段,该插入片段含有CT613ORF的一部分、CT612的完整ORF、CT611的完整ORF和CT610的部分ORF。用TCT-3细胞系鉴定的克隆19-F12-57(SEQ ID NO:82)含有405bp的插入片段,该插入片段含有部分CT858 ORF和一小部分recA ORF。用TCT-3细胞系鉴定的克隆19-F12-53(SEQ ID NO:83)含有379bp的插入片段,该插入片段是编码谷氨酰tRNA合成酶的CT455的ORF的一部分。用TCT-3细胞系鉴定的克隆19-A5-54(SEQ ID NO:84)含有715bp的插入片段,该插入片段是隐蔽性质粒的ORF3的一部分(该克隆的互补链)。用TCT-1细胞系鉴定的克隆17-E11-72(SEQ ID NO:85)含有476bp的插入片段,该插入片段是Opp_2和pmpD的ORF的一部分。该克隆的pmpD区被克隆15-H2-76的pmpD区所覆盖。用TCT-3细胞系鉴定的克隆17-C1-77(SEQ ID NO:86)含有一个1551bp的插入片段,该插入片段是CT857的ORF的一部分,以及CT858的ORF的一部分。用TCT-1细胞系鉴定的克隆15-H2-76(SEQ ID NO:87)含有3031bp的插入片段,该插入片段含有大部分pmpD ORF、部分CT089ORF,以及部分SycE ORF。克隆15-A3-26(SEQ ID NO:88)含有976bp插入片段,该插入片段含有CT858 ORF的一部分。用TCT-10细胞系鉴定的克隆17-G4-36(SEQ ID NO:267)含有680bp的插入片段,该插入片段在该质粒中与beta-gal处于读框内,并与DNA引导的RNA聚合酶beta亚基的部分ORF(SerD中的CT315)同源。
上述几个克隆与多种多形膜蛋白有同源性。沙眼衣原体的基因组序列含有9个多形膜蛋白基因的家族,称作pmp。这些基因被命名为pmpA、pmpB、pmpC、pmpD、pmpE、pmpF、pmpG、pmpH和pmpI。由这些基因表达的蛋白质被认为与产生对衣原体感染的保护性免疫应答有生物学相关性。特别是,pmpC、pmpD、pmpE和pmpI含有可预测的信号肽,提示它们是外膜蛋白,因此是潜在的免疫学靶标。
根据沙眼衣原体LGV II血清变型序列,设计引物对以PCR扩增pmpC、pmpD、pmpE、pmpG、pmpH和pmpI的全长片段。将得到的片段亚克隆到DNA疫苗载体JA4304或JAL中,JAL是含有一个修饰的接头的JA4304(SmithKline Beecham,伦敦,英格兰)。具体地,用分别如SEQ ID NO:197和198所示的5’oligo GAT AGG CGC GCC GCAATC ATG AAA TTT ATG TCA GCT ACT GCT G和3’oligo CAG AACGCG TTT AGA ATG TCA TAC GAG CAC CGC A将pmpC亚克隆到JAL载体中。在将短核苷酸序列GCAATC(SEQ ID NO:199)插入ATG下游后,在本领域众所周知的条件下PCR扩增该基因,并连接到JAL载体的5’ASCI/3’MluI位点,产生Kozak样序列。得到的表达载体含有全长pmpC基因,该基因包含具有假定信号序列的5325个氨基酸(SEQID NO:173),编码187kD蛋白质(SEQ ID NO:179)。用下列oligo PCR扩增该基因后,将pmpD基因亚克隆到JA4304疫苗载体中:5’oligo-TGCAAT CAT GAG TTC GCA GAA AGA TAT AAA AAG C(SEQ IDNO:200)和3’oligo-CAG AGC TAG CTT AAA AGA TCA ATC GCAATC CAG TAT TC(SEQ ID NO:201)。用本领域众所周知的标准技术将该基因连接到JA4304疫苗载体的5’平端HIII/3’MluI位点。将CAATC(SEQ ID NO:202)插入ATG上游,产生Kozak样序列。该克隆是唯一的,因为由于平端化过程,HinDIII位点的最后一个苏氨酸丢失,Kozak样序列的最后一个甘氨酸同样如此。插入的4593核苷酸片段(SEQ IDNO:172),是含有假定信号序列的pmpD的全长基因,其编码161kD蛋白质(SEQ ID NO:178)。用5’oligo-TGC AAT CAT GAA AAA AGCGTT TTT CTT TTT C(SEQ ID NO:203)和3’oligo-CAG AAC GCGTCT AGA ATC GCA GAG CAA TTT C(SEQ ID NO:204)将pmpE亚克隆到JA4304载体中。PCR扩增后,将该基因连接于JA4304的5’平端HIII/3’MluI位点。为便于此,向起始密码子上游添加一个短核苷酸序列--TGCAATC(SEQ ID NO:293),产生Kozak样序列,并重建HindIII位点。该插入片段是全长的pmpE基因(SEQ ID NO:171),含有假定的信号序列。pmpE基因编码105kD蛋白质(SEQ ID NO:177)。用5’oligo-GTG CAA TCA TGA TTC CTC AAG GAA TTT ACG(SEQID NO:205)和3’oligo-CAG AAC GCG TTT AGA ACC GGA CTT TACTTC C(SEQ ID NO:206)PCR扩增pmpG基因,并将其亚克隆到JA4304载体中。对pmpI和pmpK基因进行类似的克隆策略。另外,设计引物对以PCR扩增全长的或重叠的pmp基因片段,然后为蛋白质表达亚克隆到pET17b载体(Novagen,Madison,WI)中,并转染大肠杆菌BL21pLysS进行表达,随后用Novagen提供的组氨酸-镍层析法纯化。如下所述,编码重组蛋白质的几种基因缺乏天然信号序列而利于蛋白质表达。通过表达代表氨基端和羧基端的两个重叠片段完成pmpC的全长蛋白质表达。缺乏信号序列的pmpC氨基端部分(SEQ ID NO:187,其相应的氨基酸序列如SEQ ID NO:195所示)向载体5’NdeI/3’KPN克隆位点的亚克隆使用5’oligo-CAG ACATAT GCA TCA CCA TCA CCA TCACGA GGC GAG CTC GAT CCA AGA TC(SEQ ID NO:207)和3’oligo-CAG AGG TAC CTC AGA TAG CAC TCT CTC CTA TTA AAGTAG G(SEQ ID NO:208)。将该基因的羧基端部分--pmpC羧基端片段(SEQ ID NO:186,其相应的氨基酸序列如SEQ ID NO:194所示)亚克隆到该表达载体的5’NheI/3’KPN克隆位点,其中使用下列引物:5’oligo-CAG AGC TAG CAT GCA TCA CCA TCA CCA TCA CGT TAAGAT TGA GAA CTT CTC TGG C(SEQ ID NO:209)和3’oligo-CAGAGG TAC CTT AGA ATG TCA TAC GAG CAC CGC AG(SEQ IDNO:210)。PmpD也表达为两种重叠蛋白质。缺乏信号序列的pmpD氨基端部分(SEQ ID NO:185,其相应的氨基酸序列如SEQ ID NO:193所示)含有pET17b的起始密码子,表达为一种80kD的蛋白质。为了蛋白质表达和纯化,起始密码子后有一个六组氨酸标记,并在该基因的第28个氨基酸(核苷酸84)处融合。使用下列引物:5’oligo-CAG ACA TATGCA TCA CCA TCA CCA TCA CGG GTT AGC(SEQ ID NO:211)和3’oligo-CAG AGG TAC CTC AGC TCC TCC AGC ACA CTC TCT TC(SEQ ID NO:212),剪接到该载体的5’NdeI/3’KPN克隆位点。PmpD羧基端部分(SEQ ID NO:184)表达为一种92kD蛋白质(SEQ IDNO:192)。为了表达及随后的纯化,含有另外的甲硫氨酸、丙氨酸和丝氨酸,其代表pET17b的起始密码子和前两个氨基酸。甲硫氨酸、丙氨酸和丝氨酸下游的六组氨酸标记在基因的第691个氨基酸(核苷酸2073)处融合。使用5’oligo-CAG AGC TAG CCA TCA CCA TCA CCA TCACGG TGC TAT TTC TTG CTT ACG TGG(SEQ ID NO:213)和3’oligo-CAG AGG TAC TTn AAA AGA TCA ATC GCA ATC CAG TATTCG(SEQ ID NO:214),将插入片段亚克隆到表达载体的5’NheI/3’KPN克隆位点。PmpE表达为一种106kD蛋白质(SEQ ID NO:183,其相应的氨基酸序列如SEQ ID NO:191所示)。PmpE插入片段也缺乏天然信号序列。PCR扩增在本领域周知的条件下进行,使用下列oligo引物:5’oligo-CAG AGG ATC CAC ATC ACC ATC ACC ATC ACG GAC TAGCTA GAG AGG TTC(SEQ ID NO:215)和3’oligo-CAG AGA ATT CCTAGA ATC GCA GAG CAA TTT C(SEQ ID NO:216),将扩增的插入片段连接到JA4304的5’BamHI/3’EcoRI位点。如SEQ ID NO:217所示的短核苷酸序列插入起始密码子上游,产生Kozak样序列并重建HindIII位点。表达的蛋白质含有pET17b表达载体的起始密码子和下游21个氨基酸,即MASMTGGQQMGRDSSLVPSSDP(SEQ ID NO:218)。另外,如上所述的序列上游含有一个六组氨酸标记,在基因的第28个氨基酸(核苷酸84)处融合,去掉了假定的信号肽。SEQ ID NO:183所示的序列不包含这些另外的序列,其相应的氨基酸序列如SEQ ID NO:191所示。pmpG基因(SEQ ID NO:182,其相应的氨基酸序列如SEQ IDNO:190所示)在本领域周知的条件下PCR扩增,使用下列oligo引物:5’oligo-CAG AGG TAC CGC ATC ACC ATC ACC ATC ACA TGATTC CTC AAG GAA TTT ACG(SEQ ID NO:219)和3’oligo-CAGAGC GGC CGC TTA GAA CCG GAC TTT ACT TCC(SEQ IDNO:220),连接到表达载体的5’KPN/3’NotI克隆位点。表达的蛋白质在氨基端含有另外的氨基酸序列,即,MASMTGGQQNGRDSSLVPHHHHHH(SEQ ID NO:221),其含有pET17b表达载体的起始密码子和其他序列。pmpI基因(SEQ IDNO:181,其相应的氨基酸序列如SEQ ID NO:189所示)在本领域周知的条件下PCR扩增,使用下列oligo引物:5’oligo-CAG AGC TAG CCATCA CCA TCA CCA TCA CCT CTT TGG CCA GGA TCC C(SEQ IDNO:222)和3’oligo-CAG AAC TAG TCT AGA ACC TGT AAG TGGTCC(SEQ ID NO:223),连接到表达载体的5’NheI/3’SpeI克隆位点。表达的95kD蛋白质在该蛋白质的氨基端含有pET17b载体的起始密码子和另一个丙氨酸和丝氨酸。另外,在该基因的第21个氨基酸处融合有一个六组氨酸标记,这除去了假定的信号肽。
用TCT-3细胞系鉴定的克隆14H1-4(SEQ ID NO:56)含有TSA基因的完整ORF,硫醇特异的抗氧化剂-CT603(CT603 ORF是肺炎衣原体CPn0778的同系物)。扩增克隆14-H1-4中的TSA开放阅读框,使表达的蛋白质含有另一个甲硫氨酸和一个6×组氨酸标记(氨基端)。将扩增的插入片段亚克隆到pET17b载体的Nde/EcoRI位点。用IPTG诱导该克隆后,通过Ni-NTA琼脂糖亲和层析纯化22.6kDa蛋白质。SEQ IDNO:65中列出了编码TSA基因的克隆14-H1-4的195氨基酸ORF的确定的氨基酸序列。进一步的分析产生了TSA基因的全长克隆,称为CTL2-TSA-FL,其全长氨基酸序列如SEQ ID NO:92所示。
进一步的研究得到了如上所述用TCT-1和TCT-3T细胞系鉴定的另外10个克隆。用TCT-1系鉴定的这些克隆是:16-D4-22、17-C5-19、18-C5-2、20-G3-45和21-C7-66;用TCT-3细胞系鉴定的克隆是:17-C10-31、17-E2-9、22-A1-49和22-B3-53。克隆21-G12-60用TCT-1和TCT-3细胞系均能识别。用TCT-1细胞系鉴定的克隆16-D4-22(SEQ IDNO:119)含有953bp插入片段,该插入片段含有两个基因--在哺乳动物细胞中生长的沙眼衣原体质粒的开放阅读框3(ORF3)和ORF4的部分。克隆17-C5-19(SEQ ID NO:118)含有951bp插入片段,该插入片段含有编码clpP_1蛋白酶的DT431 ORF的部分,和CT430(二氨基庚酸差向异构酶)一部分ORF。克隆18-C5-2(SEQ ID NO:117)是含有446bp插入片段的S1核糖体蛋白ORF的一部分,可用TCT-1细胞系鉴定。用TCT-1细胞系鉴定的克隆20-G3-45(SEQ ID NO:116)含有是pmpB基因(CT413)一部分的437bp插入片段。用TCT-1细胞系鉴定的克隆21-C7-66(SEQ ID NO:115)含有编码dnaK样蛋白质一部分的995bp插入片段。该克隆的插入片段不与TCT-3克隆11-H4-28(SEQ ID NO:59)的插入片段重叠,它是dnaK基因CT396的一部分。用TCT-3细胞系鉴定的克隆17-C10-31(SEQ ID NO:114)含有976bp插入片段。该克隆含有CT858-含有IRBP和DHR域的蛋白酶-ORF的一部分。克隆17-E2-9(SEQ ID NO:113)含有两种基因的部分ORF:CT611和CT610,它们跨越1142bp插入片段。用TCT-3系鉴定的克隆22-A1-49(SEQ IDNO:112)在698 bp插入片段中也含有两个基因。CT660(DNA促旋酶{gyrA_2})的部分ORF位于顶链上,而假拟蛋白CT659的完整ORF位于互补链上。用TCT-1系鉴定的克隆22-B3-53(SEQ ID NO:111)含有编码GroEL(CT110)部分ORF的267bp插入片段。用TCT-1和TCT-3细胞系鉴定的克隆21-G12-60(SEQ ID NO:110)含有1461bp插入片段,该插入片段含有假拟蛋白CT875、CT229和CT228的部分ORF。
其他衣原体抗原的获得方法是,用本领域众所周知的技术,用来自几名衣原体感染个体的混合血清筛查Lambda Screen-1载体(Novagen,Madison,WI)中沙眼衣原体(LGV II血清变型)的基因组表达文库。鉴定下列免疫反应性克隆,测序含有衣原体基因的插入片段:CTL2#1(SEQ ID NO:71);CTL2#2(SEQ ID NO:70);CTL2#3-5’(SEQ IDNO:72,代表5’端的第一种确定的基因组序列);CTL2#3-3’(SEQ IDNO:73,代表3’端的第二种确定的基因组序列);CTL2#4(SEQ IDNO:53);CTL2#5(SEQ ID NO:69);CTL2#6(SEQ ID NO:68);CTL2#7(SEQ ID NO:67);CTL2#8b(SEQ ID NO:54);CTL2#9(SEQ IDNO:66);CTL2#10-5’(SEQ ID NO:74,代表5’端的第一种确定的基因组序列);CTL2#10-3’(SEQ ID NO:75,代表3’端的第二种确定的基因组序列);CTL2#11-5’(SEQ ID NO:45,代表5’端的第一种确定的基因组序列);CTL2#11-3’(SEQ ID NO:44,代表3’端的第二种确定的基因组序列);CTL2#12(SEQ ID NO:46);CTL2#16-5’(SEQ ID NO:47);CTL2#18-5’(SEQ ID NO:49,代表5’端的第一种确定的基因组序列);CTL2#18-3’(SEQ ID NO:48,代表3’端的第二种确定的基因组序列);CTL2#19-5’(SEQ ID NO:76,代表5’端的确定的基因组序列);CTL2#21(SEQ ID NO:50);CTL2#23(SEQ ID NO:51);和CTL2#24(SEQ IDNO:52)。
其他沙眼衣原体抗原用血清学表达克隆鉴定。这些研究使用如上所述来自几名衣原体感染个体的混合血清,但除用IgG作为第二抗体外还使用IgA和IgM抗体。用该方法筛查的克隆增强了根据对衣原体感染的早期免疫应答(即粘膜体液免疫应答)识别的抗原的检测。表征了下列免疫反应性克隆,并测序含有衣原体基因的插入片段:CTL2gam-1(SEQID NO:290)、CTL2gam-2(SEQ ID NO:289)、CTL2gam-5(SEQ IDNO:288)、CTL2gam-6-3’(SEQ ID NO:287,代表3’端的第二种确定的基因组序列)、CTL2gam-6-5’(SEQ ID NO:286,代表5’端的第一种确定的基因组序列)、CTL2gam-8(SEQ ID NO:285)、CTL2gam-10(SEQID NO:284)、CTL2gam-13(SEQ ID NO:283)、CTL2gam-15-3’(SEQ IDNO:282,代表3’端的第二种确定的基因组序列)、CTL2gam-15-5’(SEQID NO:281,代表5’端的第一种确定的基因组序列)、CTL2gam-17(SEQID NO:280)、CTL2gam-18(SEQ ID NO:279)、CTL2gam-21(SEQ IDNO:278)、CTL2gam-23(SEQ ID NO:277)、CTL2gam-24(SEQ IDNO:276)、CTL2gam-26(SEQ ID NO:275)、CTL2gam-27(SEQ IDNO:274)、CTL2gam-28(SEQ ID NO:273)、CTL2gam-30-3’(SEQ IDNO:272,代表3’端的第二种确定的基因组序列)和CTL2gam-30-5’(SEQID NO:271,代表5’端的第一种确定的基因组序列)。
实施例2
沙眼衣原体抗原对T细胞增殖和干扰素-γ产生的诱导
如下测定了重组沙眼衣原体抗原诱导T细胞增殖和干扰素-γ产生的能力。
蛋白质用IPTG诱导并用Ni-NTA琼脂糖亲和层析纯化(Webb等人,免疫学杂志157:5034-5041,1996)。然后根据诱导PBMC制剂中T细胞增殖的能力筛查纯化的多肽。来自于沙眼衣原体患者及已知其T细胞可因衣原体抗原而增殖的正常供体的PBMC,在补加有10%混合人血清和50μg/ml庆大霉素的RPMI 1640培养基中培养。以0.5-10μg/ml的浓度一式两份加入纯化的多肽。在96孔圆底培养板中以200μl体积培养6天后,从每一孔中取出50μl培养基,如下所述测定IFN-γ水平。然后用1μCi/孔含氚胸苷脉冲培养板18小时,收获,并用气体闪烁计数仪测定氚摄取。如果在两份中的增殖均比单独培养基中培养的细胞的增殖高3倍,则认为该级分为阳性。
IFN-γ用酶联免疫吸附测定(ELISA)测定。用溶于PBS的抗人IFN-γ鼠单克隆抗体(PharMingen,San Diego,CA)在室温下包被ELISA板4小时。然后用含5%(W/V)无脂奶粉的PBS在室温下封闭1小时。用PBS/0.2%吐温20洗板6次,在ELISA板中用培养基1∶2稀释的样品在室温下温育过夜。再次洗涤平板,向每孔中加入用PBS/10%正常山羊血清1∶3000稀释的多克隆兔抗人IFN-γ血清。然后在室温下温育平板2小时,洗涤,并以在PBS/5%无脂奶粉中1∶2000的稀释度加入辣根过氧化物酶偶联的抗兔IgG(Sigma Chemical So.,St.Louis,MO)。在室温下再温育2小时后,洗板,并加入TMB底物。20分钟后用1N硫酸终止反应。用570nm作为参照波长测定450nm的光密度。如果在两份中OD均比单独培养基中培养的细胞的平均OD高2倍,加3个标准差,则认为该级分为阳性。
利用上述方法,发现重组1B1-66蛋白(SEQ ID NO:5)以及分别对应于SEQ ID NO:5的氨基酸残基48-67(SEQ ID NO:13;称为1-B1-66/48-67)和58-77(SEQ ID NO:14,称为1B1-66/58-77)的两种合成肽可诱导衣原体特异的T细胞系的增殖反应和IFN-γ产生,用来筛查衣原体LGV II的基因组文库。
进一步的研究已鉴定了核糖体S13蛋白中沙眼衣原体特异的T细胞表位。利用本领域众所周知的标准表位作图技术,用来自供体CL-8的衣原体特异的T细胞系(T细胞系TCL-8 EB/DC)鉴定核糖体S13蛋白(rS13)中的两个T细胞表位。图8显示,第一种肽,rS131-20(SEQ IDNO:106),与相应的肺炎衣原体序列100%相同,解释了T细胞系与重组沙眼衣原体和肺炎衣原体-rS13的交叉反应性。对第二种肽rS13 56-75(SEQ ID NO:108)的应答是沙眼衣原体特异的,表明在健康无症状供体中的rS13应答是通过接触沙眼衣原体而不是肺炎衣原体或其他任何微生物感染引起的。
如实施例1所述,用TCP-21细胞系鉴定的克隆11-C12-91(SEQ IDNO:63)含有是OMP2基因(CT443)部分的269bp插入片段,与肺炎衣原体的60kDa富含半胱氨酸外膜蛋白-称为OMCB-有同源性。为进一步确定反应性表位,用一系列重叠肽和以前描述的免疫测定进行表位作图。简言之,在1×104单核细胞衍生的树突细胞存在下,通过用来源于沙眼衣原体和肺炎衣原体的非传染性原生小体,或来源于沙眼衣原体或肺炎衣原体OMCB蛋白质的蛋白序列的肽(0.1μg/ml),刺激2.5×104TCP-21 T细胞,测定增殖反应。TCP-21 T细胞对表位CT-OMCB#167-186、CT-OMCB#171-190、CT-OMCB#171-186起反应,与CT-OMCB#175-186较低程度地起反应(分别为SEQ ID NO:249-252)。尤其是,TCP-21 T细胞也对同源肺炎衣原体肽CT-OMCB#171-186(SEQ IDNO:253)有增殖反应,其等于或大于对沙眼衣原体肽的反应。位点2(即,Asp置换Glu)和位点4(即,Cys置换Ser)的氨基酸置换不改变T细胞的增殖反应,从而证明该表位是沙眼衣原体和肺炎衣原体间的交叉反应性表位。
为了进一步确定上述表位,在表位作图实验中使用另一种T细胞系--TCT-3。如上所述进行免疫测定,不同之处在于只检测来源于沙眼衣原体的肽。T细胞对CT-OMCB#152-171和CT-OMCB#157-176(分别为SEQ ID NO:246和247)两种肽有增殖反应,从而确定了在沙眼衣原体富含半胱氨酸外膜蛋白中的另一免疫原性表位。
克隆14H1-4(SEQ ID NO:56,其相应的全长氨基酸序列如SEQ IDNO:92所示)在以前所述的CD4 T细胞表达克隆系统中用TCT-3细胞系鉴定,显示其含有硫醇特异的抗氧化剂基因(CT603)的完整ORF,称为TSA。为进一步确定该表位,如上所述进行表位作图免疫测定。TCT-3T细胞系显示对重叠肽CT-TSA#96-115、CT-TSA#101-120和CT-TSA#106-125(分别为SEQ ID NO:254-256)有强增殖反应,证明其为沙眼衣原体血清变型LGV II的硫醇特异性抗氧化剂基因中的免疫反应性表位。
实施例3
合成多肽的制备
可使用Millipore 9050肽合成仪用FMOC化学以HPTU(O-苯并三唑-N,N,N’,N’-四甲基脲六氟磷酸)活化合成多肽。Gly-Cys-Gly序列可与该肽的氨基端连接,从而提供了一种偶联或标记肽的方法。从固体载体上切下肽可用下列切割混合物进行:三氟乙酸∶乙二硫醇∶茴香硫醚∶水∶酚(40∶1∶2∶2∶3)。切割2小时后,可在冷甲基叔丁醚中沉淀肽。然后将肽沉淀溶解于含0.1%三氟乙酸(TFA)的水中并冻干,之后用C18反相HPLC纯化。用0-60%的乙腈(含0.1%TFA)水(含0.1%TFA)溶液梯度洗脱肽。待纯级分冻干后,可用电喷质谱法和氨基酸分析法表征这些肽。
实施例4
用反转录病毒表达载体系统对编码衣原体抗原的DNA序列的分离和表征及随后的免疫学分析
通过用BamHI、BglII、BstYi和MboI限制酶限制性消化构建沙眼衣原体LGV II的基因组文库。随后将限制消化片段连接到反转录病毒载体pBIB-KS1,2,3的BamHI位点。修饰该载体组,使之含有Kosak翻译起始位点和终止密码子,以便能从短DNA基因组片段表达蛋白质,如图2所示。如Pear,W.S.,Scott,M.L.和Nolan,G.P.,“通过瞬时转染产生高效价、无辅助病毒的反转录病毒。”《分子医学方法:基因治疗方法》,人类出版社,Totowa,NJ,41-57所述,制备80个克隆的DNA集合体,转染反转录病毒包装系Phoenix-Ampho。然后用反转录病毒形式的衣原体文库转导表达H2-Ld的P815细胞,然后用作靶细胞刺激抗原特异的T细胞系。
如Starnbach,M.,免疫学杂志,153:5183,1994所述,通过用照射的沙眼衣原体感染的J774细胞和照射的同源脾细胞重复刺激,在培养中扩充衣原体特异的鼠H2d限制CD8+T细胞系。用该衣原体特异的T细胞系筛查上述由反转录病毒转导的P815细胞表达的衣原体基因组文库。用Elispot分析通过检测IFN-γ产生鉴定阳性DNA集合体(参见Lalvani等人,实验医学杂志(J.Experimental Medicine)186:859-865,1997)。
通过IFN-γ Elispot测定鉴定出两个阳性集合体,称为2C7和2E10。通过有限稀释,克隆集合体2C7的P815细胞的稳定转导子,并根据其引起衣原体特异CTL系产生IFN-γ的能力筛选各克隆。从这一筛查过程中鉴定出4个阳性克隆,称为2C7-8、2C7-9、2C7-19和2C7-21。同样,进一步筛查阳性集合体2E10,产生含有三个插入片段的另一个阳性克隆。这三个插入片段是CT016、tRNA合酶和clpX基因片段(分别为SEQ IDNO:268-270)。
为选择性扩增衣原体DNA插入片段,用pBIB-KS特异性引物PCR扩增来自这4种阳性2C7.8克隆的转基因DNA。凝胶纯化并测序扩增的插入片段。一个免疫反应性克隆,2C7-8(SEQ ID NO:15,其预测的氨基酸序列如SEQ ID NO:32所示),是与沙眼衣原体血清变型D的核苷酸597304-597145(NCBI,BLASTN检索;SEQ ID NO:33,预测的氨基酸序列如SEQ ID NO:34所示)同源的160bp片段。上述高度同源区的两个推断开放阅读框内的克隆2C7-8图谱序列,尤其是由298个氨基酸片段组成的这两个推断开放阅读框之一(SEQ ID NO:16,预测的氨基酸序列如SEQ ID NO:17所示),证明有免疫活性。
用纯化的沙眼衣原体L2基因组DNA作为模板,用5’-ttttgaagcaggtaggtgaatatg(正向)(SEQ ID NO:159)和 5’-ttaagaaatttaaaaaatccctta(反向)(SEQ ID NO:160)引物PCR扩增,获得血清变型L2的298个氨基酸片段的全长克隆(称为CT529和/或Cap1基因)。凝胶纯化该PCR产物,克隆到pCRBlunt(Invitrogen,Carlsbad,CA)中测序,然后亚克隆到pBIB-KMS的EcoRI位点,pBIB-KMS是pBIB-KS的用于表达的衍生物。SEQ ID NO:291列出了CT529的肺炎衣原体同系物,SEQ ID NO:292列出了其相应的氨基酸序列。
基本如述(Denamur,E.,C.Sayada,A.Souriau,J.Orfila,A.Rodolakis和J.Elion,1991,普通微生物学杂志(J.Gen.Microbiol.)137:2525),从含105 IFU的细菌裂解物中PCR扩增编码多种CT529血清变型的全长DNA。如述扩增下列血清变型:Ba(SEQ ID NO:134,其相应的预测氨基酸序列如SEQ ID NO:135所示);E(BOUR)和E(MTW447)(SEQ ID NO:122,其相应的预测氨基酸序列如SEQ ID NO:123所示);F(NI1)(SEQ ID NO:128,其相应的预测氨基酸序列如SEQ ID NO:129所示);G(SEQ ID NO:126,其相应的预测氨基酸序列如SEQ ID NO:127所示);Ia(SEQ ID NO:124,其相应的预测氨基酸序列如SEQ ID NO:125所示);L1(SEQ ID NO:130,其相应的预测氨基酸序列如SEQ ID NO:131所示);L3(SEQ ID NO:132,其相应的预测氨基酸序列如SEQ ID NO:133所示);I(SEQ ID NO:263,其相应的预测氨基酸序列如SEQ ID NO:264所示);K(SEQ ID NO:265,其相应的预测氨基酸序列如SEQ ID NO:266所示);和MoPn(SEQ ID NO:136,其相应的预测氨基酸序列如SEQ IDNO:137所示)。用Advantage Genomic PCR试剂盒(Clontech,Palo Alto,CA),用血清变型L2 DNA(ORF外部)特异的引物进行PCR反应。引物序列为5’-ggtataatatctctctaaattttg(正向-SEQ ID NO:161)和5’-agataaaaaaggctgtttc’(反向-SEQ ID NO:162),而MoPn需要5’-ttttgaagcaggtaggtgaatatg(正向-SEQ ID NO:163)和5’-tttacaataagaaaagctaagcactttgt(反向-SEQ ID NO:164)。PCR扩增的DNA用QIAquick PCR纯化试剂盒(Qiagen,Valencia,CA)纯化,并克隆到pCR2.1(Invitrogen,Carlsbad,CA)中测序。
用自动化测序仪(ABI 377),用pBIB-KS特异正向引物5’-ccttacacagtcctgctgac(SEQ ID NO:165)和反向引物3’-gtttccgggccctcacattg(SEQ ID NO:166),对从免疫反应性克隆的PCR扩增片段获得的DNA测序。用T7启动子引物和通用M13正向及M13反向引物,对编码CT529血清变型L2的PCRBlunt克隆的DNA和编码CT529血清变型Ba、E(BOUR)、E(MTW447)、F(NI1)、G、Ia、K、L1、L3和MoPn的pCR2.1克隆的DNA测序。
为确定这两种推断的开放阅读框(SEQ ID NO:16和20)是否编码具有相关免疫功能的蛋白质,如实施例3所述合成横跨两个开放阅读框长度的重叠肽(17-20个氨基酸长)。用标准铬释放试验测定肽脉冲的H2d限制性靶细胞的百分特异裂解。在该测定中,在1μg/ml指定肽存在或不存在下,在37℃下用100μCi 51Cr标记P815细胞(H2d)等份1小时。温育后,洗涤标记的P815细胞以除去过量的51Cr和肽,随后一式两份以1000个细胞/孔的浓度接种于微量培养板中。以指定的效应物:靶比值加入效应CTL(衣原体特异的CD8 T细胞)。温育4小时后,收集上清液,用γ-计数仪测定51Cr向上清液中的释放。源自298氨基酸开放阅读框的两种重叠肽可特异刺激CTL系。合成SEQ ID NO:138-156所示的肽,代表血清变型D的CT529开放阅读框(Cap1基因)和216氨基酸开放阅读框的L2同源物的翻译。如图3所示,以10∶1的效应物靶比值,肽CtC7.8-12(SEQ ID NO:18,也称为Cap1#132-147,SEQ ID NO:139)和CtC7.8-13(SEQ ID NO:19,也称为Cap1#138-155,SEQ ID NO:140)分别能引发38-52%的特异裂解。尤其是,这两种肽之间的重叠含有预测的H2d(Kd和Ld)结合肽。合成对应于该重叠序列(SEQ ID NO:31)的10氨基酸肽,经elispot测定发现产生对抗衣原体CTL系的强免疫应答。值得注意的是,最近对Genbank数据库的检索显示以前未描述该基因的蛋白质。因此,编码克隆2C7-8(SEQ ID NO:15)的推断的开放阅读框确定为一种基因,其包含能以MHC-I限制方式刺激抗原特异性CD8+T细胞的衣原体抗原,证明该抗原能用来发展针对衣原体的疫苗。
为了证实这些结果并进一步对表位作图,制备了截短的肽(SEQ IDNO:138-156),并在IFN-γELISPOT测定中测试其被T细胞的识别。Ser139(Cap1#140-147,SEQ ID NO:146)或Leu147(Cap1#138-146,SEQ ID NO:147)的截短消除了T细胞识别。这些结果表明,9-mer肽Cap1#139-147(SFIGGITYL,SEQ ID NO:145)是可被衣原体特异的T细胞识别的最小表位。
选择的沙眼衣原体血清变型的Cap1(CT529)的序列对比(SEQ IDNO:121,123,125,127,129,131,133,135,137和139)显示,在所述表位的位点2中发现有氨基酸差异之一。同源的血清变型D肽是SIIGGITYL(SEQ ID NO:168)。比较了SFIGGITYL和SIIGGITYL对于靶细胞被衣原体特异T细胞识别的能力。连续稀释的每种肽与P815细胞温育,并如上所述在51Cr释放测定中检测被T细胞的识别。衣原体特异的T细胞可识别最小浓度为1nM的血清变型L2肽,和最小浓度为10nM的血清变型D肽。
进一步的研究显示,Cap1#139-147特异的T细胞克隆可识别沙眼衣原体感染的细胞。为了证实Cap1139-147存在于衣原体感染的细胞表面,用沙眼衣原体血清变型L2感染Balb-3T3(H-2d)细胞,并检测确定这些细胞是否能被对于Cap1#139-147表位(SEQ ID NO:145)特异的CD8+T细胞克隆识别。通过有限稀释69系T细胞获得对于Cap1#139-147表位特异的T细胞克隆。该T细胞克隆可特异识别衣原体感染的细胞。在这些实验中,靶细胞是沙眼衣原体感染的(阳性对照)或未感染的Balb/3T3细胞,以30∶1、10∶1和3∶1的效应物靶比值分别显示45%、36%和30%的特异性裂解;或是Cap1#139-147表位(SEQ ID NO:145)包被的或未处理的P815细胞,以30∶1、10∶1和3∶1的效应物靶比值分别显示83%、75%和58%的特异性裂解(阴性对照在所有情况中均有低于5%的裂解)。数据表明感染过程中存在表位。
体内研究显示,在鼠感染沙眼衣原体过程中,启动了Cap1#139-147表位特异的T细胞。为确定感染沙眼衣原体是否引发Cap1#139-147表位特异的T细胞应答,小鼠腹膜内感染108 IFU沙眼衣原体血清变型L2。感染两周后,杀死小鼠,在用Cap1#139-147表位肽脉冲的照射的同源脾细胞上刺激脾细胞。刺激5天后,在标准51Cr释放测定中用培养物确定培养物中是否存在Cap1#139-147表位特异的T细胞。具体而言,沙眼衣原体血清变型L2免疫的小鼠或注射PBS的对照小鼠的脾细胞,在与Cap1#139-147肽包被的同源脾细胞和能特异识别Cap1#139-147表位的CD8+T细胞培养5天后,以30∶1、10∶1和3∶1的效应物靶比值,分别引起73%、60%和32%的特异性裂解。对照小鼠以30∶1的效应物靶比值具有近似10%的百分裂解,并随E∶T比降低稳定下降。靶细胞是Cap1#139-147肽包被的或未处理的P815细胞。数据表明,在鼠感染沙眼衣原体过程中引发了(primed)Cap1#139-147肽特异的T细胞。
实施例5
衣原体抗原免疫的小鼠中的抗体产生和T细胞应答
进行免疫原性研究,以测定用纯化的SWIB或与Montanide佐剂配制的S13蛋白质免疫的小鼠中的抗体和CD4+T细胞应答,或用含有SWIB或S13的DNA序列的pcDNA-3表达载体进行基于DNA的免疫。SWIB也称作克隆1-B1-66(SEQ ID NO:1,相应的氨基酸序列如SEQ ID NO:5所示),S13核糖体蛋白也称作克隆10-C10-31(SEQ ID NO:4,相应的氨基酸序列如SEQ ID NO:12所示)。在第一组实验中,每组3只C57BL/6小鼠免疫两次,并监测抗体和CD4+T细胞应答。在尾部皮内进行DNA免疫,多肽免疫通过皮下途径施行。对免疫小鼠脾细胞的标准3H掺入试验结果显示,纯化的重组SWIB多肽(SEQ ID NO:5)免疫的组具有强增殖反应。如前所述,通过细胞因子诱导测定的进一步分析证明,SWIB多肽免疫的组产生可测得的IFN-γ和IL-4应答。随后进行基于ELISA的测定,以测定SWIB多肽免疫的实验组中的优势抗体同种型应答。图4显示SWIB免疫的组产生主要为IgG1的体液应答。
在第二组实验中,以3周的间隔,用在PBS或Montanide中配制的10μg纯化的SWIB蛋白(也称作克隆1-B1-66,SEQ ID NO:5)免疫C3H小鼠3次,第3次免疫2周后收获。用本领域众所周知的基于ELISA的标准技术测定针对SWIB蛋白的抗体效价,证明用Montanide佐剂配制的SWIB蛋白可诱导强体液免疫应答。T细胞增殖反应用基于XTT的试验测定(Scudiero等人,癌症研究(Cancer Research)1988,48:4827)。如图5所示,SWIB多肽加Montanide免疫的小鼠的脾细胞引发抗原特异的增殖反应。另外,用上述细胞因子诱导试验测定免疫动物的脾细胞响应可溶性重组SWIB多肽而分泌IFN-γ的能力。Montanide佐剂配制的SWIB多肽免疫组中的所有动物的脾细胞均由于接触SWIB衣原体抗原而分泌IFN-γ,证明衣原体特异的免疫应答。
在另一组实验中,在不同的3个时间点,用与SBAS2佐剂(SmithKline Beecham,伦敦,英格兰)配制的10μg纯化的SWIB或S13蛋白(沙眼衣原体,SWIB蛋白,克隆1-B1-66,SEQ ID NO:5,S13蛋白,克隆10-C10-31,SEQ ID NO:4)在尾部免疫C3H小鼠。抗原特异的抗体效价用ELISA测定,显示两种抗体均可诱导强IgG应答,效价为1×10-4~1×10-5。该反应中的IgG1和IgG2a成分以相当的量存在。通过标准3H掺入测定对分离自免疫小鼠的脾细胞测定,抗原特异的T细胞增殖反应对于SWIB而言极强(阴性对照以上50,000cpm),而对于S13甚至更强(阴性对照以上100,000cpm)。IFN-γ产生通过标准ELISA技术从增殖培养上清液中测定。用S13蛋白体外重新刺激培养物诱导高水平的IFN-γ产生,约25ng/ml,而阴性对照为2ng/ml。用SWIB蛋白重新刺激也诱导IFN-γ,但程度较低。
在相关实验中,在不同的3个时间点,用与10μg霍乱毒素混合的10μg纯化的SWIB或S13蛋白(沙眼衣原体,SWIB蛋白,克隆1-B1-66,SEQID NO:5,S13蛋白,克隆10-C10-31,SEQ ID NO:4)免疫C3H小鼠。抗原特异的抗体反应用标准ELISA技术测定。SWIB免疫的小鼠的血液中存在抗原特异的IgG抗体,效价为1×10-3~1×10-4,但在S13免疫的动物中检测不到。根据IFN-γ产生测定,分离的脾细胞的抗原特异T细胞应答,产生与以上对于全身免疫所述类似的结果。
进行动物研究,以测定CT529血清变型LGV II CTL表位的免疫原性,该表位由CT529 10mer共有肽(CSFIGGITYL--SEQ IDNO:31)限定,确定为H2-Kd限制性CTL表位。BALB/c小鼠(每组3只小鼠)用结合不同佐剂的25μg肽免疫3次。在SKB佐剂系统SBAS-2”、SBAS-7(SmithKline Beecham,伦敦,英格兰)或Montanide中,在尾部全身施用该肽。该肽也与10μg霍乱毒素(CT)混合鼻内施用。用普通小鼠作为对照。第3次免疫4周后,用10μg/ml CT529 10mer共有肽脉冲的LPS-胚细胞以不同的效应细胞LPS-胚细胞比:6、1.5和0.4以1×106细胞/ml重新刺激脾细胞。两次重复刺激后,用标准铬释放试验检测效应细胞裂解肽脉冲的P815细胞的能力。来源于鸡蛋卵清蛋白的无关肽用作阴性对照。结果证明,对CT529 10mer共有肽引发明显的免疫应答,用肽免疫可产生能裂解肽脉冲靶标的抗原特异性T细胞。特别是,在SBAS-7和CT辅助的组中发现抗原特异的裂解活性,而Montanide和SBAS-2”不能辅助CTL表位免疫。
实施例6
肺炎衣原体基因的表达与表征
实施例1所述的人T细胞系TCL-8可识别沙眼衣原体及肺炎衣原体感染的单核细胞衍生的树突细胞,提示沙眼衣原体和肺炎衣原体可编码交叉反应性T细胞表位。为了分离与沙眼衣原体LGV II克隆1B1-66--也称作SWIB(SEQ ID NO:1)和克隆10C10-31--也称作S13核糖体蛋白(SEQ ID NO:4)同源的肺炎衣原体基因,用肺炎衣原体TWAR株(CDC/CWL-029)感染HeLa 229细胞。温育3天后,收获肺炎衣原体感染的HeLa细胞,洗涤并重悬浮于200μl水中,在沸水浴中加热20分钟。用10μl破碎细胞悬液作为PCR模板。
为克隆1B1-66和10C10-31设计肺炎衣原体特异的引物,使5’端插入6X-组氨酸尾和一个Nde I位点,3’端含有一个终止密码子和一个BamHI位点(图6)。用本领域周知的标准技术扩增并测序PCR产物。将肺炎衣原体特异的PCR产物克隆到表达载体pET17B(Novagen,Madison,WI)中,转染大肠杆菌BL21 pLysS进行表达,随后用Novagen提供的组氨酸镍层析法纯化。这样产生来源于肺炎衣原体的两种蛋白质,10-11kDa蛋白称为CpSWIB(分别为SEQ ID NO:27,含6X His尾的SEQID NO:78,相应的氨基酸序列如SEQ ID NO:28所示),15kDa蛋白称作CPS13(分别为SEQ ID NO:29,含6X His尾的SEQ ID NO:77,相应的氨基酸序列如SEQ ID NO:33和91所示)。
实施例7
肺炎衣原体抗原对T细胞增殖和干扰素-γ产生的诱导
重组肺炎衣原体抗原诱导T细胞增殖和干扰素-γ产生的能力如下测定。
蛋白质用IPTG诱导,并通过Ni-NTA琼脂糖亲和层析纯化(Webb等人,免疫学杂志157:5034-5041,1996)。然后根据在PBMC制剂中诱导T细胞增殖的能力筛查纯化的多肽。来源于肺炎衣原体患者及已知其T细胞可因衣原体抗原而扩增的正常供体的PBMC,在含补充有10%合并人血清和50μg/ml庆大霉素的RPMI 1640的培养基中培养。一式两份以0.5~10μg/mL的浓度加入纯化多肽。在96孔圆底培养板中培养6天后,从每孔中取出50μl培养基,如下所述测定IFN-γ水平。然后用1μCi/孔含氚胸苷脉冲18小时,收获并用气体闪烁计数仪测定氚摄取。如果在两份中的增殖均比单独培养基中培养的细胞的增殖高3倍,则认为该级分为阳性。
IFN-γ用酶联免疫吸附测定(ELISA)测定。ELISA板用溶于PBS中的抗人IFN-γ鼠单克隆抗体(PharMingen,San Diego,CA)在室温下包被4小时。然后用含5%(W/V)无脂奶粉的PBS在室温下封闭1小时。用PBS/0.2%吐温20洗板6次,在ELISA板中用培养基1∶2稀释的样品在室温下温育过夜。再次洗涤平板,向每孔中加入用PBS/10%正常山羊血清1∶3000稀释的多克隆兔抗人IFN-γ血清。然后在室温下温育平板2小时,洗涤,并以在PBS/5%无脂奶粉中1∶2000的稀释度加入辣根过氧化物酶偶联的抗兔IgG(Sigma Chemical So.,St.Louis,MO)。在室温下再温育2小时后,洗板,并加入TMB底物。20分钟后用1N硫酸终止反应。用570nm作为参照波长测定450nm的光密度。如果在两份中OD均比单独培养基中培养的细胞的OD高2倍,加3个标准差,则认为该级分为阳性。
用能与沙眼衣原体和肺炎衣原体交叉反应的人抗衣原体T细胞系(TCL-8)确定以上实施例所述的表达蛋白质(即,CpSWIB,分别为SEQID NO:27,含6X His标记的SEQ ID NO:78,相应的氨基酸序列如SEQ IDNO:28所示,以及称作CpS13的15kDa蛋白,分别为SEQ ID NO:29,含6X His标记的SEQ ID NO:77,相应的氨基酸序列如SEQ ID NO:30和91所示)是否具有沙眼衣原体和肺炎衣原本共有的T细胞表位。简言之,对1×104单核细胞衍生的树突细胞滴定表达衣原体蛋白的大肠杆菌。2小时后,洗涤树突细胞培养物,加入2.5×104个T细胞(TCL-8),再温育72小时。然后通过ELISA测定培养上清液中IFN-γ的量。如图7A和7B所示,经IFN-γ的抗原特异性诱导证明,TCT-8 T细胞系可特异识别来源于沙眼衣原体和肺炎衣原体的S13核糖体蛋白,而只有来源于沙眼衣原体的SWIB蛋白能被该T细胞系识别。为了证实这些结果,用一系列重叠肽脉冲的靶细胞和T细胞系TCL-8经表位作图鉴定沙眼衣原体SWIB的T细胞表位。3H胸苷掺入试验证明,称作C.T.SWIB 52-67的SEQID NO:39的肽引起最强的TCL-8系增殖。合成对应于肺炎衣原体序列的SWIB(SEQ ID NO:40)、肺炎衣原体(SEQ ID NO:43)和沙眼衣原体(SEQ ID NO:42)的拓扑异构酶-SWIB融合蛋白及人SWI域(SEQ IDNO:41)的同源肽,并经上述试验检测。T细胞系TCL-8只能识别SEQ IDNO:39的沙眼衣原体肽,不能识别相应的肺炎衣原体肽(SEQ IDNO:40),或上述其他相应的肽(SEQ ID NO:41-43)。
分别用沙眼衣原体或肺炎衣原体感染的单核细胞衍生的树突细胞刺激供体PBMC,由具有肺炎衣原体阳性血清效价的供体CP-21产生衣原体特异的T细胞系。对肺炎衣原体产生的T细胞可对重组肺炎衣原体-SWIB反应,但不对沙眼衣原体-SWIB反应,而对沙眼衣原体产生的T细胞系不对沙眼衣原体或肺炎衣原体-SWIB反应(见图9)。供体CP-21的肺炎衣原体-SWIB特异的免疫应答证实了肺炎衣原体感染,表明在体内肺炎衣原体感染期间产生肺炎衣原体-SWIB特异的T细胞。
对肺炎衣原体-SWIB的T细胞应答的表位作图显示,Cp-SWIB-特异的T细胞可对重叠肽Cp-SWIB 32-51(SEQ ID NO:101)和Cp-SWIB37-56(SEQ ID NO:102)反应,表明肺炎衣原体-SWIB特异的T细胞表位Cp-SWIB 37-51(SEQ ID NO:100)。
在其他实验中,分别用来源于沙眼衣原体或肺炎衣原体的非传染性原生小体刺激PBMC,由供体CP1,也是肺炎衣原体血清反应阳性的供体,产生T细胞系。特别是,在1×104单核细胞衍生的树突细胞和来源于沙眼衣原体或肺炎衣原体的非传染性原生小体,或重组沙眼衣原体或肺炎衣原体SWIB蛋白存在下,刺激2.5×104 T细胞,测定增殖反应。对SWIB的T细胞反应类似于用CP21的T细胞获得的数据,因为肺炎衣原体-SWIB而不是沙眼衣原体-SWIB引发肺炎衣原体T细胞系的反应。另外,沙眼衣原体T细胞系不能响应沙眼衣原体或肺炎衣原体SWIB增殖,但它能响应CT和CP原生小体增殖。如实施例1所述,用TCP-21细胞系鉴定的克隆11-C12-91(SEQ ID NO:63)具有269bp的插入片段,它是OMP2基因(CCCT443)的部分,与肺炎衣原体富含半胱氨酸的60kDa外膜蛋白-称作OMCB-有同源性。为了进一步确定反应性表位,用一系列重叠肽和以前所述的免疫测定法进行表位作图。简言之,在1×104单核细胞衍生的树突细胞存在下,用来源于沙眼衣原体或肺炎衣原体的非传染性原生小体,或来源于沙眼衣原体或肺炎衣原体OMCB蛋白序列的肽(0.1μg/ml)刺激2.5×104 TCP-21 T细胞,测定增殖反应。TCP-21 T细胞对表位CT-OMCB#167-186、CT-OMCB#171-190、CT-OMCB#171-186起反应,与CT-OMCB#175-186较低程度地起反应(分别为SEQ ID NO:249-252)。尤其是,TCP-21 T细胞也对同源的肺炎衣原体肽CT-OMCB#171-186(SEQ ID NO:253)有增殖反应,其等于或大于对沙眼衣原体肽的反应。位点2(即,Asp置换Glu)和位点4(即,Cys置换Ser)的氨基酸置换不改变T细胞的增殖反应,从而证明该表位是沙眼衣原体和肺炎衣原体间的交叉反应性表位。
实施例8
人PBMC和T细胞系对衣原体抗原的免疫应答
此处提供的实施例提示,在已感染沙眼衣原体并产生控制沙眼衣原体感染的保护性免疫应答的普通人群中,有一群健康供体。这此供体仍无临床症状,并且沙眼衣原体血清反应阴性。为了表征正常供体对已经过CD4表达克隆鉴定的衣原体抗原的免疫应答,针对包括沙眼衣原体-SWIB、肺炎衣原体-SWIB、和沙眼衣原体-S13和肺炎衣原体-S13在内的一系列重组衣原体抗原检测从12名健康供体中获得的PBMC。数据总结于下面的表1中。所有供体均为沙眼衣原体血清反应阴性,而6/12有阳性肺炎衣原体滴度。用刺激指数>4作为阳性反应,11/12受试者对沙眼衣原体原生小体起反应,12/12对肺炎衣原体原生小体起反应。一名供体,AD104,对重组肺炎衣原体-S13蛋白起反应,但不对重组沙眼衣原体-S13蛋白起反应,表明是肺炎衣原体特异的反应。12名患者中的3名有沙眼衣原体-SWIB而不是肺炎衣原体特异的反应,证实为沙眼衣原体感染。沙眼衣原体-S13和肺炎衣原体-S13在8/12患者中引起反应,提示衣原体感染。这些数据证明了SWIB和S13在正常受试者的PBMC中引发T细胞应答的能力。
表I
正常受试者对衣原体的免疫应答 | ||||||||||
性别 | 衣原体IgG滴度 | CTEB | CPEB | CTSwib | CPSwib | CTS13 | CPS13 | CTlpdA | CTTSA | |
D100D104D108D112D120D124D128D132D136D140D142D146 | 男女男女男女男女女男女女 | 阴性阴性CP1:256阴性阴性CP1:128CP1:512阴性CP1:128CP1:256CP1:512阴性 | +++++++++-++++++++++++ | ++++++++++++++++++++++++ | +-++-------- | --+/---------- | ++-++--++++/-++++ | +++++---++-+++ | --++/---++---++ | n.t.n.t.n.t.n.t.n.t.n.t.------ |
CT=沙眼衣原体;CP=肺炎衣原体;EB=衣原体原生小体;Swib=重组衣原体Swib蛋白;S13=重组衣原体S13蛋白;lpdA=重组衣原体lpdA蛋白;TSA=重组衣原体TSA蛋白。数值代表标准增殖测定的结果。增殖反应的测定是,用与各重组抗原或原生小体(EB)预温育的1×104单核细胞衍生的树突细胞刺激3×105PBMC。6天后用3H胸苷脉冲最后18小时进行测定。
SI:刺激指数
+/-:SI~ 4
+: SI> 4
++: SI 10-30
+++:SI> 30
在第一系列实验中,如前所述,通过用沙眼衣原体LGV II原生小体刺激T细胞,从有生殖器接触沙眼衣原体史的女性个体(CT-10)中获得T细胞系。虽然受试者曾接触沙眼衣原体,但没有血清转化,不发展为临床症状,提示供体CT-10可能已发展了针对沙眼衣原体的保护性免疫应答。如图10所示,来源于供体CT-10的初级衣原体特异性T细胞系可对沙眼衣原体-SWIB但不对肺炎衣原体-SWIB重组蛋白起反应,证实CT-10接触过沙眼衣原体。对沙眼衣原体-SWIB的T细胞应答的表位作图显示,该供体对同一表位Ct-SWIB 52-67(SEQ ID NO:39)如T细胞系TCL-8起反应,如图11所示。
如上所述,对于不同沙眼衣原体患者产生其他T细胞系。表II总结了患者临床概况及对沙眼衣原体和肺炎衣原体原生小体和重组蛋白的增殖反应。
表II
沙眼衣原体患者的免疫应答 | ||||||||||
患者 | 临床表现 | IgG滴度 | CTEB | CPEB | CTSwib | CPSwib | CTS13 | CPS13 | CTlpdA | CTTSA |
CT-1CT-2CT-3CT-4CT-5CT-6CT-7CT-8CT-9CT-10CT-11CT-12 | NGUNGU无症状释放EbDx为HPV无症状释放EbBV会阴皮疹BV生殖器溃疡未知无症状外阴轻度掻痒BV,异常pap无症状 | 阴性阴性Ct1:512Cp1:1024Cps1:256Ct1:1024Ct1:256Cp1:256Cp1:1024Ct1:512Cp1:1024未测Ct1:128Cp1:128阴性Ct1:512Cp1:512 | +++++++++++++++++++++ | ++++++++++++++++++++ | ------------ | ------------ | ++++-+-+-++-+++++ | +++/-----+-+-+/-+ | ++-+---+-+-+++ | +---------+- |
NGU=非淋菌性尿道炎;BV=细菌性阴道炎;CT=沙眼衣原体;CP=肺炎衣原体;EB=衣原体原生小体;Swib=重组衣原体Swib蛋白;S13=重组衣原体S13蛋白;lpdA=重组衣原体lpdA蛋白;TSA=重组衣原体TSA蛋白。数值代表标准增殖测定的结果。增殖反应的测定是,用与各重组抗原或原生小体(EB)预温育的1×104单核细胞衍生的树突细胞刺激3×105PBMC。6天后用3H胸苷脉冲最后18小时进行测定。
SI:刺激指数
+/-: SI~ 4
+: SI> 4
++: SI 10-30
+++: SI >30
用如表I和表II总结的一组无症状(如所定义)受试者和沙眼衣原体患者,进行两组PBMC的免疫应答的全面研究。简言之,肺炎衣原体患者及正常供体的PBMC在含补充有10%混合人血清和50μg/ml庆大霉素的RPMI 1640的培养基中培养。一式两份以0.5~10μg/ml的浓度加入纯化的多肽、包括沙眼衣原体-SWIB、肺炎衣原体-SWIB和S13及沙眼衣原体lpdA和TSA在内的一组重组衣原体抗原。在96孔圆底培养板中以200μl体积培养6天后,从每孔中取出50μl培养基,如下所述测定IFN-γ水平。然后用1μCi/孔含氚胸苷脉冲培养板18小时,收集,并用气体闪烁计数仪测定氚摄取。如果在两份中的增殖均比单独培养基中培养的细胞的增殖高3倍,则认为该级分为阳性。
对重组衣原体抗原的增殖反应证明,大多数无症状供体和沙眼衣原体患者可识别沙眼衣原体S13抗原(8/12),大多数沙眼衣原体患者可识别肺炎衣原体S13抗原(8/12),4/12的无症状供体也可识别肺炎衣原体S13抗原。6/12的沙眼衣原体患者和4/12的无症状供体也产生对沙眼衣原体lpdA抗原的增殖反应。结果证明,无症状供体可识别沙眼衣原体和肺炎衣原体S13抗原、沙眼衣原体Swib抗原和沙眼衣原体lpdA抗原,表明这些抗原在接触衣原体期间识别,并引发针对它们的免疫应答。这意味着,这些抗原可能在为人类宿主提供保护性免疫中起作用。另外,沙眼衣原体和肺炎衣原体S13抗原在沙眼衣原体患者中同样识别,因此表明在S13蛋白中可能有沙眼衣原体和肺炎衣原体所共有的表位。表III总结了这些研究的结果。
表III
抗原 | 正常供体 | 沙眼衣原体患者 |
沙眼衣原体-Swib | 3/12 | 0/12 |
肺炎衣原体-Swib | 0/12 | 0/12 |
沙眼衣原体-S13 | 8/12 | 8/12 |
肺炎衣原体-S13 | 4/12 | 8/12 |
LpdA | 4/12 | 6/12 |
TSA | 0/12 | 2/12 |
进行一系列研究测定针对无症状供体和沙眼衣原体患者产生的短期T细胞系的细胞免疫应答。细胞免疫应答如实施例7所述通过标准增殖测定和IFN-γ测定。特别是,大多数抗原为表达衣原体抗原的单大肠杆菌克隆,但在测定中也可使用某些重组蛋白。单大肠杆菌克隆在1×104单核细胞衍生的树突细胞上滴定,2小时后洗涤培养物并加入2.5×104个T细胞。使用重组蛋白的测定如前所述进行。用标准3H-胸苷脉冲最后18小时4天后测定增殖。如上所述,用标准ELISA测定法测定4天后收集的培养上清液的IFN-γ诱导。结果显示,除了沙眼衣原体Swib外,所测的所有沙眼衣原体抗原都引发来源于沙眼衣原体患者的一种或多种不同T细胞系的增殖反应。另外,沙眼衣原体患者和无症状供体中都对下列衣原体基因引发增殖反应:CT622、groEL、pmpD、CT610和rS13。
12G3-83克隆除CT622之外也含有CT734和CT764的序列,因此,这些基因序列也可能具有免疫反应性表位。类似地,克隆21G12-60除CT875外还含有假拟蛋白基因CT229和CT228的序列;15H2-76也含有CT812和CT088的序列,并与sycE基因有同源性。克隆11H3-61也含有与PGP6-D毒性蛋白有同源性的序列。
表IV
克隆 | 沙眼衣原体抗原(推断的*) | 无症状供体的TCL | 沙眼衣原体患者的TCL | SEQ IDNO: |
1B1-66(大肠杆菌) | Swib | 2/2 | 0/4 | 5 |
1B1-66(蛋白质) | Swib | 2/2 | 0/4 | 5 |
12G3-83(大肠杆菌) | CT622* | 2/2 | 4/4 | 57 |
22B3-53(大肠杆菌) | groEL | 1/2 | 4/4 | 111 |
22B3-53(蛋白质) | groEL | 1/2 | 4/4 | 111 |
15H2-76(大肠杆菌) | PmpD* | 1/2 | 3/4 | 87 |
11H3-61(大肠杆菌) | rL1* | 0/2 | 3/4 | 60 |
14H1-4(大肠杆菌) | TSA | 0/2 | 3/4 | 56 |
14H1-4(蛋白质) | TSA | 0/2 | 3/4 | 56 |
11G10-46(大肠杆菌) | CT610 | 1/2 | 1/4 | 62 |
10C10-17(大肠杆菌) | rS13 | 1/2 | 1/4 | 62 |
10C10-17(蛋白质) | rS13 | 1/2 | 1/4 | 62 |
21G12-60(大肠杆菌) | CT875* | 0/2 | 2/4 | 110 |
11H4-32(大肠杆菌) | dnaK | 0/2 | 2/4 | 59 |
21C7-8(大肠杆菌) | dnaK | 0/2 | 2/4 | 115 |
17C10-31(大肠杆菌) | CT858 | 0/2 | 2/4 | 114 |
实施例9
利用衣原体抗原的保护性研究
用小鼠进行保护性研究,以确定衣原体抗原免疫是否能影响衣原体接种引起的生殖道疾病。使用两种模型:使用含有鹦鹉热衣原体(Chlamydia psittaci)株(MTW447)的人分离物的阴道内接种,和使用确定为沙眼衣原体血清变型F(NI1株)的人分离物的子宫内接种模式。这两种菌株均可诱导上生殖道炎症,其类似于妇女中由沙眼衣原体引起的子宫内膜炎和输卵管炎。在第一组实验中,C3H小鼠(每组4只鼠)用含沙眼衣原体SWIB DNA(SEQ ID NO:1,其相应的氨基酸序列如SEQID NO:5所述)的100μg pcDNA-3表达载体免疫3次。在尾部接种以全身免疫。最后一次免疫两周后,用孕酮处理动物,通过阴道或通过向子宫内注射接种体感染。感染两周后,杀死小鼠,切下生殖道,染色并进行组织病理学检查。对炎症水平评分(从+极轻到+++++极严重)。将归因于每一输卵管/卵巢的分数加和,除以检查的器官数,得到该组的炎症平均得分。在子宫接种模型中,接受空载体的阴性对照免疫的动物显示一致的炎症,卵巢/输卵管平均炎症得分为6.12,而DNA免疫组为2.62。在阴道接种和上行性感染模型中,阴性对照免疫的小鼠卵巢/输卵管平均炎症得分为8.37,而DNA免疫组为5.00。在后一模型中,接种的小鼠显示无输卵管闭塞迹象,而阴性对照接种组在输卵管内腔中有炎症细胞。
在第二组实验中,C3H小鼠(每组4只鼠)用丙交酯乙交酯共聚物微球体(PLG)包裹的含沙眼衣原体SWIB DNA(SEQ ID NO:1,其相应的氨基酸序列如SEQ ID NO:5所述)的50μg pcDNA-3表达载体免疫3次;腹膜内进行免疫。最后一次免疫两周后,孕酮处理动物,通过阴道内接种鹦鹉热衣原体感染。感染两周后,杀死小鼠,切下生殖道,染色并进行组织病理学检查。如前所述对炎症水平评分。将归因于每一输卵管/卵巢的分数加和,除以检查的器官数,得到该组的炎症平均值。接受PLG包裹的空载体的阴性对照免疫的动物显示一致的炎症,卵巢/输卵管平均炎症得分为7.28,而PLG包裹的DNA免疫组为5.71。对于腹膜中炎症,接种组为1.75,对照组为3.75。
在第三组实验中,C3H小鼠(每组4只鼠)用10μg纯化的重组蛋白--与霍乱毒素(CT)混合的SWIB(SEQ ID NO:1,其相应的氨基酸序列如SEQ ID NO:5所述)或S13(SEQ ID NO:4,其相应的氨基酸序列如SEQ ID NO:12所述)--免疫3次;麻醉后以20μl体积鼻内施用该制剂。最后一次免疫两周后,用孕酮处理动物,通过阴道接种鹦鹉热衣原体或通过向子宫内注射沙眼衣原体血清变型F感染。感染两周后,杀死小鼠,切下生殖道,染色并进行组织病理学检查。炎症程度如上所述评分。将归因于每一输卵管/卵巢的分数加和,除以检查的器官数,得到该组的炎症平均得分。在子宫接种模型中,只接受霍乱毒素的阴性对照免疫动物显示卵巢/输卵管平均炎症得分为4.25(只分析了2只小鼠;另2只死亡),而S13加霍乱毒素免疫组为5.00,SWIB加霍乱毒素组为1.00。未治疗的感染动物的卵巢/输卵管平均炎症得分为7。在阴道接种和上行性感染模型中,阴性对照免疫小鼠的卵巢/输卵管平均炎症得分为7.37,S13加霍乱毒素免疫组为6.75,SWIB加霍乱毒素免疫组为5.37。未治疗的感染动物的卵巢/输卵管平均炎症得分为8。
上述三组实验表明,SWIB特异的保护是可获得的。这种保护作用在同源感染模型中更为明显,但在异源感染鹦鹉热衣原体时也存在。
尽管为便于清楚地理解,已通过说明和实施例详细描述了本发明,但也能在不背离附加权利要求书范围所限制的本发明范围的情况下进行改变和修改。
本发明可由以下段落进一步限定:
1.一种含有衣原体抗原的免疫原性部分的分离的多肽,其中该抗原含有由选自下列的多核苷酸序列编码的氨基酸序列:(a)SEQ ID NO:1,15,21-25,44-64,66-76,79-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-290所示的序列;(b)与(a)的序列互补的序列;和(c)在中度严格条件下可与(a)或(b)的序列杂交的多核苷酸序列。
2.段落1的多肽,其中该多肽包含选自SEQ ID NO:5,26,32,65,90,92-98,103-108,121,123,125,127,129,131,133,135,137,175-180,189-196,264和266的序列。
3.一种分离的多核苷酸分子,其包含编码根据段落1和2任一的多肽的核苷酸序列。
4.一种含有根据段落3的多核苷酸分子的重组表达载体。
5.一种用根据段落4的表达载体转化的宿主细胞。
6.段落5的宿主细胞,其中该宿主细胞选自大肠杆菌、酵母和哺乳动物细胞。
7.一种包含根据段落1和2任一的多肽的融合蛋白。
8.根据段落7的融合蛋白,其中该融合蛋白包含一种表达增强子,该增强子可增强该融合蛋白在用编码该融合蛋白的多核苷酸转染的宿主细胞中的表达。
9.根据段落7的融合蛋白,其中该融合蛋白包含一种在段落1的多肽中不存在的T辅助表位。
10.根据段落7的融合蛋白,其中该融合蛋白包含一种亲和标记。
11.一种分离的多核苷酸,其编码根据段落7的融合蛋白。
12.一种分离的单克隆抗体,或其抗原结合片段,其可特异结合包含由根据段落1的多核苷酸序列,或上述任一种多核苷酸序列的互补序列编码的氨基酸序列之衣原体蛋白。
13.一种药用组合物,其含有根据段落1的多肽和一种生理学可接受的载体。
14.一种药用组合物,其含有根据段落3的多核苷酸分子和一种生理学可接受的载体。
15.一种药用组合物,其含有一种多肽和一种生理学可接受的载体,其中该多肽由选自下列的多核苷酸分子编码:(a)SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列;(b)与(a)的序列互补的序列;和(c)在中度严格条件下可与(a)或(b)的序列杂交的序列。
16.一种药用组合物,其含有一种多核苷酸分子和一种生理学可接受的载体,其中该多核苷酸分子包含选自下列的序列:(a)SEQ IDNO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列;(b)与(a)的序列互补的序列;和(c)在中度严格条件下可与(a)或(b)的序列杂交的序列。
17.一种药用组合物,其含有一种生理学可接受的载体和至少一种选自下列的成分:
(a)根据段落7的融合蛋白;
(b)根据段落11的多核苷酸;和
(c)根据段落12的抗体。
18.一种含有根据段落1的多肽和一种免疫刺激剂的疫苗。
19.一种含有根据段落3的多核苷酸分子和一种免疫刺激剂的疫苗。
20.一种含有一种多肽和一种免疫刺激剂的疫苗,其中该多肽由选自下列的序列编码:(a)SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列;(b)与(a)的序列互补的序列;和(c)在中度严格条件下可与(a)或(b)的序列杂交的序列。
21.一种含有一种DNA分子和一种免疫刺激剂的疫苗,其中该DNA分子包含选自下列的序列:(a)SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列;(b)与(a)的序列互补的序列;和(c)在中度严格条件下可与(a)或(b)的序列杂交的序列。
22.一种疫苗,其含有一种免疫刺激剂和至少一种选自下列的成分:
(a)根据段落7的融合蛋白;
(b)根据段落11的多核苷酸;和
(c)根据段落12的抗体。
23.段落18-22中任一的疫苗,其中所述免疫刺激剂是一种佐剂。
24.一种诱导患者的保护性免疫的方法,其包括向患者施用根据段落13-17中任一的药用组合物。
25.一种诱导患者的保护性免疫的方法,其包括向患者施用根据段落18-22中任一的疫苗。
26.一种分离的多克隆抗体或其抗原结合片段,其可特异结合包含由根据段落1的多核苷酸序列或上述任一种多核苷酸序列的互补序列编码的氨基酸序列之衣原体蛋白。
27.一种检测患者衣原体感染的方法,其包括:
(a)从患者中获得生物样品;
(b)使该样品接触一种含有衣原体抗原免疫原性部分的多肽,其中该抗原包含由选自下列的多核苷酸序列编码的氨基酸序列:(i)SEQ IDNO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列,(ii)与(i)的序列互补的序列;和(iii)在中度严格条件下可与(i)或(ii)的序列杂交的多核苷酸序列;和
(c)检测可与该多肽结合的抗体的存在。
28.一种检测患者衣原体感染的方法,其包括:
(a)从患者中获得生物样品;
(b)使该样品接触一种含多肽的融合蛋白,该多肽含有衣原体抗原的免疫原性部分,其中该抗原包含由选自下列的多核苷酸序列编码的氨基酸序列:(i)SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列,(ii)与(i)的序列互补的序列;和(iii)在中度严格条件下可与(i)或(ii)的序列杂交的多核苷酸序列;和
(c)检测可与该多肽结合的抗体的存在。
29.段落27和28任一的方法,其中所述生物样品选自全血、血清、血浆、唾液、脑脊液和尿。
30.一种检测生物样品中衣原体感染的方法,其包括:
(a)在聚合酶链反应中使样品接触至少两种寡核苷酸引物,其中至少一种寡核苷酸引物对于包含下列序列的多核苷酸分子是特异的:SEQID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291;和
(b)检测样品中在该寡核苷酸引物存在下扩增的多核苷酸序列,从而检测衣原体感染。
31.段落30的方法,其中至少一种寡核苷酸引物含有下列多核苷酸序列的至少约10个连续核苷酸:SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291。
32.一种检测生物样品中衣原体感染的方法,其包括:
(a)使样品接触一种或两种寡核苷酸探针,所述探针对于包含下列序列的多核苷酸分子是特异的:SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291;和
(b)检测样品中可与该寡核苷酸探针杂交的多核苷酸序列,从而检测衣原体感染。
33.段落32的方法,其中所述探针含有下列多核苷酸序列的至少约15个连续核苷酸:SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291。
34.一种检测生物样品中衣原体感染的方法,其包括:
(a)使生物样品接触一种能与包含衣原体抗原免疫原性部分的多肽结合的结合剂,其中该抗原包含由选自下列的多核苷酸序列编码的氨基酸序列:(i)SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列,(ii)与(i)的序列互补的序列;和(iii)在中度严格条件下可与(i)或(ii)的序列杂交的多核苷酸序列;和
(b)检测样品中可与该结合剂结合的多肽,从而检测生物样品中的衣原体感染。
35.一种检测生物样品中衣原体感染的方法,其包括:
(a)使生物样品接触一种能与含多肽的融合蛋白结合的结合剂,该多肽含有衣原体抗原的免疫原性部分,其中该抗原包含由选自下列的多核苷酸序列编码的氨基酸序列:(i)SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列,(ii)与(i)的序列互补的序列;和(iii)在中度严格条件下可与(i)或(ii)的序列杂交的多核苷酸序列;和
(b)检测样品中可与该结合剂结合的多肽,从而检测生物样品中的衣原体感染。
36.段落34和35任一的方法,其中所述结合剂是一种单克隆抗体。
37.段落34和35任一的方法,其中所述结合剂是一种多克隆抗体。
38.段落34和35中任一的方法,其中所述生物样品选自全血、痰、血清、血浆、唾液、脑脊液和尿。
39.一种诊断试剂盒,其含有:
(a)一种含有衣原体抗原免疫原性部分的多肽,其中该抗原包含由选自下列的多核苷酸序列编码的氨基酸序列:(i)SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列,(ii)与(i)的序列互补的序列;和(iii)在中度严格条件下可与(i)或(ii)的序列杂交的多核苷酸序列;和
(b)一种检测试剂。
40.一种诊断试剂盒,其含有:
(a)一种含有一种多肽的融合蛋白,该多肽含有衣原体抗原的免疫原性部分,其中该抗原包含由选自下列的多核苷酸序列编码的氨基酸序列:(i)SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列,(ii)与(i)的序列互补的序列;和(iii)在中度严格条件下可与(i)或(ii)的序列杂交的多核苷酸序列;和
(b)一种检测试剂。
41.段落39或40的试剂盒,其中所述多肽固定于固体支持物上。
42.段落39或40的试剂盒,其中所述检测试剂含有一种与结合剂偶联的报道基团。
43.段落42的试剂盒,其中所述结合剂选自抗免疫球蛋白、蛋白G、蛋白A和凝集素。
44.段落42的试剂盒,其中所述报道基团选自放射性同位素、荧光团、发光团、酶、生物素和染料颗粒。
45.一种含有至少两种寡核苷酸引物的诊断试剂盒,其中至少一种寡核苷酸引物对于包含下列多核苷酸序列的多核苷酸分子是特异的:SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291。
46.根据段落43的诊断试剂盒,其中至少一种寡核苷酸引物含有下列序列的至少约10个连续核苷酸:SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291。
47.一种含有至少一种寡核苷酸探针的诊断试剂盒,该寡核苷酸探针对于包含下列序列的多核苷酸分子是特异的:SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291。
48.根据段落47的试剂盒,其中寡核苷酸探针含有下列多核苷酸序列的至少约15个连续核苷酸:SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291。
49.一种诊断试剂盒,其含有:
(a)至少一种根据段落22的抗体,或其抗原结合片段;和
(b)一种检测试剂。
50.一种治疗患者衣原体感染的方法,其包括下列步骤:
(a)从患者中获得外周血细胞;
(b)在至少一种多肽存在下温育该细胞,该多肽含有衣原体抗原的免疫原性部分,其中该抗原包含由选自下列的多核苷酸序列编码的氨基酸序列:(i)SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列,(ii)与(i)的序列互补的序列;和(iii)在中度严格条件下可与(i)或(ii)的序列杂交的多核苷酸序列,使得T细胞增殖;和
(c)对患者施用增殖的T细胞。
51.一种治疗患者衣原体感染的方法,其包括下列步骤:
(a)从患者中获得外周血细胞;
(b)在至少一种多核苷酸存在下温育该细胞,该多核苷酸包含选自下列的多核苷酸序列:(i)SEQ ID NO:1-4,15,16,21-25,27,29,33,44-64,66-88,110-119,120,122,124,126,128,130,132,134,136,169-174,181-188,263,265和267-291所示的序列,(ii)与(i)的序列互补的序列;和(iii)在中度严格条件下可与(i)或(ii)的序列杂交的多核苷酸序列,使得T细胞增殖;和
(c)对患者施用增殖的T细胞。
52.段落50和51中任一的方法,其中温育T细胞的步骤重复一次或两次。
53.段落50和51中任一的方法,其中步骤(a)进一步包括从外周血细胞中分离T细胞,步骤(b)中温育的细胞是T细胞。
54.段落50和51中任一的方法,其中步骤(a)进一步包括从外周血细胞中分离CD4+细胞或CD8+T细胞,步骤(b)中增殖的细胞是CD4+或CD8+T细胞。
55.段落50和51中任一的方法,其中步骤(a)进一步包括从外周血细胞中分离γ/δT淋巴细胞,步骤(b)中增殖的细胞是γ/δT淋巴细胞。
56.段落50和51任一的方法,其中步骤(b)进一步包括克隆一种或多种在多肽存在下增殖的T细胞。
57.一种用于治疗患者衣原体感染的药用组合物,其包含在段落1的多肽存在下增殖的T细胞,以及一种生理学可接受的载体。
58.一种用于治疗患者衣原体感染的药用组合物,其包含在段落3的多核苷酸存在下增殖的T细胞,以及一种生理学可接受的载体。
59.一种治疗患者衣原体感染的方法,其包括下列步骤:
(a)在至少一种段落1的多肽存在下温育抗原递呈细胞:
(b)向患者施用温育的抗原递呈细胞。
60.一种治疗患者衣原体感染的方法,其包括下列步骤:
(a)将至少一种段落3的多核苷酸导入抗原递呈细胞中;
(b)向患者施用该抗原递呈细胞。
61.段落59或60的方法,其中抗原递呈细胞选自树突细胞、巨噬细胞、B细胞、成纤维细胞、单核细胞和干细胞。
62.一种用于治疗患者衣原体感染的药用组合物,其包含在段落1的多肽存在下温育的抗原递呈细胞,以及一种生理学可接受的载体。
63.一种用于治疗患者衣原体感染的药用组合物,其包含在段落3的多核苷酸存在下温育的抗原递呈细胞,以及一种生理学可接受的载体。
64.一种含有衣原体抗原的免疫原性部分的多肽,其中该免疫原性部分包含SEQ ID NO:18,19,31,39,93-96,98,100-102,106,108,138-140,158,167,168,246,247和254-256的序列。
65.一种衣原体抗原的免疫原性表位,其包含SEQ ID NO:31,98,106,108,138-140,158,167,168,246,247或254-256的序列。
66.一种分离的多肽,其包含SEQ ID NO:5-14,17-20,26,28,30-32,34,39-43,65,89-109,138-158,167,168,224-262,246,247,254-256和292任一个所示的序列。
序列表
<110>Corixa Corporation
Probst,Peter
Bhatia,Ajay
Skeiky,Yasir
Fling,Steve
Maisonneuve,Jeff
<120>用于治疗及诊断衣原体感染的组合物及方法
<130>210121.469PC
<140>PCT/US99/29012
<141>1999-12-08
<160>303
<170>FastSEQ for Windows Version 3.0/4.0
<210>1
<211>481
<212>DNA
<213>Chlamydia trachomatis
<400>1
ctgaagactt ggctatgttt tttattttga cgataaacct agttaaggca taaaagagtt 60
gcgaaggaag agccctcaac ttttcttatc accttcttta actaggagtc atccatgagt 120
caaaataaga actctgcttt catgcagcct gtgaacgtat ccgctgattt agctgccatc 180
gttggtgcag gacctatgcc tcgcacagag atcattaaga aaatgtggga ttacattaag 240
gagaatagtc ttcaagatcc tacaaacaaa cgtaatatca atcccgatga taaattggct 300
aaagtttttg gaactgaaaa acctatcgat atgttccaaa tgacaaaaat ggtttctcaa 360
cacatcatta aataaaatag aaattgactc acgtgttcct cgtctttaag atgaggaact 420
agttcattct ttttgttcgt ttttgtgggt attactgtat ctttaacaac tatcttagca 480
g 481
<210>2
<211>183
<212>DNA
<213>Chlamydia trachomatis
<400>2
atcgttggtg caggacctat gcctcgcaca gagatcatta agaaaatgtg ggattacatt 60
aaggagaata gtcttcaaga tcctacaaac aaacgtaata tcaatcccga tgataaattg 120
gctaaagttt ttggaactga aaaacctatc gatatgttcc aaatgacaaa aatggtttct 180
caa 183
<210>3
<211>110
<212>DNA
<213>Chlamydia trachomatis
<400>3
gctgcgacat catgcgagct tgcaaaccaa catggacatc tccaatttcc ccttctaact 60
cgctctttgg aactaatgct gctaccgagt caatcacaat cacatcgacc 110
<210>4
<211>555
<212>DNA
<213>Chlamydia trachomatis
<400>4
cggcacgagc ctaagatgct tatactactt taagggaggc ccttcgtatg ccgcgcatca 60
ttggaataga tattcctgcg aaaaagaaat taaaaataag tcttacatat atttatggaa 120
tagggccagc tctttctaaa gagattattg ctagattgca gttgaatccc gaagctagag 180
ctgcagagtt gactgaggaa gaggttggtc gactaaacgc tcttttacag tcggattacg 240
ttgttgaagg ggatttgcgc cgtcgtgtgc aatctgatat caaacgtctg attactatcc 300
atgcttatcg tggacaaaga catagacttt ctttgcctgt tcgtggtcag agaacaaaaa 360
caaattctcg cacgcgtaag ggtaaacgta aaactattgc aggtaagaag aaataataat 420
ttttaggaga gagtgttttg gttaaaaatc aagcgcaaaa aagaggcgta aaaagaaaac 480
aagtaaaaaa cattccttcg ggcgttgtcc atgttaaggc tacttttaat aatacaattg 540
taaccataac agacc 555
<210>5
<211>86
<212>PRT
<213>Chlamydia trachomatis
<400>5
Met Ser Gln Asn Lys Asn Ser Ala Phe Met Gln Pro Val Asn Val Ser
1 5 10 15
Ala Asp Leu Ala Ala Ile Val Gly Ala Gly Pro Met Pro Arg Thr Glu
20 25 30
Ile Ile Lys Lys Met Trp Asp Tyr Ile Lys Glu Asn Ser Leu Gln Asp
35 40 45
Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val
50 55 60
Phe Gly Thr Glu Lys Pro Ile Asp Met Phe Gln Met Thr Lys Met Val
65 70 75 80
Ser Gln His Ile Ile Lys
85
<210>6
<211>61
<212>PRT
<213>Chlamydia trachomatis
<400>6
Ile Val Gly Ala Gly Pro Met Pro Arg Thr Glu Ile Ile Lys Lys Met
1 5 10 15
Trp Asp Tyr Ile Lys Glu Asn Ser Leu Gln Asp Pro Thr Asn Lys Arg
20 25 30
Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val Phe Gly Thr Glu Lys
35 40 45
Pro Ile Asp Met Phe Gln Met Thr Lys Met Val Ser Gln
50 55 60
<210>7
<211>36
<212>PRT
<213>Chlamyida trachomatis
<400>7
Ala Ala Thr Ser Cys Glu Leu Ala Asn Gln His Gly His Leu Gln Phe
1 5 10 15
Pro Leu Leu Thr Arg Ser Leu Glu Leu Met Leu Leu Pro Ser Gln Ser
20 25 30
Gln Ser His Arg
35
<210>8
<211>18
<212>PRT
<213>Chlamydia trachomatis
<400>8
Leu Arg His His Ala Ser Leu Gln Thr Asn Met Asp Ile Ser Asn Phe
1 5 10 15
Pro Phe
<210>9
<211>5
<212>PRT
<213>Chlamydia trachomatis
<400>9
Leu Ala Leu Trp Asn
1 5
<210>10
<211>11
<212>PRT
<213>Chlamydia trachomatis
<400>10
Cys Cys Tyr Arg Val Asn His Asn His Ile Asp
1 5 10
<210>11
<211>36
<212>PRT
<213>Chlamydia trachomatis
<400>11
Val Asp Val Ile Val Ile Asp Ser Val Ala Ala Leu Val Pro Lys Ser
1 5 10 15
Glu Leu Glu Gly Glu Ile Gly Asp Val His Val Gly Leu Gln Ala Arg
20 25 30
Met Met Ser Gln
35
<210>12
<211>122
<212>PRT
<213>Chlamydia trachomatis
<400>12
Met Pro Arg Ile Ile Gly Ile Asp Ile Pro Ala Lys Lys Lys Leu Lys
1 5 10 15
Ile Ser Leu Thr Tyr Ile Tyr Gly Ile Gly Pro Ala Leu Ser Lys Glu
20 25 30
Ile Ile Ala Arg Leu Gln Leu Asn Pro Glu Ala Arg Ala Ala Glu Leu
35 40 45
Thr Glu Glu Glu Val Gly Arg Leu Asn Ala Leu Leu Gln Ser Asp Tyr
50 55 60
Val Val Glu Gly Asp Leu Arg Arg Arg Val Gln Ser Asp Ile Lys Arg
65 70 75 80
Leu Ile Thr Ile His Ala Tyr Arg Gly Gln Arg His Arg Leu Ser Leu
85 90 95
Pro Val Arg Gly Gln Arg Thr Lys Thr Asn Ser Arg Thr Arg Lys Gly
100 105 110
Lys Arg Lys Thr Ile Ala Gly Lys Lys Lys
115 120
<210>13
<211>20
<212>PRT
<213>Chlamydia trachomatis
<400>13
Asp Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys
1 5 10 15
Val Phe Gly Thr
20
<210>14
<211>20
<212>PRT
<213>Chlamydia trachomatis
<400>14
Asp Asp Lys Leu Ala Lys Val Phe Gly Thr Glu Lys Pro Ile Asp Met
1 5 10 15
Phe Gln Met Thr
20
<210>15
<211>161
<212>DNA
<213>Chlymidia trachomatis
<400>15
atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcttc atcggaggaa 60
ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac aaaatgctgg 120
cgcaaccgtt tctttcttcc caaactaaag caaatatggg a 161
<210>16
<211>897
<212>DNA
<213>Chlymidia trachomatis
<400>16
atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca acaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120
attaaggttg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240
actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctctcacat gaaagctgct agtcagaaaa cgcaagaagg ggatgagggg 360
ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480
aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600
gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660
gaagtgccgg gagaggaaaa tgcttgcgag aagaaagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840
ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897
<210>17
<211>298
<212>PRT
<213>Chlamydia trachomatis
<400>17
Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
100 105 110
Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
180 185 190
Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Pro Gly
210 215 220
Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
275 280 285
Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
290 295
<210>18
<211>18
<212>PRT
<213>Chlamydia trachomatis
<400>18
Arg Ala Ala Ala Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile Thr
1 5 10 15
Tyr Leu
<210>19
<211>18
<212>PRT
<213>Chlamydia trachomatis
<400>19
Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe Gly Ala Ile
1 5 10 15
Arg Pro
<210>20
<211>216
<212>PRT
<213>Chlamydia trachomatis
<400>20
Met Arg Gly Ser Gln Gln Ile Phe Val Cys Leu Ile Ser Ala Glu Arg
1 5 10 15
Leu Arg Leu Ser Val Ala Ser Ser Glu Glu Leu Pro Thr Ser Arg His
20 25 30
Ser Glu Leu Ser Val Arg Phe Cys Leu Ser Thr Lys Cys Trp Gln Asn
35 40 45
Arg Phe Phe Leu Pro Lys Leu Lys Gln Ile Trp Asp Leu Leu Leu Ala
50 55 60
Ile Leu Trp Arg Leu Thr Met Gln Arg Leu Trp Trp Val Leu Asp Ser
65 70 75 80
Leu Ser Val Arg Lys Glu Gln Ile Ala Lys Pro Ala Ala Leu Val Leu
85 90 95
Arg Glu Lys Ser Arg Tyr Ser Lys Cys Arg Glu Arg Lys Met Leu Ala
100 105 110
Arg Arg Lys Ser Leu Glu Arg Lys Pro Arg Arg Ser Arg Ala Ser Ser
115 120 125
Met His Ser Ser Leu Cys Ser Arg Ser Phe Trp Asn Ala Leu Pro Thr
130 135 140
Phe Ser Asn Trp Cys Arg Cys Leu Leu Gln Trp Val Phe Val Arg Leu
145 150 155 160
Trp Leu Leu Asp Val Arg Ser Leu Leu Gln Leu Leu Asp Cys Ala Leu
165 170 175
Ser Ala Pro Glu His Lys Gly Phe Phe Lys Phe Leu Lys Lys Lys Ala
180 185 190
Val Ser Lys Lys Lys Gln Pro Phe Leu Ser Thr Lys Cys Leu Ala Phe
195 200 205
Leu Ile Val Lys Ile Val Phe Leu
210 215
<210>21
<211>1256
<212>DNA
<213>Chlamydia trachomatis
<400>21
ctcgtgccgg cacgagcaaa gaaatccctc aaaaaatggc cattattggc ggtggtgtga 60
tcggttgcga attcgcttcc ttattccata cgttaggctc cgaagtttct gtgatcgaag 120
caagctctca aatccttgct ttgaataatc cagatatttc aaaaaccatg ttcgataaat 180
tcacccgaca aggactccgt ttcgtactag aagcctctgt atcaaatatt gaggatatag 240
gagatcgcgt tcggttaact atcaatggga atgtcgaaga atacgattac gttctcgtat 300
ctataggacg ccgtttgaat acagaaaata ttggcttgga taaagctggt gttatttgtg 360
atgaacgcgg agtcatccct accgatgcca caatgcgcac aaacgtacct aacatttatg 420
ctattggaga tatcacagga aaatggcaac ttgcccatgt agcttctcat caaggaatca 480
ttgcagcacg gaatataggt ggccataaag aggaaatcga ttactctgct gtcccttctg 540
tgatctttac cttccctgaa gtcgcttcag taggcctctc cccaacagca gctcaacaac 600
atctccttct tcgcttactt tttctgaaaa atttgataca gaagaagaat tcctcgcaca 660
cttgcgagga ggagggcgtc tggaagacca gttgaattta gctaagtttt ctgagcgttt 720
tgattctttg cgagaattat ccgctaagct tggttacgat agcgatggag agactgggga 780
tttcttcaac gaggagtacg acgacgaaga agaggaaatc aaaccgaaga aaactacgaa 840
acgtggacgt aagaagagcc gttcataagc cttgctttta aggtttggta gttttacttc 900
tctaaaatcc aaatggttgc tgtgccaaaa agtagtttgc gtttccggat agggcgtaaa 960
tgcgctgcat gaaagattgc ttcgagagcg gcatcgcgtg ggagatcccg gatactttct 1020
ttcagatacg aataagcata gctgttccca gaataaaaac ggccgacgct aggaacaaca 1080
agatttagat agagcttgtg tagcaggtaa actgggttat atgttgctgg gcgtgttagt 1140
tctagaatac ccaagtgtcc tccaggttgt aatactcgat acacttccct aagagcctct 1200
aatggatagg ataagttccg taatccatag gccatagaag ctaaacgaaa cgtatt 1256
<210>22
<211>601
<212>DNA
<213>Chlamydia trachomatis
<400>22
ctcgtgccgg cacgagcaaa gaaatccctc aaaaaatggc cattattggc ggtggtgtga 60
tcggttgcga attcgcttcc ttattccata cgttaggctc cgaagtttct gtgatcgaag 120
caagctctca aatccttgct ttgaataatc cagatatttc aaaaaccatg ttcgataaat 180
tcacccgaca aggactccgt ttcgtactag aagcctctgt atcaaatatt gaggatatag 240
gagatcgcgt tcggttaact atcaatggga atgtcgaaga atacgattac gttctcgtat 300
ctataggacg ccgtttgaat acagaaaata ttggcttgga taaagctggt gttatttgtg 360
atgaacgcgg agtcatccct accgatgcca caatgcgcac aaacgtacct aacatttatg 420
ctattggaga tatcacagga aaatggcaac ttgcccatgt agcttctcat caaggaatca 480
ttgcagcacg gaatataggt ggccataaag aggaaatcga ttactctgct gtcccttctg 540
tgatctttac cttccctgaa gtcgcttcag taggcctctc cccaacagca gctcaacaac 600
a 601
<210>23
<211>270
<212>DNA
<213>Chlamydia trachomatis
<400>23
acatctcctt cttcgcttac tttttctgaa aaatttgata cagaagaaga attcctcgca 60
cacttgcgag gaggagggcg tctggaagac cagttgaatt tagctaagtt ttctgagcgt 120
tttgattctt tgcgagaatt atccgctaag cttggttacg atagcgatgg agagactggg 180
gatttcttca acgaggagta cgacgacgaa gaagaggaaa tcaaaccgaa gaaaactacg 240
aaacgtggac gtaagaagag ccgttcataa 270
<210>24
<211>363
<212>DNA
<213>Chlamydia trachomatis
<400>24
ttacttctct aaaatccaaa tggttgctgt gccaaaaagt agtttgcgtt tccggatagg 60
gcgtaaatgc gctgcatgaa agattgcttc gagagcggca tcgcgtggga gatcccggat 120
actttctttc agatacgaat aagcatagct gttcccagaa taaaaacggc cgacgctagg 180
aacaacaaga tttagataga gcttgtgtag caggtaaact gggttatatg ttgctgggcg 240
tgttagttct agaataccca agtgtcctcc aggttgtaat actcgataca cttccctaag 300
agcctctaat ggataggata agttccgtaa tccataggcc atagaagcta aacgaaacgt 360
att 363
<210>25
<211>696
<212>DNA
<213>Chlamydia trachomatis
<400>25
gctcgtgccg gcacgagcaa agaaatccct caaaaaatgg ccattattgg cggtggtgtg 60
atcggttgcg aattcgcttc cttattccat acgttaggct ccgaagtttc tgtgatcgaa 120
gcaagctctc aaatccttgc tttgaataat ccagatattt caaaaaccat gttcgataaa 180
ttcacccgac aaggactccg tttcgtacta gaagcctctg tatcaaatat tgaggatata 240
ggagatcgcg ttcggttaac tatcaatggg aatgtcgaag aatacgatta cgttctcgta 300
tctataggac gccgtttgaa tacagaaaat attggcttgg ataaagctgg tgttatttgt 360
gatgaacgcg gagtcatccc taccgatgcc acaatgcgca caaacgtacc taacatttat 420
gctattggag atatcacagg aaaatggcaa cttgcccatg tagcttctca tcaaggaatc 480
attgcagcac ggaatatagg tggccataaa gaggaaatcg attactctgc tgtcccttct 540
gtgatcttta ccttccctga agtcgcttca gtaggcctct ccccaacagc agctcaacaa 600
catctccttc ttcgcttact ttttctgaaa aatttgatac agaagaagaa ttcctcgcac 660
acttgcgagg aggagggcgt ctggaagacc agttga 696
<210>26
<211>231
<212>PRT
<213>Chlamydia trachomatis
<400>26
Ala Arg Ala Gly Thr Ser Lys Glu Ile Pro Gln Lys Met Ala Ile Ile
1 5 10 15
Gly Gly Gly Val Ile Gly Cys Glu Phe Ala Ser Leu Phe His Thr Leu
20 25 30
Gly Ser Glu Val Ser Val Ile Glu Ala Ser Ser Gln Ile Leu Ala Leu
35 40 45
Asn Asn Pro Asp Ile Ser Lys Thr Met Phe Asp Lys Phe Thr Arg Gln
50 55 60
Gly Leu Arg Phe Val Leu Glu Ala Ser Val Ser Asn Ile Glu Asp Ile
65 70 75 80
Gly Asp Arg Val Arg Leu Thr Ile Asn Gly Asn Val Glu Glu Tyr Asp
85 90 95
Tyr Val Leu Val Ser Ile Gly Arg Arg Leu Asn Thr Glu Asn Ile Gly
100 105 110
Leu Asp Lys Ala Gly Val Ile Cys Asp Glu Arg Gly Val Ile Pro Thr
115 120 125
Asp Ala Thr Met Arg Thr Asn Val Pro Asn Ile Tyr Ala Ile Gly Asp
130 135 140
Ile Thr Gly Lys Trp Gln Leu Ala His Val Ala Ser His Gln Gly Ile
145 150 155 160
Ile Ala Ala Arg Asn Ile Gly Gly His Lys Glu Glu Ile Asp Tyr Ser
165 170 175
Ala Val Pro Ser Val Ile Phe Thr Phe Pro Glu Val Ala Ser Val Gly
180 185 190
Leu Ser Pro Thr Ala Ala Gln Gln His Leu Leu Leu Arg Leu Leu Phe
195 200 205
Leu Lys Asn Leu Ile Gln Lys Lys Asn Ser Ser His Thr Cys Glu Glu
210 215 220
Glu Gly Val Trp Lys Thr Ser
225 230
<210>27
<211>264
<212>DNA
<213>Chlamydia pneumoniae
<400>27
atgagtcaaa aaaataaaaa ctctgctttt atgcatcccg tgaatatttc cacagattta 60
gcagttatag ttggcaaggg acctatgccc agaaccgaaa ttgtaaagaa agtttgggaa 120
tacattaaaa aacacaactg tcaggatcaa aaaaataaac gtaatatcct tcccgatgcg 180
aatcttgcca aagtctttgg ctctagtgat cctatcgaca tgttccaaat gaccaaagcc 240
ctttccaaac atattgtaaa ataa 264
<210>28
<211>87
<212>PRT
<213>Chlamydia pneumoniae
<400>28
Met Ser Gln Lys Asn Lys Asn Ser Ala Phe Met His Pro Val Asn Ile
1 5 10 15
Ser Thr Asp Leu Ala Val Ile Val Gly Lys Gly Pro Met Pro Arg Thr
20 25 30
Glu Ile Val Lys Lys Val Trp Glu Tyr Ile Lys Lys His Asn Cys Gln
35 40 45
Asp Gln Lys Asn Lys Arg Asn Ile Leu Pro Asp Ala Asn Leu Ala Lys
50 55 60
Val Phe Gly Ser Ser Asp Pro Ile Asp Met Phe Gln Met Thr Lys Ala
65 70 75 80
Leu Ser Lys His Ile Val Lys
85
<210>29
<211>369
<212>DNA
<213>Chlamydia pneumoniae
<400>29
atgccacgca tcattggaat tgatattcct gcaaagaaaa agttaaaaat aagtctgaca 60
tatatttatg gaataggatc agctcgttct gatgaaatca ttaaaaagtt gaagttagat 120
cctgaggcaa gagcctctga attaactgaa gaagaagtag gacgactgaa ctctctgcta 180
caatcagaat ataccgtaga aggggatttg cgacgtcgtg ttcaatcgga tatcaaaaga 240
ttgatcgcca tccattctta tcgaggtcag agacatagac tttctttacc agtaagagga 300
caacgtacaa aaactaattc tcgtactcga aaaggtaaaa gaaaaacagt cgcaggtaag 360
aagaaataa 369
<210>30
<211>122
<212>PRT
<213>Chlamydia pneumoniae
<400>30
Met Pro Arg Ile Ile Gly Ile Asp Ile Pro Ala Lys Lys Lys Leu Lys
1 5 10 15
Ile Ser Leu Thr Tyr Ile Tyr Gly Ile Gly Ser Ala Arg Ser Asp Glu
20 25 30
Ile Ile Lys Lys Leu Lys Leu Asp Pro Glu Ala Arg Ala Ser Glu Leu
35 40 45
Thr Glu Glu Glu Val Gly Arg Leu Asn Ser Leu Leu Gln Ser Glu Tyr
50 55 60
Thr Val Glu Gly Asp Leu Arg Arg Arg Val Gln Ser Asp Ile Lys Arg
65 70 75 80
Leu Ile Ala Ile His Ser Tyr Arg Gly Gln Arg His Arg Leu Ser Leu
85 90 95
Pro Val Arg Gly Gln Arg Thr Lys Thr Asn Ser Arg Thr Arg Lys Gly
100 105 110
Lys Arg Lys Thr Val Ala Gly Lys Lys Lys
115 120
<210>31
<211>10
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in the lab
<400>31
Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu
1 5 10
<210>32
<211>53
<212>PRT
<213>Chlamydia trachomatis
<400>32
Leu Cys Val Ser His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Phe
1 5 10 15
Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile
20 25 30
Leu Phe Val Asn Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Thr
35 40 45
Lys Ala Asn Met Gly
50
<210>33
<211>161
<212>DNA
<213>Chlamydia trachomatis
<400>33
atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatc atcggaggaa 60
ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac aaaatgctgg 120
caaaaccgtt tctttcttcc caaactaaag caaatatggg a 161
<210>34
<211>53
<212>PRT
<213>Chlamydia trachomatis
<400>34
Leu Cys Val Ser His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Ile
1 5 10 15
Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile
20 25 30
Leu Phe Val Asn Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr
35 40 45
Lys Ala Asn Met Gly
50
<210>35
<211>55
<212>DNA
<213>Chlamydia pneumoniae
<400>35
gatatacata tgcatcacca tcaccatcac atgagtcaaa aaaaataaaa actct 55
<210>36
<211>33
<212>DNA
<213>Chlamydia pneumoniae
<400>36
ctcgaggaat tcttatttta caatatgttt gga 33
<210>37
<211>53
<212>DNA
<213>Chlamydia pneumoniae
<400>37
gatatacata tgcatcacca tcaccatcac atgccacgca tcattggaat gat 53
<210>38
<211>30
<212>DNA
<213>Chlamydia pneumoniae
<400>38
ctcgaggaat tcttatttct tcttacctgc 30
<210>39
<211>16
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in the lab
<400>39
Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val Phe Gly Thr
1 5 10 15
<210>40
<211>16
<212>PRT
<213>Artificial Sequence
<220>
<223>made in the lab
<400>40
Lys Arg Asn Ile Leu Pro Asp Ala Asn Leu Ala Lys Val Phe Gly Ser
1 5 10 15
<210>41
<211>15
<212>PRT
<213>Artificial Sequence
<220>
<223>made in the lab
<400>41
Lys Glu Tyr Ile Asn Gly Asp Lys Tyr Phe Gln Gln Ile Phe Asp
1 5 10 15
<210>42
<211>16
<212>PRT
<213>Artificial Sequence
<220>
<223>made in the lab
<400>42
Lys Lys Ile Ile Ile Pro Asp Ser Lys Leu Gln Gly Val Ile Gly Ala
1 5 10 15
<210>43
<211>15
<212>PRT
<213>Artificial Sequence
<220>
<223>made in the lab
<400>43
Lys Lys Leu Leu Val Pro Asp Asn Asn Leu Ala Thr Ile Ile Gly
1 5 10 15
<210>44
<211>509
<212>DNA
<213>Chlamydia
<400>44
ggagctcgaa ttcggcacga gagtgcctat tgttttgcag gctttgtctg atgatagcga 60
taccgtacgt gagattgctg tacaagtagc tgttatgtat ggttctagtt gcttactgcg 120
cgccgtgggc gatttagcga aaaatgattc ttctattcaa gtacgcatca ctgcttatcg 180
tgctgcagcc gtgttggaga tacaagatct tgtgcctcat ttacgagttg tagtccaaaa 240
tacacaatta gatggaacgg aaagaagaga agcttggaga tctttatgtg ttcttactcg 300
gcctcatagt ggtgtattaa ctggcataga tcaagcttta atgacctgtg agatgttaaa 360
ggaatatcct gaaaagtgta cggaagaaca gattcgtaca ttattggctg cagatcatcc 420
agaagtgcag gtagctactt tacagatcat tctgagagga ggtagagtat tccggtcatc 480
ttctataatg gaatcggttc tcgtgccgg 509
<210>45
<211>481
<212>DNA
<213>Chlamydia
<220>
<221>unsure
<222>(23)
<223>n=A,T,C or G
<400>45
gatccgaatt cggcacgagg cantatttac tcccaacatt acggttccaa ataagcgata 60
aggtcttcta ataaggaagt taatgtaaga ggctttttta ttgcttttcg taaggtagta 120
ttgcaaccgc acgcgattga atgatacgca agccatttcc atcatggaaa agaacccttg 180
gacaaaaata caaaggaggt tcactcctaa ccagaaaaag ggagagttag tttccatggg 240
ttttccttat atacacccgt ttcacacaat taggagccgc gtctagtatt tggaatacaa 300
attgtcccca agcgaatttt gttcctgttt cagggatttc tcctaattgt tctgtcagcc 360
atccgcctat ggtaacgcaa ttagctgtag taggaagatc aactccaaac aggtcataga 420
aatcagaaag ctcataggtg cctgcagcaa taacaacatt cttgtctgag tgagcgaatt 480
g 481
<210>46
<211>427
<212>DNA
<213>Chlamydia
<220>
<221>unsure
<222>(20)
<223>n=A,T,C or G
<400>46
gatccgaatt cggcacgagn tttttcctgt tttttcttag tttttagtgt tcccggagca 60
ataacacaga tcaaagaacg gccattcagt ttaggctctg actcaacaaa acctatgtcc 120
tctaagccct gacacattct ttgaacaacc ttatgcccgt gttcgggata agccaactct 180
cgcccccgaa acatacaaga aacctttact ttatttcctt tctcaataaa ggctctagct 240
tgctttgctt tcgtaagaaa gtcgttatca tcgatattag gcttaagctt aacctctttg 300
atacgcactt ggtgctgtgc tttcttacta tctttttctt ttttagttat gtcgtaacga 360
tacttcccgt agtccatgat tttgcacaca ggaggctctg agtttgaagc aacctcgtgc 420
cgaattc 427
<210>47
<211>600
<212>DNA
<213>Chlamydia
<220>
<221>unsure
<222>(522)
<223>n=A,T,Cor G
<400>47
gatccgaatt cggcacgaga tgcttctatt acaattggtt tggatgcgga aaaagcttac 60
cagcttattc tagaaaagtt gggagatcaa attcttggtg gaattgctga tactattgtt 120
gatagtacag tccaagatat tttagacaaa atcacaacag acccttctct aggtttgttg 180
aaagctttta acaactttcc aatcactaat aaaattcaat gcaacgggtt attcactccc 240
aggaacattg aaactttatt aggaggaact gaaataggaa aattcacagt cacacccaaa 300
agctctggga gcatgttctt agtctcagca gatattattg catcaagaat ggaaggcggc 360
gttgttctag ctttggtacg agaaggtgat tctaagccct acgcgattag ttatggatac 420
tcatcaggcg ttcctaattt atgtagtcta agaaccagaa ttattaatac aggattgact 480
ccgacaacgt attcattacg tgtaggcggt ttagaaagcg gngtggtatg ggttaatgcc 540
ctttctaatg gcaatgatat tttaggaata acaaatcttc taatgtatct tttttggagg 600
<210>48
<211>600
<212>DNA
<213>Chlamydia
<400> 48
ggagctcgaa ttcggcacga gctctatgaa tatccaattc tctaaactgt tcggataaaa 60
atgatgcagg aattaggtcc acactatctt tttttgtttc gcaaatgatt gattttaaat 120
cgtttgatgt gtatactatg tcgtgtaagc ctttttggtt acttctgaca ctagccccca 180
atccagaaga taaattggat tgcgggtcta ggtcagcaag taacactttt ttccctaaaa 240
attgggccaa gttgcatccc acgtttagag aaagtgttgt ttttccagtt cctcccttaa 300
aagagcaaaa aactaaggtg tgcaaatcaa ctccaacgtt agagtaagtt atctattcag 360
ccttggaaaa catgtctttt ctagacaaga taagcataat caaagccttt tttagcttta 420
aactgttatc ctctaatttt tcaagaacag gagagtctgg gaataatcct aaagagtttt 480
ctatttgttg aagcagtcct agaattagtg agacactttt atggtagagt tctaagggag 540
aatttaagaa agttactttt tccttgttta ctcgtatttt taggtctaat tcggggaaat 600
<210>49
<211>600
<212>DNA
<213>Chlamydia
<400>49
gatccgaatt cggcacgaga tgcttctatt acaattggtt tggatgcgga aaaagcttac 60
cagcttattc tagaaaagtt gggagatcaa attcttggtg gaattgctga tactattgtt 120
gatagtacag tccaagatat tttagacaaa atcacaacag acccttctct aggtttgttg 180
aaagctttta acaactttcc aatcactaat aaaattcaat gcaacgggtt attcactccc 240
aggaacattg aaactttatt aggaggaact gaaataggaa aattcacagt cacacccaaa 300
agctctggga gcatgttctt agtctcagca gatattattg catcaagaat ggaaggcggc 360
gttgttctag ctttggtacg agaaggtgat tctaagccct acgcgattag ttatggatac 420
tcatcaggcg ttcctaattt atgtagtcta agaaccagaa ttattaatac aggattgact 480
ccgacaacgt attcattacg tgtaggcggt ttagaaagcg gtgtggtatg ggttaatgcc 540
ctttctaatg gcaatgatat tttaggaata acaaatactt ctaatgtatc ttttttggag 600
<210>50
<211>406
<212>DNA
<213>Chlamydia
<400>50
gatccgaatt cggcacgagt tcttagcttg cttaattacg taattaacca aactaaaggg 60
gctatcaaat agcttattca gtctttcatt agttaaacga tcttttctag ccatgactca 120
tcctatgttc ttcagctata aaaatacttc ttaaaacttg atatgctgta atcaaatcat 180
cattaaccac aacataatca aattcgctag cggcagcaat ttcgacagcg ctatgctcta 240
atctttcttt cttctggaaa tctttctctg aatcccgagc attcaaacgg cgctcaagtt 300
cttcttgaga gggagcttga ataaaaatgt gactgccggc atttgcttct tcagagccaa 360
agctccttgt acatcaatca cggctatgca gtctcgtgcc gaattc 406
<210>51
<211>602
<212>DNA
<213>Chlamydia
<400>51
gatccgaatt cggcacgaga tattttagac aaaatcacaa cagacccttc tctaggtttg 60
ttgaaagctt ttaacaactt tccaatcact aataaaattc aatgcaacgg gttattcact 120
cccaggaaca ttgaaacttt attaggagga actgaaatag gaaaattcac agtcacaccc 180
aaaagctctg ggagcatgtt cttagtctca gcagatatta ttgcatcaag aatggaaggc 240
ggcgttgttc tagctttggt acgagaaggt gattctaagc cctacgcgat tagttatgga 300
tactcatcag gcgttcctaa tttatgtagt ctaagaacca gaattattaa tacaggattg 360
actccgacaa cgtattcatt acgtgtaggc ggtttagaaa gcggtgtggt atgggttaat 420
gccctttcta atggcaatga tattttagga ataacaaata cttctaatgt atcttttttg 480
gaggtaatac ctcaaacaaa cgcttaaaca atttttattg gatttttctt ataggtttta 540
tatttagaga aaaaagttcg aattacgggg tttgttatgc aaaataaact cgtgccgaat 600
tc 602
<210>52
<211>145
<212>DNA
<213>Chlamydia
<400>52
gatccgaatt cggcacgagc tcgtgccgat gtgttcaaca gcatccatag gatgggcagt 60
caaatatact ccaagtaatt ctttttctct tttcaacaac tccttaggag agcgttggat 120
aacattttca gctcgtgccg aattc 145
<210>53
<211>450
<212>DNA
<213>Chlamydia
<400>53
gatccgaatt cggcacgagg taatcggcac cgcactgctg acactcatct cctcgagctc 60
gatcaaaccc acacttggga caagtaccta caacataacg gtccgctaaa aacttccctt 120
cttcctcaga atacagctgt tcggtcacct gattctctac cagtccgcgt tcctgcaagt 180
ttcgatagaa atcttgcaca atagcaggat gataagcgtt cgtagttctg gaaaagaaat 240
ctacagaaat tcccaatttc ttgaaggtat ctttatgaag cttatgatac atgtcgacat 300
attcttgata ccccatgcct gccaactctg cattaagggt aattgcgatt ccgtattcat 360
cagaaccaca aatatacaaa acctctttgc cttgtagtct ctgaaaacgc gcataaacat 420
ctgcaggcaa ataagcctcg tgccgaattc 450
<210>54
<211>716
<212>DNA
<213>Chlamydia
<400>54
gatcgaaatt cggcacgagc ggcacgagtt ttctgatagc gatttacaat cctttattca 60
acttttgcct agagaggcac actatactaa gaagtttctt gggtgtgtgg cacagtcctg 120
tcgtcagggg attctgctag aggggtaggg gaaaaaaccc ttattactat gaccatgcgc 180
atgtggaatt acattccata gactttcgca tcattcccaa catttacaca gctctacacc 240
tcttaagaag aggtgacgtg gattgggtgg ggcagccttg gcaccaaggg attccttttg 300
agcttcggac tacctctgct ctctacaccc attaccctgt agatggcaca ttctggctta 360
ttcttaatcc caaagatcct gtactttcct ctctatctaa tcgtcagcga ttgattgctg 420
ccatccaaaa ggaaaaactg gtgaagcaag ctttaggaac acaatatcga gtagctgaaa 480
gctctccatc tccagaggga atcatagctc atcaagaagc ttctactcct tttcctggga 540
aaattacttt gatatatccc aataatatta cgcgctgtca gcgtttggcc gaggtatcca 600
aaaaatgatc gacaaggagc acgctaaatt tgtacatacc ccaaaatcaa tcagccatct 660
aggcaaatgg aatatcaaag taaacagtat acaactgggg atctcgtgcc gaattc 716
<210>55
<211>463
<212>DNA
<213>Chlamydia trachomatis
<400>55
tctcaaatcc ttgctttgaa taatccagat atttcaaaaa ccatgttcga taaattcacc 60
cgacaaggac tccgtttcgt actagaagcc tctgtatcaa atattgagga tataggagat 120
cgcgttcggt taactatcaa tgggaatgtc gaagaatacg attacgttct cgtatctata 180
ggacgccgtt tgaatacaga aaatattggc ttggataaag ctggtgttat ttgtgatgaa 240
cgcggagtca tccctaccga tgccacaatg cgcacaaacg tacctaacat ttatgctatt 300
ggagatatca caggaaaatg gcaacttgcc catgtagctt ctcatcaagg aatcattgca 360
gcacggaata taggtggcca taaagaggaa atcgattact ctgctgtccc ttctgtgatc 420
tttaccttcc ctgaagtcgc ttcagtaggc ctctccccaa cag 463
<210>56
<211>829
<212>DNA
<213>Chlamydia trachomatis
<400>56
gtactatggg atcattagtt ggaagacagg ctccggattt ttctggtaaa gccgttgttt 60
gtggagaaga gaaagaaatc tctctagcag actttcgtgg taagtatgta gtgctcttct 120
tttatcctaa agattttacc tatgtttgtc ctacagaatt acatgctttt caagatagat 180
tggtagattt tgaagagcat ggtgcagtcg tccttggttg ctccgttgac gacattgaga 240
cacattctcg ttggctcact gtagcgagag atgcaggagg gatagaggga acagaatatc 300
ctctgttagc agacccctct tttaaaatat cagaagcttt tggtgttttg aatcctgaag 360
gatcgctcgc tttaagagct actttcctta tcgataaaca tggggttatt cgtcatgcgg 420
ttatcaatga tcttccttta gggcgttcca ttgacgagga attgcgtatt ttagattcat 480
tgatcttctt tgagaaccac ggaatggttt gtccagctaa ctggcgttct ggagagcgtg 540
gaatggtgcc ttctgaagag ggattaaaag aatacttcca gacgatggat taagcatctt 600
tgaaagtaag aaagtcgtac agatcttgat ctgaaaagag aagaaggctt tttaattttc 660
tgcagagagc cagcgaggct tcaataatgt tgaagtctcc gacaccaggc aatgctaagg 720
cgacgatatt agttagtgaa gtctgagtat taaggaaatg aaggccaaag aaatagctat 780
caataaagaa gccttcttcc ttgactctaa agaatagtat gtcgtatcc 829
<210>57
<211>1537
<212>DNA
<213>Chlamydia trachomatis
<400>57
acatcaagaa atagcggact cgcctttagt gaaaaaagct gaggagcaga ttaatcaagc 60
acaacaagat attcaaacga tcacacctag tggtttggat attcctatcg ttggtccgag 120
tgggtcagct gcttccgcag gaagtgcggc aggagcgttg aaatcctcta acaattcagg 180
aagaatttcc ttgttgcttg atgatgtaga caatgaaatg gcagcgattg caatgcaagg 240
ttttcgatct atgatcgaac aatttaatgt aaacaatcct gcaacagcta aagagctaca 300
agctatggag gctcagctga ctgcgatgtc agatcaactg gttggtgcgg atggcgagct 360
cccagccgaa atacaagcaa tcaaagatgc tcttgcgcaa gctttgaaac aaccatcagc 420
agatggttta gctacagcta tgggacaagt ggcttttgca gctgccaagg ttggaggagg 480
ctccgcagga acagctggca ctgtccagat gaatgtaaaa cagctttaca agacagcgtt 540
ttcttcgact tcttccagct cttatgcagc agcactttcc gatggatatt ctgcttacaa 600
aacactgaac tctttatatt ccgaaagcag aagcggcgtg cagtcagcta ttagtcaaac 660
tgcaaatccc gcgctttcca gaagcgtttc tcgttctggc atagaaagtc aaggacgcag 720
tgcagatgct agccaaagag cagcagaaac tattgtcaga gatagccaaa cgttaggtga 780
tgtatatagc cgcttacagg ttctggattc tttgatgtct acgattgtga gcaatccgca 840
agcaaatcaa gaagagatta tgcagaagct cacggcatct attagcaaag ctccacaatt 900
tgggtatcct gctgttcaga attctgtgga tagcttgcag aagtttgctg cacaattgga 960
aagagagttt gttgatgggg aacgtagtct cgcagaatct caagagaatg cgtttagaaa 1020
acagcccgct ttcattcaac aggtgttggt aaacattgct tctctattct ctggttatct 1080
ttcttaacgt gtgattgaag tttgtgaatt gagggggagc caaaaaagaa tttctttttt 1140
ggctcttttt tcttttcaaa ggaatctcgt gtctacagaa gtcttttcaa taataagttc 1200
ttagttccaa aagaagaaaa tatataaaag aaaaaactcc taattcattt aaaaagtgct 1260
cggcagactt cgtggaaaat gtctgtaaag ctggagggga atcagcagaa agatgcaaga 1320
tatccgagaa aaaaggctca ggctcgtgcc gaattcggca cgagactacg aaagaaaggt 1380
cttttctttc ggaatctgtc attggatctg cgtaagactt aaagttcggc aacacaggct 1440
ctgtcttctc tttaggtttc ttgcgcgaga aaaattttct caagtaacaa gaagatttct 1500
ttttacagcc ggcatccggc ttctcgcgaa gtataac 1537
<210>58
<211>463
<212>DNA
<213>Chlamydia trachomatis
<400>58
tctcaaatcc ttgctttgaa taatccagat atttcaaaaa ccatgttcga taaattcacc 60
cgacaaggac tccgtttcgt actagaagcc tctgtatcaa atattgagga tataggagat 120
cgcgttcggt taactatcaa tgggaatgtc gaagaatacg attacgttct cgtatctata 180
ggacgccgtt tgaatacaga aaatattggc ttggataaag ctggtgttat ttgtgatgaa 240
cgcggagtca tccctaccga tgccacaatg cgcacaaacg tacctaacat ttatgctatt 300
ggagatatca caggaaaatg gcaacttgcc catgtagctt ctcatcaagg aatcattgca 360
gcacggaata taggtggcca taaagaggaa atcgattact ctgctgtccc ttctgtgatc 420
tttaccttcc ctgaagtcgc ttcagtaggc ctctccccaa cag 463
<210>59
<211>552
<212>DNA
<213>Chlamydia trachomatis
<400>59
acattcctcc tgctcctcgc ggccatccac aaattgaggt aaccttcgat attgatgcca 60
acggaatttt acacgtttct gctaaagatg ctgctagtgg acgcgaacaa aaaatccgta 120
ttgaagcaag ctctggatta aaagaagatg aaattcaaca aatgatccgc gatgcagagc 180
ttcataaaga ggaagacaaa caacgaaaag aagcttctga tgtgaaaaat gaagccgatg 240
gaatgatctt tagagccgaa aaagctgtga aagattacca cgacaaaatt cctgcagaac 300
ttgttaaaga aattgaagag catattgaga aagtacgcca agcaatcaaa gaagatgctt 360
ccacaacagc tatcaaagca gcttctgatg agttgagtac tcgtatgcaa aaaatcggag 420
aagctatgca ggctcaatcc gcatccgcag cagcatcttc tgcagcgaat gctcaaggag 480
ggccaaacat taactccgaa gatctgaaaa aacatagttt cagcacacga cctccagcag 540
gaggaagcgc ct 552
<210>60
<211>1180
<212>DNA
<213>Chlamydia trachomatis
<400>60
atcctagcgg taaaactgct tactggtcag ataaaatcca tacagaagca acacgtactt 60
cttttaggag aaaaaatcta taatgctaga aaaatcctga gtaaggatca cttctcctca 120
acaacttttt catcttggat agagttagtt tttagaacta agtcttctgc ttacaatgct 180
cttgcatatt acgagctttt tataaacctc cccaaccaaa ctctacaaaa agagtttcaa 240
tcgatcccct ataaatccgc atatattttg gccgctagaa aaggcgattt aaaaaccaag 300
gtcgatgtga tagggaaagt atgtggaatc tcgtgccgaa ttcggcacga gcggcacgag 360
gatgtagagt aattagttaa agagctgcat aattatgaca aagcatggaa aacgcattcg 420
tggtatccaa gagacttacg atttagctaa gtcgtattct ttgggtgaag cgatagatat 480
tttaaaacag tgtcctactg tgcgtttcga tcaaacggtt gatgtgtctg ttaaattagg 540
gatcgatcca agaaagagtg atcagcaaat tcgtggttcg gtttctttac ctcacggtac 600
aggtaaagtt ttgcgaattt tagtttttgc tgctggagat aaggctgcag aggctattga 660
agcaggagcg gactttgttg gtagcgacga cttggtagaa aaaatcaaag gtggatgggt 720
tgacttcgat gttgcggttg ccactcccga tatgatgaga gaggtcggaa agctaggaaa 780
agttttaggt ccaagaaacc ttatgcctac gcctaaagcc ggaactgtaa caacagatgt 840
ggttaaaact attgcggaac tgcgaaaagg taaaattgaa tttaaagctg atcgagctgg 900
tgtatgcaac gtcggagttg cgaagctttc tttcgatagt gcgcaaatca aagaaaatgt 960
tgaagcgttg tgtgcagcct tagttaaagc taagcccgca actgctaaag gacaatattt 1020
agttaatttc actatttcct cgaccatggg gccaggggtt accgtggata ctagggagtt 1080
gattgcgtta taattctaag tttaaagagg aaaaatgaaa gaagagaaaa agttgctgct 1140
tcgcgaggtt gaagaaaaga taaccgcttc tcggcacgag 1180
<210>61
<211>1215
<212>DNA
<213>Chlamydia trachomatis
<400>61
attacagcgt gtgcaggtaa cgacatcatt gcatgatgct tttgatggca ttgatgcggc 60
attccttata gggtcagttc ctagaggccc aggaatggag agaagagatc ttctaaagaa 120
aaatggggag attgttgcta cgcaaggaaa agctttgaac acaacagcca agcgggatgc 180
aaagattttt gttgttggga accctgtgaa taccaattgc tggatagcaa tgaatcatgc 240
tcccagatta ttgagaaaga actttcatgc gatgctacga ttggaccaga atcgtatgca 300
tagcatgtta tcgcatagag cagaagtacc tttatcggct gtatcacaag ttgtggtttg 360
gggaaatcac tccgccaaac aagtgcctga ttttacgcaa gctctgatta atgaccgtcc 420
tatcgcagag acgatagcgg atcgtgattg gttagagaat attatggtgc cttctgtaca 480
gagtcgtggt agtgcagtaa ttgaagcacg agggaagtct tcggcagctt ctgcagcacg 540
agctttagca gaggctgctc gatcaatata tcagccaaaa gaaggactcg tgccgaattc 600
ggcacgagta tcgaaattgc aggcatttct agtgaatggt cgtatgctta taaactacgt 660
ggtacagact tgagctctca aaagtttgct acagattctt acatcgcaga cccttattct 720
aagaatatct actcccctca actatttgga tcccctaaac aagaaaagga ttacgcattt 780
agttacctga aatatgagga ttttgactgg gaaggcgaca ctcctttgca ccttccaaaa 840
gaaaattact tcatttatga aatgcatgtt cggtcattca cccgagatcc gtcttcccag 900
gtttcccatc ctggaacttt ccttggtatc atcgaaaaaa tagaccacct caaacaacta 960
ggcgttcatg cagttgaact ccttcctatt ttcgaattcg atgaaaccgt ccatccattt 1020
aaaaatcagg acttccccca cctgtgtaac tattgggggt attcttcggt gaattttttc 1080
tgcccctctc gccgttatac ttatggggca gacccttgcg ctccggcccg agagttcaag 1140
actcttgtca aagcgttaca ccgtgcggga atcgaagtca ttctcgatgt cgttttcaat 1200
catacaggct ttgaa 1215
<210>62
<211>688
<212>DNA
<213>Chlamydia trachomatis
<400>62
gtggatccaa aaaagaatct aaaaagccat acaaagattg cgttacttct tgcgatgcct 60
ctaacacttt atcagcgtca tctttgagaa gcatctcaat gagcgctttt tcttctctag 120
catgccgcac atccgcttct tcatgttctg tgaaatatgc atagtcttca ggattggaaa 180
atccaaagta ctcagtcaat ccacgaattt tctctctagc gatacgtgga atttgactct 240
cataagaata caaagcagcc actcctgcag ctaaagaatc tcctgtacac caccgcatga 300
aagtagctac tttcgctttt gctgcttcac taggctcatg agcctctaac tcttctggag 360
taactcctag agcaaacaca aactgcttcc acaaatcaat atgattaggg taaccgttct 420
cttcatccat caagttatct aacaataact tacgcgcctc taaatcatcg caacgactat 480
gaatcgcaga taaatattta ggaaaggctt tgatatgtaa ataatagtct ttggcacgag 540
cctgtaattg ctctttagta agctccccct tcgaccattt cacataaaac gtgtgttcta 600
gcatatgctt attttgaata attaaatcta actgatctaa aaaattcata aacacctcca 660
tcatttcttt tcttgactcc acgtaacc 688
<210>63
<211>269
<212>DNA
<213>Chlamydia trachomatis
<400>63
atgttgaaat cacacaagct gttcctaaat atgctacggt aggatctccc tatcctgttg 60
aaattactgc tacaggtaaa agggattgtg ttgatgttat cattactcag caattaccat 120
gtgaagcaga gttcgtacgc agtgatccag cgacaactcc tactgctgat ggtaagctag 180
tttggaaaat tgaccgctta ggacaaggcg aaaagagtaa aattactgta tgggtaaaac 240
ctcttaaaga aggttgctgc tttacagct 269
<210>64
<211>1339
<212>DNA
<213>Chlamydia trachomatis
<400>64
cttttattat ggcttctggg gatgatgtca acgatatcga cctgctatct cgaggagatt 60
ttaaaattgt tatacagacg gctccagagg agatgcatgg attagcggac tttttggctc 120
ccccggcgaa ggatcttggt attctctccg cctgggaagc tggtgagctg cgttacaaac 180
agctagttaa tccttaggaa acatttctgg acctatgccc atcacattgg ctccgtgatc 240
cacatagaga gtttctcccg taattgcgct agctagggga gagactaaga aggctgctgc 300
tgcgcctact tgctcagctt ccattggaga aggtagtgga gcccagtctt ggtagtaatc 360
caccattctc tcaataaatc caatagcttt tcctgcacgg ctagctaatg gccctgccga 420
gatagtattc actcggactc cccaacgtcg gccggcttcc caagccagta cttttgtatc 480
actttctaaa gcagcttttg ctgcgttcat tcctccgcca taccctggaa cagcacgcat 540
ggaagcaaga taagttagag agatggtgct agctcctgca ttcataattg ggccaaaatg 600
agagagaagg ctgataaagg agtagctgga tgtacttaag gcggcaagat agcctttacg 660
agaggtatca agtaatggtt tagcaatttc cggactgttt gctaaagagt gaacaagaat 720
atcaatgtgt ccaaaatctt ttttcacctg ttctacaact tcggatacag tgtacccaga 780
aagatctttg taacgtttat tttccaaaat ttcctgagga atatcttctg gggtgtcgaa 840
actggcatcc atgggataga ttttagcgaa agttagcaat tctccattgg agagttcacg 900
agatgcattg aattttccta actcccaaga ttgagagaaa attttataga taggaaccca 960
ggtccccaca agtatggttg cgcctgcttc tgctaacatt ttggcaatgc cccagccata 1020
cccgttatca tcgcctatgc cggctatgaa agcaattttt cctgttaaat caattttcaa 1080
catgagctaa ccccattttg tcttcttgag agaggagagt agcagattct ttattattga 1140
gaaacgggcc tcataataca taaggagtag attcactggc tggatccagg tttctagagt 1200
aaagagtttc cttgtcaaat tcttatatgg gtagagttaa tcaactgttt tcaagtgatt 1260
tatgtttatt ttaaaataat ttgttttaac aactgtttaa tagttttaat ttttaaagtg 1320
tgaaaaacag gttttatat 1339
<210>65
<211>195
<212>PRT
<213>Chlamydia trachomatis
<400>65
Met Gly Ser Leu Val Gly Arg Gln Ala Pro Asp Phe Ser Gly Lys Ala
5 10 15
Val Val Cys Gly Glu Glu Lys Glu Ile Ser Leu Ala Asp Phe Arg Gly
20 25 30
Lys Tyr Val Val Leu Phe Phe Tyr Pro Lys Asp Phe Thr Tyr Val Cys
35 40 45
Pro Thr Glu Leu His Ala Phe Gln Asp Arg Leu Val Asp Phe Glu Glu
50 55 60
His Gly Ala Val Val Leu Gly Cys Set Val Asp Asp Ile Glu Thr His
65 70 75 80
Ser Arg Trp Leu Thr Va1 Ala Arg Asp Ala Gly Gly Ile Glu Gly Thr
85 90 95
Glu Tyr Pro Leu Leu Ala Asp Pro Ser Phe Lys Ile Ser Glu Ala Phe
100 105 110
Gly Val Leu Asn Pro Glu Gly Ser Leu Ala Leu Arg Ala Thr Phe Leu
115 120 125
Ile Asp Lys His Gly Val Ile Arg His Ala Val Ile Asn Asp Leu Pro
130 135 140
Leu Gly Arg Ser Ile Asp Glu Glu Leu Arg Ile Leu Asp Ser Leu Ile
145 150 155 160
Phe Phe Glu Asn His Gly Met Val Cys Pro Ala Asn Trp Arg Ser Gly
165 170 175
Glu Arg Gly Met Val Pro Ser Glu Glu Gly Leu Lys Glu Tyr Phe Gln
180 185 190
Thr Met Asp
195
<210>66
<211>520
<212>DNA
<213>Chlamydia
<400>66
gatccgaatt cggcacgagg aggaatggaa gggccctccg attttaaatc tgctaccatg 60
ccattcacta gaaactccat aacagcggtt ttctctgatg gcgagtaaga agcaagcatt 120
tgatgtaaat tagcgcaatt agagggggat gaggttactt ggaaatataa ggagcgaagc 180
gatgaaggag atgtatttgc tctggaagca aaggtttctg aagctaacag aacattgcgt 240
cctccaacaa tcgcctgagg attctggctc atcagttgat gctttgcctg aatgagagcg 300
gacttaagtt tcccatcaga gggagctatt tgaattagat aatcaagagc tagatccttt 360
attgtgggat cagaaaattt acttgtgagc gcatcgagaa tttcgtcaga agaagaatca 420
tcatcgaacg aatttttcaa tcctcgaaaa tcttctccag agacttcgga aagatcttct 480
gtgaaacgat cttcaagagg agtatcgcct ttttcctctg 520
<210>67
<211>276
<212>DNA
<213>Chlamydia
<400>67
gatccgaatt cggcacgagg tattgaagga gaaggatctg actcgatcta tgaaatcatg 60
atgcctatct atgaagttat gaatatggat ctagaaacac gaagatcttt tgcggtacag 120
caagggcact atcaggaccc aagagcttca gattatgacc tcccacgtgc tagcgactat 180
gatttgccta gaagcccata tcctactcca cctttgcctt ctagatatca gctacagaat 240
atggatgtag aagcagggtt ccgtgaggca gtttat 276
<210>68
<211>248
<212>DNA
<213>Chlamydia
<400>68
gatccgaatt cggcacgagg tgttcaagaa tatgtccttc aagaatgggt taaattgaaa 60
gatctaccgg tagaagagtt gctagaaaaa cgatatcaga aattccgaac gataggtcta 120
tatgaaactt cttctgaaag cgattctgag gcataagaag catttagttt tattcggttt 180
ttctctttta tccatattag ggctaacgat aacgtctcaa gcagaaattt tttctctagg 240
tcttattg 248
<210>69
<211>715
<212>DNA
<213>Chlamydia
<220>
<221>unsure
<222>(34)
<223>n=A,T,C or G
<400>69
gatccgaatt cggcacgaga aggtagatcc gatntcagca aaagtgctcc taaaggaaga 60
ttccttcggt atcctgcagc aaataaggtg gcacactcca tctcggacag tttgagcttt 120
attttcatat agttttcgac ggaactcttt attaaactcc caaaaccgaa tgttagtcgt 180
gtgggtgatg cctatatggt aagggaggtt tttggcttcg agaatattgg tgatcatttt 240
ttgtacgaca aaattagcta atgcagggac ctctgggggg aagtatgcat ctgatgttcc 300
atcttttcgg atgctagcaa cagggacaaa ataatctcct atttggtagt gggatcttaa 360
gcctccgcac atgcccaaca tgatcgctgc tgtagcattg ggaaggaaag aacacagatc 420
tacggtaaga gctgctcctg gagagcctaa tttaaaatcg atgattgagg tgtgaatttg 480
aggcgcatgc gctgccgaaa acatggatcc tcgagaaaca gggacctgat agatttcagc 540
gaaaacatcc acggtaatac ccmaaattag taagaaggag atagggctgg aactcttgaa 600
tggtagagcc ggtatagcgc tctagcatgt cacaggcgat tgtttcttcg ctgatttttt 660
tatgttgatg ggtcataaat cacagatatt ataatggtta gagaatcttt ttttc 715
<210>70
<211>323
<212>DNA
<213>Chlamydia
<400>70
gatccgaatt cggcacgagc agaacgtaaa cagcacactt aaaccgtgta tgaggtttaa 60
cactgtttgg caagcaaaca accattcctc tttccacatc gttcttacca atacctctga 120
ggagcaatcc aacattctct cctgcacgac cttctgggag ttcttttctg aacatttcaa 180
ccccagtaac aatcgtttct ttagtatctc taagaccgac caactgaact ttatcggaaa 240
ctttaacaat tccacgctca atacgtccag ttactacagt tcctcgtccg gagatagaga 300
acacgtcctc aatgggcatt aag 323
<210>71
<211>715
<212>DNA
<213>Chlamydia
<400>71
gatccgaatt cggcacgagg aaaaaaagat tctctaacca ttataatatc tgtgatttat 60
gacccatcaa cataaaaaaa tcagcgaaga aacaatcgcc tgtgacatgc tagagcggct 120
ataccggctc taccattcaa gagttccagc cctatctcct tcttactaat tttgggtatt 180
acgtggatgt tttcgctgaa atctatcagg tccctgtttc tcgaggatcc atgttttcgg 240
gcagcgcatg cgcctcaaat tcacacctca atcatcgatt ttaaattagg ctctccagga 300
gcagctctta ccgtagatct gtgttctttc cttcccaatg ctacagcagc gatcatgttg 360
ggcatgtgcg gaggcttaag atcccactac caaataggag attattttgt ccctgttgct 420
agcatccgaa aagatggaac atcagatgca tacttccccc cagaggtccc tgcattagct 480
aattttgtcg tacaaaaaat gatcaccaat attctcgaag ccaaaaacct cccttaccat 540
ataggcatca cccacacgac taacattcgg ttttgggagt ttaataaaga gttccgtcga 600
aaactatatg aaaataaagc tcaaactgtc gagatggagt gtgccacctt atttgctgca 660
ggataccgaa ggaatcttcc tttaggagca cttttgctga tatcggatct acctt 715
<210>72
<211>641
<212>DNA
<213>Chlamydia
<220>
<221>unsure
<222>(550)
<223>n=A,T,C or G
<221>unsure
<222>(559)
<223>n=A,T,C or G
<221>unsure
<222>(575)
<223>n=A,T,C or G
<221>unsure
<222>(583)
<223>n=A,T,C or G
<221>unsure
<222>(634)
<223>n=A,T,C or G
<221>unsure
<222>(638)
<223>n=A,T,C or G
<400>72
gatccgaatt cggcacgaga tctcctcgag ctcgatcaaa cccacacttg ggacaagtac 60
ctacaacata acggtccgct aaaaacttcc cttcttcctc agaatacagc tgttcggtca 120
cctgattctc taccagtccg cgttcctgca agtttcgata gaaatcttgc acaatagcag 180
gatgataagc gttcgtagtt ctggaaaaga aatctacaga aattcccaat ttcttgaagg 240
tatctttatg aagcttatga tacatgtcga catattcttg ataccccatg cctgccaact 300
ctgcattaag ggtaattgcg attccgtatt catcagaacc acaaatatac aaaacctctt 360
tgccttgtag tctctgaaaa cgcgcataaa catctgcagg caaataagca ccggtaatat 420
gtccaaaatg caaaggacca tttgcgtaag gcaacgcaga agtaataaga atacgggaag 480
attccactat ttcacgtcgc tccagttgta cagagaagga tcttttcttc tggatgttcc 540
gaaaccttgn tctcttcgnc tctctcctgt agcanacaaa tgnctctctc gacatctctt 600
tcagcgtatt cggactgatg ccctaaagat cccnggangt t 641
<210>73
<211>584
<212>DNA
<213>Chlamydia
<220>
<221>unsure
<222>(460)
<223>n=A,T,C or G
<221>unsure
<222>(523)
<223>n=A,T,C or G
<221>unsure
<222>(541)
<223>n=A,T,C or G
<221>unsure
<222>(546)
<223>n=A,T,C or G
<400>73
gaattcggca cgagacattt ctagaatgga accggcaaca aacaaaaact ttgtatctga 60
agatgacttt aagcaatctt tagataggga agattttttg gaatgggtct ttttatttgg 120
gacttattac ggaacgagta aggcggagat ttctagagtt ctgcaaaagg gtaagcactg 180
catagccgtg attgatgtac aaggagcttt ggctctgaag aagcaaatgc cggcagtcac 240
tatttttatt caagctccct ctcaagaaga acttgagcgc cgtttgaatg ctcgggattc 300
agagaaagat ttccagaaga aagaaagatt agagcatagc gctgtcgaaa ttgctgccgc 360
tagcgaattt gattatgttg tggttaatga tgatttgatt acagcatatc aagttttaag 420
aagtattttt atagctgaag aacataggat gagtcatggn tagaaaagat cgtttaacta 480
atgaaagact gaataagcta tttgatagcc cctttagttt ggntaattac gtaattaagc 540
nagctnagaa caaaattgct agaggagatg ttcgttcttc taac 584
<210>74
<211>465
<212>DNA
<213>Chlamydia
<400>74
gatccgaatt cggcacgagc tcgtgccgtt tgggatcgtg taatcgcatc ggagaatggt 60
taagaaatta ttttcgagtg aaagagctag gcgtaatcat tacagatagc catactactc 120
caatgcggcg tggagtactg ggtatcgggc tgtgttggta tggattttct ccattacaca 180
actatatagg atcgctagat tgtttcggtc gtcccttaca gatgacgcaa agtaatcttg 240
tagatgcctt agcagttgcg gctgttgttt gtatgggaga ggggaatgag caaacaccgt 300
tagcggtgat agagcaggca cctaatatgg tctaccattc atatcctact tctcgagaag 360
agtattgttc tttgcgcata gatgaaacag aggacttata cggacctttt ttgcaagcgg 420
ttaccgtgga gtcaagaaaa gaaatgatgg aggtgtttat gaatt 465
<210>75
<211>545
<212>DNA
<213>Chlamydia
<400>75
gaattcggca cgagatgaaa agttagcgtc acaggggatt ctcctaccaa agaattccga 60
aaagttttct tccaaaaacc tcttcctctc ttgattagtg atccctctgc aactacttta 120
ctatatgttc tgtgaaatat gcatagtctt caggattgga aaatccaaag tactcagtca 180
atccacgaat tttctctcta gcgatacgtg gaatttgact ctcataagaa tacaaagcag 240
ccactcctgc agctaaagaa tctcctgtac accaccgcat gaaagtagct actttcgctt 300
ttgctgcttc actaggctca tgagcctcta actcttctgg agtaactcct agagcaaaca 360
caaactgctt ccacaaatca atatgattag ggtaaccgtt ctcttcatcc atcaagttat 420
ctaacaataa cttacgcgcc tctaaatcat cgcaacgact atgaatcgca gataaatatt 480
taggaaaggc tttgatatgt aaataatagt ctttggcata cgcctgtaat tgctctttag 540
taagc 545
<210>76
<211>797
<212>DNA
<213>Chlamydia
<220>
<221>unsure
<222>(788)
<223>n=A,T,C or G
<221>unsure
<222>(789)
<223>n=A,T,C or G
<400>76
gatccgaatt cggcacgaga tacgctagat gcgataaatg cggataatga ggattatcct 60
aaaccaggtg acttcccacg atcttccttc tctagtacgc ctcctcatgc tccagtacct 120
caatctgaga ttccaacgtc acctacctca acacagcctc catcacccta acttgtaaaa 180
actgtaataa aaagagcgcg cttcctttat gcaaaatcaa tttgaacaac tccttactga 240
attagggact caaatcaaca gccctcttac tcctgattcc aataatgcct gtatagttcg 300
ctttggatac aacaatgttg ctgtacaaat tgaagaggat ggtaattcag gatttttagt 360
tgctggagtc atgcttggaa aacttccaga gaataccttt agacaaaaaa ttttcaaagc 420
tgctttgtct atcaatggat ctccgcaatc taatattaaa ggcactctag gatacggtga 480
aatctctaac caactctatc tctgtgatcg gcttaacatg acctatctaa atggagaaaa 540
gctcgcccgt tacttagttc ttttttcgca gcatgccaat atctggatgc aatctatctc 600
aaaaggagaa cttccagatt tacatgctct aggtatgtat cacctgtaaa ttatgccgtc 660
attatcccaa tcccgacgta tcatccagca atcttccatt cgaaagattt ggaatcagat 720
agatacttct cctaagcatg ggggtatgcg taccggttat ttttctcttc atactcaaaa 780
aaagttgnng gggaata 797
<210>77
<211>399
<212>DNA
<213>Chlamydia
<400>77
catatgcatc accatcacca tcacatgcca cgcatcattg gaattgatat tcctgcaaag 60
aaaaagttaa aaataagtct gacatatatt tatggaatag gatcagctcg ttctgatgaa 120
atcattaaaa agttgaagtt agatcctgag gcaagagcct ctgaattaac tgaagaagaa 180
gtaggacgac tgaactctct gctacaatca gaatataccg tagaagggga tttgcgacgt 240
cgtgttcaat cggatatcaa aagattgatc gccatccatt cttatcgagg tcagagacat 300
agactttctt taccagtaag aggacaacgt acaaaaacta attctcgtac tcgaaaaggt 360
aaaagaaaaa cagtcgcagg taagaagaaa taagaattc 399
<210>78
<211>285
<212>DNA
<213>Chlamydia
<400>78
atgcatcacc atcaccatca catgagtcaa aaaaataaaa actctgcttt tatgcatccc 60
gtgaatattt ccacagattt agcagttata gttggcaagg gacctatgcc cagaaccgaa 120
attgtaaaga aagtttggga atacattaaa aaacacaact gtcaggatca aaaaaataaa 180
cgtaatatcc ttcccgatgc gaatcttgcc aaagtctttg gctctagtga tcctatcgac 240
atgttccaaa tgaccaaagc cctttccaaa catattgtaa aataa 285
<210>79
<211>950
<212>DNA
<213>Chlamydia
<400>79
aaattaactc gagcacaaat tacggcaatt gctgagcaaa agatgaagga catggatgtc 60
gttcttttag agtccgccga gagaatggtt gaagggactg cccgaagcat gggtgtagat 120
gtagagtaat tagttaaaga gctgcataat tatgacaaag catggaaaac gcattcgtgg 180
tatccaagag acttacgatt tagctaagtc gtattctttg ggtgaagcga tagatatttt 240
aaaacagtgt cctactgtgc gtttcgatca aacggttgat gtgtctgtta aattagggat 300
cgatccaaga aagagtgatc agcaaattcg tggttcggtt tctttacctc acggtacagg 360
taaagttttg cgaattttag tttttgctgc tggagataag gctgcagagg ctattgaagc 420
aggagcggac tttgttggta gcgacgactt ggtagaaaaa atcaaaggtg gatgggttga 480
cttcgatgtt gcggttgcca ctcccgatat gatgagagag gtcggaaagc taggaaaagt 540
tttaggtcca agaaacctta tgcctacgcc taaagccgga actgtaacaa cagatgtggt 600
taaaactatt gcggaactgc gaaaaggtaa aattgaattt aaagctgatc gagctggtgt 660
atgcaacgtc ggagttgcga agctttcttt cgatagtgcg caaatcaaag aaaatgttga 720
agcgttgtgt gcagccttag ttaaagctaa gcccgcaact gctaaaggac aatatttagt 780
taatttcact atttcctcga ccatggggcc aggggttacc gtggatacta gggagttgat 840
tgcgttataa ttctaagttt aaagaggaaa aatgaaagaa gagaaaaagt tgctgcttcg 900
cgaggttgaa gaaaagataa ccgcttctca aggttttatt ttgttgagat 950
<210>80
<211>395
<212>DNA
<213>Chlamydia
<400>80
tttcaaggat tttgttttcc cgatcatctt actaaatgca gctccaacaa tcacatcatg 60
ggctggttta gcatctaagg caacagaagc tcctctgctg taataagtga attcttcaga 120
agtaggtgtt cctacttgcg atagcatcgt tcctagtcct gatatccaca ggttgttata 180
gctaacttca tcaaagcgag ctagattcat tttatcgttg agcaagcctt gtttgactgt 240
gaccattgac atttgagatc ccagaatcga gttcgcatag aaatgattgt ctctaggtac 300
ataagcccat tgtctataag agtcaaattt ccagagcgct gagatcgttc cattttgtag 360
ttgatcagga tccagagtga gtgttcctgt atatc 395
<210>81
<211>2085
<212>DNA
<213>Chlamydia
<400>81
atttggcgaa ggagtttggg ctacggctat taataaatca ttcgtgttcg ctgcctccaa 60
gaccagattg tgtactttct tatgaagaat ctcctattga gcaaatgttg cgttggggag 120
agtctcagtt agaacaattt gctcaagtag gtttagatac aagttggcaa gttgttttcg 180
atccaggaat aggatttggg aagactcccg ttcagtcgat gttattgatg gatggagtaa 240
agcagtttaa acgtgtttta gagtgtcctg tattaatagg ccattctaga aaatcgtgtt 300
tgagtatgtt gggccgattt aatagtgacg atcgtgattg ggaaacgatc ggctgttctg 360
tatctcttca tgatcgagga gttgattatc tacgtgtgca tcaggttgaa ggtaacagac 420
gtgccttagc cgctgctgct tgggctggta tgtttgtatg atccaagcaa caggtatcgt 480
tgctattgat cccagaggag tgatgggagc tttaggcaag ctcccttgga gttatcccga 540
agatctacgt ttttttgcag aaaccattcg aaatcatccc atcattatgg gacgaaagac 600
ttgggagtct cttccagaca agtataagca tgggcgggat atcgttgtct tttctcgcag 660
gatgcatcca ccacaatgca taggagtttc ttcctttgca gagtatggga cactatcttt 720
gaatcatccg tttttaattg ggggagcgga gctctttgaa agttttttcc aacaaaacct 780
tctgaaagct tgttttgtca cacatatcaa aaagaaatat tggggcgata ctttcttccc 840
tatcacgcga ttatcaggat ggaagaagga atgtatttgt aatacagagg atttcagtat 900
ttattattat gaaaataact ccgatcaaaa cacgtaaagt atttgcacat gattcgcttc 960
aagagatctt gcaagaggct ttgccgcctc tgcaagaacg gagtgtggta gttgtctctt 1020
caaagattgt gagtttatgt gaaggcgctg tcgctgatgc aagaatgtgc aaagcagagt 1080
tgataaaaaa agaagcggat gcttatttgt tttgtgagaa aagcgggata tatctaacga 1140
aaaaagaagg tattttgatt ccttctgcag ggattgatga atcgaatacg gaccagcctt 1200
ttgttttata tcctaaagat attttgggat cgtgtaatcg catcggagaa tggttaagaa 1260
attattttcg agtgaaagag ctaggcgtaa tcattacaga tagccatact actccaatgc 1320
ggcgtggagt actgggtatc gggctgtgtt ggtatggatt ttctccatta cacaactata 1380
taggatcgct agattgtttc ggtcgtccct tacagatgac gcaaagtaat cttgtagatg 1440
ccttagcagt tgcggctgtt gtttgtatgg gagaggggaa tgagcaaaca ccgttagcgg 1500
tgatagagca ggcacctaat atggtctacc attcatatcc tacttctcga gaagagtatt 1560
gttctttgcg catagatgaa acagaggact tatacggacc ttttttgcaa gcggttacgt 1620
ggagtcaaga aaagaaatga tggaggtgtt tatgaatttt ttagatcagt tagatttaat 1680
tattcaaaat aagcatatgc tagaacacac gttttatgtg aaatggtcga agggggagct 1740
tactaaagag caattacagg cgtatgccaa agactattat ttacatatca aagcctttcc 1800
taaatattta tctgcgattc atagtcgttg cgatgattta gaggcgcgta agttattgtt 1860
agataacttg atggatgaag agaacggtta ccctaatcat attgatttgt ggaagcagtt 1920
tgtgtttgct ctaggagtta ctccagaaga gttagaggct catgagccta gtgaagcagc 1980
aaaagcgaaa gtagctactt tcatgcggtg gtgtacagga gattctttag ctgcaggagt 2040
ggctgctttg tattcttatg agagtcaaat tccacgtatc gcctc 2085
<210>82
<211>405
<212>DNA
<213>Chlamydia
<400>82
ttcatcggtc tagttcgcta ttctactctc caatggttcc gcatttttgg gcagagcttc 60
gcaatcatta tgcaacgagt ggtttgaaaa gcgggtacaa tattgggagt accgatgggt 120
ttctccctgt cattgggcct gttatatggg agtcggaggg tcttttccgc gcttatattt 180
cttcggtgac tgatggggat ggtaagagcc ataaagtagg atttctaaga attcctacat 240
atagttggca ggacatggaa gattttgatc cttcaggacc gcctccttgg gaagaattgt 300
attggctcca taaagggagg agaaaacttc gatataggga atcgtatcaa ggtgaaagta 360
gcaaaaaata aattagctcc tccattccga actgcagaat ttgat 405
<210>83
<211>379
<212>DNA
<213>Chlamydia
<400>83
tataccattc gtttgaaagt gcctttgacg ggagaaagtg tttttgaaga tcaatgcaaa 60
ggtcgtgtcg ttttcccttg ggcagatgtt gacgatcaag ttttggttaa atcagacggg 120
ttccctacgt atcactttgc taatgtagtt gatgatcatt tgatggggat tacccatgtg 180
ttgcgagggg aagagtggtt aagttctaca cctaaacacc ttcttcttta caaagctttt 240
gggtgggagc ctccgcagtt tttccatatg ccgcttcttc taaatcctga tggaagtaag 300
ctttccaaga gaaagaatcc tacttctatt ttttactatc gggatgctgg atacaaaaaa 360
gaagcgttca tgaatttcc 379
<210>84
<211>715
<212>DNA
<213>Chlamydia
<400>84
tcaatcctgt attaataatt ctggttctta gactacataa attaggaacg cctgatgagt 60
atccataact aatcgcgtag ggcttagaat caccttctcg taccaaagct agaacaacgc 120
cgccttccat tcttgatgca ataatatctg ctgagactaa gaacatgctc ccagagcttt 180
tgggtgtgac tgtgaatttt cctatttcag ttcctcctaa taaagtttca atgttcctgg 240
gagtgaataa cccgttgcat tgaattttat tagtgattgg aaagttgtta aaagctttca 300
acaaacctag agaagggtct gttgtgattt tgtctaaaat atcttggact gtactatcaa 360
caatagtatc agcaattcca ccaagaattt gatctcccaa cttttctaga ataagctggt 420
aagctttttc cgcatccaaa ccaattgtaa tagaagcatt ggttgatgga ttattggaga 480
ctgttaaaga tattccatca gaagctgtca ttttggctgc gacaggtgtt gatgttgtcc 540
caaggattat ttgctggtcc ttgagcggct ctgtcatttg cccaactttg atattatcag 600
caaagacgca gttttgagtg ttatacaaat aaaaaccaga atttcccatt ttaaaactct 660
tttttatttt gagctttaaa taaattaggt ttttagtttc aagtttgcta ttaat 715
<210>85
<211>476
<212>DNA
<213>Chlamydia
<400>85
ctcgtgccgc tcgtgccgct cgtgccggtc ttttagaaga gcgtgaagct ttaaataatt 60
cgattacgtt tatcatggat aagcgtaatt ggatagaaac cgagtctgaa caggtacaag 120
tggttttcag agatagtaca gcttgcttag gaggaggcgc tattgcagct caagaaattg 180
tttctattca gaacaatcag gctgggattt ccttcgaggg aggtaaggct agtttcggag 240
gaggtattgc gtgtggatct ttttcttccg caggcggtgc ttctgtttta gggactattg 300
atatttcgaa gaatttaggc gcgatttcgt tctctcgtac tttatgtacg acctcagatt 360
taggacaaat ggagtaccag ggaggaggag ctctatttgg tgaaaatatt tctctttctg 420
agaatgctgg tgtgctcacc tttaaagaca acattgtgaa gacttttgct tcgaat 476
<210>86
<211>1551
<212>DNA
<213>Chlamydia
<400>86
gcgtatcgat atttcttctg ttacattctt tatagggatt ctgttggctg ttaatgcgct 60
aacctactct catgtattac gggatttatc tgtgagtatg gatgcgctgt tttctcgtaa 120
cacgcttgct gttcttttag gtttagtctc tagcgtttta gataatgtgc cattagtcgc 180
tgcaacaata ggtatgtatg acttacctat gaacgatcct ctttggaaac tcattgccta 240
tacagcaggc acagggggaa gtattctcat cattggatcc gctgcaggtg ttgcctacat 300
gggaatggaa aaagtgagtt tcggctggta tgtcaaacac gcttcttgga ttgctttagc 360
cagttatttt ggaggtctag cagtctattt tctaatggaa aattgtgtga atttgttcgt 420
ttgaggtagt cagtatggca gagtttcttt aaaaattctt ttaataaaag ggttctctgc 480
ctattctagg cccctttttg aatggaaaaa tgggtttttg gagaacatcg attatgaaaa 540
tgaataggat ttggctatta ctgcttacct tttcttctgc catacattct cctgtacgag 600
gagaaagctt ggtttgcaag aatgctcttc aagatttgag ttttttagag catttattac 660
aggttaaata tgctcctaaa acatggaaag agcaatactt aggatgggat cttgttcaaa 720
gctccgtttc tgcacagcag aagcttcgta cacaagaaaa tccatcaaca agtttttgcc 780
agcaggtcct tgctgatttt atcggaggat taaatgactt tcacgctgga gtaactttct 840
ttgcgataga aagtgcttac cttccttata ccgtacaaaa aagtagtgac ggccgtttct 900
actttgtaga tatcatgact ttttcttcag agatccgtgt tggagatgag ttgctagagg 960
tggatggggc gcctgtccaa gatgtgctcg ctactctata tggaagcaat cacaaaggga 1020
ctgcagctga agagtcggct gctttaagaa cactattttc tcgcatggcc tctttagggc 1080
acaaagtacc ttctgggcgc actactttaa agattcgtcg tccttttggt actacgagag 1140
aagttcgtgt gaaatggcgt tatgttcctg aaggtgtagg agatttggct accatagctc 1200
cttctatcag ggctccacag ttacagaaat cgatgagaag ctttttccct aagaaagatg 1260
atgcgtttca tcggtctagt tcgctattct actctccaat ggttccgcat ttttgggcag 1320
agcttcgcaa tcattatgca acgagtggtt tgaaaagcgg gtacaatatt gggagtaccg 1380
atgggtttct ccctgtcatt gggcctgtta tatgggagtc ggagggtctt ttccgcgctt 1440
atatttcttc ggtgactgat ggggatggta agagccataa agtaggattt ctaagaattc 1500
ctacatatag ttggcaggac atggaagatt ttgatccttc aggaccgcct c 1551
<210>87
<211>3031
<212>DNA
<213>Chlamydia
<400>87
atgtaggccc tcaagcggtt ttattgttag accaaattcg agatctattc gttgggtcta 60
aagatagtca ggctgaagga cagtataggt taattgtagg agatccaagt tctttccaag 120
agaaagatgc agatactctt cccgggaagg tagagcaaag tactttgttc tcagtaacca 180
atcccgtggt tttccaaggt gtggaccaac aggatcaagt ctcttcccaa gggttaattt 240
gtagttttac gagcagcaac cttgattctc cccgtgacgg agaatctttt ttaggtattg 300
cttttgttgg ggatagtagt aaggctggaa tcacattaac tgacgtgaaa gcttctttgt 360
ctggagcggc tttatattct acagaagatc ttatctttga aaagattaag ggtggattgg 420
aatttgcatc atgttcttct ctagaacagg ggggagcttg tgcagctcaa agtattttga 480
ttcatgattg tcaaggattg caggttaaac actgtactac agccgtgaat gctgaggggt 540
ctagtgcgaa tgatcatctt ggatttggag gaggcgcttt ctttgttacg ggttctcttt 600
ctggagagaa aagtctctat atgcctgcag gagatatggt agttgcgaat tgtgatgggg 660
ctatatcttt tgaaggaaac agcgcgaact ttgctaatgg aggagcgatt gctgcctctg 720
ggaaagtgct ttttgtcgct aatgataaaa agacttcttt tatagagaac cgagctttgt 780
ctggaggagc gattgcagcc tcttctgata ttgcctttca aaactgcgca gaactagttt 840
tcaaaggcaa ttgtgcaatt ggaacagagg ataaaggttc tttaggtgga ggggctatat 900
cttctctagg caccgttctt ttgcaaggga atcacgggat aacttgtgat aataatgagt 960
ctgcttcgca aggaggcgcc atttttggca aaaattgtca gatttctgac aacgaggggc 1020
cagtggtttt cagagatagt acagcttgct taggaggagg cgctattgca gctcaagaaa 1080
ttgtttctat tcagaacaat caggctggga tttccttcga gggaggtaag gctagtttcg 1140
gaggaggtat tgcgtgtgga tctttttctt ccgcaggcgg tgcttctgtt ttagggacta 1200
ttgatatttc gaagaattta ggcgcgattt cgttctctcg tactttatgt acgacctcag 1260
atttaggaca aatggagtac cagggaggag gagctctatt tggtgaaaat atttctcttt 1320
ctgagaatgc tggtgtgctc acctttaaag acaacattgt gaagactttt gcttcgaatg 1380
ggaaaattct gggaggagga gcgattttag ctactggtaa ggtggaaatt accaataatt 1440
ccggaggaat ttcttttaca ggaaatgcga gagctccaca agctcttcca actcaagagg 1500
agtttccttt attcagcaaa aaagaagggc gaccactctc ttcaggatat tctgggggag 1560
gagcgatttt aggaagagaa gtagctattc tccacaacgc tgcagtagta tttgagcaaa 1620
atcgtttgca gtgcagcgaa gaagaagcga cattattagg ttgttgtgga ggaggcgctg 1680
ttcatgggat ggatagcact tcgattgttg gcaactcttc agtaagattt ggtaataatt 1740
acgcaatggg acaaggagtc tcaggaggag ctcttttatc taaaacagtg cagttagctg 1800
gaaatggaag cgtcgatttt tctcgaaata ttgctagttt gggaggacgc aatgttctgt 1860
tagcttcaga aacctttgct tccagagcaa atacatctcc ttcatcgctt cgctccttat 1920
atttccaagt aacctcatcc ccctctaatt gcgctaattt acatcaaatg cttgcttctt 1980
actcgccatc agagaaaacc gctgttatgg agtttctagt gaatggcatg gtagcagatt 2040
taaaatcgga gggcccttcc attcctcctg caaaattgca agtatatatg acggaactaa 2100
gcaatctcca agccttacac tctgtagata gcttttttga tagaaatatt gggaacttgg 2160
aaaatagctt aaagcatgaa ggacatgccc ctattccatc cttaacgaca ggaaatttaa 2220
ctaaaacctt cttacaatta gtagaagata aattcccttc ctcttccaaa gctcaaaagg 2280
cattaaatga actggtaggc ccagatactg gtcctcaaac tgaagtttta aacttattct 2340
tccgcgctct taatggctgt tcgcctagaa tattctctgg agctgaaaaa aaacagcagc 2400
tggcatcggt tatcacaaat acgctagatg cgataaatgc ggataatgag gattatccta 2460
aaccaggtga cttcccacga tcttccttct ctagtacgcc tcctcatgct ccagtacctc 2520
aatctgagat tccaacgtca cctacctcaa cacagcctcc atcaccctaa cttgtaaaaa 2580
ctgtaataaa aagagcgcgc ttcctttatg caaaatcaat ttgaacaact ccttactgaa 2640
ttagggactc aaatcaacag ccctcttact cctgattcca ataatgcctg tatagttcgc 2700
tttggataca acaatgttgc tgtacaaatt gaagaggatg gtaattcagg atttttagtt 2760
gctggagtca tgcttggaaa acttccagag aataccttta gacaaaaaat tttcaaagct 2820
gctttgtcta tcaatggatc tccgcaatct aatattaaag gcactctagg atacggtgaa 2880
atctctaacc aactctatct ctgtgatcgg cttaacatga cctatctaaa tggagaaaag 2940
ctcgcccgtt acttagttct tttttcgcag catgccaata tctggatgca atctatctca 3000
aaaggagaac ttccagattt acatgctcta g 3031
<210>88
<211>976
<212>DNA
<213>Chlamydia
<400>88
aggtggatgg ggcgcctgtc caagatgtgc tcgctactct atatggaagc aatcacaaag 60
ggactgcagc tgaagagtcg gctgctttaa gaacactatt ttctcgcatg gcctctttag 120
ggcacaaagt accttctggg cgcactactt taaagattcg tcgtcctttt ggtactacga 180
gagaagttcg tgtgaaatgg cgttatgttc ctgaaggtgt aggagatttg gctaccatag 240
ctccttctat cagggctcca cagttacaga aatcgatgag aagctttttc cctaagaaag 300
atgatgcgtt tcatcggtct agttcgctat tctactctcc aatggttccg catttttggg 360
cagagcttcg caatcattat gcaacgagtg gtttgaaaag cgggtacaat attgggagta 420
ccgatgggtt tctccctgtc attgggcctg ttatatggga gtcggagggt cttttccgcg 480
cttatatttc ttcggtgact gatggggatg gtaagagcca taaagtagga tttctaagaa 540
ttcctacata tagttggcag gacatggaag attttgatcc ttcaggaccg cctccttggg 600
aagaatttgc taagattatt caagtatttt cttctaatac agaagctttg attatcgacc 660
aaacgaacaa cccaggtggt agtgtccttt atctttatgc actgctttcc atgttgacag 720
accgtccttt agaacttcct aaacatagaa tgattctgac tcaggatgaa gtggttgatg 780
ctttagattg gttaaccctg ttggaaaacg tagacacaaa cgtggagtct cgccttgctc 840
tgggagacaa catggaagga tatactgtgg atctacaggt tgccgagtat ttaaaaagct 900
ttggacgtca agtattgaat tgttggagta aaggggatat cgagttatca acacctattc 960
ctctttttgg ttttga 976
<210>89
<211>94
<212>PRT
<213>Chlamydia
<400>89
Met His His His His His His Met Ser Gln Lys Asn Lys Asn Ser Ala
5 10 15
Phe Met His Pro Val Asn Ile Ser Thr Asp Leu Ala Val Ile Val Gly
20 25 30
Lys Gly Pro Met Pro Arg Thr Glu Ile Val Lys Lys Val Trp Glu Tyr
35 40 45
Ile Lys Lys His Asn Cys Gln Asp Gln Lys Asn Lys Arg Asn Ile Leu
50 55 60
Pro Asp Ala Asn Leu Ala Lys Val Phe Gly Ser Ser Asp Pro Ile Asp
65 70 75 80
Met Phe Gln Met Thr Lys Ala Leu Ser Lys His Ile Val Lys
85 90
<210>90
<211>474
<212>PRT
<213>Chlamydia
<400>90
Met Ala Ser His His His His His His Met Asn Glu Ala Phe Asp Cys
5 10 15
Val Val Ile Gly Ala Gly Pro Gly Gly Tyr Val Ala Ala Ile Thr Ala
20 25 30
Ala Gln Ala Gly Leu Lys Thr Ala Leu Ile Glu Lys Arg Glu Ala Gly
35 40 45
Gly Thr Cys Leu Asn Arg Gly Cys Ile Pro Ser Lys Ala Leu Leu Ala
50 55 60
Gly Ala Glu Val Val Thr Gln Ile Arg His Ala Asp Gln Phe Gly Ile
65 70 75 80
His Val Glu Gly Phe Ser Ile Asn Tyr Pro Ala Met Val Gln Arg Lys
85 90 95
Asp Ser Val Val Arg Ser Ile Arg Asp Gly Leu Asn Gly Leu Ile Arg
100 105 110
Ser Asn Lys Ile Thr Val Phe Ser Gly Arg Gly Ser Leu Ile Ser Ser
115 120 125
Thr Glu Val Lys Ile Leu Gly Glu Asn Pro Ser Val Ile Lys Ala His
130 135 140
Ser Ile Ile Leu Ala Thr Gly Ser Glu Pro Arg Ala Phe Pro Gly Ile
145 150 155 160
Pro Phe Ser Ala Glu Ser Pro Arg Ile Leu Cys Ser Thr Gly Val Leu
165 170 175
Asn Leu Lys Glu Ile Pro Gln Lys Met Ala Ile Ile Gly Gly Gly Val
180 185 190
Ile Gly Cys Glu Phe Ala Ser Leu Phe His Thr Leu Gly Ser Glu Val
195 200 205
Ser Val Ile Glu Ala Ser Ser Gln Ile Leu Ala Leu Asn Asn Pro Asp
210 215 220
Ile Ser Lys Thr Met Phe Asp Lys Phe Thr Arg Gln Gly Leu Arg Phe
225 230 235 240
Val Leu Glu Ala Ser Val Ser Asn Ile Glu Asp Ile Gly Asp Arg Val
245 250 255
Arg Leu Thr Ile Asn Gly Asn Val Glu Glu Tyr Asp Tyr Val Leu Val
260 265 270
Ser Ile Gly Arg Arg Leu Asn Thr Glu Asn Ile Gly Leu Asp Lys Ala
275 280 285
Gly Val Ile Cys Asp Glu Arg Gly Val Ile Pro Thr Asp Ala Thr Met
290 295 300
Arg Thr Asn Val Pro Asn Ile Tyr Ala Ile Gly Asp Ile Thr Gly Lys
305 310 315 320
Trp Gln Leu Ala His Val Ala Ser His Gln Gly Ile Ile Ala Ala Arg
325 330 335
Asn Ile Gly Gly His Lys Glu Glu Ile Asp Tyr Ser Ala Val Pro Ser
340 345 350
Val Ile Phe Thr Phe Pro Glu Val Ala Ser Val Gly Leu Ser Pro Thr
355 360 365
Ala Ala Gln Gln Gln Lys Ile Pro Val Lys Val Thr Lys Phe Pro Phe
370 375 380
Arg Ala Ile Gly Lys Ala Val Ala Met Gly Glu Ala Asp Gly Phe Ala
385 390 395 400
Ala Ile Ile Ser His Glu Thr Thr Gln Gln Ile Leu Gly Ala Tyr Val
405 410 415
Ile Gly Pro His Ala Ser Ser Leu Ile Ser Glu Ile Thr Leu Ala Val
420 425 430
Arg Asn Glu Leu Thr Leu Pro Cys Ile Tyr Glu Thr Ile His Ala His
435 440 445
Pro Thr Leu Ala Glu Val Trp Ala Glu Ser Ala Leu Leu Ala Val Asp
450 455 460
Thr Pro Leu His Met Pro Pro Ala Lys Lys
465 470
<210>91
<211>129
<212>PRT
<213>Chlamydia
<400>91
Met His His His His His His Met Pro Arg Ile Ile Gly Ile Asp Ile
5 10 15
Pro Ala Lys Lys Lys Leu Lys Ile Ser Leu Thr Tyr Ile Tyr Gly Ile
20 25 30
Gly Ser Ala Arg Ser Asp Glu Ile Ile Lys Lys Leu Lys Leu Asp Pro
35 40 45
Glu Ala Arg Ala Ser Glu Leu Thr Glu Glu Glu Val Gly Arg Leu Asn
50 55 60
Ser Leu Leu Gln Ser Glu Tyr Thr Val Glu Gly Asp Leu Arg Arg Arg
65 70 75 80
Val Gln Ser Asp Ile Lys Arg Leu Ile Ala Ile His Ser Tyr Arg Gly
85 90 95
Gln Arg His Arg Leu Ser Leu Pro Val Arg Gly Gln Arg Thr Lys Thr
100 105 110
Asn Ser Arg Thr Arg Lys Gly Lys Arg Lys Thr Val Ala Gly Lys Lys
115 120 125
Lys
<210>92
<211>202
<212>PRT
<213>Chlamydia
<400>92
Met His His His His His His Met Gly Ser Leu Val Gly Arg Gln Ala
5 10 15
Pro Asp Phe Ser Gly Lys Ala Val Val Cys Gly Glu Glu Lys Glu Ile
20 25 30
Ser Leu Ala Asp Phe Arg Gly Lys Tyr Val Val Leu Phe Phe Tyr Pro
35 40 45
Lys Asp Phe Thr Tyr Val Cys Pro Thr Glu Leu His Ala Phe Gln Asp
50 55 60
Arg Leu Val Asp Phe Glu Glu His Gly Ala Val Val Leu Gly Cys Ser
65 70 75 80
Val Asp Asp Ile Glu Thr His Ser Arg Trp Leu Thr Val Ala Arg Asp
85 90 95
Ala Gly Gly Ile Glu Gly Thr Glu Tyr Pro Leu Leu Ala Asp Pro Ser
100 105 110
Phe Lys Ile Ser Glu Ala Phe Gly Val Leu Asn Pro Glu Gly Ser Leu
115 120 125
Ala Leu Arg Ala Thr Phe Leu Ile Asp Lys His Gly Val Ile Arg His
130 135 140
Ala Val Ile Asn Asp Leu Pro Leu Gly Arg Ser Ile Asp Glu Glu Leu
145 150 155 160
Arg Ile Leu Asp Ser Leu Ile Phe Phe Glu Asn His Gly Met Val Cys
165 170 175
Pro Ala Asn Trp Arg Ser Gly Glu Arg Gly Met Val Pro Ser Glu Glu
180 185 190
Gly Leu Lys Glu Tyr Phe Gln Thr Met Asp
195 200
<210>93
<211>19
<212>PRT
<213>Artificial Sequence
<220>
<223>made in a lab
<400>93
Glu Asn Ser Leu Gln Asp Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp
1 5 10 15
Asp Lys Leu
<210> 94
<211> 20
<212> PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>94
Asp Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys
1 5 10 15
Val Phe Gly Thr
20
<210>95
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>95
Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val Phe Gly Thr
1 5 10 15
Glu Lys Pro Ile
20
<210>96
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>96
Asp Asp Lys Leu Ala Lys Val Phe Gly Thr Glu Lys Pro Ile Asp Met
1 5 10 15
Phe Gln Met Thr
20
<210>97
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>97
Lys Val Phe Giy Thr Glu Lys Pro Ile Asp Met Phe Gln Met Thr Lys
1 5 10 15
Met Val Ser Gln
20
<210>98
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>98
Asn Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val Phe Gly
1 5 10 15
Thr Glu Lys Pro
20
<210>99
<211>16
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>99
Asn Lys Arg Asn Ile Leu Pro Asp Ala Asn Leu Ala Lys Val Phe Gly
1 5 10 15
<210>100
<211>15
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>100
Lys Met Trp Asp Tyr Ile Lys Glu Asn Ser Leu Gln Asp Pro Thr
1 5 10 15
<210>101
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>101
Thr Glu Ile Val Lys Lys Val Trp Glu Tyr Ile Lys Lys His Asn Cys
1 5 10 15
Gln Asp Gln Lys
20
<210>102
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>102
Lys Val Trp Glu Tyr Ile Lys Lys His Asn Cys Gln Asp Gln Lys Asn
1 5 10 15
Lys Arg Asn Ile
20
<210>103
<211>15
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>103
Lys Val Trp Glu Tyr Ile Lys Lys His Asn Cys Gln Asp Gln Lys
1 5 10 15
<210>104
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>104
Ala Glu Leu Thr Glu Glu Glu Val Gly Arg Leu Asn Ala Leu Leu Gln
1 5 10 15
Ser Asp Tyr Val
20
<210>105
<211>21
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>105
Leu Gln Ser Asp Tyr Val Val Glu Gly Asp Leu Arg Arg Arg Val Gln
1 5 10 15
Ser Asp Ile Lys Arg
20
<210>106
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>106
Met Pro Arg Ile Ile Gly Ile Asp Ile Pro Ala Lys Lys Lys Leu Lys
1 5 10 15
Ile Ser Leu Thr
20
<210>107
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>107
Ala Glu Leu Thr Glu Glu Glu Val Gly Arg Leu Asn Ala Leu Leu Gln
1 5 10 15
Ser Asp Tyr Val
20
<210>108
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>108
Leu Asn Ala Leu Leu Gln Ser Asp Tyr Val Val Glu Gly Asp Leu Arg
1 5 10 15
Arg Arg Val Gln
20
<210>109
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>109
Leu Asn Ser Leu Leu Gln Ser Glu Tyr Thr Val Glu Gly Asp Leu Arg
1 5 10 15
Arg Arg Val Gln
20
<210>110
<211>1461
<212>DNA
<213>Chlamydia
<400>110
ctatctatga agttatgaat atggatctag aaacacgaag atcttttgcg gtacagcaag 60
ggcactatca ggacccaaga gcttcagatt atgacctccc acgtgctagc gactatgatt 120
tgcctagaag cccatatcct actccacctt tgccttctag atatcagcta cagaatatgg 180
atgtagaagc agggttccgt gaggcagttt atgcttcttt tgtagcagga atgtacaatt 240
atgtagtgac acagccgcaa gagcgtattc ccaatagtca gcaggtggaa gggattctgc 300
gtgatatgct taccaacggg tcacagacat ttagcaacct gatgcagcgt tgggatagag 360
aagtcgatag ggaataaact ggtatctacc ataggtttgt atcaaaaaac taagcccacc 420
aagaagaaat tctctttggt gggcttcttt ttttattcaa aaaagaaagc cctcttcaag 480
attatctcgt gccgctcgtg ccgaattcgg cacgagcggc acgaggagct gtaagtaagt 540
attgccaaga gttggaagaa aaaatattag atttgtgtaa gcgtcatgcc gcaacaattt 600
gctccattga ggaggatgct aaacaagaaa ttcgtcatca gacagaaagg tttaaacagc 660
ggttgcaaca aaatcagaac acttgcagtc aattaacagc agagttgtgt aaattgagat 720
ctgagaataa ggcattatcg gagcggctgc aggtgcaggc atcccgtcgt aaaaaataat 780
taaagactcc tcagatattg catctgagag ttaggggttc cttttgctta cggcgcttta 840
gttctgcatg ttgcggattt atagtgattt gcgagtaaag cgccgttctg atacagtttt 900
tccgctttaa aaataaaaag gtggaaaaat gagtactact attagcggag acgcttcttc 960
tttaccgttg ccaacagctt cctgcgtaga gacaaaatct acttcgtctt caacaaaagg 1020
gaatacttgt tccaaaattt tggatatagc tttagctatc gtaggcgctt tagttgttgt 1080
cgctggggta ttagctttgg ttttgtgcgc tagcaatgtc atatttactg taataggtat 1140
tcctgcatta attattggat ctgcttgtgt gggtgcggga atatctcgtc ttatgtatcg 1200
atcctcttat gctagcttag aagcaaaaaa tgttttggct gagcaacgtt tgcgtaatct 1260
ttcagaagag aaggacgctt tggcctccgt ctctttcatt aataagatgt ttctgcgagg 1320
tcttacggac gatctccaag ctttggaagc taaggtaatg gaatttgaga ttgattgttt 1380
ggacagatta gagaaaaatg agcaagcttt attgtccgat gtgcgcttag ttttatctag 1440
ctacacaaga tggttggata g 1461
<210>111
<211>267
<212>DNA
<213>Chlamydia
<400>111
gtcctcttct tattatagca gaagacattg aaggcgaagc tttagctact ttggtcgtga 60
acagaattcg tggaggattc cgggtttgcg cagttaaagc tccaggcttt ggagatagaa 120
gaaaagctat gttggaagac atcgctatct taactggcgg tcaactcatt agcgaagagt 180
tgggcatgaa attagaaaac gctaacttag ctatgttagg taaagctaaa aaagttatcg 240
tttctaaaga agacacgacc atcgtcg 267
<210>112
<211>698
<212>DNA
<213>Chlamydia
<400>112
tgataagcaa gcaaccgctc aactagcagc tctaactatt aaaaaaatcc tctgttttga 60
tgaaaattcc tacgagaagg agctggcatg cttagaaaag aaacgcagta gcgtacaaaa 120
agatctgagc caactgaaaa aatacacagt tctctacatc aagaagctgc tcgaaaccta 180
cagacaactc gggcatcgaa agacaaaaat tgcaaaattt gatgacctac ctaccgagag 240
agtctccgct cataagaaag caaaagaact cgctgcgctc gatcaagaag agaacttcta 300
aaacgtgact cggcccttga gatccttaaa ctctcgggcc aaaaagacta cagtcttctc 360
gagaagaaaa acggtgttag aaaatacgcg cgctaagact ttctctaaca atgactcaaa 420
aagctgtaaa cgtatacgtt taccgctctt ccataatttc taggctgact ttcacattat 480
ctcgacttgc tacggaaacc aataaagtac ggatagcctt aatagtgcgt ccttctttac 540
cgataatttt accgatatct cccttagcaa cagtcaattc gtagataatc gtattggttc 600
cctgcacctc tttcagatgc acttcctctg gcttatcaac aagatttttt acaatgtacg 660
ctaaaaactc tttcatgcga agcaaatcct acacaagc 698
<210>113
<211>1142
<212>DNA
<213>Chlamydia
<400>113
ctcttcaaag attgtgagtt tatgtgaagg cgctgtcgct gatgcaagaa tgtgcaaagc 60
agagttgata aaaaaagaag cggatgctta tttgttttgt gagaaaagcg ggatatatct 120
aacgaaaaaa gaaggtattt tgattccttc tgcagggatt gatgaatcga atacggacca 180
gccttttgtt ttatatccta aagatatttt gggatcgtgt aatcgcatcg gagaatggtt 240
aagaaattat tttcgagtga aagagctagg cgtaatcatt acagatagcc atactactcc 300
aatgcggcgt ggagtactgg gtatcgggct gtgttggtat ggattttctc cattacacaa 360
ctatatagga tcgctagatt gtttcggtcg tcccttacag atgacgcaaa gtaatcttgt 420
agatgcctta gcagttgcgg ctgttgtttg tatgggagag gggaatgagc aaacaccgtt 480
agcggtgata gagcaggcac ctaatatggt ctaccattca tatcctactt ctcgagaaga 540
gtattgttct ttgcgcatag atgaaacaga ggacttatac ggaccttttt tgcaagcggt 600
tacgtggagt caagaaaaga aatgatggag gtgtttatga attttttaga tcagttagat 660
ttaattattc aaaataagca tatgctagaa cacacgtttt atgtgaaatg gtcgaagggg 720
gagcttacta aagagcaatt acaggcgtat gccaaagact attatttaca tatcaaagcc 780
tttcctaaat atttatctgc gattcatagt cgttgcgatg atttagaggc gcgtaagtta 840
ttgttagata acttgatgga tgaagagaac ggttacccta atcatattga tttgtggaag 900
cagtttgtgt ttgctctagg agttactcca gaagagttag aggctcatga gcctagtgaa 960
gcagcaaaag cgaaagtagc tactttcatg cggtggtgta caggagattc tttagctgca 1020
ggagtggctg ctttgtattc ttatgagagt caaattccac gtatcgctag agagaaaatt 1080
cgtggattga ctgagtactt tggattttcc aatcctgaag actatgcata tttcacagaa 1140
ca 1142
<210>114
<211>976
<212>DNA
<213>Chlamydia
<400>114
aggtggatgg ggcgcctgtc caagatgtgc tcgctactct atatggaagc aatcacaaag 60
ggactgcagc tgaagagtcg gctgctttaa gaacactatt ttctcgcatg gcctctttag 120
ggcacaaagt accttctggg cgcactactt taaagattcg tcgtcctttt ggtactacga 180
gagaagttcg tgtgaaatgg cgttatgttc ctgaaggtgt aggagatttg gctaccatag 240
ctccttctat cagggctcca cagttacaga aatcgatgag aagctttttc cctaagaaag 300
atgatgcgtt tcatcggtct agttcgctat tctactctcc aatggttccg catttttggg 360
cagagcttcg caatcattat gcaacgagtg gtttgaaaag cgggtacaat attgggagta 420
ccgatgggtt tctccctgtc attgggcctg ttatatggga gtcggagggt cttttccgcg 480
cttatatttc ttcggtgact gatggggatg gtaagagcca taaagtagga tttctaagaa 540
ttcctacata tagttggcag gacatggaag attttgatcc ttcaggaccg cctccttggg 600
aagaatttgc taagattatt caagtatttt cttctaatac agaagctttg attatcgacc 660
aaacgaacaa cccaggtggt agtgtccttt atctttatgc actgctttcc atgttgacag 720
accgtccttt agaacttcct aaacatagaa tgattctgac tcaggatgaa gtggttgatg 780
ctttagattg gttaaccctg ttggaaaacg tagacacaaa cgtggagtct cgccttgctc 840
tgggagacaa catggaagga tatactgtgg atctacaggt tgccgagtat ttaaaaagct 900
ttggacgtca agtattgaat tgttggagta aaggggatat cgagttatca acacctattc 960
ctctttttgg ttttga 976
<210>115
<211>995
<212>DNA
<213>Chlamydia
<400>115
ttatcctaga aatttggtgt tcaatatgag cgaaaaaaga aagtctaaca aaattattgg 60
tatcgaccta gggacgacca actcttgcgt ctctgttatg gaaggtggcc aacctaaagt 120
tattgcctct tctgaaggaa ctcgtactac tccttctatc gttgctttta aaggtggcga 180
aactcttgtt ggaattcctg caaaacgtca ggcagtaacc aatcctgaaa aaacattggc 240
ttctactaag cgattcatcg gtagaaaatt ctctgaagtc gaatctgaaa ttaaaacagt 300
cccctacaaa gttgctccta actcgaaagg agatgcggtc tttgatgtgg aacaaaaact 360
gtacactcca gaagaaatcg gcgctcagat cctcatgaag atgaaggaaa ctgctgaggc 420
ttatctcgga gaaacagtaa cggaagcagt cattaccgta ccagcttact ttaacgattc 480
tcaaagagct tctacaaaag atgctggacg tatcgcagga ttagatgtta aacgcattat 540
tcctgaacca acagcggccg ctcttgctta tggtattgat aaggaaggag ataaaaaaat 600
cgccgtcttc gacttaggag gaggaacttt cgatatttct atcttggaaa tcggtgacgg 660
agtttttgaa gttctctcaa ccaacgggga tactcacttg ggaggagacg acttcgacgg 720
agtcatcatc aactggatgc ttgatgaatt caaaaaacaa gaaggcattg atctaagcaa 780
agataacatg gctttgcaaa gattgaaaga tgctgctgaa aaagcaaaaa tagaattgtc 840
tggtgtatcg tctactgaaa tcaatcagcc attcatcact atcgacgcta atggacctaa 900
acatttggct ttaactctaa ctcgcgctca attcgaacac ctagcttcct ctctcattga 960
gcgaaccaaa caaccttgtg ctcaggcttt aaaag 995
<210>116
<211>437
<212>DNA
<213>Chlamydia
<400>116
gtcacagcta aaggcggtgg gctttatact gataagaatc tttcgattac taacatcaca 60
ggaattatcg aaattgcaaa taacaaagcg acagatgttg gaggtggtgc ttacgtaaaa 120
ggaaccctta cttgtaaaaa ctctcaccgt ctacaatttt tgaaaaactc ttccgataaa 180
caaggtggag gaatctacgg agaagacaac atcaccctat ctaatttgac agggaagact 240
ctattccaag agaatactgc caaaaaagag ggcggtggac tcttcataaa aggtacagat 300
aaagctctta caatgacagg actggatagt ttctgtttaa ttaataacac atcagaaaaa 360
catggtggtg gagcctttgt taccaaagaa atctctcaga cttacacctc tgatgtggaa 420
acaattccag gaatcac 437
<210>117
<211>446
<212>DNA
<213>Chlamydia
<400>117
aagtttacct agaccaaact gaagatgacg aaggaaaagt tgttttatcc agagaaaaag 60
caacaagaca acgacaatgg gaatacattc ttgctcactg cgaggaaggt tctattgtta 120
agggacaaat tacccgaaaa gttaagggtg gtttgatcgt agatattggt atggaagcct 180
tccttccagg atcccaaata gacaataaga agatcaagaa cttagatgat tacgtaggca 240
aggtttgtga gttcaaaatt ctcaaaatca acgtggatcg tcggaacgtt gttgtatcta 300
gaagagaact tctcgaagct gaacgcattt ctaagaaagc agagttgatc gagcaaatca 360
ctatcggtga acgtcgcaaa ggtatcgtta agaatatcac agatttcgga gtattcttgg 420
atcttgatgg cattgacggc ctactc 446
<210>118
<211>951
<212>DNA
<213>Chlamydia
<400>118
agtattgcga aatattactg tgagaagcaa tgctgagagc ggttctagta aaagtgaggg 60
gagagctgtc agaagggatc gctcaggaag cgagacaacg tgtggctgat ttattaggaa 120
gattccctct ttatcctgaa atcgatctgg aaacgctagt ttagtgggag actctatgcc 180
tgaaggggaa atgatgcata agttgcaaga tgtcatagat agaaagttgt tggattctcg 240
tcgtattttc ttctccgaac ctgtaacgga gaaaagtgct gcagaagcca tcaaaaagct 300
ttggtatttg gaactcacca atcctgggca gccaattgta tttgtcatta atagccctgg 360
agggtctgtt gatgctgggt ttgctgtttg ggaccaaatt aaaatgatct cttctccttt 420
gactacagtt gttacaggtt tagcagcatc tatgggatct gtattgagtt tgtgtgctgt 480
tccaggaaga cgttttgcta cgcctcatgc gcgcattatg attcaccagc cttctattgg 540
aggaaccatt actggtcaag ccacggactt ggatattcat gctcgtgaaa ttttaaaaac 600
aaaagcacgc attattgatg tgtatgtcga ggcaactgga caatctccag aggtgataga 660
gaaagctatc gatcgagata tgtggatgag tgcaaatgaa gcaatggagt ttggactgtt 720
agatgggatt ctcttctctt ttaacgactt gtagatatct tttatattct ggagcaggaa 780
acagtttcat tttgggagaa tcgatgcctt ctcttgagga tgttctgttt ttatgccagg 840
aagagatggt tgatgggttt ttatgtgtag agtcttctga aatagcagat gctaaactca 900
ctgtttttaa tagtgatgga tctatcgcgt ctatgtgcgg gaatgggttg c 951
<210>119
<211>953
<212>DNA
<213>Chlamydia
<400>119
atatcaaagt tgggcaaatg acagagccgc tcaaggacca gcaaataatc cttgggacaa 60
catcaacacc tgtcgcagcc aaaatgacag cttctgatgg aatatcttta acagtctcca 120
ataatccatc aaccaatgct tctattacaa ttggtttgga tgcggaaaaa gcttaccagc 180
ttattctaga aaagttggga gatcaaattc ttggtggaat tgctgatact attgttgata 240
gtacagtcca agatatttta gacaaaatca caacagaccc ttctctaggt ttgttgaaag 300
cttttaacaa ctttccaatc actaataaaa ttcaatgcaa cgggttattc actcccagga 360
acattgaaac tttattagga ggaactgaaa taggaaaatt cacagtcaca cccaaaagct 420
ctgggagcat gttcttagtc tcagcagata ttattgcatc aagaatggaa ggcggcgttg 480
ttctagcttt ggtacgagaa ggtgattcta agccctacgc gattagttat ggatactcat 540
caggcgttcc taatttatgt agtctaagaa ccagaattat taatacagga ttgactccga 600
caacgtattc attacgtgta ggcggtttag aaagcggtgt ggtatgggtt aatgcccttt 660
ctaatggcaa tgatatttta ggaataacaa atacttctaa tgtatctttt ttggaggtaa 720
tacctcaaac aaacgcttaa acaattttta ttggattttt cttataggtt ttatatttag 780
agaaaaaagt tcgaattacg gggtttgtta tgcaaaataa aagcaaagtg agggacgatt 840
ttattaaaat tgttaaagat tcctggtatc ggtctgcgat tccgactcgt ccaacatcaa 900
tacaacctat taatttcccc tcgtcaaaaa taaggttatc aagtgagaaa tca 953
<210>120
<211>897
<212>DNA
<213>Chlamydia
<400>120
atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca gcaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120
gttaaggtcg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240
actgttctcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctcttacat gaaagctgct agtcagaaac cgcaagaagg ggatgagggg 360
ctcgtagcag atctttgtgt gtctcataag cgcanagcgg ctgcggctgt ctgtagcttc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480
aaaatgctgg cgcaaccgtt tctttcttcc caaattaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tttgtggtgg gttctggact cgctatcagt 600
gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgtcactc 660
gaattgtcgg gagaggaaaa tgcttgcgag aggagagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gttgcctatt acaatgggta ttcgtgcaat tgtggctgcg 840
ggatgtacgt tcacttctgc agttattgga ttgtggactt tctgcgccag agcataa 897
<210>121
<211>298
<212>PRT
<213>Chlamydia
<400>121
Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Leu Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser Tyr Met Lys Ala Ala Ser Gln
100 105 110
Lys Pro Gln Glu Gly Asp Glu Gly Leu Val Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Ile Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Phe Val
180 185 190
Val Gly Ser Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Ser Leu Glu Leu Ser Gly
210 215 220
Glu Glu Asn Ala Cys Glu Arg Arg Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Val
275 280 285
Ile Gly Leu Trp Thr Phe Cys Ala Arg Ala
290 295
<210>122
<211>897
<212>DNA
<213>Chlamydia
<400>122
atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca gcaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120
gttaaggtcg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatacgaga 240
actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctctcacat gaaagctgct agtcagaaaa cgcaagaagg ggatgagggg 360
ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtggcttc 420
atcggaggaa ttacctacct cgcgacattc ggagttatcc gtccgattct gtttgtcaac 480
aaaatgctgg tgaacccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600
gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660
gaagtgtcgg gagaggaaaa tgcttgcgag aagagagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840
ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897
<210>123
<211>298
<212>PRT
<213>Chlamydia
<400>123
Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Thr Arg
65 70 75 80
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
100 105 110
Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Gly Phe Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Val Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Val Asn Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
180 185 190
Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Ser Gly
210 215 220
Glu Glu Asn Ala Cys Glu Lys Arg Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
275 280 285
Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
290 295
<210>124
<211>897
<212>DNA
<213>Chlamydia
<400>124
atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca acaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120
attaaggttg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240
actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctctcacat gaaagctgct agtcagaaaa cgcaagaagg ggatgagggg 360
ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480
aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600
gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660
gaagtgccgg gagaggaaaa tgcttgcgag aagaaagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840
ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897
<210>125
<211>298
<212>PRT
<213>Chlamydia
<400>125
Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
100 105 110
Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
180 185 190
Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Pro Gly
210 215 220
Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
275 280 285
Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
290 295
<210>126
<211>897
<212>DNA
<213>Chlamydia
<400>126
atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca acaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120
attaaggttg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240
actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctctcacat gaaagctgct agtcagaaaa cgcaagaagg ggatgagggg 360
ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480
aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600
gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660
gaagtgccgg gagaggaaaa tgcttgcgag aagaaagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840
ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897
<210>127
<211>298
<212>PRT
<213>Chlamydia
<400>127
Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
100 105 110
Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
180 185 190
Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Pro Gly
210 215 220
Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
275 280 285
Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
290 295
<210>128
<211>897
<212>DNA
<213>Chlamydia
<400>128
atggcttcta tatgtggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca gcaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120
gttaaggtcg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatacgaga 240
actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctctcacat gaaagcytgct agtcagaaaa cgcaagaagg ggatgaggg 360
ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtggcttc 420
atcggaggaa ttacctacct cgcgacattc ggagttatcc gtccgattct gtttgtcaac 480
aaaatgctgg tgaacccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600
gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660
gaagtgtcgg gagaggaaaa tgcttgcgag aagagagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840
ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897
<210>129
<211>298
<212>PRT
<213>Chlamydia
<400>129
Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Ash
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Thr Arg
65 70 75 80
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
100 105 110
Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Gly Phe Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Val Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Val Asn Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
180 185 190
Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Ser Gly
210 215 220
Glu Glu Asn Ala Cys Glu Lys Arg Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
275 280 285
Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
290 295
<210>130
<211>897
<212>DNA
<213>Chlamydia
<400>130
atggctgcta tatgtggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca gcaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120
gttaaggtcg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240
actgttctcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctcttacat gaaagctgct agtcagaaac cgcaagaagg ggatgagggg 360
ctcgtagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcttc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480
aaaatgctgg cgcaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tttgtggtgg gttctggact cgctatcagt 600
gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgtcactc 660
gaattgtcgg gagaggaaaa tgcttgcgag aggggagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gttgcctatt acaatgggta ttcgtgcaat tgtggctgcg 840
ggatgtacgt tcacttctgc agttattgga ttgtggactt tctgcaacag agtataa 897
<210>131
<211>298
<212>PRT
<213>Chlamydia
<400>131
Met Ala Ala Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Leu Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser Tyr Met Lys Ala Ala Ser Gln
100 105 110
Lys Pro Gln Glu Gly Asp Glu Gly Leu Val Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Ash
145 150 155 160
Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Phe Val
180 185 190
Val Gly Ser Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Ser Leu Glu Leu Ser Gly
210 215 220
Glu Glu Asn Ala Cys Glu Arg Gly Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Val
275 280 285
Ile Gly Leu Trp Thr Phe Cys Asn Arg Val
290 295
<210>132
<211>897
<212>DNA
<213>Chlamydia
<400>132
atggctgcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca gcaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120
gttaaggtcg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240
actgttctcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctcttacat gaaagctgct agtcagaaac cgcaagaagg ggatgagggg 360
ctcgtagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcttc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480
aaaatgctgg cgcaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tttgtggtgg gttctggact cgctatcagt 600
gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgtcactc 660
gaattgtcgg gagaggaaaa tgcttgtgag aggagagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gttgcctatt acaatgggta ttcgtgcaat tgtggctgcg 840
ggatgtacgt tcacttctgc agttattgga ttgtggactt tctgcaacag agtataa 897
<210>133
<211>298
<212>PRT
<213>Chlamydia
<400>133
Met Ala Ala Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Leu Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser Tyr Met Lys Ala Ala Ser Gln
100 105 110
Lys Pro Gln Glu Gly Asp Glu Gly Leu Val Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Phe Val
180 185 190
Val Gly Ser Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Ser Leu Glu Leu Ser Gly
210 215 220
Glu Glu Asn Ala Cys Glu Arg Arg Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Val
275 280 285
Ile Gly Leu Trp Thr Phe Cys Asn Arg Val
290 295
<210>134
<211>897
<212>DNA
<213>Chlamydia
<400>134
atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca acaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120
attaaggttg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240
actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctctcacat gaaagctgct agtcagaaaa cgcaagaagg ggatgagggg 360
ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480
aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600
gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660
gaaatgccgg gagaggaaaa tgcttgcgag aagaaagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840
ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897
<210>135
<211>298
<212>PRT
<213>Chlamydia
<400>135
Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
100 105 110
Lys Thr Gln Glu G1y Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
180 185 190
Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Met Pro Gly
210 215 220
Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
275 280 285
Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
290 295
<210>136
<211>882
<212>DNA
<213>Chlamydia
<400>136
atggcttctg tatgtgggcg attaagtgct ggggtgggga acagatttaa cgcatttttc 60
acgcgtcccg gtaacaagct atcacggttt gtaaatagcg caaaaggatt agacagatca 120
ataaaggttg ggaagtctgc tgctgaatta acggcgagta ttttagagca aactgggggg 180
gcagggactg atgcacatgt tacggcggcc aaggtgtcta aagcacttgg ggacgcgcga 240
acagtaatgg ctctagggaa tgtcttcaat gggtctgtgc cagcaaccat tcaaagtgcg 300
cgaagctgtc tcgcccattt acgagcggcc ggcaaagaag aagaaacatg ctccaaggtg 360
aaagatctct gtgtttctca tagacgaaga gctgcggctg aggcttgtaa tgttattgga 420
ggagcaactt atattacaac tttcggagcg attcgtccga cattactcgt taacaagctt 480
cttgccaaac cattcctttc ctcccaagcc aaagaagggt tgggagcttc tgttggttat 540
atcatggcag cgaaccatgc ggcatctgtg cttgggtctg ctttaagtat tagcgcagaa 600
agagcagact gtgaagagcg gtgtgatcgc attcgatgta gtgaggatgg tgaaatttgc 660
gaaggcaata aattaacagc tatttcggaa gagaaggcta gatcatggac tctcattaag 720
tacagattcc ttactatgat agaaaaacta tttgagatgg tggcggatat cttcaagtta 780
attcctttgc caatttcgca tggaattcgt gctattgttg ctgcgggatg tacgttgact 840
tctgcagtta ttggcttagg tactttttgg tctagagcat aa 882
<210>137
<211>293
<212>PRT
<213>Chlamydia
<400>137
Met Ala Ser Val Cys Gly Arg Leu Ser Ala Gly Val Gly Asn Arg Phe
1 5 10 15
Asn Ala Phe Phe Thr Arg Pro Gly Asn Lys Leu Ser Arg Phe Val Asn
20 25 30
Ser Ala Lys Gly Leu Asp Arg Ser Ile Lys Val Gly Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Ser Ile Leu Glu Gln Thr Gly Gly Ala Gly Thr Asp
50 55 60
Ala His Val Thr Ala Ala Lys Val Ser Lys Ala Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Met Ala Leu Gly Asn Val Phe Asn Gly Ser Val Pro Ala Thr
85 90 95
Ile Gln Ser Ala Arg Ser Cys Leu Ala His Leu Arg Ala Ala Gly Lys
100 105 110
Glu Glu Glu Thr Cys Ser Lys Val Lys Asp Leu Cys Val Ser His Arg
115 120 125
Arg Arg Ala Ala Ala Glu Ala Cys Asn Val Ile Gly Gly Ala Thr Tyr
130 135 140
Ile Thr Thr Phe Gly Ala Ile Arg Pro Thr Leu Leu Val Asn Lys Leu
145 150 155 160
Leu Ala Lys Pro Phe Leu Ser Ser Gln Ala Lys Glu Gly Leu Gly Ala
165 170 175
Ser Val Gly Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val Leu Gly
180 185 190
Ser Ala Leu Ser Ile Ser Ala Glu Arg Ala Asp Cys Glu Glu Arg Cys
195 200 205
Asp Arg Ile Arg Cys Ser Glu Asp Gly Glu Ile Cys Glu Gly Asn Lys
210 215 220
Leu Thr Ala Ile Ser Glu Glu Lys Ala Arg Ser Trp Thr Leu Ile Lys
225 230 235 240
Tyr Arg Phe Leu Thr Met Ile Glu Lys Leu Phe Glu Met Val Ala Asp
245 250 255
Ile Phe Lys Leu Ile Pro Leu Pro Ile Ser His Gly Ile Arg Ala Ile
260 265 270
Val Ala Ala Gly Cys Thr Leu Thr Ser Ala Val Ile Gly Leu Gly Thr
275 280 285
Phe Trp Ser Arg Ala
290
<210>138
<211>16
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>138
Asp Leu Cys Val Ser His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser
1 5 10 15
<210>139
<211>16
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>139
Arg Ala Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu
1 5 10 15
<210>140
<211>18
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>140
Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe Gly Ala Ile
1 5 10 15
Arg Pro
<210>141
<211>18
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>14
Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn Lys
1 5 10 15
Met Leu
<210>142
<211>18
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>142
Arg Pro Ile Leu Phe Val Asn Lys Met Leu Ala Gln Pro Phe Leu Ser
1 5 10 15
Ser Gln
<210>143
<211>17
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>143
Met Leu Ala Gln Pro Phe Leu Set Ser Gln Thr Lys Ala Asn Met Gly
1 5 10 15
Ser
<210>144
<211>10
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>144
Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu
1 5 10
<210>145
<211>9
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>145
Ser Phe Ile Gly Gly Ile Thr Tyr Leu
1 5
<210>146
<211>8
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>146
Phe Ile Gly Gly Ile Thr Tyr Leu
1 5
<210>147
<211>9
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>147
Cys Ser Phe Ile Gly Gly Ile Thr Tyr
1 5
<210>148
<211>8
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>148
Cys Ser Phe Ile Gly Gly Ile Thr
1 5
<210>149
<211>10
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>149
Cys Ser Ile Ile Gly Gly Ile Thr Tyr Leu
1 5 10
<210>150
<211>10
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>150
Cys Gly Phe Ile Gly Gly Ile Thr Tyr Leu
1 5 10
<210>151
<211>9
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>151
Gly Phe Ile Gly Gly Ile Thr Tyr Leu
1 5
<210>152
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>152
Gln Ile Phe Val Cys Leu Ile Ser Ala Glu Arg Leu Arg Leu Arg Leu
1 5 10 15
Ser Val Ala Ser
20
<210>153
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>153
Glu Arg Leu Arg Leu Arg Leu Ser Val Ala Ser Ser Glu Glu Leu Pro
1 5 10 15
Thr Ser Arg His
20
<210>154
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>154
Ala Ser Ser Glu Glu Leu Pro Thr Ser Arg His Ser Glu Leu Ser Val
1 5 10 15
Arg Phe Cys Leu
20
<210>155
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>155
Arg His Ser Glu Leu Ser Val Arg Phe Cys Leu Ser Thr Lys Cys Trp
1 5 10 15
Arg Asn Arg Phe
20
<210>156
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>156
Leu Ser Thr Lys Cys Trp Arg Asn Arg Phe Phe Leu Pro Lys Leu Lys
1 5 10 15
Gln Ile Trp Asp
20
<210>157
<211>53
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>157
Ile Phe Val Cys Leu Ile Ser Ala Glu Arg Leu Arg Leu Ser Val Ala
1 5 10 15
Ser Ser Glu Glu Leu Pro Thr Ser Arg His Ser Glu Leu Ser Val Arg
20 25 30
Phe Cys Leu Ser Thr Lys Cys Trp Arg Asn Arg Phe Phe Leu Pro Lys
35 40 45
Leu Lys Gln Ile Trp
50
<210>158
<211>52
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>158
Leu Cys Val Ser His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Phe
1 5 10 15
Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile
20 25 30
Leu Phe Val Asn Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Ile
35 40 45
Lys Ala Asn Met
50
<210>159
<211>24
<212>DNA
<213>Chlamydia
<400>159
ttttgaagca ggtaggtgaa tatg 24
<210>160
<211>24
<212>DNA
<213>Chlamydia
<400>160
ttaagaaatt taaaaaatcc ctta 24
<210>161
<211>24
<212>DNA
<213>Chlamydia
<400>161
ggtataatat ctctctaaat tttg 24
<210>162
<211>19
<212>DNA
<213>Chlamydia
<400>162
agataaaaaa ggctgtttc 19
<210>163
<211>24
<212>DNA
<213>Chlamydia
<400>163
ttttgaagca ggtaggtgaa tatg 24
<210>164
<211>29
<212>DNA
<213>Chlamydia
<400>164
tttacaataa gaaaagctaa gcactttgt 29
<210>165
<211>20
<212>DNA
<213>Chlamydia
<400>165
ccttacacag tcctgctgc 20
<210>166
<211>20
<212>DNA
<213>Chlamydia
<400>166
gtttccgggc cctcacattg 20
<210>167
<211>9
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>167
Ser Phe Ile Gly Gly Ile Thr Tyr Leu
1 5
<210>168
<211>9
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>168
Ser Ile Ile Gly Gly Ile Thr Tyr Leu
1 5
<210>169
<211>2643
<212>DNA
<213>Chlamydia
<400>169
gcaatcatgc gacctgatca tatgaacttc tgttgtctat gtgctgctat tttgtcatcc 60
acagcggtcc tctttggcca ggatccctta ggtgaaaccg ccctcctcac taaaaatcct 120
aatcatgtcg tctgtacatt ttttgaggac tgtaccatgg agagcctctt tcctgctctt 180
tgtgctcatg catcacaaga cgatcctttg tatgtacttg gaaattccta ctgttggttc 240
gtatctaaac tccatatcac ggaccccaaa gaggctcttt ttaaagaaaa aggagatctt 300
tccattcaaa actttcgctt cctttccttc acagattgct cttccaagga aagctctcct 360
tctattattc atcaaaagaa tggtcagtta tccttgcgca ataatggtag catgagtttc 420
tgtcgaaatc atgctgaagg ctctggagga gccatctctg cggatgcctt ttctctacag 480
cacaactatc ttttcacagc ttttgaagag aattcttcta aaggaaatgg cggagccatt 540
caggctcaaa ccttctcttt atctagaaat gtgtcgccta tttctttcgc ccgtaatcgt 600
gcggatttaa atggcggcgc tatttgctgt agtaatctta tttgttcagg gaatgtaaac 660
cctctctttt tcactggaaa ctccgccacg aatggaggcg ctatttgttg tatcagcgat 720
ctaaacacct cagaaaaagg ctctctctct cttgcttgta accaagaaac gctatttgca 780
agcaattctg ctaaagaaaa aggcggggct atttatgcca agcacatggt attgcgttat 840
aacggtcctg tttccttcat taacaacagc gctaaaatag gtggagctat cgccatccag 900
tccggaggga gtctctctat ccttgcaggt gaaggatctg ttctgttcca gaataactcc 960
caacgcacct ccgaccaagg tctagtaaga aacgccatct acttaragaa agatgcgatt 1020
ctttcttcct tagaagctcg caacggagat attcttttct ttgatcctat tgtacaagaa 1080
agtagcagca aagaatcgcc tcttccctcc tctttgcaag ccagcgtgac ttctcccacc 1140
ccagccaccg catctccttt agttattcag acaagtgcaa accgttcagt gattttctcg 1200
agcgaacgtc tttctgaaga agaaaaaact cctgataacc tcacttccca actacagcag 1260
cctatcgaac tgaaatccgg acgcttagtt ttaaaagatc gcgctgtcct ttccgcgcct 1320
tctctctctc aggatcctca agctctcctc attatggaag cgggaacttc tttaaaaact 1380
tcctctgatt tgaagttagc tacgctaagt attccccttc attccttaga tactgaaaaa 1440
agcgtaacta tccacgcccc taatctttct atccaaaaga tcttcctctc taactctgga 1500
gatgagaatt tttatgaaaa tgtagagctt ctcagtaaag agcaaaacaa tattcctctc 1560
cttactctcc ctaaagagca atctcattta catcttcctg atgggaacct ctcttctcac 1620
tttggatatc aaggagattg gactttttct tggaaagatt ctgatgaagg gcattctctg 1680
attgctaatt ggacgcctaa aaactatgtg cctcatccag aacgtcaatc tacactcgtt 1740
gcgaacactc tttggaacac ctattccgat atgcaagctg tgcagtcgat gattaataca 1800
acagcgcacg gaggagccta tctatttgga acgtggggat ctgctgtttc taatttattc 1860
tatgttcacg acagctctgg gaaacctatc gataattggc atcatagaag ccttggctac 1920
ctattcggta tcagtactca cagtttagat gaccattctt tctgcttggc tgcaggacaa 1980
ttactcggga aatcgtccga ttcctttatt acgtctacag aaacgacctc ctatatagct 2040
actgtacaag cgcaactcgc tacctctcta atgaaaatct ctgcacaggc atgctacaat 2100
gaaagtatcc atgagctaaa aacaaaatat cgctccttct ctaaagaagg attcggatcc 2160
tggcatagcg ttgcagtatc cggagaagtg tgcgcatcga ttcctattgt atccaatggt 2220
tccggactgt tcagctcctt ctctattttc tctaaactgc aaggattttc aggaacacag 2280
gacggttttg aggagagttc gggagagatt cggtcctttt ctgccagctc tttcagaaat 2340
atttcacttc ctataggaat aacatttgaa aaaaaatccc aaaaaacacg aacctactat 2400
tactttctag gagcctacat ccaagacctg aaacgtgatg tggaatcggg acctgtagtg 2460
ttactcaaaa atgccgtctc ctgggatgct cctatggcga acttggattc acgagcctac 2520
atgttccggc ttacgaatca aagagctcta cacagacttc agacgctgtt aaatgtgtct 2580
tgtgtgctgc gtgggcaaag ccatagttac tccctggatc tggggaccac ttacaggttc 2640
tag 2643
<210>170
<211>2949
<212>DNA
<213>Chlamydia
<400>170
atgattcctc aaggaattta cgatggggag acgttaactg tatcatttcc ctatactgtt 60
ataggagatc cgagtgggac tactgttttt tctgcaggag agttaacatt aaaaaatctt 120
gacaattcta ttgcagcttt gcctttaagt tgttttggga acttattagg gagttttact 180
gttttaggga gaggacactc gttgactttc gagaacatac ggacttctac aaatggggca 240
gctctaagta atagcgctgc tgatggactg tttactattg agggttttaa agaattatcc 300
ttttccaatt gcaattcatt acttgccgta ctgcctgctg caacgactaa taagggtagc 360
cagactccga cgacaacatc tacaccgtct aatggtacta tttattctaa aacagatctt 420
ttgttactca ataatgagaa gttctcattc tatagtaatt tagtctctgg agatggggga 480
gctatagatg ctaagagctt aacggttcaa ggaattagca agctttgtgt cttccaagaa 540
aatactgctc aagctgatgg gggagcttgt caagtagtca ccagtttctc tgctatggct 600
aacgaggctc ctattgcctt tgtagcgaat gttgcaggag taagaggggg agggattgct 660
gctgttcagg atgggcagca gggagtgtca tcatctactt caacagaaga tccagtagta 720
agtttttcca gaaatactgc ggtagagttt gatgggaacg tagcccgagt aggaggaggg 780
atttactcct acgggaacgt tgctttcctg aataatggaa aaaccttgtt tctcaacaat 840
gttgcttctc ctgtttacat tgctgctaag caaccaacaa gtggacaggc ttctaatacg 900
agtaataatt acggagatgg aggagctatc ttctgtaaga atggtgcgca agcaggatcc 960
aataactctg gatcagtttc ctttgatgga gagggagtag ttttctttag tagcaatgta 1020
gctgctggga aagggggagc tatttatgcc aaaaagctct cggttgctaa ctgtggccct 1080
gtacaatttt taaggaatat cgctaatgat ggtggagcga tttatttagg agaatctgga 1140
gagctcagtt tatctgctga ttatggagat attattttcg atgggaatct taaaagaaca 1200
gccaaagaga atgctgccga tgttaatggc gtaactgtgt cctcacaagc catttcgatg 1260
ggatcgggag ggaaaataac gacattaaga gctaaagcag ggcatcagat tctctttaat 1320
gatcccatcg agatggcaaa cggaaataac cagccagcgc agtcttccaa acttctaaaa 1380
attaacgatg gtgaaggata cacaggggat attgtttttg ctaatggaag cagtactttg 1440
taccaaaatg ttacgataga gcaaggaagg attgttcttc gtgaaaaggc aaaattatca 1500
gtgaattctc taagtcagac aggtgggagt ctgtatatgg aagctgggag tacattggat 1560
tttgtaactc cacaaccacc acaacagcct cctgccgcta atcagttgat cacgctttcc 1620
aatctgcatt tgtctctttc ttctttgtta gcaaacaatg cagttacgaa tcctcctacc 1680
aatcctccag cgcaagattc tcatcctgca gtcattggta gcacaactgc tggttctgtt 1740
acaattagtg ggcctatctt ttttgaggat ttggatgata cagcttatga taggtatgat 1800
tggctaggtt ctaatcaaaa aatcaatgtc ctgaaattac agttagggac taagccccca 1860
gctaatgccc catcagattt gactctaggg aatgagatgc ctaagtatgg ctatcaagga 1920
agctggaagc ttgcgtggga tcctaataca gcaaataatg gtccttatac tctgaaagct 1980
acatggacta aaactgggta taatcctggg cctgagcgag tagcttcttt ggttccaaat 2040
agtttatggg gatccatttt agatatacga tctgcgcatt cagcaattca agcaagtgtg 2100
gatgggcgct cttattgtcg aggattatgg gtttctggag tttcgaattt cttctatcat 2160
gaccgcgatg ctttaggtca gggatatcgg tatattagtg ggggttattc cttaggagca 2220
aactcctact ttggatcatc gatgtttggt ctagcattta ccgaagtatt tggtagatct 2280
aaagattatg tagtgtgtcg ttccaatcat catgcttgca taggatccgt ttatctatct 2340
acccaacaag ctttatgtgg atcctatttg ttcggagatg cgtttatccg tgctagctac 2400
gggtttggga atcagcatat gaaaacctca tatacatttg cagaggagag cgatgttcgt 2460
tgggataata actgtctggc tggagagatt ggagcgggat taccgattgt gattactcca 2520
tctaagctct atttgaatga gttgcgtcct ttcgtgcaag ctgagttttc ttatgccgat 2580
catgaatctt ttacagagga aggcgatcaa gctcgggcat tcaagagcgg acatctccta 2640
aatctatcag ttcctgttgg agtgaagttt gatcgatgtt ctagtacaca tcctaataaa 2700
tatagcttta tggcggctta tatctgtgat gcttatcgca ccatctctgg tactgagaca 2760
acgctcctat cccatcaaga gacatggaca acagatgcct ttcatttagc aagacatgga 2820
gttgtggtta gaggatctat gtatgcttct ctaacaagta atatagaagt atatggccat 2880
ggaagatatg agtatcgaga tgcttctcga ggctatggtt tgagtgcagg magtaaagtc 2940
yggttctaa 2949
<210>171
<211>2895
<212>DNA
<213>Chlamydia
<400>171
atgaaaaaag cgtttttctt tttccttatc ggaaactccc tatcaggact agctagagag 60
gttccttcta gaatctttct tatgcccaac tcagttccag atcctacgaa agagtcgcta 120
tcaaataaaa ttagtttgac aggagacact cacaatctca ctaactgcta tctcgataac 180
ctacgctaca tactggctat tctacaaaaa actcccaatg aaggagctgc tgtcacaata 240
acagattacc taagcttttt tgatacacaa aaagaaggta tttattttgc aaaaaatctc 300
acccctgaaa gtggtggtgc gattggttat gcgagtccca attctcctac cgtggagatt 360
cgtgatacaa taggtcctgt aatctttgaa aataatactt gttgcagact atttacatgg 420
agaaatcctt atgctgctga taaaataaga gaaggcggag ccattcatgc tcaaaatctt 480
tacataaatc ataatcatga tgtggtcgga tttatgaaga acttttctta tgtccaagga 540
ggagccatta gtaccgctaa tacctttgtt gtgagcgaga atcagtcttg ttttctcttt 600
atggacaaca tctgtattca aactaataca gcaggaaaag gtggcgctat ctatgctgga 660
acgagcaatt cttttgagag taataactgc gatctcttct tcatcaataa cgcctgttgt 720
gcaggaggag cgatcttctc ccctatctgt tctctaacag gaaatcgtgg taacatcgtt 780
ttctataaca atcgctgctt taaaaatgta gaaacagctt cttcagaagc ttctgatgga 840
ggagcaatta aagtaactac tcgcctagat gttacaggca atcgtggtag gatctttttt 900
agtgacaata tcacaaaaaa ttatggcgga gctatttacg ctcctgtagt taccctagtg 960
gataatggcc ctacctactt tataaacaat atcgccaata ataagggggg cgctatctat 1020
atagacggaa ccagtaactc caaaatttct gccgaccgcc atgctattat ttttaatgaa 1080
aatattgtga ctaatgtaac taatgcaaat ggtaccagta cgtcagctaa tcctcctaga 1140
agaaatgcaa taacagtagc aagctcctct ggtgaaattc tattaggagc agggagtagc 1200
caaaatttaa ttttttatga tcctattgaa gttagcaatg caggggtctc tgtgtccttc 1260
aataaggaag ctgatcaaac aggctctgta gtattttcag gagctactgt taattctgca 1320
gattttcatc aacgcaattt acaaacaaaa acacctgcac cccttactct cagtaatggt 1380
tttctatgta tcgaagatca tgctcagctt acagtgaatc gattcacaca aactgggggt 1440
gttgtttctc ttgggaatgg agcagttctg agttgctata aaaatggtac aggagattct 1500
gctagcaatg cctctataac actgaagcat attggattga atctttcttc cattctgaaa 1560
agtggtgctg agattccttt attgtgggta gagcctacaa ataacagcaa taactataca 1620
gcagatactg cagctacctt ttcattaagt gatgtaaaac tctcactcat tgatgactac 1680
gggaactctc cttatgaatc cacagatctg acccatgctc tgtcatcaca gcctatgcta 1740
tctatttctg aagctagcga taaccagcta caatcagaaa atatagattt ttcgggacta 1800
aatgtccctc attatggatg gcaaggactt tggacttggg gctgggcaaa aactcaagat 1860
ccagaaccag catcttcagc aacaatcact gatccacaaa aagccaatag atttcataga 1920
accttactac taacatggct tcctgccggg tatgttccta gcccaaaaca cagaagtccc 1980
ctcatagcta acaccttatg ggggaatatg ctgcttgcaa cagaaagctt aaaaaatagt 2040
gcagagctga cacctagtgg tcatcctttc tggggaatta caggaggagg actaggcatg 2100
atggtttacc aagatcctcg agaaaatcat cctggattcc atatgcgctc ttccggatac 2160
tctgcgggga tgatagcagg gcagacacac accttctcat tgaaattcag tcagacctac 2220
accaaactca atgagcgtta cgcaaaaaac aacgtatctt ctaaaaatta ctcatgccaa 2280
ggagaaatgc tcttctcatt gcaagaaggt ttcttgctga ctaaattagt tgggctttac 2340
agctatggag accataactg tcaccatttc tatactcaag gagaaaatct aacatctcaa 2400
gggacgttcc gcagtcaaac gatgggaggt gctgtctttt ttgatctccc tatgaaaccc 2460
tttggatcaa cgcatatact gacagctccc tttttaggtg ctcttggtat ttattctagc 2520
ctgtctcact ttactgaggtgggagcctat ccgcgaagct tttctacaaa gactcctttg 2580
atcaatgtcc tagtccctat tggagttaaa ggtagcttta tgaatgctac ccacagacct 2640
caagcctgga ctgtagaatt ggcataccaa cccgttctgt atagacaaga accagggatc 2700
gcgacccagc tcctagccag taaaggtatt tggtttggta gtggaagccc ctcatcgcgt 2760
catgccatgt cctataaaat ctcacagcaa acacaacctt tgagttggtt aactctccat 2820
ttccagtatc atggattcta ctcctcttca accttctgta attatctcaa tggggaaatt 2880
gctctgcgat tctag 2895
<210>172
<211>4593
<212>DNA
<213>Chlamydia
<400>172
atgagttccg agaaagatat aaaaagcacc tgttctaagt tttctttgtc tgtagtagca 60
gctatccttg cctctgttag cgggttagct agttgcgtag atcttcatgc tggaggacag 120
tctgtaaatg agctggtata tgtaggccct caagcggttt tattgttaga ccaaattcga 180
gatctattcg ttgggtctaa agatagtcag gctgaaggac agtataggtt aattgtagga 240
gatccaagtt ctttccaaga gaaagatgca gatactcttc ccgggaaggt agagcaaagt 300
actttgttct cagtaaccaa tcccgtggtt ttccaaggtg tggaccaaca ggatcaagtc 360
tcttcccaag ggttaatttg tagttttacg agcagcaacc ttgattctcc ccgtgacgga 420
gaatcttttt taggtattgc ttttgttggg gatagtagta aggctggaat cacattaact 480
gacgtgaaag cttctttgtc tggagcggct ttatattcta cagaagatct tatctttgaa 540
aagattaagg gtggattgga atttgcatca tgttcttctc tagaacaggg gggagcttgt 600
gcagctcaaa gtattttgat tcatgattgt caaggattgc aggttaaaca ctgtactaca 660
gccgtgaatg ctgaggggtc tagtgcgaat gatcatcttg gatttggagg aggcgctttc 720
tttgttacgg gttctctttc tggagagaaa agtctctata tgcctgcagg agatatggta 780
gttgcgaatt gtgatggggc tatatctttt gaaggaaaca gcgcgaactt tgctaatgga 840
ggagcgattg ctgcctctgg gaaagtgctt tttgtcgcta atgataaaaa gacttctttt 900
atagagaacc gagctttgtc tggaggagcg attgcagcct cttctgatat tgcctttcaa 960
aactgcgcag aactagtttt caaaggcaat tgtgcaattg gaacagagga taaaggttct 1020
ttaggtggag gggctatatc ttctctaggc accgttcttt tgcaagggaa tcacgggata 1080
acttgtgata agaatgagtc tgcttcgcaa ggaggcgcca tttttggcaa aaattgtcag 1140
atttctgaca acgaggggcc agtggttttc agagatagta cagcttgctt aggaggaggc 1200
gctattgcag ctcaagaaat tgtttctatt cagaacaatc aggctgggat ttccttcgag 1260
ggaggtaagg ctagtttcgg aggaggtatt gcgtgtggat ctttttcttc cgcaggcggt 1320
gcttctgttt tagggactat tgatatttcg aagaatttag gcgcgatttc gttctctcgt 1380
adtttatgta cgacctcaga tttaggacaa atggagtacc agggaggagg agctctattt 1440
ggtgaaaata tttctctttc tgagaatgct ggtgtgctca cctttaaaga caacattgtg 1500
aagacttttg cttcgaatgg gaaaattctg ggaggaggag cgattttagc tactggtaag 1560
gtggaaatta ccaataattc cggaggaatt tcttttacag gaaatgcgag agctccacaa 1620
gctcttccaa ctcaagagga gtttccttta ttcagcaaaa aagaagggcg accactctct 1680
tcaggatatt ctgggggagg agcgatttta ggaagagaag tagctattct ccacaacgct 1740
gcagtagtat ttgagcaaaa tcgtttgcag tgcagcgaag aagaagcgac attattaggt 1800
tgttgtggag gaggcgctgt tcatgggatg gatagcactt cgattgttgg caactcttca 1860
gtaagatttg gtaataatta cgcaatggga caaggagtct caggaggagc tcttttatct 1920
aaaacagtgc agttagctgg aaatggaagc gtcgattttt ctcgaaatat tgctagtttg 1980
ggaggaggag ctcttcaagc ttctgaagga aattgtgagc tagttgataa cggctatgtg 2040
ctattcagag ataatcgagg gagggtttat gggggtgcta tttcttgctt acgtggagat 2100
gtagtcattt ctggaaacaa gggtagagtt gaatttaaag acaacatagc aacacgtctt 2160
tatgtggaag aaactgtaga aaaggttgaa gaggtagagc cagctcctga gcaaaaagac 2220
aataatgagc tttctttctt agggagtgta gaacagagtt ttattactgc agctaatcaa 2280
gctcttttcg catctgaaga tggggattta tcacctgagt catccatttc ttctgaagaa 2340
cttgcgaaaa gaagagagtg tgctggagga gctatttttg caaaacgggt tcgtattgta 2400
gataaccaag aggccgttgt attctcgaat aacttctctg atatttatgg cggcgccatt 2460
tttacaggtt ctcttcgaga agaggataag ttagatgggc aaatccctga agtcttgatc 2520
tcaggcaatg caggggatgt tgttttttcc ggaaattcct cgaagcgtga tgagcatctt 2580
cctcatacag gtgggggagc catttgtact caaaatttga cgatttctca gaatacaggg 2640
aatgttctgt tttataacaa cgtggcctgt tcgggaggag ctgttcgtat agaggatcat 2700
ggtaatgttc ttttagaagc ttttggagga gatattgttt ttaaaggaaa ttcttctttc 2760
agagcacaag gatccgatgc tatctatttt gcaggtaaag aatcgcatat tacagccctg 2820
aatgctacgg aaggacatgc tattgttttc cacgacgcat tagtttttga aaatctaaaa 2880
gaaaggaaat ctgctgaagt attgttaatc aatagtcgag aaaatccagg ttacactgga 2940
tctattcgat ttttagaagc agaaagtaaa gttcctcaat gtattcatgt acaacaagga 3000
agccttgagt tgctaaatgg agctacatta tgtagttatg gttttaaaca agatgctgga 3060
gctaagttgg tattggctgc tggatctaaa ctgaagattt tagattcagg aactcctgta 3120
caagggcatg ctatcagtaa acctgaagca gaaatcgagt catcttctga accagagggt 3180
gcacattctc tttggattgc gaagaatgct caaacaacag ttcctatggt tgatatccat 3240
actatttctg tagatttagc ctccttctct tctagtcaac aggaggggac agtagaagct 3300
cctcaggtta ttgttcctgg aggaagttat gttcgatctg gagagcttaa tttggagtta 3360
gttaacacaa caggtactgg ttatgaaaat catgctttgt tgaagaatga ggctaaagtt 3420
ccattgatgt ctttcgttgc ttctagtgat gaagcttcag ccgaaatcag taacttgtcg 3480
gtttctgatt tacagattca tgtagcaact ccagagattg aagaagacac atacggccat 3540
atgggagatt ggtctgaggc taaaattcaa gatggaactc ttgtcattaa ttggaatcct 3600
actggatatc gattagatcc tcaaaaagca ggggctttag tatttaatgc attatgggaa 3660
gaaggggctg tcttgtctgc tctgaaaaat gcacgctttg ctcataatct cactgctcag 3720
cgtatggaat tcgattattc tacaaatgtg tggggattcg cctttggtgg tttccgaact 3780
ctatctgcag agaatctggt tgctattgat ggatacaaag gagcttatgg tggtgcttct 3840
gctggagtcg atattcaatt gatggaagat tttgttctag gagttagtgg agctgctttc 3900
ctaggtaaaa tggatagtca gaagtttgat gcggaggttt ctcggaaggg agttgttggt 3960
tctgtatata caggattttt agctggatcc tggttcttca aaggacaata tagccttgga 4020
gaaacacaga acgatatgaa aacgcgttat ggagtactag gagagtcgag tgcttcttgg 4080
acatctcgag gagtactggc agatgcttta gttgaatacc gaagtttagt tggtcctgtg 4140
agacctactt tttatgcttt gcatttcaat ccttatgtcg aagtatctta tgcttctatg 4200
aaattccctg gctttacaga acaaggaaga gaagcgcgtt cttttgaaga cgcttccctt 4260
accaatatca ccattccttt agggatgaag tttgaattgg cgttcataaa aggacagttt 4320
tcagaggtga actctttggg aataagttat gcatgggaag cttatcgaaa agtagaagga 4380
ggcgcggtgc agcttttaga agctgggttt gattgggagg gagctccaat ggatcttcct 4440
agacaggagc tgcgtgtcgc tctggaaaat aatacggaat ggagttctta cttoagcaca 4500
gtcttaggat taacagcttt ttgtggagga tttacttcta cagatagtaa actaggatat 4560
gaggcgaata ctggattgcg attgatcttt taa 4593
<210>173
<211>5331
<212>DNA
<213>Chlamydia
<400>173
gcaatcatga aatttatgtc agctactgct gtatttgctg cagtactctc ctccgttact 60
gaggcgagct cgatccaaga tcaaataaag aataccgact gcaatgttag caaagtagga 120
tattcaactt ctcaagcatt tactgatatg atgctagcag acaacacaga gtatcgagct 180
gctgatagtg tttcattcta tgacttttcg acatcttccg gattacctag aaaacatctt 240
agtagtagta gtgaagcttc tccaacgaca gaaggagtgt cttcatcttc atctggagaa 300
aatactgaga attcacaaga ttcagctccc tcttctggag aaactgataa gaaaacagaa 360
gaagaactag acaatggcgg aatcatttat gctagagaga aactaactat ctcagaatct 420
caggactctc tctctaatcc aagcatagaa ctccatgaca atagtttttt cttcggagaa 480
ggtgaagtta tctttgatca cagagttgcc ctcaaaaacg gaggagctat ttatggagag 540
aaagaggtag tctttgaaaa cataaaatct ctactagtag aagtaaatat ctcggtcgag 600
aaagggggta gcgtctatgc aaaagaacga gtatctttag aaaatgttac cgaagcaacc 660
ttctcctcca atggtgggga acaaggtggt ggtggaatct attcagaaca agatatgtta 720
atcagtgatt gcaacaatgt acatttccaa gggaatgctg caggagcaac agcagtaaaa 780
caatgtctgg atgaagaaat gatcgtattg ctcacagaat gcgttgatag cttatccgaa 840
gatacactgg atagcactcc agaaacggaa cagactaagt caaatggaaa tcaagatggt 900
tcgtctgaaa caaaagatac acaagtatca gaatcaccag aatcaactcc tagccccgac 960
gatgttttag gtaaaggtgg tggtatctat acagaaaaat ctttgaccat cactggaatt 1020
acagggacta tagattttgt cagtaacata gctaccgatt ctggagcagg tgtattcact 1080
aaagaaaact tgtcttgcac caacacgaat agcctacagt ttttgaaaaa ctcggcaggt 1140
caacatggag gaggagccta cgttactcaa accatgtctg ttactaatac aactagtgaa 1200
agtataacta ctccccctct cgtaggagaa gtgattttct ctgaaaatac agctaaaggg 1260
cacggtggtg gtatctgcac taacaaactt tctttatcta atttaaaaac ggtgactctc 1320
actaaaaact ctgcaaagga gtctggagga gctattttta cagatctagc gtctatacca 1380
acaacagata ccccagagtc ttctaccccc tcttcctcct cgcctgcaag cactcccgaa 1440
gtagttgctt ctgctaaaat aaatcgattc tttgcctcta cggcagaacc ggcagcccct 1500
tctctaacag aggctgagtc tgatcaaacg gatcaaacag aaacttctga tactaatagc 1560
gatatagacg tgtcgattga gaacattttg aatgtcgcta tcaatcaaaa cacttctgcg 1620
aaaaaaggag gggctattta cgggaaaaaa gctaaacttt cccgtattaa caatcttgaa 1680
ctttcaggga attcatccca ggatgtagga ggaggtctct gtttaactga aagcgtagaa 1740
tttgatgcaa ttggatcgct cttatcccac tataactctg ctgctaaaga aggtggggtt 1800
attcattcta aaacggttac tctatctaac ctcaagtcta ccttcacttt tgcagataac 1860
actgttaaag caatagtaga aagcactcct gaagctccag aagagattcc tccagtagaa 1920
ggagaagagt ctacagcaac agaaaatccg aattctaata cagaaggaag ttcggctaac 1980
actaaccttg aaggatctca aggggatact gctgatacag ggactggtgt tgttaacaat 2040
gagtctcaag acacatcaga tactggaaac gctgaatctg gagaacaact acaagattct 2100
acacaatcta atgaagaaaa tacccttccc aatagtagta ttgatcaatc taacgaaaac 2160
acagacgaat catctgatag ccacactgag gaaataactg acgagagtgt ctcatcgtcc 2220
tctaaaagtg gatcatctac tcctcaagat ggaggagcag cttcttcagg ggctccctca 2280
ggagatcaat ctatctctgc aaacgcttgt ttagctaaaa gctatgctgc gagtactgat 2340
agctcccctg tatctaattc ttcaggttca gacgttactg catcttctga taatccagac 2400
tcttcctcat ctggagatag cgctggagac tctgaaggac cgactgagcc agaagctggt 2460
tctacaacag aaactcctac tttaatagga ggaggtgcta tctatggaga aactgttaag 2520
attgagaact tctctggcca aggaatattt tctggaaaca aagctatcga taacaccaca 2580
gaaggctcct cttccaaatc taacgtcctc ggaggtgcgg tctatgctaa aacattgttt 2640
aatctcgata gcgggagctc tagacgaact gtcaccttct ccgggaatac tgtctcttct 2700
caatctacaa caggtcaggt tgctggagga gctatctact ctcctactgt aaccattgct 2760
actcctgtag tattttctaa aaactctgca acaaacaatg ctaataacgc tacagatact 2820
cagagaaaag acacctttgg aggagctatc ggagctactt ctgctgtttc tctatcagga 2880
ggggctcatt tcttagaaaa cgttgctgac ctcggatctg ctattgggtt ggtgccagac 2940
acacaaaata cagaaacagt gaaattagag tctggctcct actactttga aaaaaataaa 3000
gctttaaaac gagctactat ttacgcacct gtcgtttcca ttaaagccta tactgcgaca 3060
tttaaccaaa acagatctct agaagaagga agcgcgattt actttacaaa agaagcatct 3120
attgagtctt taggctctgt tctcttcaca ggaaacttag taaccccaac gctaagcaca 3180
actacagaag gcacaccagc cacaacctca ggagatgtaa caaaatatgg tgctgctatc 3240
tttggacaaa tagcaagctc aaacggatct cagacggata accttcccct gaaactcatt 3300
gcttcaggag gaaatatttg tttccgaaac aatgaatacc gtcctacttc ttctgatacc 3360
ggaacctcta ctttctgtag tattgcggga gatgttaaat taaccatgca agctgcaaaa 3420
gggaaaacga tcagtttctt tgatgcaatc cggacctcta ctaagaaaac aggtacacag 3480
gcaactgcct acgatactct cgatattaat aaatctgagg attcagaaac tgtaaactct 3540
gcgtttacag gaacgattct gttctcctct gaattacatg aaaataaatc ctatattcca 3600
caaaacgtag ttctacacag tggatctctt gtattgaagc caaataccga gcttcatgtc 3660
atttcttttg agcagaaaga aggctcttct ctcgttatga cacctggatc tgttctttcg 3720
aaccagactg ttgctgatgg agctttggtc ataaataaca tgaccattga tttatccagc 3780
gtagagaaaa atggtattgc tgaaggaaat atctttactc ctccagaatt gagaatcata 3840
gacactacta caagtggaag cggtggaacc ccatctacag atagtgaaag taaccagaat 3900
agtgatgata ccaaggagca aaataataat gacgcctcga atcaaggaga aagcgcgaat 3960
ggatcgtctt ctcctgcagt agctgctgca cacacatctc gtacaagaaa ctttgccgct 4020
gcagctacag ccacacctac gacaacacca acggctacaa ctacaacaag caaccaagta 4080
atcctaggag gagaaatcaa actcatcgat cctaatggga ccttcttcca gaaccctgca 4140
ttaagatccg accaacaaat ctccttgtta gtgctcccta cagactcatc aaaaatgcaa 4200
gctcagaaaa tagtactgac gggtgatatt gctcctcaga aaggatatac aggaacactc 4260
actctggatc ctgatcaact acaaaatgga acgatctcag cgctctggaa atttgactct 4320
tatagacaat gggcttatgt acctagagac aatcatttct atgcgaactc gattctggga 4380
tctcaaatgt caatggtcac agtcaaacaa ggcttgctca acgataaaat gaatctagct 4440
cgctttgatg aagttagcta taacaacctg tggatatcag gactaggaac gatgctatcg 4500
caagtaggaa cacctacttc tgaagaattc acttattaca gcagaggagc ttctgttgcc 4560
ttagatgcta aaccagccca tgatgtgatt gttggagctg catttagtaa gatgatcggg 4620
aaaacaaaat ccttgaaaag agagaataac tacactcaca aaggatccga atattcttac 4680
caagcatcgg tatacggagg caaaccattc cactttgtaa tcaataaaaa aacggaaaaa 4740
tcgctaccgc tattgttaca aggagtcatc tcttacggat atatcaaaca tgatacagtg 4800
actcactatc caacgatccg tgaacgaaac caaggagaat gggaagactt aggatggctg 4860
acagctctcc gtgtctcctc tgtcttaaga actcctgcac aaggggatac taaacgtatc 4920
actgtttacg gagaattgga atactccagt atccgtcaga aacaattcac agaaacagaa 4980
tacgatcctc gttacttcga caactgcacc tatagaaact tagcaattcc tatggggtta 5040
gcattcgaag gagagctctc tggtaacgat attttgatgt acaacagatt ctctgtagca 5100
tacatgccat caatctatcg aaattctcca acatgcaaat accaagtgct ctcttcagga 5160
gaaggcggag aaattatttg tggagtaccg acaagaaact cagctcgcgg agaatacagc 5220
acgcagctgt acccgggacc tttgtggact ctgtatggat cctacacgat agaagcagac 5280
gcacatacac tagctcatat gatgaactgc ggtgctcgta tgacattcta a 5331
<210>174
<211>5265
<212>DNA
<213>Chlamydia
<400>174
gcaatcatga aatggctgtc agctactgcg gtgtttgctg ctgttctccc ctcagtttca 60
gggttttgct tcccagaacc taaagaatta aatttctctc gcgtagaaac ttcttcctct 120
accactttta ctgaaacaat tggagaagct ggggcagaat atatcgtctc tggtaacgca 180
tctttcacaa aatttaccaa cattcctact accgatacaa caactcccac gaactcaaac 240
tcctctagct ctagcggaga aactgcttcc gtttctgagg atagtgactc tacaacaacg 300
actcctgatc ctaaaggtgg cggcgccttt tataacgcgc actccggagt tttgtccttt 360
atgacacgat caggaacaga aggttcctta actctgtctg agataaaaat gactggtgaa 420
ggcggtgcta tcttctctca aggagagctg ctatttacag atctgacaag tctaaccatc 480
caaaataact tatcccagct atccggagga gcgatttttg gaggatctac aatctcccta 540
tcagggatta ctaaagcgac tttctcctgc aactctgcag aagttcctgc tcctgttaag 600
aaacctacag aacctaaagc tcaaacagca agcgaaacgt cgggttctag tagttctagc 660
ggaaatgatt cggtgtcttc ccccagttcc agtagagctg aacccgcagc agctaatctt 720
caaagtcact ttatttgtgc tacagctact cctgctgctc aaaccgatac agaaacatca 780
actccctctc ataagccagg atctggggga gctatctatg ctaaaggcga ccttactatc 840
gcagactctc aagaggtact attctcaata aataaagctactaaagatgg aggagcgatc 900
tttgctgaga aagatgtttc tttcgagaat attacatcattaaaagtaca aactaacggt 960
gctgaagaaa agggaggagc tatctatgct aaaggtgacc tctcaattca atcttctaaa 1020
cagagtcttt ttaattctaa ctacagtaaa caaggtgggg gggctctata tgttgaagga 1080
ggtataaact tccaagatct tgaagaaatt cgcattaagt acaataaagc tggaacgttc 1140
gaaacaaaaa aaatcacttt accttcttta aaagctcaag catctgcagg aaatgcagat 1200
gcttgggcct cttcctctcc tcaatctggt tctggagcaa ctacagtctc cgactcagga 1260
gactctagct ctggctcaga ctcggatacc tcagaaacag ttccagtcac agctaaaggc 1320
ggtgggcttt atactgataa gaatctttcg attactaaca tcacaggaat tatcgaaatt 1380
gcaaataaca aagcgacaga tgttggaggt ggtgcttacg taaaaggaac ccttacttgt 1440
gaaaactctc accgtctaca atttttgaaa aactcttccg ataaacaagg tggaggaatc 1500
tacggagaag acaacatcac cctatctaat ttgacaggga agactctatt ccaagagaat 1560
actgccaaag aagagggcgg tggactcttc ataaaaggta cagataaagc tcttacaatg 1620
acaggactgg atagtttctg tttaattaat aacacatcag aaaaacatgg tggtggagcc 1680
tttgttacca aagaaatctc tcagacttac acctctgatg tggaaacaat tccaggaatc 1740
acgcctgtac atggtgaaac agtcattact ggcaataaat ctacaggagg taatggtgga 1800
ggcgtgtgta caaaacgtct tgccttatct aaccttcaaa gcatttctat atccgggaat 1860
tctgcagcag aaaatggtgg tggagcccac acatgcccag atagcttccc aacggcggat 1920
actgcagaac agcccgcagc agcttctgcc gcgacgtcta ctcccaaatc tgccccggtc 1980
tcaactgctc taagcacacc ttcatcttct accgtctctt cattaacctt actagcagcc 2040
tcttcacaag cctctcctgc aacctctaat aaggaaactc aagatcctaa tgctgataca 2100
gacttattga tcgattatgt agttgatacg actatcagca aaaacactgc taagaaaggc 2160
ggtggaatct atgctaaaaa agccaagatg tcccgcatag accaactgaa tatctctgag 2220
aactccgcta cagagatagg tggaggtatc tgctgtaaag aatctttaga actagatgct 2280
ctagtctcct tatctgtaac agagaacctt gttgggaaag aaggtggagg cttacatgct 2340
aaaactgtaa atatttctaa tctgaaatca ggcttctctt tctcgaacaa caaagcaaac 2400
tcctcatcca caggagtcgc aacaacagct tcagcacctg ctgcagctgc tgcttcccta 2460
caagcagccg cagcagccgc accatcatct ccagcaacac caacttattc aggtgtagta 2520
ggaggagcta tctatggaga aaaggttaca ttctctcaat gtagcgggac ttgtcagttc 2580
tctgggaacc aagctatcga taacaatccc tcccaatcat cgttgaacgt acaaggagga 2640
gccatctatg ccaaaacctc tttgtctatt ggatcttccg atgctggaac ctcctatatt 2700
ttctcgggga acagtgtctc cactgggaaa tctcaaacaa cagggcaaat agcgggagga 2760
gcgatctact cccctactgt tacattgaat tgtcctgcga cattctctaa caatacagcc 2820
tctatagcta caccgaagac ttcttctgaa gatggatcct caggaaattc tattaaagat 2880
accattggag gagccattgc agggacagcc attaccctat ctggagtctc tcgattttca 2940
gggaatacgg ctgatttagg agctgcaata ggaactctag ctaatgcaaa tacacccagt 3000
gcaactagcg gatctcaaaa tagcattaca gaaaaaatta ctttagaaaa cggttctttt 3060
atttttgaaa gaaaccaagc taataaacgt ggagcgattt actctcctag cgtttccatt 3120
aaagggaata atattacctt caatcaaaat acatccactc atgatggaag cgctatctac 3180
tttacaaaag atgctacgat tgagtcttta ggatctgttc tttttacagg aaataacgtt 3240
acagctacac aagctagttc tgcaacatct ggacaaaata caaatactgc caactatggg 3300
gcagccatct ttggagatcc aggaaccact caatcgtctc aaacagatgc cattttaacc 3360
cttcttgctt cttctggaaa cattactttt agcaacaaca gtttacagaa taaccaaggt 3420
gatactcccg ctagcaagtt ttgtagtatt gcaggatacg tcaaactctc tctacaagcc 3480
gctaaaggga agactattag ctttttcgat tgtgtgcaca cctctaccaa aaaaacaggt 3540
tcaacacaaa acgtttatga aactttagat attaataaag aagagaacag taatccatat 3600
acaggaacta ttgtgttctc ttctgaatta catgaaaaca aatcttacat cccacagaat 3660
gcaatccttc acaacggaac tttagttctt aaagagaaaa cagaactcca cgtagtctct 3720
tttgagcaga aagaagggtc taaattaatt atggaacccg gagctgtgtt atctaaccaa 3780
aacatagcta acggagctct agctatcaat gggttaacga ttgatctttc cagtatgggg 3840
actcctcaag caggggaaat cttctctcct ccagaattac gtatcgttgc cacgacctct 3900
agtgcatccg gaggaagcgg ggtcagcagt agtataccaa caaatcctaa aaggatttct 3960
gcagcagtgc cttcaggttc tgccgcaact actccaacta tgagcgagaa caaagttttc 4020
ctaacaggag accttacttt aatagatcct aatggaaact tttaccaaaa ccctatgtta 4080
ggaagcgatc tagatgtacc actaattaag cttccgacta acacaagtga cgtccaagtc 4140
tatgatttaa ctttatctgg ggatcttttc cctcagaaag ggtacatggg aacctggaca 4200
ttagattcta atccacaaac agggaaactt caagccagat ggacattcga tacctatcgt 4260
cgctgggtat acatacctag ggataatcat ttttatgcga actctatctt aggctcccaa 4320
aactcaatga ttgttgtgaa gcaagggctt atcaacaaca tgttgaataa tgcccgcttc 4380
gatgatatcg cttacaataa cttctgggtt tcaggagtag gaactttctt agctcaacaa 4440
ggaactcctc tttccgaaga attcagttac tacagccgcg gaacttcagt tgccatcgat 4500
gccaaaccta gacaagattt tatcctagga gctgcattta gtaagatagt ggggaaaacc 4560
aaagccatca aaaaaatgca taattacttc cataagggct ctgagtactc ttaccaagct 4620
tctgtctatg gaggtaaatt cctgtatttc ttgctcaata agcaacatgg ttgggcactt 4680
cctttcctaa tacaaggagt cgtgtcctat ggacatatta aacatgatac aacaacactt 4740
tacccttcta tccatgaaag aaataaagga gattgggaag atttaggatg gttagcggat 4800
cttcgtatct ctatggatct taaagaacct tctaaagatt cttctaaacg gatcactgtc 4860
tatggggaac tcgagtattc cagcattcgc cagaaacagt tcacagaaat cgattacgat 4920
ccaagacact tcgatgattg tgcttacaga aatctgtcgc ttcctgtggg atgcgctgtc 4980
gaaggagcta tcatgaactg taatattctt atgtataata agcttgcatt agcctacatg 5040
ccttctatct acagaaataa tcctgtctgt aaatatcggg tattgtcttc gaatgaagct 5100
ggtcaagtta tctgcggagt gccaactaga acctctgcta gagcagaata cagtactcaa 5160
ctatatcttg gtcccttctg gactctctac ggaaactata ctatcgatgt aggcatgtat 5220
acgctatcgc aaatgactag ctgcggtgct cgcatgatct tctaa 5265
<210>175
<211>880
<212>PRT
<213>Chlamydia
<220>
<221>VARIANT
<222>(1)...(880)
<223>Xaa=Any Amino Acid
<400>175
Ala Ile Met Arg Pro Asp His Met Asn Phe Cys Cys Leu Cys Ala Ala
1 5 10 15
Ile Leu Ser Ser Thr Ala Val Leu Phe Gly Gln Asp Pro Leu Gly Glu
20 25 30
Thr Ala Leu Leu Thr Lys Asn Pro Asn His Val Val Cys Thr Phe Phe
35 40 45
Glu Asp Cys Thr Met Glu Ser Leu Phe Pro Ala Leu Cys Ala His Ala
50 55 60
Ser Gln Asp Asp Pro Leu Tyr Val Leu Gly Asn Ser Tyr Cys Trp Phe
65 70 75 80
Val Ser Lys Leu His Ile Thr Asp Pro Lys Glu Ala Leu Phe Lys Glu
85 90 95
Lys Gly Asp Leu Ser Ile Gln Asn Phe Arg Phe Leu Ser Phe Thr Asp
100 105 110
Cys Ser Ser Lys Glu Ser Ser Pro Ser Ile Ile His Gln Lys Asn Gly
115 120 125
Gln Leu Ser Leu Arg Asn Asn Gly Ser Met Ser Phe Cys Arg Asn His
130 135 140
Ala Glu Gly Ser Gly Gly Ala Ile Ser Ala Asp Ala Phe Ser Leu Gln
145 150 155 160
His Asn Tyr Leu Phe Thr Ala Phe Glu Glu Asn Ser Ser Lys Gly Asn
165 170 175
Gly Gly Ala Ile Gln Ala Gln Thr Phe Ser Leu Ser Arg Asn Val Ser
180 185 190
Pro Ile Ser Phe Ala Arg Asn Arg Ala Asp Leu Asn Gly Gly Ala Ile
195 200 205
Cys Cys Ser Asn Leu Ile Cys Ser Gly Asn Val Asn Pro Leu Phe Phe
210 215 220
Thr Gly Asn Ser Ala Thr Asn Gly Gly Ala Ile Cys Cys Ile Ser Asp
225 230 235 240
Leu Asn Thr Ser Glu Lys Gly Ser Leu Ser Leu Ala Cys Asn Gln Glu
245 250 255
Thr Leu Phe Ala Ser Asn Ser Ala Lys Glu Lys Gly Gly Ala Ile Tyr
260 265 270
Ala Lys His Met Val Leu Arg Tyr Asn GlyPro Val Ser Phe Ile Asn
275 280 285
Asn Ser Ala Lys Ile Gly Gly Ala Ile Ala Ile Gln Ser Gly Gly Ser
290 295 300
Leu Ser Ile Leu Ala Gly Glu Gly Ser Val Leu Phe Gln Asn Asn Ser
305 310 315 320
Gln Arg Thr Ser Asp Gln Gly Leu Val Arg Asn Ala Ile Tyr Leu Xaa
325 330 335
Lys Asp Ala Ile Leu Ser Ser Leu Glu Ala Arg Asn Gly Asp Ile Leu
340 345 350
Phe Phe Asp Pro Ile Val Gln Glu Ser Ser Ser Lys Glu Ser Pro Leu
355 360 365
Pro Ser Ser Leu Gln Ala Ser Val Thr Ser Pro Thr Pro Ala Thr Ala
370 375 380
Ser Pro Leu Val Ile Gln Thr Ser Ala Asn Arg Ser Val Ile Phe Ser
385 390 395 400
Ser Glu Arg Leu Ser Glu Glu Glu Lys Thr Pro Asp Asn Leu Thr Ser
405 410 415
Gln Leu Gln Gln Pro Ile Glu Leu Lys Ser Gly Arg Leu Val Leu Lys
420 425 430
Asp Arg Ala Val Leu Ser Ala Pro Ser Leu Ser Gln Asp Pro Gln Ala
435 440 445
Leu Leu Ile Met Glu Ala Gly Thr Ser Leu Lys Thr Ser Ser Asp Leu
450 455 460
Lys Leu Ala Thr Leu Ser Ile Pro Leu His Ser Leu Asp Thr Glu Lys
465 470 475 480
Ser Val Thr Ile His Ala Pro Asn Leu Ser Ile Gln Lys Ile Phe Leu
485 490 495
Ser Asn Ser Gly Asp Glu Asn Phe Tyr Glu Asn Val Glu Leu Leu Ser
500 505 510
Lys Glu Gln Asn Asn Ile Pro Leu Leu Thr Leu Pro Lys Glu Gln Ser
515 520 525
His Leu His Leu Pro Asp Gly Asn Leu Ser Ser His Phe Gly Tyr Gln
530 535 540
Gly Asp Trp Thr Phe Ser Trp Lys Asp Ser Asp Glu Gly His Ser Leu
545 550 555 560
Ile Ala Asn Trp Thr Pro Lys Asn Tyr Val Pro His Pro Glu Arg Gln
565 570 575
Ser Thr Leu Val Ala Asn Thr Leu Trp Asn Thr Tyr Ser Asp Met Gln
580 585 590
Ala Val Gln Ser Met Ile Asn Thr Thr Ala His Gly Gly Ala Tyr Leu
595 600 605
Phe Gly Thr Trp Gly Ser Ala Val Ser Asn Leu Phe Tyr Val His Asp
610 615 620
Ser Ser Gly Lys Pro Ile Asp Asn Trp His His Arg Ser Leu Gly Tyr
625 630 635 640
Leu Phe Gly Ile Ser Thr His Ser Leu Asp Asp His Ser Phe Cys Leu
645 650 655
Ala Ala Gly Gln Leu Leu Gly Lys Ser Ser Asp Ser Phe Ile Thr Ser
660 665 670
Thr Glu Thr Thr Ser Tyr Ile Ala Thr Val Gln Ala Gln Leu Ala Thr
675 680 685
Ser Leu Met Lys Ile Ser Ala Gln Ala Cys Tyr Asn Glu Ser Ile His
690 695 700
Glu Leu Lys Thr Lys Tyr Arg Ser Phe Ser Lys Glu Gly Phe Gly Ser
705 710 715 720
Trp His Ser Val Ala Val Ser Gly Glu Val Cys Ala Ser Ile Pro Ile
725 730 735
Val Ser Asn Gly Ser Gly Leu Phe Ser Ser Phe Ser Ile Phe Ser Lys
740 745 750
Leu Gln Gly Phe Ser Gly Thr Gln Asp Gly Phe Glu Glu Ser Ser Gly
755 760 765
Glu Ile Arg Ser Phe Ser Ala Ser Ser Phe Arg Asn Ile Ser Leu Pro
770 775 780
Ile Gly Ile Thr Phe Glu Lys Lys Ser Gln Lys Thr Arg Thr Tyr Tyr
785 790 795 800
Tyr Phe Leu Gly Ala Tyr Ile Gln Asp Leu Lys Arg Asp Val Glu Ser
805 810 815
Gly Pro Val Val Leu Leu Lys Asn Ala Val ser Trp Asp Ala Pro Met
820 825 830
Ala Asn Leu Asp Ser Arg Ala Tyr Met Phe Arg Leu Thr Asn Gln Arg
835 840 845
Ala Leu His Arg Leu Gln Thr Leu Leu Asn Val Ser Cys Val Leu Arg
850 855 860
Gly Gln Ser His Ser Tyr Ser Leu Asp Leu Gly Thr Thr Tyr Arg Phe
865 870 875 880
<210>176
<211>982
<212>PRT
<213>Chlamydia
<220>
<221>VARIANT
<222>(1)...(982)
<223>Xaa = Any Amino Acid
<400>176
Met Ile Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val Ser Phe
1 5 10 15
Pro Tyr Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe Ser Ala
20 25 30
Gly Glu Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala Leu Pro
35 40 45
Leu Ser Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val Leu Gly Arg
50 55 60
Gly His Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn Gly Ala
65 70 75 80
Ala Leu Ser Asn Ser Ala Ala Asp Gly Leu Phe Thr Ile Glu Gly Phe
85 90 95
Lys Glu Leu Ser Phe Ser Asn Cys Asn Ser Leu Leu Ala Val Leu Pro
100 105 110
Ala Ala Thr Thr Asn Lys Gly Ser Gln Thr Pro Thr Thr Thr SerThr
115 120 125
Pro Ser Asn Gly Thr Ile Tyr Ser Lys Thr Asp Leu Leu Leu Leu Asn
130 135 140
Asn Glu Lys Phe Ser Phe Tyr Ser Asn Leu Val Ser Gly Asp Gly Gly
145 150 155 160
Ala Ile Asp Ala Lys Ser Leu Thr Val Gln Gly Ile Ser Lys Leu Cys
165 170 175
Val Phe Gln Glu Asn Thr Ala Gln Ala Asp Gly Gly Ala Cys Gln Val
180 185 190
Val Thr Ser Phe Ser Ala Met Ala Asn Glu Ala Pro Ile Ala Phe Val
195 200 205
Ala Asn Val Ala Gly Val Arg Gly Gly Gly Ile Ala Ala Val Gln Asp
210 215 220
Gly Gln Gln Gly Val Ser Ser Ser Thr Ser Thr Glu Asp Pro Val Val
225 230 235 240
Ser Phe Ser Arg Asn Thr Ala Val Glu Phe Asp Gly Asn Val Ala Arg
245 250 255
Val Gly Gly Gly Ile Tyr Ser Tyr Gly Asn Val Ala Phe Leu Asn Asn
260 265 270
Gly Lys Thr Leu Phe Leu Asn Asn Val Ala Ser Pro Val Tyr Ile Ala
275 280 285
Ala Lys Gln Pro Thr Ser Gly Gln Ala Ser Asn Thr Ser Asn Asn Tyr
290 295 300
Gly Asp Gly Gly Ala Ile Phe Cys Lys Asn Gly Ala Gln Ala Gly Ser
305 310 315 320
Asn Asn Ser Gly Ser Val Ser Phe Asp Gly Glu Gly Val Val Phe Phe
325 330 335
Ser Ser Asn Val Ala Ala Gly Lys Gly Gly Ala Ile Tyr Ala Lys Lys
340 345 350
Leu Ser Val Ala Asn Cys Gly Pro Val Gln Phe Leu Arg Asn Ile Ala
355 360 365
Asn Asp Gly Gly Ala Ile Tyr Leu Gly Glu Ser Gly Glu Leu Ser Leu
370 375 380
Ser Ala Asp Tyr Gly Asp Ile Ile Phe Asp Gly Asn Leu Lys Arg Thr
385 390 395 400
Ala Lys Glu Asn Ala Ala Asp Val Asn Gly Val Thr Val Ser Ser Gln
405 410 415
Ala Ile Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu Arg Ala Lys
420 425 430
Ala Gly His Gln Ile Leu Phe Asn Asp Pro Ile Glu Met Ala Asn Gly
435 440 445
Asn Asn Gln Pro Ala Gln Ser Ser Lys Leu Leu Lys Ile Asn Asp Gly
450 455 460
Glu Gly Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Ser Ser Thr Leu
465 470 475 480
Tyr Gln Asn Val Thr Ile Glu Gln Gly Arg Ile Val Leu Arg Glu Lys
485 490 495
Ala Lys Leu Ser Val Asn Ser Leu Ser Gln Thr Gly Gly Ser Leu Tyr
500 505 510
Met Glu Ala Gly Ser Thr Leu Asp Phe Val Thr Pro Gln Pro Pro Gln
515 520 525
Gln Pro Pro Ala Ala Asn Gln Leu Ile Thr Leu Ser Asn Leu His Leu
530 535 540
Ser Leu Ser Ser Leu Leu Ala Asn Asn Ala Val Thr Asn Pro Pro Thr
545 550 555 560
Asn Pro Pro Ala Gln Asp Ser His Pro Ala Val Ile Gly Ser Thr Thr
565 570 575
Ala Gly Ser Val Thr Ile Ser Gly Pro Ile Phe Phe Glu Asp Leu Asp
580 585 590
Asp Thr Ala Tyr Asp Arg Tyr Asp Trp Leu Gly Ser Asn Gln Lys Ile
595 600 605
Asn Val Leu Lys Leu Gln Leu Gly Thr Lys Pro Pro Ala Asn Ala Pro
610 615 620
Ser Asp Leu Thr Leu Gly Asn Glu Met Pro Lys Tyr Gly Tyr Gln Gly
625 630 635 640
Ser Trp Lys Leu Ala Trp Asp Pro Asn Thr Ala Asn Asn Gly Pro Tyr
645 650 655
Thr Leu Lys Ala Thr Trp Thr Lys Thr Gly Tyr Asn Pro Gly Pro Glu
660 665 670
Arg Val Ala Ser Leu Val Pro Asn Ser Leu Trp Gly Ser Ile Leu Asp
675 680 685
Ile Arg Ser Ala His Ser Ala Ile Gln Ala Ser Val Asp Gly Arg Ser
690 695 700
Tyr Cys Arg Gly Leu Trp Val Ser Gly Val Ser Asn Phe Phe Tyr His
705 710 715 720
Asp Arg Asp Ala Leu Gly Gln Gly Tyr Arg Tyr Ile Ser Gly Gly Tyr
725 730 735
Ser Leu Gly Ala Asn Ser Tyr Phe Gly Ser Ser Met Phe Gly Leu Ala
740 745 750
Phe Thr Glu Val Phe Gly Arg Ser Lys Asp Tyr Val Val Cys Arg Ser
755 760 765
Asn His His Ala Cys Ile Gly Ser Val Tyr Leu Ser Thr Gln Gln Ala
770 775 780
Leu Cys Gly Ser Tyr Leu Phe Gly Asp Ala Phe Ile Arg Ala Ser Tyr
785 790 795 800
Gly Phe Gly Asn Gln His Met Lys Thr Ser Tyr Thr Phe Ala Glu Glu
805 810 815
Ser Asp Val Arg Trp Asp Asn Asn Cys Leu Ala Gly Glu Ile Gly Ala
820 825 830
Gly Leu Pro Ile Val Ile Thr Pro Ser Lys Leu Tyr Leu Asn Glu Leu
835 840 845
Arg Pro Phe Val Gln Ala Glu Phe Ser Tyr Ala Asp His Glu Ser Phe
850 855 860
Thr Glu Glu Gly Asp Gln Ala Arg Ala Phe Lys Ser Gly His Leu Leu
865 870 875 880
Asn Leu Ser Val Pro Val Gly Val Lys Phe Asp Arg Cys Ser Ser Thr
885 890 895
His Pro Asn Lys Tyr Ser Phe Met Ala Ala Tyr Ile Cys Asp Ala Tyr
900 905 910
Arg Thr Ile Ser GlyThr Glu Thr Thr Leu Leu Ser His Gln Glu Thr
915 920 925
Trp Thr Thr Asp Ala Phe His Leu Ala Arg His Gly Val Val Val Arg
930 935 940
Gly Ser Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val Tyr Gly His
945 950 955 960
Gly Arg Tyr Glu Tyr Arg Asp Ala Ser Arg Gly Tyr Gly Leu Ser Ala
965 970 975
Gly Ser Lys Val Xaa Phe
980
<210>177
<211>964
<212>PRT
<213>Chlamydia
<400>177
Met Lys Lys Ala Phe Phe Phe Phe Leu Ile Gly Asn Ser Leu Ser Gly
1 5 10 15
Leu Ala Arg Glu Val Pro Ser Arg Ile Phe Leu Met Pro Asn Ser Val
20 25 30
Pro Asp Pro Thr Lys Glu Ser Leu Ser Asn Lys Ile Ser Leu Thr Gly
35 40 45
Asp Thr His Asn Leu Thr Asn Cys Tyr Leu Asp Asn Leu Arg Tyr Ile
50 55 60
Leu Ala Ile Leu Gln Lys Thr Pro Asn Glu Gly Ala Ala Val Thr Ile
65 70 75 80
Thr Asp Tyr Leu Ser Phe Phe Asp Thr Gln Lys Glu Gly Ile Tyr Phe
85 90 95
Ala Lys Asn Leu Thr Pro Glu Ser Gly Gly Ala Ile Gly Tyr Ala Ser
100 105 110
Pro Asn Ser Pro Thr Val Glu Ile Arg Asp Thr Ile Gly Pro Val Ile
115 120 125
Phe Glu Asn Asn Thr Cys Cys Arg Leu Phe Thr Trp Arg Asn Pro Tyr
130 135 140
Ala Ala Asp Lys Ile Arg Glu Gly Gly Ala Ile His Ala Gln Asn Leu
145 150 155 160
Tyr Ile Asn His Asn His Asp Val Val Gly Phe Met Lys Asn Phe Ser
165 170 175
Tyr Val Gln Gly Gly Ala Ile Ser Thr Ala Asn Thr Phe Val Val Ser
180 185 190
Glu Asn Gln Ser Cys Phe Leu Phe Met Asp Asn Ile Cys Ile Gln Thr
195 200 205
Asn Thr Ala Gly Lys Gly Gly Ala Ile Tyr Ala Gly Thr Ser Asn Ser
210 215 220
Phe Glu Ser Asn Asn Cys Asp Leu Phe Phe Ile Asn Asn Ala Cys Cys
225 230 235 240
Ala Gly Gly Ala Ile Phe Ser Pro Ile Cys Ser Leu Thr Gly Asn Arg
245 250 255
Gly Asn Ile Val Phe Tyr Asn Asn Arg Cys Phe Lys Asn Val Glu Thr
260 265 270
Ala Ser Ser Glu Ala Ser Asp Gly Gly Ala Ile Lys Val Thr Thr Arg
275 280 285
Leu Asp Val Thr Gly Asn Arg Gly Arg Ile Phe Phe Ser Asp Asn Ile
290 295 300
Thr Lys Asn Tyr Gly Gly Ala Ile Tyr Ala Pro Val Val Thr Leu Val
305 310 315 320
Asp Asn Gly Pro Thr Tyr Phe Ile Asn Asn Ile Ala Asn Asn Lys Gly
325 330 335
Gly Ala Ile Tyr Ile Asp Gly Thr Ser Asn Ser Lys Ile Ser Ala Asp
340 345 350
Arg His Ala Ile Ile Phe Asn Glu Asn Ile Val Thr Asn Val Thr Asn
355 360 365
Ala Asn Gly Thr Ser Thr Ser Ala Asn Pro Pro Arg Arg Asn Ala Ile
370 375 380
Thr Val Ala Ser Ser Ser Gly Glu Ile Leu Leu Gly Ala Gly Ser Ser
385 390 395 400
Gln Asn Leu Ile Phe Tyr Asp Pro Ile Glu Val Ser Asn Ala Gly Val
405 410 415
Ser Val Ser Phe Asn Lys Glu Ala Asp Gln Thr Gly Ser Val Val Phe
420 425 430
Ser Gly Ala Thr Val Asn Ser Ala Asp Phe His Gln Arg Asn Leu Gln
435 440 445
Thr Lys Thr Pro Ala Pro Leu Thr Leu Ser Asn Gly Phe Leu Cys Ile
450 455 460
Glu Asp His Ala Gln Leu Thr Val Asn Arg Phe Thr Gln Thr Gly Gly
465 470 475 480
Val Val Ser Leu Gly Asn Gly Ala Val Leu Ser Cys Tyr Lys Asn Gly
485 490 495
Thr Gly Asp Ser Ala Ser Asn Ala Ser Ile Thr Leu Lys His Ile Gly
500 505 510
Leu Asn Leu Ser Ser Ile Leu Lys Ser Gly Ala Glu Ile Pro Leu Leu
515 520 525
Trp Val Glu Pro Thr Asn Asn Ser Asn Asn Tyr Thr Ala Asp Thr Ala
530 535 540
Ala Thr Phe Ser Leu Ser Asp Val Lys Leu Ser Leu Ile Asp Asp Tyr
545 550 555 560
Gly Asn Ser Pro Tyr Glu Ser Thr Asp Leu Thr His Ala Leu Ser Ser
565 570 575
Gln Pro Met Leu Ser Ile Ser Glu Ala Ser Asp Asn Gln Leu Gln Ser
580 585 590
Glu Asn Ile Asp Phe Ser Gly Leu Asn Val Pro His Tyr Gly Trp Gln
595 600 605
Gly Leu Trp Thr Trp Gly Trp Ala Lys Thr Gln Asp Pro Glu Pro Ala
610 615 620
Ser Ser Ala Thr Ile Thr Asp Pro Gln Lys Ala Asn Arg Phe His Arg
625 630 635 640
Thr Leu Leu Leu Thr Trp Leu Pro Ala Gly Tyr Val Pro Ser Pro Lys
645 650 655
His Arg Ser Pro Leu Ile Ala Asn Thr Leu Trp Gly Asn Met Leu Leu
660 665 670
Ala Thr Glu Ser Leu Lys Asn Ser Ala Glu Leu Thr Pro Ser Gly His
675 680 685
Pro Phe Trp Gly Ile Thr Gly Gly Gly Leu Gly Met Met Val Tyr Gln
690 695 700
Asp Pro Arg Glu Asn His Pro Gly Phe His Met Arg Ser Ser Gly Tyr
705 710 715 720
Ser Ala Gly Met Ile Ala Gly Gln Thr His Thr Phe Ser Leu Lys Phe
725 730 735
Ser Gln Thr Tyr Thr Lys Leu Asn Glu Arg Tyr Ala Lys Asn Asn Val
740 745 750
Ser Ser Lys Asn Tyr Ser Cys Gln Gly Glu Met Leu Phe Ser Leu Gln
755 760 765
Glu Gly Phe Leu Leu Thr Lys Leu Val Gly Leu Tyr Ser Tyr Gly Asp
770 775 780
His Asn Cys His His Phe Tyr Thr Gln Gly Glu Asn Leu Thr Ser Gln
785 790 795 800
Gly Thr Phe Arg Ser Gln Thr Met Gly Gly Ala Val Phe Phe Asp Leu
805 810 815
Pro Met Lys Pro Phe Gly Ser Thr His Ile Leu Thr Ala Pro Phe Leu
820 825 830
Gly Ala Leu Gly Ile Tyr Ser Ser Leu Ser His Phe Thr Glu Val Gly
835 840 845
Ala Tyr Pro Arg Ser Phe Ser Thr Lys Thr Pro Leu Ile Asn Val Leu
850 855 860
Val Pro Ile Gly Val Lys Gly Ser Phe Met Asn Ala Thr His Arg Pro
865 870 875 880
Gln Ala Trp Thr Val Glu Leu Ala Tyr Gln Pro Val Leu Tyr Arg Gln
885 890 895
Glu Pro Gly Ile Ala Thr Gln Leu Leu Ala Ser Lys Gly Ile Trp Phe
900 905 910
Gly Ser Gly Ser Pro Ser Ser Arg His Ala Met Ser Tyr Lys Ile Ser
915 920 925
Gln Gln Thr Gln Pro Leu Ser Trp Leu Thr Leu His Phe Gln Tyr His
930 935 940
Gly Phe Tyr Ser Ser Ser Thr Phe Cys Asn Tyr Leu Asn Gly Glu Ile
945 950 955 960
Ala Leu Arg Phe
<210>178
<211>1530
<212>PRT
<213>Chlamydia
<400>178
Met Ser Ser Glu Lys Asp Ile Lys Ser Thr Cys Ser Lys Phe Ser Leu
1 5 10 15
Ser Val Val Ala Ala Ile Leu Ala Ser Val Ser Gly Leu Ala Ser Cys
20 25 30
Val Asp Leu His Ala Gly Gly Gln Ser Val Asn Glu Leu Val Tyr Val
35 40 45
Gly Pro Gln Ala Val Leu Leu Leu Asp Gln Ile Arg Asp Leu Phe Val
50 55 60
Gly Ser Lys Asp Ser Gln Ala Glu Gly Gln Tyr Arg Leu Ile Val Gly
65 70 75 80
Asp Pro Ser Ser Phe Gln Glu Lys Asp Ala Asp Thr Leu Pro Gly Lys
85 90 95
Val Glu Gln Ser Thr Leu Phe Ser Val Thr Asn Pro Val Val Phe Gln
100 105 110
Gly Val Asp Gln Gln Asp Gln Val Ser Ser Gln Gly Leu Ile Cys Ser
115 120 125
Phe Thr Ser Ser Asn Leu Asp Ser Pro Arg Asp Gly Glu Ser Phe Leu
130 135 140
Gly Ile Ala Phe Val Gly Asp Ser Ser Lys Ala Gly Ile Thr Leu Thr
145 150 155 160
Asp Val Lys Ala Ser Leu Ser Gly Ala Ala Leu Tyr Ser Thr Glu Asp
165 170 175
Leu Ile Phe Glu Lys Ile Lys Gly Gly Leu Glu Phe Ala Ser Cys Ser
180 185 190
Ser Leu Glu Gln Gly Gly Ala Cys Ala Ala Gln Ser Ile Leu Ile His
195 200 205
Asp Cys Gln Gly Leu Gln Val Lys His Cys Thr Thr Ala Val Asn Ala
210 215 220
Glu Gly Ser Ser Ala Asn Asp His Leu Gly Phe Gly Gly Gly Ala Phe
225 230 235 240
Phe Val Thr Gly Ser Leu Ser Gly Glu Lys Ser Leu Tyr Met Pro Ala
245 250 255
Gly Asp Met Val Val Ala Asn Cys Asp Gly Ala Ile Ser Phe Glu Gly
260 265 270
Asn Ser Ala Asn Phe Ala Asn Gly Gly Ala Ile Ala Ala Ser Gly Lys
275 280 285
Val Leu Phe Val Ala Asn Asp Lys Lys Thr Ser Phe Ile Glu Asn Arg
290 295 300
Ala Leu Ser Gly Gly Ala Ile Ala Ala Ser Ser Asp Ile Ala Phe Gln
305 310 315 320
Asn Cys Ala Glu Leu Val Phe Lys Gly Asn Cys Ala Ile Gly Thr Glu
325 330 335
Asp Lys Gly Ser Leu Gly Gly Gly Ala Ile Ser Ser Leu Gly Thr Val
340 345 350
Leu Leu Gln Gly Asn His Gly Ile Thr Cys Asp Lys Asn Glu Ser Ala
355 360 365
Ser Gln Gly Gly Ala Ile Phe Gly Lys Asn Cys Gln Ile Ser Asp Asn
370 375 380
Glu Gly Pro Val Val Phe Arg Asp Ser Thr Ala Cys Leu Gly Gly Gly
385 390 395 400
Ala Ile Ala Ala Gln Glu Ile Val Ser Ile Gln Asn Asn Gln Ala Gly
405 410 415
Ile Ser Phe Glu Gly Gly Lys Ala Ser Phe Gly Gly Gly Ile Ala Cys
420 425 430
Gly Ser Phe Ser Ser Ala Gly Gly Ala Ser Val Leu Gly Thr Ile Asp
435 440 445
Ile Ser Lys Asn Leu Gly Ala Ile Ser Phe Ser Arg Thr Leu Cys Thr
450 455 460
Thr Ser Asp Leu Gly Gln Met Glu Tyr Gln Gly Gly Gly Ala Leu Phe
465 470 475 480
Gly Glu Asn Ile Ser Leu Ser Glu Asn Ala Gly Val Leu Thr Phe Lys
485 490 495
Asp Asn Ile Val Lys Thr Phe Ala Ser Asn Gly Lys Ile Leu Gly Gly
500 505 510
Gly Ala Ile Leu Ala Thr Gly Lys Val Glu Ile Thr Asn Asn Ser Gly
515 520 525
Gly Ile Ser Phe Thr Gly Asn Ala Arg Ala Pro Gln Ala Leu Pro Thr
530 535 540
Gln Glu Glu Phe Pro Leu Phe Ser Lys Lys Glu Gly Arg Pro Leu Ser
545 550 555 560
Ser Gly Tyr Ser Gly Gly Gly Ala Ile Leu Gly Arg Glu Val Ala Ile
565 570 575
Leu His Asn Ala Ala Val Val Phe Glu Gln Asn Arg Leu Gln Cys Ser
580 585 590
Glu Glu Glu Ala Thr Leu Leu Gly Cys Cys Gly Gly Gly Ala Val His
595 600 605
Gly Met Asp Ser Thr Ser Ile Val Gly Asn Ser Ser Val Arg Phe Gly
610 615 620
Asn Asn Tyr Ala Met Gly Gln Gly Val Ser Gly Gly Ala Leu Leu Ser
625 630 635 640
Lys Thr Val Gln Leu Ala Gly Asn Gly Ser Val Asp Phe Ser Arg Asn
645 650 655
Ile Ala Ser Leu Gly Gly Gly Ala Leu Gln Ala Ser Glu Gly Asn Cys
660 665 670
Glu Leu Val Asp Asn Gly Tyr Val Leu Phe Arg Asp Asn Arg Gly Arg
675 680 685
Val Tyr Gly Gly Ala Ile Ser Cys Leu Arg Gly Asp Val Val Ile Ser
690 695 700
Gly Asn Lys Gly Arg Val Glu Phe Lys Asp Asn Ile Ala Thr Arg Leu
705 710 715 720
Tyr Val Glu Glu Thr Val Glu Lys Val Glu Glu Val Glu Pro Ala Pro
725 730 735
Glu Gln Lys Asp Asn Asn Glu Leu Ser Phe Leu Gly Ser Val Glu Gln
740 745 750
Ser Phe Ile Thr Ala Ala Asn Gln Ala Leu Phe Ala Ser Glu Asp Gly
755 760 765
Asp Leu Ser Pro Glu Ser Ser Ile Ser Ser Glu Glu Leu Ala Lys Arg
770 775 780
Arg Glu Cys Ala Gly Gly Ala Ile Phe Ala Lys Arg Val Arg Ile Val
785 790 795 800
Asp Asn Gln Glu Ala Val Val Phe Ser Asn Asn Phe Ser Asp Ile Tyr
805 810 815
Gly Gly Ala Ile Phe Thr Gly Ser Leu Arg Glu Glu Asp Lys Leu Asp
820 825 830
Gly Gln Ile Pro Glu Val Leu Ile Ser Gly Asn Ala Gly Asp Val Val
835 840 845
Phe Ser Gly Asn Ser Ser Lys Arg Asp Glu His Leu Pro His Thr Gly
850 855 860
Gly Gly Ala Ile Cys Thr Gln Asn Leu Thr Ile Ser Gln Asn Thr Gly
865 870 875 880
Asn Val Leu Phe Tyr Asn Asn Val Ala Cys Ser Gly Gly Ala Val Arg
885 890 895
Ile Glu Asp His Gly Asn Val Leu Leu Glu Ala Phe Gly Gly Asp Ile
900 905 910
Val Phe Lys Gly Asn Ser Ser Phe Arg Ala Gln Gly Ser Asp Ala Ile
915 920 925
Tyr Phe Ala Gly Lys Glu Ser His Ile Thr Ala Leu Asn Ala Thr Glu
930 935 940
Gly His Ala Ile Val Phe His Asp Ala Leu Val Phe Glu Asn Leu Lys
945 950 955 960
Glu Arg Lys Ser Ala Glu Val Leu Leu Ile Asn Ser Arg Glu Asn Pro
965 970 975
Gly Tyr Thr Gly Ser Ile Arg Phe Leu Glu Ala Glu Ser Lys Val Pro
980 985 990
Gln Cys Ile His Val Gln Gln Gly Ser Leu Glu Leu Leu Asn Gly Ala
995 1000 1005
Thr Leu Cys Ser Tyr Gly Phe Lys Gln Asp Ala Gly Ala Lys Leu Val
1010 1015 1020
Leu Ala Ala Gly Ser Lys Leu Lys Ile Leu Asp Ser Gly Thr Pro Val
1025 1030 1035 1040
Gln Gly His Ala Ile Ser Lys Pro Glu Ala Glu Ile Glu Ser Ser Ser
1045 1050 1055
Glu Pro Glu Gly Ala His Ser Leu Trp Ile Ala Lys Asn Ala Gln Thr
1060 1065 1070
Thr Val Pro Met Val Asp Ile His Thr Ile Ser Val Asp Leu Ala Ser
1075 1080 1085
Phe Ser Ser Ser Gln Gln Glu Gly Thr Val Glu Ala Pro Gln Val Ile
1090 1095 1100
Val Pro Gly Gly Ser Tyr Val Arg Ser Gly Glu Leu Asn Leu Glu Leu
1105 1110 1115 1120
Val Asn Thr Thr Gly Thr Gly Tyr Glu Asn His Ala Leu Leu Lys Asn
1125 1130 1135
Glu Ala Lys Val Pro Leu Met Ser Phe Val Ala Ser Ser Asp Glu Ala
1140 1145 1150
Ser Ala Glu Ile Ser Asn Leu Ser Val Ser Asp Leu Gln Ile His Val
1155 1160 1165
Ala Thr Pro Glu Ile Glu Glu Asp Thr Tyr Gly His Met Gly Asp Trp
1170 1175 1180
Ser Glu Ala Lys Ile Gln Asp Gly Thr Leu Val Ile Asn Trp Asn Pro
1185 1190 1195 1200
Thr Gly Tyr Arg Leu Asp Pro Gln Lys Ala Gly Ala Leu Val Phe Asn
1205 1210 1215
Ala Leu Trp Glu Glu Gly Ala Val Leu Ser Ala Leu Lys Asn Ala Arg
1220 1225 1230
Phe Ala His Asn Leu Thr Ala Gln Arg Met Glu Phe Asp Tyr Ser Thr
1235 1240 1245
Asn Val Trp Gly Phe Ala Phe Gly Gly Phe Arg Thr Leu Ser Ala Glu
1250 1255 1260
Asn Leu Val Ala Ile Asp Gly Tyr Lys Gly Ala Tyr Gly Gly Ala Ser
1265 1270 1275 1280
Ala Gly Val Asp Ile Gln Leu Met Glu Asp Phe Val Leu Gly Val Ser
1285 1290 1295
Gly Ala Ala Phe Leu Gly Lys Met Asp Ser Gln Lys Phe Asp Ala Glu
1300 1305 1310
Val Ser Arg Lys Gly Val Val Gly Ser Val Tyr Thr Gly Phe Leu Ala
1315 1320 1325
Gly Ser Trp Phe Phe Lys Gly Gln Tyr Ser Leu Gly Glu Thr Gln Asn
1330 1335 1340
Asp Met Lys Thr Arg Tyr Gly Val Leu Gly Glu Ser Ser Ala Ser Trp
1345 1350 1355 1360
Thr Ser Arg Gly Val Leu Ala Asp Ala Leu Val Glu Tyr Arg Ser Leu
1365 1370 1375
Val Gly Pro Val Arg Pro Thr Phe Tyr Ala Leu His Phe Asn Pro Tyr
1380 1385 1390
Val Glu Val Ser Tyr Ala Ser Met Lys Phe Pro Gly Phe Thr Glu Gln
1395 1400 1405
Gly Arg Glu Ala Arg Ser Phe Glu Asp Ala Ser Leu Thr Asn Ile Thr
1410 1415 1420
Ile Pro Leu Gly Met Lys Phe Glu Leu Ala Phe Ile Lys Gly Gln Phe
1425 1430 1435 1440
Ser Glu Val Asn Ser Leu Gly Ile Ser Tyr Ala Trp Glu Ala Tyr Arg
1445 1450 1455
Lys Val Glu Gly Gly Ala Val Gln Leu Leu Glu Ala Gly Phe Asp Trp
1460 1465 1470
Glu Gly Ala Pro Met Asp Leu Pro Arg Gln Glu Leu Arg Val Ala Leu
1475 1480 1485
Glu Asn Asn Thr Glu Trp Ser Ser Tyr Phe Ser Thr Val Leu Gly Leu
1490 1495 1500
Thr Ala Phe Cys Gly Gly Phe Thr Ser Thr Asp Ser Lys Leu Gly Tyr
1505 1510 1515 1520
Glu Ala Asn Thr Gly Leu Arg Leu Ile Phe
1525 1530
<210>179
<211>1776
<212>PRT
<213>Chlamydia
<400>179
Ala Ile Met Lys Phe Met Ser Ala Thr Ala Val Phe Ala Ala Val Leu
1 5 10 15
Ser Ser Val Thr Glu Ala Ser Ser Ile Gln Asp Gln Ile Lys Asn Thr
20 25 30
Asp Cys Asn Va1 Ser Lys Val Gly Tyr Ser Thr Ser Gln Ala Phe Thr
35 40 45
Asp Met Met Leu Ala Asp Asn Thr Glu Tyr Arg Ala Ala Asp Ser Val
50 55 60
Ser Phe Tyr Asp Phe Ser Thr Ser Ser Gly Leu Pro Arg Lys His Leu
65 70 75 80
Ser Ser Ser Ser Glu Ala Ser Pro Thr Thr Glu Gly Val Ser Ser Ser
85 90 95
Ser Ser Gly Glu Asn Thr Glu Asn Ser Gln Asp Ser Ala Pro Ser Ser
100 105 110
Gly Glu Thr Asp Lys Lys Thr Glu Glu Glu Leu Asp Asn Gly Gly Ile
115 120 125
Ile Tyr Ala Arg Glu Lys Leu Thr Ile Ser Glu Ser Gln Asp Ser Leu
130 135 140
Ser Asn Pro Ser Ile Glu Leu His Asp Asn Ser Phe Phe Phe Gly Glu
145 150 155 160
Gly Glu Val Ile Phe Asp His Arg Val Ala Leu Lys Asn Gly Gly Ala
165 170 175
Ile Tyr Gly Glu Lys Glu Val Val Phe Glu Asn Ile Lys Ser Leu Leu
180 185 190
Val Glu Val Asn Ile Ser Val Glu Lys Gly Gly Ser Val Tyr Ala Lys
195 200 205
Glu Arg Val Ser Leu Glu Asn Val Thr Glu Ala Thr Phe Ser Ser Asn
210 215 220
Gly Gly Glu Gln Gly Gly Gly Gly Ile Tyr Ser Glu Gln Asp Met Leu
225 230 235 240
Ile Ser Asp Cys Asn Asn Val His Phe Gln Gly Asn Ala Ala Gly Ala
245 250 255
Thr Ala Val Lys Gln Cys Leu Asp Glu Glu Met Ile Val Leu Leu Thr
260 265 270
Glu Cys Val Asp Ser Leu Ser Glu Asp Thr Leu Asp Ser Thr Pro Glu
275 280 285
Thr Glu Gln Thr Lys Ser Asn Gly Asn Gln Asp Gly Ser Ser Glu Thr
290 295 300
Lys Asp Thr Gln Val Ser Glu Ser Pro Glu Ser Thr Pro Ser Pro Asp
305 310 315 320
Asp Val Leu Gly Lys Gly Gly Gly Ile Tyr Thr Glu Lys Ser Leu Thr
325 330 335
Ile Thr Gly Ile Thr Gly Thr Ile Asp Phe Val Ser Asn Ile Ala Thr
340 345 350
Asp Ser Gly Ala Gly Val Phe Thr Lys Glu Asn Leu Ser Cys Thr Asn
355 360 365
Thr Asn Ser Leu Gln Phe Leu Lys Asn Ser Ala Gly Gln His Gly Gly
370 375 380
Gly Ala Tyr Val Thr Gln Thr Met Ser Val Thr Asn Thr Thr Ser Glu
385 390 395 400
Ser Ile Thr Thr Pro Pro Leu Val Gly Glu Val Ile Phe Ser Glu Asn
405 410 415
Thr Ala Lys Gly His Gly Gly Gly Ile Cys Thr Asn Lys Leu Ser Leu
420 425 430
Ser Asn Leu Lys Thr Val Thr Leu Thr Lys Asn Ser Ala Lys Glu Ser
435 440 445
Gly Gly Ala Ile Phe Thr Asp Leu Ala Ser Ile Pro Thr Thr Asp Thr
450 455 460
Pro Glu Ser Ser Thr Pro Ser Ser Ser Ser Pro Ala Ser Thr Pro Glu
465 470 475 480
Val Val Ala Ser Ala Lys Ile Asn Arg Phe Phe Ala Ser Thr Ala Glu
485 490 495
Pro Ala Ala Pro Ser Leu Thr Glu Ala Glu Ser Asp Gln Thr Asp Gln
500 505 510
Thr Glu Thr Ser Asp Thr Asn Ser Asp Ile Asp Val Ser Ile Glu Asn
515 520 525
Ile Leu Asn Val Ala Ile Asn Gln Asn Thr Ser Ala Lys Lys Gly Gly
530 535 540
Ala Ile Tyr Gly Lys Lys Ala Lys Leu Ser Arg Ile Asn Asn Leu Glu
545 550 555 560
Leu Ser Gly Asn Ser Ser Gln Asp Val Gly Gly Gly Leu Cys Leu Thr
565 570 575
Glu Ser Val Glu Phe Asp Ala Ile Gly Ser Leu Leu Ser His Tyr Asn
580 585 590
Ser Ala Ala Lys Glu Gly Gly Val Ile His Ser Lys Thr Val Thr Leu
595 600 605
Ser Asn Leu Lys Ser Thr Phe Thr Phe Ala Asp Asn Thr Val Lys Ala
610 615 620
Ile Val Glu Ser Thr Pro Glu Ala Pro Glu Glu Ile Pro Pro Val Glu
625 630 635 640
Gly Glu Glu Ser Thr Ala Thr Glu Asn Pro Asn Ser Asn Thr Glu Gly
645 650 655
Ser Ser Ala Asn Thr Asn Leu Glu Gly Ser Gln Gly Asp Thr Ala Asp
660 665 670
Thr Gly Thr Gly Val Val Asn Asn Glu Ser Gln Asp Thr Ser Asp Thr
675 680 685
Gly Asn Ala Glu Ser Gly Glu Gln Leu Gln Asp Ser Thr Gln Ser Asn
690 695 700
Glu Glu Asn Thr Leu Pro Asn Ser Ser Ile Asp Gln Ser Asn Glu Asn
705 710 715 720
Thr Asp Glu Ser Ser Asp Ser His Thr Glu Glu Ile Thr Asp Glu Ser
725 730 735
Val Ser Ser Ser Ser Lys Ser Gly Ser Ser Thr Pro Gln Asp Gly Gly
740 745 750
Ala Ala Ser Ser Gly Ala Pro Ser Gly Asp Gln Ser Ile Ser Ala Asn
755 760 765
Ala Cys Leu Ala Lys Ser Tyr Ala Ala Ser Thr Asp Ser Ser Pro Val
770 775 780
Ser Asn ser Ser Gly Ser Asp Val Thr Ala Ser Ser Asp Asn Pro Asp
785 790 795 800
Ser Ser Ser Ser Gly Asp Ser Ala Gly Asp Ser Glu Gly Pro Thr Glu
805 810 815
Pro Glu Ala Gly Ser Thr Thr Glu Thr Pro Thr Leu Ile Gly Gly Gly
820 825 830
Ala Ile Tyr Gly Glu Thr Val Lys Ile Glu Asn Phe Ser Gly Gln Gly
835 840 845
Ile Phe Ser Gly Asn Lys Ala Ile Asp Asn Thr Thr Glu Gly Ser Ser
850 855 860
Ser Lys Ser Asn Val Leu Gly Gly Ala Val Tyr Ala Lys Thr Leu Phe
865 870 875 880
Asn Leu Asp Ser Gly Ser Ser Arg Arg Thr Val Thr Phe Ser Gly Asn
885 890 895
Thr Val Ser Ser Gln Ser Thr Thr Gly Gln Val Ala Gly Gly Ala Ile
900 905 910
Tyr Ser Pro Thr Val Thr Ile Ala Thr Pro Val Val Phe Ser Lys Asn
915 920 925
Ser Ala Thr Asn Asn Ala Asn Asn Ala Thr Asp Thr Gln Arg Lys Asp
930 935 940
Thr Phe Gly Gly Ala Ile Gly Ala Thr Ser Ala Val Ser Leu Ser Gly
945 950 955 960
Gly Ala His Phe Leu Glu Asn Val Ala Asp Leu Gly Ser Ala Ile Gly
965 970 975
Leu Val Pro Asp Thr Gln Asn Thr Glu Thr Val Lys Leu Glu Ser Gly
980 985 990
Ser Tyr Tyr Phe Glu Lys Asn Lys Ala Leu Lys Arg Ala Thr Ile Tyr
995 1000 1005
Ala Pro Val Val Ser Ile Lys Ala Tyr Thr Ala Thr Phe Asn Gln Asn
1010 1015 1020
Arg Ser Leu Glu Glu Gly Ser Ala Ile Tyr Phe Thr Lys Glu Ala Ser
1025 1030 1035 1040
Ile Glu Ser Leu Gly Ser Val Leu Phe Thr Gly Asn Leu Val Thr Pro
1045 1050 1055
Thr Leu Ser Thr Thr Thr Glu Gly Thr Pro Ala Thr Thr Ser Gly Asp
1060 1065 1070
Val Thr Lys Tyr Gly Ala Ala Ile Phe Gly Gln Ile Ala Ser Ser Asn
1075 1080 1085
Gly Ser Gln Thr Asp Asn Leu Pro Leu Lys Leu Ile Ala Ser Gly Gly
1090 1095 1100
Asn Ile Cys Phe Arg Asn Asn Glu Tyr Arg Pro Thr Ser Ser Asp Thr
1105 1110 1115 1120
Gly Thr Ser Thr Phe Cys Ser Ile Ala Gly Asp Val Lys Leu Thr Met
1125 1130 1135
Gln Ala Ala Lys Gly Lys Thr Ile Ser Phe Phe Asp Ala Ile Arg Thr
1140 1145 1150
Ser Thr Lys Lys Thr Gly Thr Gln Ala Thr Ala Tyr Asp Thr Leu Asp
1155 1160 1165
Ile Asn Lys Ser Glu Asp Ser Glu Thr Val Asn Ser Ala Phe Thr Gly
1170 1175 1180
Thr Ile Leu Phe Ser Ser Glu Leu His Glu Asn Lys Ser Tyr Ile Pro
1185 1190 1195 1200
Gln Asn Val Val Leu His Ser Gly Ser Leu Val Leu Lys Pro Asn Thr
1205 1210 1215
Glu Leu His Val Ile Ser Phe Glu Gln Lys Glu Gly Ser Ser Leu Val
1220 1225 1230
Met Thr Pro Gly Ser Val Leu Ser Asn Gln Thr Val Ala Asp Gly Ala
1235 1240 1245
Leu Val Ile Asn Asn Met Thr Ile Asp Leu Ser Ser Val Glu Lys Asn
1250 1255 1260
Gly Ile Ala Glu Gly Asn Ile Phe Thr Pro Pro Glu Leu Arg Ile Ile
1265 1270 1275 1280
Asp Thr Thr Thr Ser Gly Ser Gly Gly Thr Pro Ser Thr Asp Ser Glu
1285 1290 1295
Ser Asn Gln Asn Ser Asp Asp Thr Lys Glu Gln Asn Asn Asn Asp Ala
1300 1305 1310
Ser Asn Gln Gly Glu Ser Ala Asn Gly Ser Ser Ser Pro Ala Val Ala
1315 1320 1325
Ala Ala His Thr Ser Arg Thr Arg Asn Phe Ala Ala Ala Ala Thr Ala
1330 1335 1340
Thr Pro Thr Thr Thr Pro Thr Ala Thr Thr Thr Thr Ser Asn Gln Val
1345 1350 1355 1360
Ile Leu Gly Gly Glu Ile Lys Leu Ile Asp Pro Asn Gly Thr Phe Phe
1365 1370 1375
Gln Asn Pro Ala Leu Arg Ser Asp Gln Gln Ile Ser Leu Leu Val Leu
1380 1385 1390
Pro Thr Asp Ser Ser Lys Met Gln Ala Gln Lys Ile Val Leu Thr Gly
1395 1400 1405
Asp Ile Ala Pro Gln Lys Gly Tyr Thr Gly Thr Leu Thr Leu Asp Pro
1410 1415 1420
Asp Gln Leu Gln Asn Gly Thr Ile Ser Ala Leu Trp Lys Phe Asp Ser
1425 1430 1435 1440
Tyr Arg Gln Trp Ala Tyr Val Pro Arg Asp Asn His Phe Tyr Ala Asn
1445 1450 1455
Ser Ile Leu Gly Ser Gln Met Ser Met Val Thr Va1 Lys Gln Gly Leu
1460 1465 1470
Leu Asn Asp Lys Met Asn Leu Ala Arg Phe Asp Glu Val Ser Tyr Asn
1475 1480 1485
Asn Leu Trp Ile Ser Gly Leu Gly Thr Met Leu Ser Gln Val Gly Thr
1490 1495 1500
Pro Thr Ser Glu Glu Phe Thr Tyr Tyr Ser Arg Gly Ala Ser Val Ala
1505 1510 1515 1520
Leu Asp Ala Lys Pro Ala His Asp Val Ile Val Gly Ala Ala Phe Ser
1525 1530 1535
Lys Met Ile Gly Lys Thr Lys Ser Leu Lys Arg Glu Asn Asn Tyr Thr
1540 1545 1550
His Lys Gly Ser Glu Tyr Ser Tyr Gln Ala Ser Val Tyr Gly Gly Lys
1555 1560 1565
Pro Phe His Phe Val Ile Asn Lys Lys Thr Glu Lys Ser Leu Pro Leu
1570 1575 1580
Leu Leu Gln Gly Val Ile Ser Tyr Gly Tyr Ile Lys His Asp Thr Val
1585 1590 1595 1600
Thr His Tyr Pro Thr Ile Arg Glu Arg Asn Gln Gly Glu Trp Glu Asp
1605 1610 1615
Leu Gly Trp Leu Thr Ala Leu Arg Val Ser Ser Val Leu Arg Thr Pro
1620 1625 1630
Ala Gln Gly Asp Thr Lys Arg Ile Thr Val Tyr Gly Glu Leu Glu Tyr
1635 1640 1645
Ser Ser Ile Arg Gln Lys Gln Phe Thr Glu Thr Glu Tyr Asp Pro Arg
1650 1655 1660
Tyr Phe Asp Asn Cys Thr Tyr Arg Asn Leu Ala Ile Pro Met Gly Leu
1665 1670 1675 1680
Ala Phe Glu Gly Glu Leu Ser Gly Asn Asp Ile Leu Met Tyr Asn Arg
1685 1690 1695
Phe Ser Val Ala Tyr Met Pro Ser Ile Tyr Arg Asn Ser Pro Thr Cys
1700 1705 1710
Lys Tyr Gln Val Leu Ser Ser Gly Glu Gly Gly Glu Ile Ile Cys Gly
1715 1720 1725
Val Pro Thr Arg Asn Ser Ala Arg Gly Glu Tyr Ser Thr Gln Leu Tyr
1730 1735 1740
Pro Gly Pro Leu Trp Thr Leu Tyr Gly Ser Tyr Thr Ile Glu Ala Asp
1745 1750 1755 1760
Ala His Thr Leu Ala His Met Met Asn Cys Gly Ala Arg Met Thr Phe
1765 1770 1775
<210>180
<211>1752
<212>PRT
<213>Chlamydia
<400>180
Met Lys Trp Leu Ser Ala Thr Ala Val Phe Ala Ala Val Leu Pro Ser
1 5 10 15
Val Ser Gly Phe Cys Phe Pro Glu Pro Lys Glu Leu Asn Phe Ser Arg
20 25 30
Val Glu Thr Ser Ser Ser Thr Thr Phe Thr Glu Thr Ile Gly Glu Ala
35 40 45
Gly Ala Glu Tyr Ile Val Ser Gly Asn Ala Ser Phe Thr Lys Phe Thr
50 55 60
Asn Ile Pro Thr Thr Asp Thr Thr Thr Pro Thr Asn Ser Asn Ser Ser
65 70 75 80
Ser Ser Ser Gly Glu Thr Ala Ser Val Ser Glu Asp Ser Asp Ser Thr
85 90 95
Thr Thr Thr Pro Asp Pro Lys Gly Gly Gly Ala Phe Tyr Asn Ala His
100 105 110
Ser Gly Val Leu Ser Phe Met Thr Arg Ser Gly Thr Glu Gly Ser Leu
115 120 125
Thr Leu Ser Glu Ile Lys Met Thr Gly Glu Gly Gly Ala Ile Phe Ser
130 135 140
Gln Gly Glu Leu Leu Phe Thr Asp Leu Thr Ser Leu Thr Ile Gln Asn
145 150 155 160
Asn Leu Ser Gln Leu Ser Gly Gly Ala Ile Phe Gly Gly Ser Thr Ile
165 170 175
Ser Leu Ser Gly Ile Thr Lys Ala Thr Phe Ser Cys Asn Ser Ala Glu
180 185 190
Val Pro Ala Pro Val Lys Lys Pro Thr Glu Pro Lys Ala Gln Thr Ala
195 200 205
Ser Glu Thr Ser Gly Ser Ser Ser Ser Ser Gly Asn Asp Ser Val Ser
210 215 220
Ser Pro Ser Ser Ser Arg Ala Glu Pro Ala Ala Ala Asn Leu Gln Ser
225 230 235 240
His Phe Ile Cys Ala Thr Ala Thr Pro Ala Ala Gln Thr Asp Thr Glu
245 250 255
Thr Ser Thr Pro Ser His Lys Pro Gly Ser Gly Gly Ala Ile Tyr Ala
260 265 270
Lys Gly Asp Leu Thr Ile Ala Asp Ser Gln Glu Val Leu Phe Ser Ile
275 280 285
Asn Lys Ala Thr Lys Asp Gly Gly Ala Ile Phe Ala Glu Lys Asp Val
290 295 300
Ser Phe Glu Asn Ile Thr Ser Leu Lys Val Gln Thr Asn Gly Ala Glu
305 310 315 320
Glu Lys Gly Gly Ala Ile Tyr Ala Lys Gly Asp Leu Ser Ile Gln Ser
325 330 335
Ser Lys Gln Ser Leu Phe Asn Ser Asn Tyr Ser Lys Gln Gly Gly Gly
340 345 350
Ala Leu Tyr Val Glu Gly Gly Ile Asn Phe Gln Asp Leu Glu Glu Ile
355 360 365
Arg Ile Lys Tyr Asn Lys Ala Gly Thr Phe Glu Thr Lys Lys Ile Thr
370 375 380
Leu Pro Ser Leu Lys Ala Gln Ala Ser Ala Gly Asn Ala Asp Ala Trp
385 390 395 400
Ala Ser Ser Ser Pro Gln Ser Gly Ser Gly Ala Thr Thr Val Ser Asp
405 410 415
Ser Gly Asp Ser Ser Ser Gly Ser Asp Ser Asp Thr Ser Glu Thr Val
420 425 430
Pro Val Thr Ala Lys Gly Gly Gly Leu Tyr Thr Asp Lys Asn Leu Ser
435 440 445
Ile Thr Asn Ile Thr Gly Ile Ile Glu Ile Ala Asn Asn Lys Ala Thr
450 455 460
Asp Val Gly Gly Gly Ala Tyr Val Lys Gly Thr Leu Thr Cys Glu Asn
465 470 475 480
Ser His Arg Leu Gln Phe Leu Lys Asn Ser Ser Asp Lys Gln Gly Gly
485 490 495
Gly Ile Tyr Gly Glu Asp Asn Ile Thr Leu Ser Asn Leu Thr Gly Lys
500 505 510
Thr Leu Phe Gln Glu Asn Thr Ala Lys Glu Glu Gly Gly Gly Leu Phe
515 520 525
Ile Lys Gly Thr Asp Lys Ala Leu Thr Met Thr Gly Leu Asp Ser Phe
530 535 540
Cys Leu Ile Asn Asn Thr Ser Glu Lys His Gly Gly Gly Ala Phe Val
545 550 555 560
Thr Lys Glu Ile Ser Gln Thr Tyr Thr Ser Asp Va1 Glu Thr Ile Pro
565 570 575
Gly Ile Thr Pro Val His Gly Glu Thr Val Ile Thr Gly Asn Lys Ser
580 585 590
Thr Gly Gly Asn Gly Gly Gly Val Cys Thr Lys Arg Leu Ala Leu Ser
595 600 605
Asn Leu Gln Ser Ile Ser Ile Ser Gly Asn Ser Ala Ala Glu Asn Gly
610 615 620
Gly Gly Ala His Thr Cys Pro Asp Ser Phe Pro Thr Ala Asp Thr Ala
625 630 635 640
Glu Gln Pro Ala Ala Ala Ser Ala Ala Thr Ser Thr Pro Lys Ser Ala
645 650 655
Pro Val Ser Thr Ala Leu Ser Thr Pro Ser Ser Ser Thr Val Ser Ser
660 665 670
Leu Thr Leu Leu Ala Ala Ser Ser Gln Ala Ser Pro Ala Thr Ser Asn
675 680 685
Lys Glu Thr Gln Asp Pro Asn Ala Asp Thr Asp Leu Leu Ile Asp Tyr
690 695 700
Val Val Asp Thr Thr Ile Ser Lys Asn Thr Ala Lys Lys Gly Gly Gly
705 710 715 720
Ile Tyr Ala Lys Lys Ala Lys Met Ser Arg Ile Asp Gln Leu Asn Ile
725 730 735
Ser Glu Asn Ser Ala Thr Glu Ile Gly Gly Gly Ile Cys Cys Lys Glu
740 745 750
Ser Leu Glu Leu Asp Ala Leu Val Ser Leu Ser Val Thr Glu Asn Leu
755 760 765
Val Gly Lys Glu Gly Gly Gly Leu His Ala Lys Thr Val Asn Ile Ser
770 775 780
Asn Leu Lys Ser Gly Phe Ser Phe Ser Asn Asn Lys Ala Asn Ser Ser
785 790 795 800
Ser Thr Gly Val Ala Thr Thr Ala Ser Ala Pro Ala Ala Ala Ala Ala
805 810 815
Ser Leu Gln Ala Ala Ala Ala Ala Ala Pro Ser Ser Pro Ala Thr Pro
820 825 830
Thr Tyr Ser Gly Val Val Gly Gly Ala Ile Tyr Gly Glu Lys Val Thr
835 840 845
Phe Ser Gln Cys Ser Gly Thr Cys Gln Phe Ser Gly Asn Gln Ala Ile
850 855 860
Asp Asn Asn Pro Ser Gln Ser Ser Leu Asn Val Gln Gly Gly Ala Ile
865 870 875 880
Tyr Ala Lys Thr Ser Leu Ser Ile Gly Ser Ser Asp Ala Gly Thr Ser
885 890 895
Tyr Ile Phe Ser Gly Asn Ser Val Ser Thr Gly Lys Ser Gln Thr Thr
900 905 910
Gly Gln Ile Ala Gly Gly Ala Ile Tyr Ser Pro Thr Val Thr Leu Asn
915 920 925
Cys Pro Ala Thr Phe Ser Asn Asn Thr Ala Ser Ile Ala Thr Pro Lys
930 935 940
Thr Ser Ser Glu Asp Gly Ser Ser Gly Asn Ser Ile Lys Asp Thr Ile
945 950 955 960
Gly Gly Ala Ile Ala Gly Thr Ala Ile Thr Leu Ser Gly Val Ser Arg
965 970 975
Phe Ser Gly Asn Thr Ala Asp Leu Gly Ala Ala Ile Gly Thr Leu Ala
980 985 990
Asn Ala Asn Thr Pro Ser Ala Thr Ser Gly Ser Gln Asn Ser Ile Thr
995 1000 1005
Glu Lys Ile Thr Leu Glu Asn Gly Ser Phe Ile Phe Glu Arg Asn Gln
1010 1015 1020
Ala Asn Lys Arg Gly Ala Ile Tyr Ser Pro Ser Val Ser Ile Lys Gly
1025 1030 1035 1040
Asn Asn Ile Thr Phe Asn Gln Asn Thr Ser Thr His Asp Gly Ser Ala
1045 1050 1055
Ile Tyr Phe Thr Lys Asp Ala Thr Ile Glu Ser Leu Gly Ser Val Leu
1060 1065 1070
Phe Thr Gly Asn Asn Val Thr Ala Thr Gln Ala Ser Ser Ala Thr Ser
1075 1080 1085
Gly Gln Asn Thr Asn Thr Ala Asn Tyr Gly Ala Ala Ile Phe Gly Asp
1090 1095 1100
Pro Gly Thr Thr Gln Ser Ser Gln Thr Asp Ala Ile Leu Thr Leu Leu
1105 1110 1115 1120
Ala Ser Ser Gly Asn Ile Thr Phe Ser Asn Asn Ser Leu Gln Asn Asn
1125 1130 1135
Gln Gly Asp Thr Pro Ala Ser Lys Phe Cys Ser Ile Ala Gly Tyr Val
1140 1145 1150
Lys Leu Ser Leu Gln Ala Ala Lys Gly Lys Thr Ile Ser Phe Phe Asp
1155 1160 1165
Cys Val His Thr Ser Thr Lys Lys Thr Gly Ser Thr Gln Asn Val Tyr
1170 1175 1180
Glu Thr Leu Asp Ile Asn Lys Glu Glu Asn Ser Asn Pro Tyr Thr Gly
1185 1190 1195 1200
Thr Ile Val Phe Ser Ser Glu Leu His Glu Asn Lys Ser Tyr Ile Pro
1205 1210 1215
Gln Asn Ala Ile Leu His Asn Gly Thr Leu Val Leu Lys Glu Lys Thr
1220 1225 1230
Glu Leu His Val Val Ser Phe Glu Gln Lys Glu Gly Ser Lys Leu Ile
1235 1240 1245
Met Glu Pro Gly Ala Val Leu Ser Asn Gln Asn Ile Ala Asn Gly Ala
1250 1255 1260
Leu Ala Ile Asn Gly Leu Thr Ile Asp Leu Ser Ser Met Gly Thr Pro
1265 1270 1275 1280
Gln Ala Gly Glu Ile Phe Ser Pro Pro Glu Leu Arg Ile Val Ala Thr
1285 1290 1295
Thr Ser Ser Ala Ser Gly Gly Ser Gly Val Ser Ser Ser Ile Pro Thr
1300 1305 1310
Asn Pro Lys Arg Ile Ser Ala Ala Val Pro Ser Gly Ser Ala Ala Thr
1315 1320 1325
Thr Pro Thr Met Ser Glu Asn Lys Val Phe Leu Thr Gly Asp Leu Thr
1330 1335 1340
Leu Ile Asp Pro Asn Gly Asn Phe Tyr Gln Asn Pro Met Leu Gly Ser
1345 1350 1355 1360
Asp Leu Asp Val Pro Leu Ile Lys Leu Pro Thr Asn Thr Ser Asp Val
1365 1370 1375
Gln Val Tyr Asp Leu Thr Leu Ser Gly Asp Leu Phe Pro Gln Lys Gly
1380 1385 1390
Tyr Met Gly Thr Trp Thr Leu Asp Ser Asn Pro Gln Thr Gly Lys Leu
1395 1400 1405
Gln Ala Arg Trp Thr Phe Asp Thr Tyr Arg Arg Trp Val Tyr Ile Pro
1410 1415 1420
Arg Asp Asn His Phe Tyr Ala Asn Ser Ile Leu Gly Ser Gln Asn Ser
1425 1430 1435 1440
Met Ile Val Val Lys Gln Gly Leu Ile Asn Asn Met Leu Asn Asn Ala
1445 1450 1455
Arg Phe Asp Asp Ile Ala Tyr Asn Asn Phe Trp Val Ser Gly Val Gly
1460 1465 1470
Thr Phe Leu Ala Gln Gln Gly Thr Pro Leu Ser Glu Glu Phe Ser Tyr
1475 1480 1485
Tyr Ser Arg Gly Thr Ser Val Ala Ile Asp Ala Lys Pro Arg Gln Asp
1490 1495 1500
Phe Ile Leu Gly Ala Ala Phe Ser Lys Ile Val Gly Lys Thr Lys Ala
1505 1510 1515 1520
Ile Lys Lys Met His Asn Tyr Phe His Lys Gly Ser Glu Tyr Ser Tyr
1525 1530 1535
Gln Ala Ser Val Tyr Gly Gly Lys Phe Leu Tyr Phe Leu Leu Asn Lys
1540 1545 1550
Gln His Gly Trp Ala Leu Pro Phe Leu Ile Gln Gly Val Val Ser Tyr
1555 1560 1565
Gly His Ile Lys His Asp Thr Thr Thr Leu Tyr Pro Ser Ile His Glu
1570 1575 1580
Arg Asn Lys Gly Asp Trp Glu Asp Leu Gly Trp Leu Ala Asp Leu Arg
1585 1590 1595 1600
Ile Ser Met Asp Leu Lys Glu Pro Ser Lys Asp Ser Ser Lys Arg Ile
1605 1610 1615
Thr Val Tyr Gly Glu Leu Glu Tyr Ser Ser Ile Arg Gln Lys Gln Phe
1620 1625 1630
Thr Glu Ile Asp Tyr Asp Pro Arg His Phe Asp Asp Cys Ala Tyr Arg
1635 1640 1645
Asn Leu Ser Leu Pro Val Gly Cys Ala Val Glu Gly Ala Ile Met Asn
1650 1655 1660
Cys Asn Ile Leu Met Tyr Asn Lys Leu Ala Leu Ala Tyr Met Pro Ser
1665 1670 1675 1680
Ile Tyr Arg Asn Asn Pro Val Cys Lys Tyr Arg Val Leu Ser Ser Asn
1685 1690 1695
Glu Ala Gly Gln Val Ile Cys Gly Val Pro Thr Arg Thr Ser Ala Arg
1700 1705 1710
Ala Glu Tyr Ser Thr Gln Leu Tyr Leu Gly Pro Phe Trp Thr Leu Tyr
1715 1720 1725
Gly Asn Tyr Thr Ile Asp Val Gly Met Tyr Thr Leu Ser Gln Met Thr
1730 1735 1740
Ser Cys Gly Ala Arg Met Ile Phe
1745 1750
<210>181
<211>2601
<212>DNA
<213>Chlamydia
<400>181
atggctagcc atcaccatca ccatcacctc tttggccagg atcccttagg tgaaaccgcc 60
ctcctcacta aaaatcctaa tcatgtcgtc tgtacatttt ttgaggactg taccatggag 120
agcctctttc ctgctctttg tgctcatgca tcacaagacg atcctttgta tgtacttgga 180
aattcctact gttggttcgt atctaaactc catatcacgg accccaaaga ggctcttttt 240
aaagaaaaag gagatctttc cattcaaaac tttcgcttcc tttccttcac agattgctct 300
tccaaggaaa gctctccttc tattattcat caaaagaatg gtcagttatc cttgcgcaat 360
aatggtagca tgagtttctg tcgaaatcat gctgaaggct ctggaggagc catctctgcg 420
gatgcctttt ctctacagca caactatctt ttcacagctt ttgaagagaa ttcttctaaa 480
ggaaatggcg gagccattca ggctcaaacc ttctctttat ctagaaatgt gtcgcctatt 540
tctttcgccc gtaatcgtgc ggatttaaat ggcggcgcta tttgctgtag taatcttatt 600
tgttcaggga atgtaaaccc tctctttttc actggaaact ccgccacraa tggaggcsct 660
atttgttgta tcagcgatct aaacacctca gaaaaaggct ctctctctct tgcttgtaac 720
caaraaacgc tatttgcaag caattctgct aaagaaaaag gcggggctat ttatgccaag 780
cacatggtat tgcgttataa cggtcctgtt tccttcatta acaacagcgc taaaataggt 840
ggagctatcg ccatccagtc cggagggagt ctctctatcc ttgcaggtga aggatctgtt 900
ctgttccaga ataactccca acgcacctcc gaccaaggtc tagtaagaaa cgccatctac 960
ttagagaaag atgcgattct ttcttcctta gaagctcgca acggagatat tcttttcttt 1020
gatcctattg tacaagaaag tagcagcaaa gaatcgcctc ttccctcctc tttgcaagcc 1080
agcgtgactt ctcccacccc agccaccgca tctcctttag ttattcagac aagtgcaaac 1140
cgttcagtga ttttctcgag cgaacgtctt tctgaagaag aaaaaactcc tgataacctc 1200
acttcccaac tacagcagcc tatcgaactg aaatccggac gcttagtttt aaaagatcgc 1260
gctgtccttt ccgsgccttc tctctctcag gatcctcaag ctctcctcat tatggaagcg 1320
ggaacttctt taaaaacttc ctytgatttg aagttagsta cgstaagtat tccccttcat 1380
tccttagata ctgaaaaaag cgtaactatc cacgccccta atctttctat ccaaaagatc 1440
ttcctctcta actctggaga tgagaatttt tatgaaaatg tagagcttct cagtaaagag 1500
caaaacaata ttcctctcct tactctccct aaagagcaat ctcatttaca tcttcctgat 1560
gggaacctct cttctcactt tggatatcaa ggagattgga ctttttcttg gaaagattct 1620
gatgaagggc attctctgat tgctaattgg acgcctaaaa actatgtgcc tcatccagaa 1680
cgtcaatcta cactcgttgc gaacactctt tggaacacct attccgatat gcaagctgtg 1740
cagtcgatga ttaatacaac agcgcacgga ggagcctatc tatttggaac gtggggatct 1800
gctgtttcta atttattcta tgttcacgac agctctggga aacctatcga taattggcat 1860
catagaagcc ttggctacct attcggtatc agtactcaca gtttagatga ccattctttc 1920
tgcttggctg caggacaatt actcgggaaa tcgtccgatt cctttattac gtctacagaa 1980
acgacctcct atatagctac tgtacaagcg caactcgcta cctctctaat gaaaatctct 2040
gcacaggcat gctacaatga aagtatccat gagctaaaaa caaaatatcg ctccttctct 2100
aaagaaggat tcggatcctg gcatagcgtt gcagtatccg gagaagtgtg cgcatcgatt 2160
cctattgtat ccaatggttc cggactgttc agctccttct ctattttctc taaactgcaa 2220
ggattttcag gaacacagga cggttttgag gagagttcgg gagagattcg gtccttttct 2280
gccagctctt tcagaaatat ttcacttcct ataggaataa catttgaaaa aaaatcccaa 2340
aaaacacgaa cctactatta ctttctagga gcctacatcc aagacctgaa acgtgatgtg 2400
gaatcgggac ctgtagtgtt actcaaaaat gccgtctcct gggatgctcc tatggcgaac 2460
ttggattcac gagcctacat gttccggctt acgaatcaaa gagctctaca cagacttcag 2520
acgctgttaa atgtgtcttg tgtgctgcgt gggcaaagcc atagttactc cctggatctg 2580
gggaccactt acaggttcta g 2601
<210>182
<211>3021
<212>DNA
<213>Chlamydia
<400>182
atggctagca tgactggtgg acagcaaatg ggtcgggatt caagcttggt accgcatcac 60
catcaccatc acatgattcc tcaaggaatt tacgatgggg agacgttaac tgtatcattt 120
ccctatactg ttataggaga tccgagtggg actactgttt tttctgcagg agagttaaca 180
ttaaaaaatc ttgacaattc tattgcagct ttgcctttaa gttgttttgg gaacttatta 240
gggagtttta ctgttttagg gagaggacac tcgttgactt tcgagaacat acggacttct 300
acaaatgggg cagctctaag taatagcgct gctgatggac tgtttactat tgagggtttt 360
aaagaattat ccttttccaa ttgcaattca ttacttgccg tactgcctgc tgcaacgact 420
aataagggta gccagactcc gacgacaaca tctacaccgt ctaatggtac tatttattct 480
aaaacagatc ttttgttact caataatgag aagttctcat tctatagtaa tttagtctct 540
ggagatgggg gagctataga tgctaagagc ttaacggttc aaggaattag caagctttgt 600
gtcttccaag aaaatactgc tcaagctgat gggggagctt gtcaagtagt caccagtttc 660
tctgctatgg ctaacgaggc tcctattgcc tttgtagcga atgttgcagg agtaagaggg 720
ggagggattg ctgctgttca ggatgggcag cagggagtgt catcatctac ttcaacagaa 780
gatccagtag taagtttttc cagaaatact gcggtagagt ttgatgggaa cgtagcccga 840
gtaggaggag ggatttactc ctacgggaac gttgctttcc tgaataatgg aaaaaccttg 900
tttctcaaca atgttgcttc tcctgtttac attgctgcta agcaaccaac aagtggacag 960
gcttctaata cgagtaataa ttacggagat ggaggagcta tcttctgtaa gaatggtgcg 1020
caagcaggat ccaataactc tggatcagtt tcctttgatg gagagggagt agttttcttt 1080
agtagcaatg tagctgctgg gaaaggggga gctatttatg ccaaaaagct ctcggttgct 1140
aactgtggcc ctgtacaatt tttaaggaat atcgctaatg atggtggagc gatttattta 1200
ggagaatctg gagagctcag tttatctgct gattatggag atattatttt cgatgggaat 1260
cttaaaagaa cagccaaaga gaatgctgcc gatgttaatg gcgtaactgt gtcctcacaa 1320
gccatttcga tgggatcggg agggaaaata acgacattaa gagctaaagc agggcatcag 1380
attctcttta atgatcccat cgagatggca aacggaaata accagccagc gcagtcttcc 1440
aaacttctaa aaattaacga tggtgaagga tacacagggg atattgtttt tgctaatgga 1500
agcagtactt tgtaccaaaa tgttacgata gagcaaggaa ggattgttct tcgtgaaaag 1560
gcaaaattat cagtgaattc tctaagtcag acaggtggga gtctgtatat ggaagctggg 1620
agtacattgg attttgtaac tccacaacca ccacaacagc ctcctgccgc taatcagttg 1680
atcacgcttt ccaatctgca tttgtctctt tcttctttgt tagcaaacaa tgcagttacg 1740
aatcctccta ccaatcctcc agcgcaagat tctcatcctg cagtcattgg tagcacaact 1800
gctggttctg ttacaattag tgggcctatc ttttttgagg atttggatga tacagcttat 1860
gataggtatg attggctagg ttctaatcaa aaaatcaatg tcctgaaatt acagttaggg 1920
actaagcccc cagctaatgc cccatcagat ttgactctag ggaatgagat gcctaagtat 1980
ggctatcaag gaagctggaa gcttgcgtgg gatcctaata cagcaaataa tggtccttat 2040
actctgaaag ctacatggac taaaactggg tataatcctg ggcctgagcg agtagcttct 2100
ttggttccaa atagtttatg gggatccatt ttagatatac gatctgcgca ttcagcaatt 2160
caagcaagtg tggatgggcg ctcttattgt cgaggattat gggtttctgg agtttcgaat 2220
ttcttctatc atgaccgcga tgctttaggt cagggatatc ggtatattag tgggggttat 2280
tccttaggag caaactccta ctttggatca tcgatgtttg gtctagcatt taccgaagta 2340
tttggtagat ctaaagatta tgtagtgtgt cgttccaatc atcatgcttg cataggatcc 2400
gtttatctat ctacccaaca agctttatgt ggatcctatt tgttcggaga tgcgtttatc 2460
cgtgctagct acgggtttgg gaatcagcat atgaaaacct catatacatt tgcagaggag 2520
agcgatgttc gttgggataa taactgtctg gctggagaga ttggagcggg attaccgatt 2580
gtgattactc catctaagct ctatttgaat gagttgcgtc ctttcgtgca agctgagttt 2640
tcttatgccg atcatgaatc ttttacagag gaaggcgatc aagctcgggc attcaagagc 2700
ggacatctcc taaatctatc agttcctgtt ggagtgaagt ttgatcgatg ttctagtaca 2760
catcctaata aatatagctt tatggcggct tatatctgtg atgcttatcg caccatctct 2820
ggtactgaga caacgctcct atcccatcaa gagacatgga caacagatgc ctttcattta 2880
gcaagacatg gagttgtggt tagaggatct atgtatgctt ctctaacaag taatatagaa 2940
gtatatggcc atggaagata tgagtatcga gatgcttctc gaggctatgg tttgagtgca 3000
ggaagtaaag tccggttcta a 3021
<210>183
<211>2934
<212>DNA
<213>Chlamydia
<400>183
atggctagca tgactggtgg acagcaaatg ggtcgggatt caagcttggt accgagctcg 60
gatccacatc accatcacca tcacggacta gctagagagg ttccttctag aatctttctt 120
atgcccaact cagttccaga tcctacgaaa gagtcgctat caaataaaat tagtttgaca 180
ggagacactc acaatctcac taactgctat ctcgataacc tacgctacat actggctatt 240
ctacaaaaaa ctcccaatga aggagctgct gtcacaataa cagattacct aagctttttt 300
gatacacaaa aagaaggtat ttattttgca aaaaatctca cccctgaaag tggtggtgcg 360
attggttatg cgagtcccaa ttctcctacc gtggagattc gtgatacaat aggtcctgta 420
atctttgaaa ataatacttg ttgcagacta tttacatgga gaaatcctta tgctgctgat 480
aaaataagag aaggcggagc cattcatgct caaaatcttt acataaatca taatcatgat 540
gtggtcggat ttatgaagaa cttttcttat gtccaaggag gagccattag taccgctaat 600
acctttgttg tgagcgagaa tcagtcttgt tttctcttta tggacaacat ctgtattcaa 660
actaatacag caggaaaagg tggcgctatc tatgctggaa cgagcaattc ttttgagagt 720
aataactgcg atctcttctt catcaataac gcctgttgtg caggaggagc gatcttctcc 780
cctatctgtt ctctaacagg aaatcgtggt aacatcgttt tctataacaa tcgctgcttt 840
aaaaatgtag aaacagcttc ttcagaagct tctgatggag gagcaattaa agtaactact 900
cgcctagatg ttacaggcaa tcgtggtagg atctttttta gtgacaatat cacaaaaaat 960
tatggcggag ctatttacgc tcctgtagtt accctagtgg ataatggccc tacctacttt 1020
ataaacaata tcgccaataa taaggggggc gctatctata tagacggaac cagtaactcc 1080
aaaatttctg ccgaccgcca tgctattatt tttaatgaaa atattgtgac taatgtaact 1140
aatgcaaatg gtaccagtac gtcagctaat cctcctagaa gaaatgcaat aacagtagca 1200
agctcctctg gtgaaattct attaggagca gggagtagcc aaaatttaat tttttatgat 1260
cctattgaag ttagcaatgc aggggtctct gtgtccttca ataaggaagc tgatcaaaca 1320
ggctctgtag tattttcagg agctactgtt aattctgcag attttcatca acgcaattta 1380
caaacaaaaa cacctgcacc ccttactctc agtaatggtt ttctatgtat cgaagatcat 1440
gctcagctta cagtgaatcg attcacacaa actgggggtg ttgtttctct tgggaatgga 1500
gcagttctga gttgctataa aaatggtaca ggagattctg ctagcaatgc ctctataaca 1560
ctgaagcata ttggattgaa tctttcttcc attctgaaaa gtggtgctga gattccttta 1620
ttgtgggtag agcctacaaa taacagcaat aactatacag cagatactgc agctaccttt 1680
tcattaagtg atgtaaaact ctcactcatt gatgactacg ggaactctcc ttatgaatcc 1740
acagatctga cccatgctct gtcatcacag cctatgctat ctatttctga agctagcgat 1800
aaccagctac aatcagaaaa tatagatttt tcgggactaa atgtccctca ttatggatgg 1860
caaggacttt ggacttgggg ctgggcaaaa actcaagatc cagaaccagc atcttcagca 1920
acaatcactg atccacaaaa agccaataga tttcatagaa ccttactact aacatggctt 1980
cctgccgggt atgttcctag cccaaaacac agaagtcccc tcatagctaa caccttatgg 2040
gggaatatgc tgcttgcaac agaaagctta aaaaatagtg cagagctgac acctagtggt 2100
catcctttct ggggaattac aggaggagga ctaggcatga tggtttacca agatcctcga 2160
gaaaatcatc ctggattcca tatgcgctct tccggatact ctgcggggat gatagcaggg 2220
cagacacaca ccttctcatt gaaattcagt cagacctaca ccaaactcaa tgagcgttac 2280
gcaaaaaaca acgtatcttc taaaaattac tcatgccaag gagaaatgct cttctcattg 2340
caagaaggtt tcttgctgac taaattagtt gggctttaca gctatggaga ccataactgt 2400
caccatttct atactcaagg agaaaatcta acatctcaag ggacgttccg cagtcaaacg 2460
atgggaggtg ctgtcttttt tgatctccct atgaaaccct ttggatcaac gcatatactg 2520
acagctccct ttttaggtgc tcttggtatt tattctagcc tgtctcactt tactgaggtg 2580
ggagcctatc cgcgaagctt ttctacaaag actcctttga tcaatgtcct agtccctatt 2640
ggagttaaag gtagctttat gaatgctacc cacagacctc aagcctggac tgtagaattg 2700
gcataccaac ccgttctgta tagacaagaa ccagggatcg cgacccagct cctagccagt 2760
aaaggtattt ggtttggtag tggaagcccc tcatcgcgtc atgccatgtc ctataaaatc 2820
tcacagcaaa cacaaccttt gagttggtta actctccatt tccagtatca tggattctac 2880
tcctcttcaa ccttctgtaa ttatctcaat ggggaaattg ctctgcgatt ctag 2934
<210>184
<211>2547
<212>DNA
<213>Chlamydia
<400>184
atggctagcc atcaccatca ccatcacggt gctatttctt gcttacgtgg agatgtagtc 60
atttctggaa acaagggtag agttgaattt aaagacaaca tagcaacacg tctttatgtg 120
gaagaaactg tagaaaaggt tgaagaggta gagccagctc ctgagcaaaa agacaataat 180
gagctttctt tcttagggag tgtagaacag agttttatta ctgcagctaa tcaagctctt 240
ttcgcatctg aagatgggga tttatcacct gagtcatcca tttcttctga agaacttgcg 300
aaaagaagag agtgtgctgg aggagctatt tttgcaaaac gggttcgtat tgtagataac 360
caagaggccg ttgtattctc gaataacttc tctgatattt atggcggcgc catttttaca 420
ggttctcttc gagaagagga taagttagat gggcaaatcc ctgaagtctt gatctcaggc 480
aatgcagggg atgttgtttt ttccggaaat tcctcgaagc gtgatgagca tcttcctcat 540
acaggtgggg gagccatttg tactcaaaat ttgacgattt ctcagaatac agggaatgtt 600
ctgttttata acaacgtggc ctgttcggga ggagctgttc gtatagagga tcatggtaat 660
gttcttttag aagcttttgg aggagatatt gtttttaaag gaaattcttc tttcagagca 720
caaggatccg atgctatcta ttttgcaggt aaagaatcgc atattacagc cctgaatgct 780
acggaaggac atgctattgt tttccacgac gcattagttt ttgaaaatct aaaagaaagg 840
aaatctgctg aagtattgtt aatcaatagt cgagaaaatc caggttacac tggatctatt 900
cgatttttag aagcagaaag taaagttcct caatgtattc atgtacaaca aggaagcctt 960
gagttgctaa atggagctac attatgtagt tatggtttta aacaagatgc tggagctaag 1020
ttggtattgg ctgctggatc taaactgaag attttagatt caggaactcc tgtacaaggg 1080
catgctatca gtaaacctga agcagaaatc gagtcatctt ctgaaccaga gggtgcacat 1140
tctctttgga ttgcgaagaa tgctcaaaca acagttccta tggttgatat ccatactatt 1200
tctgtagatt tagcctcctt ctcttctagt caacaggagg ggacagtaga agctcctcag 1260
gttattgttc ctggaggaag ttatgttcga tctggagagc ttaatttgga gttagttaac 1320
acaacaggta ctggttatga aaatcatgct ttgttgaaga atgaggctaa agttccattg 1380
atgtctttcg ttgcttctag tgatgaagct tcagccgaaa tcagtaactt gtcggtttct 1440
gatttacaga ttcatgtagc aactccagag attgaagaag acacatacgg ccatatggga 1500
gattggtctg aggctaaaat tcaagatgga actcttgtca ttaattggaa tcctactgga 1560
tatcgattag atcctcaaaa agcaggggct ttagtattta atgcattatg ggaagaaggg 1620
gctgtcttgt ctgctctgaa aaatgcacgc tttgctcata atctcactgc tcagcgtatg 1680
gaattcgatt attctacaaa tgtgtgggga ttcgcctttg gtggtttccg aactctatct 1740
gcagagaatc tggttgctat tgatggatac aaaggagctt atggtggtgc ttctgctgga 1800
gtcgatattc aattgatgga agattttgtt ctaggagtta gtggagctgc tttcctaggt 1860
aaaatggata gtcagaagtt tgatgcggag gtttctcgga agggagttgt tggttctgta 1920
tatacaggat ttttagctgg atcctggttc ttcaaaggac aatatagcct tggagaaaca 1980
cagaacgata tgaaaacgcg ttatggagta ctaggagagt cgagtgcttc ttggacatct 2040
cgaggagtac tggcagatgc tttagttgaa taccgaagtt tagttggtcc tgtgagacct 2100
actttttatg ctttgcattt caatccttat gtcgaagtat cttatgcttc tatgaaattc 2160
cctggcttta cagaacaagg aagagaagcg cgttcttttg aagacgcttc ccttaccaat 2220
atcaccattc ctttagggat gaagtttgaa ttggcgttca taaaaggaca gttttcagag 2280
gtgaactctt tgggaataag ttatgcatgg gaagcttatc gaaaagtaga aggaggcgcg 2340
gtgcagcttt tagaagctgg gtttgattgg gagggagctc caatggatct tcctagacag 2400
gagctgcgtg tcgctctgga aaataatacg gaatggagtt cttacttcag cacagtctta 2460
ggattaacag ctttttgtgg aggatttact tctacagata gtaaactagg atatgaggcg 2520
aatactggat tgcgattgat cttttaa 2547
<210>185
<211>2337
<212>DNA
<213>Chlamydia
<400>185
atgcatcacc atcaccatca cgggttagct agttgcgtag atcttcatgc tggaggacag 60
tctgtaaatg agctggtata tgtaggccct caagcggttt tattgttaga ccaaattcga 120
gatctattcg ttgggtctaa agatagtcag gctgaaggac agtataggtt aattgtagga 180
gatccaagtt ctttccaaga gaaagatgca gatactcttc ccgggaaggt agagcaaagt 240
actttgttct cagtaaccaa tcccgtggtt ttccaaggtg tggaccaaca ggatcaagtc 300
tcttcccaag ggttaatttg tagttttacg agcagcaacc ttgattctcc ccgtgacgga 360
gaatcttttt taggtattgc ttttgttggg gatagtagta aggctggaat cacattaact 420
gacgtgaaag cttctttgtc tggagcggct ttatattcta cagaagatct tatctttgaa 480
aagattaagg gtggattgga atttgcatca tgttcttctc tagaacaggg gggagcttgt 540
gcagctcaaa gtattttgat tcatgattgt caaggattgc aggttaaaca ctgtactaca 600
gccgtgaatg ctgaggggtc tagtgcgaat gatcatcttg gatttggagg aggcgctttc 660
tttgttacgg gttctctttc tggagagaaa agtctctata tgcctgcagg agatatggta 720
gttgcgaatt gtgatggggc tatatctttt gaaggaaaca gcgcgaactt tgctaatgga 780
ggagcgattg ctgcctctgg gaaagtgctt tttgtcgcta atgataaaaa gacttctttt 840
atagagaacc gagctttgtc tggaggagcg attgcagcct cttctgatat tgcctttcaa 900
aactgcgcag aactagtttt caaaggcaat tgtgcaattg gaacagagga taaaggttct 960
ttaggtggag gggctatatc ttctctaggc accgttcttt tgcaagggaa tcacgggata 1020
acttgtgata agaatgagtc tgcttcgcaa ggaggcgcca tttttggcaa aaattgtcag 1080
atttctgaca acgaggggcc agtggttttc agagatagta cagcttgctt aggaggaggc 1140
gctattgcag ctcaagaaat tgtttctatt cagaacaatc aggctgggat ttccttcgag 1200
ggaggtaagg ctagtttcgg aggaggtatt gcgtgtggat ctttttcttc cgcaggcggt 1260
gcttctgttt tagggactat tgatatttcg aagaatttag gcgcgatttc gttctctcgt 1320
actttatgta cgacctcaga tttaggacaa atggagtacc agggaggagg agctctattt 1380
ggtgaaaata tttctctttc tgagaatgct ggtgtgctca cctttaaaga caacattgtg 1440
aagacttttg cttcgaatgg gaaaattctg ggaggaggag cgattttagc tactggtaag 1500
gtggaaatta ccaataattc cggaggaatt tcttttacag gaaatgcgag agctccacaa 1560
gctcttccaa ctcaagagga gtttccttta ttcagcaaaa aagaagggcg accactctct 1620
tcaggatatt ctgggggagg agcgatttta ggaagagaag tagctattct ccacaacgct 1680
gcagtagtat ttgagcaaaa tcgtttgcag tgcagcgaag aagaagcgac attattaggt 1740
tgttgtggag gaggcgctgt tcatgggatg gatagcactt cgattgttgg caactcttca 1800
gtaagatttg gtaataatta cgcaatggga caaggagtct caggaggagc tcttttatct 1860
aaaacagtgc agttagctgg aaatggaagc gtcgattttt ctcgaaatat tgctagtttg 1920
ggaggaggag ctcttcaagc ttctgaagga aattgtgagc tagttgataa cggctatgtg 1980
ctattcagag ataatcgagg gagggtttat gggggtgcta tttcttgctt acgtggagat 2040
gtagtcattt ctggaaacaa gggtagagtt gaatttaaag acaacatagc aacacgtctt 2100
tatgtggaag aaactgtaga aaaggttgaa gaggtagagc cagctcctga gcaaaaagac 2160
aataatgagc tttctttctt agggagtgta gaacagagtt ttattactgc agctaatcaa 2220
gctcttttcg catctgaaga tggggattta tcacctgagt catccatttc ttctgaagaa 2280
cttgcgaaaa gaagagagtg tgctggagga gctgactcga gcagatccgg ctgctaa 2337
<210>186
<211>2847
<212>DNA
<213>Chlamydia
<400>186
atggctagca tgcatcacca tcaccatcac gttaagattg agaacttctc tggccaagga 60
atattttctg gaaacaaagc tatcgataac accacagaag gctcctcttc caaatctaac 120
gtcctcggag gtgcggtcta tgctaaaaca ttgtttaatc tcgatagcgg gagctctaga 180
cgaactgtca ccttctccgg gaatactgtc tcttctcaat ctacaacagg tcaggttgct 240
ggaggagcta tctactctcc tactgtaacc attgctactc ctgtagtatt ttctaaaaac 300
tctgcaacaa acaatgctaa taacgctaca gatactcaga gaaaagacac ctttggagga 360
gctatcggag ctacttctgc tgtttctcta tcaggagggg ctcatttctt agaaaacgtt 420
gctgacctcg gatctgctat tgggttggtg ccagacacac aaaatacaga aacagtgaaa 480
ttagagtctg gctcctacta ctttgaaaaa aataaagctt taaaacgagc tactatttac 540
gcacctgtcg tttccattaa agcctatact gcgacattta accaaaacag atctctagaa 600
gaaggaagcg cgatttactt tacaaaagaa gcatctattg agtctttagg ctctgttctc 660
ttcacaggaa acttagtaac cccaacgcta agcacaacta cagaaggcac accagccaca 720
acctcaggag atgtaacaaa atatggtgct gctatctttg gacaaatagc aagctcaaac 780
ggatctcaga cggataacct tcccctgaaa ctcattgctt caggaggaaa tatttgtttc 840
cgaaacaatg aataccgtcc tacttcttct gataccggaa cctctacttt ctgtagtatt 900
gcgggagatg ttaaattaac catgcaagct gcaaaaggga aaacgatcag tttctttgat 960
gcaatccgga cctctactaa gaaaacaggt acacaggcaa ctgcctacga tactctcgat 1020
attaataaat ctgaggattc agaaactgta aactctgcgt ttacaggaac gattctgttc 1080
tcctctgaat tacatgaaaa taaatcctat attccacaaa acgtagttct acacagtgga 1140
tctcttgtat tgaagccaaa taccgagctt catgtcattt cttttgagca gaaagaaggc 1200
tcttctctcg ttatgacacc tggatctgtt ctttcgaacc agactgttgc tgatggagct 1260
ttggtcataa ataacatgac cattgattta tccagcgtag agaaaaatgg tattgctgaa 1320
ggaaatatct ttactcctcc agaattgaga atcatagaca ctactacaag tggaagcggt 1380
ggaaccccat ctacagatag tgaaagtaac cagaatagtg atgataccaa ggagcaaaat 1440
aataatgacg cctcgaatca aggagaaagc gcgaatggat cgtcttctcc tgcagtagct 1500
gctgcacaca catctcgtac aagaaacttt gccgctgcag ctacagccac acctacgaca 1560
acaccaacgg ctacaactac aacaagcaac caagtaatcc taggaggaga aatcaaactc 1620
atcgatccta atgggacctt cttccagaac cctgcattaa gatccgacca acaaatctcc 1680
ttgttagtgc tccctacaga ctcatcaaaa atgcaagctc agaaaatagt actgacgggt 1740
gatattgctc ctcagaaagg atatacagga acactcactc tggatcctga tcaactacaa 1800
aatggaacga tctcagcgct ctggaaattt gactcttata gacaatgggc ttatgtacct 1860
agagacaatc atttctatgc gaactcgatt ctgggatctc aaatgtcaat ggtcacagtc 1920
aaacaaggct tgctcaacga taaaatgaat ctagctcgct ttgatgaagt tagctataac 1980
aacctgtgga tatcaggact aggaacgatg ctatcgcaag taggaacacc tacttctgaa 2040
gaattcactt attacagcag aggagcttct gttgccttag atgctaaacc agcccatgat 2100
gtgattgttg gagctgcatt tagtaagatg atcgggaaaa caaaatcctt gaaaagagag 2160
aataactaca ctcacaaagg atccgaatat tcttaccaag catcggtata cggaggcaaa 2220
ccattccact ttgtaatcaa taaaaaaacg gaaaaatcgc taccgctatt gttacaagga 2280
gtcatctctt acggatatat caaacatgat acagtgactc actatccaac gatccgtgaa 2340
cgaaaccaag gagaatggga agacttagga tggctgacag ctctccgtgt ctcctctgtc 2400
ttaagaactc ctgcacaagg ggatactaaa cgtatcactg tttacggaga attggaatac 2460
tccagtatcc gtcagaaaca attcacagaa acagaatacg atcctcgtta cttcgacaac 2520
tgcacctata gaaacttagc aattcctatg gggttagcat tcgaaggaga gctctctggt 2580
aacgatattt tgatgtacaa cagattctct gtagcataca tgccatcaat ctatcgaaat 2640
tctccaacat gcaaatacca agtgctctct tcaggagaag gcggagaaat tatttgtgga 2700
gtaccgacaa gaaactcagc tcgcggagaa tacagcacgc agctgtaccc gggacctttg 2760
tggactctgt atggatccta cacgatagaa gcagacgcac atacactagc tcatatgatg 2820
aactgcggtg ctcgtatgac attctaa 2847
<210>187
<211>2466
<212>DNA
<213>Chlamydia
<400>187
atgcatcacc atcaccatca cgaggcgagc tcgatccaag atcaaataaa gaataccgac 60
tgcaatgtta gcaaagtagg atattcaact tctcaagcat ttactgatat gatgctagca 120
gacaacacag agtatcgagc tgctgatagt gtttcattct atgacttttc gacatcttcc 180
ggattaccta gaaaacatct tagtagtagt agtgaagctt ctccaacgac agaaggagtg 240
tcttcatctt catctggaga aaatactgag aattcacaag attcagctcc ctcttctgga 300
gaaactgata agaaaacaga agaagaacta gacaatggcg gaatcattta tgctagagag 360
aaactaacta tctcagaatc tcaggactct ctctctaatc caagcataga actccatgac 420
aatagttttt tcttcggaga aggtgaagtt atctttgatc acagagttgc cctcaaaaac 480
ggaggagcta tttatggaga gaaagaggta gtctttgaaa acataaaatc tctactagta 540
gaagtaaata tctcggtcga gaaagggggt agcgtctatg caaaagaacg agtatcttta 600
gaaaatgtta ccgaagcaac cttctcctcc aatggtgggg aacaaggtgg tggtggaatc 660
tattcagaac aagatatgtt aatcagtgat tgcaacaatg tacatttcca agggaatgct 720
gcaggagcaa cagcagtaaa acaatgtctg gatgaagaaa tgatcgtatt gctcacagaa 780
tgcgttgata gcttatccga agatacactg gatagcactc cagaaacgga acagactaag 840
tcaaatggaa atcaagatgg ttcgtctgaa acaaaagata cacaagtatc agaatcacca 900
gaatcaactc ctagccccga cgatgtttta ggtaaaggtg gtggtatcta tacagaaaaa 960
tctttgacca tcactggaat tacagggact atagattttg tcagtaacat agctaccgat 1020
tctggagcag gtgtattcac taaagaaaac ttgtcttgca ccaacacgaa tagcctacag 1080
tttttgaaaa actcggcagg tcaacatgga ggaggagcct acgttactca aaccatgtct 1140
gttactaata caactagtga aagtataact actccccctc tcgtaggaga agtgattttc 1200
tctgaaaata cagctaaagg gcacggtggt ggtatctgca ctaacaaact ttctttatct 1260
aatttaaaaa cggtgactct cactaaaaac tctgcaaagg agtctggagg agctattttt 1320
acagatctag cgtctatacc aacaacagat accccagagt cttctacccc ctcttcctcc 1380
tcgcctgcaa gcactcccga agtagttgct tctgctaaaa taaatcgatt ctttgcctct 1440
acggcagaac cggcagcccc ttctctaaca gaggctgagt ctgatcaaac ggatcaaaca 1500
gaaacttctg atactaatag cgatatagac gtgtcgattg agaacatttt gaatgtcgct 1560
atcaatcaaa acacttctgc gaaaaaagga ggggctattt acgggaaaaa agctaaactt 1620
tcccgtatta acaatcttga actttcaggg aattcatccc aggatgtagg aggaggtctc 1680
tgtttaactg aaagcgtaga atttgatgca attggatcgc tcttatccca ctataactct 1740
gctgctaaag aaggtggggt tattcattct aaaacggtta ctctatctaa cctcaagtct 1800
accttcactt ttgcagataa cactgttaaa gcaatagtag aaagcactcc tgaagctcca 1860
gaagagattc ctccagtaga aggagaagag tctacagcaa cagaaaatcc gaattctaat 1920
acagaaggaa gttcggctaa cactaacctt gaaggatctc aaggggatac tgctgataca 1980
gggactggtg ttgttaacaa tgagtctcaa gacacatcag atactggaaa cgctgaatct 2040
ggagaacaac tacaagattc tacacaatct aatgaagaaa atacccttcc caatagtagt 2100
attgatcaat ctaacgaaaa cacagacgaa tcatctgata gccacactga ggaaataact 2160
gacgagagtg tctcatcgtc ctctaaaagt ggatcatcta ctcctcaaga tggaggagca 2220
gcttcttcag gggctccctc aggagatcaa tctatctctg caaacgcttg tttagctaaa 2280
agctatgctg cgagtactga tagctcccct gtatctaatt cttcaggttc agacgttact 2340
gcatcttctg ataatccaga ctcttcctca tctggagata gcgctggaga ctctgaagga 2400
ccgactgagc cagaagctgg ttctacaaca gaaactccta ctttaatagg aggaggtgct 2460
atctga 2466
<210>188
<211>1578
<212>DNA
<213>Chlamydia
<400>188
atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60
cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120
accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180
ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240
ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300
gcgcttaacg ggcatcatcc cggtgacgtc atctcggtga cctggcaaac caagtcgggc 360
ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt cccgctagta 420
cctagaggtt caccgctgcc tgtggggaat ccagctgaac caagtttatt aatcgatggc 480
actatgtggg aaggtgcttc aggagatcct tgcgatcctt gcgctacttg gtgtgacgcc 540
attagcatcc gcgcaggata ctacggagat tatgttttcg atcgtgtatt aaaagttgat 600
gtgaataaaa cttttagcgg catggctgca actcctacgc aggctatagg taacgcaagt 660
aatactaatc agccagaagc aaatggcaga ccgaacatcg cttacggaag gcatatgcaa 720
gatgcagagt ggttttcaaa tgcagccttc ctagccttaa acatttggga tcgcttcgac 780
attttctgca ccttaggggc atccaatgga tacttcaaag caagttcggc tgcattcaac 840
ttggttgggt taatagggtt ttcagctgca agctcaatct ctaccgatct tccaatgcaa 900
cttcctaacg taggcattac ccaaggtgtt gtggaatttt atacagacac atcattttct 960
tggagcgtag gtgcacgtgg agctttatgg gaatgtggtt gtgcaacttt aggagctgag 1020
ttccaatacg ctcaatctaa tcctaagatt gagatgctca acgtcacttc aagcccagca 1080
caatttgtga ttcacaaacc aagaggctat aaaggagcta gctcgaattt tcctttacct 1140
ataacggctg gaacaacaga agctacagac accaaatcag ctacaattaa ataccatgaa 1200
tggcaagtag gcctcgccct gtcttacaga ttgaatatgc ttgttccata tattggcgta 1260
aactggtcaa gagcaacttt tgatgctgat actatccgca ttgctcaacc taaattaaaa 1320
tcggagattc ttaacattac tacatggaac ccaagcctta taggatcaac cactgctttg 1380
cccaataata gtggtaagga tgttctatct gatgtcttgc aaattgcttc gattcagatc 1440
aacaaaatga agtctagaaa agcttgtggt gtagctgttg gtgcaacgtt aatcgacgct 1500
gacaaatggt caatcactgg tgaagcacgc ttaatcaatg aaagagctgc tcacatgaat 1560
gcacaattcc gcttctaa 1578
<210>189
<211>866
<212>PRT
<213>Chlamydia
<220>
<221>VARIANT
<222>(1)...(866)
<223>Xaa=Any Amino Acid
<400>189
Met Ala Ser His His His His His His Leu Phe Gly Gln Asp Pro Leu
1 5 10 15
Gly Glu Thr Ala Leu Leu Thr Lys Asn Pro Asn His Val Val Cys Thr
20 25 30
Phe Phe Glu Asp Cys Thr Met Glu Ser Leu Phe Pro Ala Leu Cys Ala
35 40 45
His Ala Ser Gln Asp Asp Pro Leu Tyr Val Leu Gly Asn Ser Tyr Cys
50 55 60
Trp Phe Val Ser Lys Leu His Ile Thr Asp Pro Lys Glu Ala Leu Phe
65 70 75 80
Lys Glu Lys Gly Asp Leu Ser Ile Gln Asn Phe Arg Phe Leu Ser Phe
85 90 95
Thr Asp Cys Ser Ser Lys Glu Ser Ser Pro Ser Ile Ile His Gln Lys
100 105 110
Asn Gly Gln Leu Ser Leu Arg Asn Asn Gly Ser Met Ser Phe Cys Arg
115 120 125
Asn His Ala Glu Gly Ser Gly Gly Ala Ile Ser Ala Asp Ala Phe Ser
130 135 140
Leu Gln His Asn Tyr Leu Phe Thr Ala Phe Glu Glu Asn Ser Ser Lys
145 150 155 160
Gly Asn Gly Gly Ala Ile Gln Ala Gln Thr Phe Ser Leu Ser Arg Asn
165 170 175
Val Ser Pro Ile Ser Phe Ala Arg Asn Arg Ala Asp Leu Asn Gly Gly
180 185 190
Ala Ile Cys Cys Ser Asn Leu Ile Cys Ser Gly Asn Val Asn Pro Leu
195 200 205
Phe Phe Thr Gly Ash Ser Ala Thr Asn Gly Gly Xaa Ile Cys Cys Ile
210 215 220
Ser Asp Leu Asn Thr Ser Glu Lys Gly Ser Leu Ser Leu Ala Cys Asn
225 230 235 240
Gln Xaa Thr Leu Phe Ala Ser Asn Ser Ala Lys Glu Lys Gly Gly Ala
245 250 255
Ile Tyr Ala Lys His Met Val Leu Arg Tyr Asn Gly Pro Val Ser Phe
260 265 270
Ile Asn Asn Ser Ala Lys Ile Gly Gly Ala Ile Ala Ile Gln Ser Gly
275 280 285
Gly Ser Leu Ser Ile Leu Ala Gly Glu Gly Ser Val Leu Phe Gln Asn
290 295 300
Asn Ser Gln Arg Thr Ser Asp Gln Gly Leu Val Arg Asn Ala Ile Tyr
305 310 315 320
Leu Glu Lys Asp Ala Ile Leu Ser Ser Leu Glu Ala Arg Asn Gly Asp
325 330 335
Ile Leu Phe Phe Asp Pro Ile Val Gln Glu Ser Ser Ser Lys Glu Ser
340 345 350
Pro Leu Pro Ser Ser Leu Gln Ala Ser Val Thr Ser Pro Thr Pro Ala
355 360 365
Thr Ala Ser Pro Leu Val Ile Gln Thr Ser Ala Asn Arg Ser Val Ile
370 375 380
Phe Ser Ser Glu Arg Leu Ser Glu Glu Glu Lys Thr Pro Asp Asn Leu
385 390 395 400
Thr Ser Gln Leu Gln Gln Pro Ile Glu Leu Lys Ser Gly Arg Leu Val
405 410 415
Leu Lys Asp Arg Ala Val Leu Ser Xaa Pro Ser Leu Ser Gln Asp Pro
420 425 430
Gln Ala Leu Leu Ile Met Glu Ala Gly Thr Ser Leu Lys Thr Ser Xaa
435 440 445
Asp Leu Lys Leu Xaa Thr Xaa Ser Ile Pro Leu His Ser Leu Asp Thr
450 455 460
Glu Lys Ser Val Thr Ile His Ala Pro Asn Leu Ser Ile Gln Lys Ile
465 470 475 480
Phe Leu Ser Asn Ser Gly Asp Glu Asn Phe Tyr Glu Asn Val Glu Leu
485 490 495
Leu Ser Lys Glu Gln Asn Asn Ile Pro Leu Leu Thr Leu Pro Lys Glu
500 505 510
Gln Ser His Leu His Leu Pro Asp Gly Asn Leu Ser Ser His Phe Gly
515 520 525
Tyr Gln Gly Asp Trp Thr Phe Ser Trp Lys Asp Ser Asp Glu Gly His
530 535 540
Ser Leu Ile Ala Asn Trp Thr Pro Lys Asn Tyr Val Pro His Pro Glu
545 550 555 560
Arg Gln Ser Thr Leu Val Ala Asn Thr Leu Trp Asn Thr Tyr Ser Asp
565 570 575
Met Gln Ala Val Gln Ser Met Ile Asn Thr Thr Ala His Gly Gly Ala
580 585 590
Tyr Leu Phe Gly Thr Trp Gly Ser Ala Val Ser Asn Leu Phe Tyr Val
595 600 605
His Asp Ser Ser Gly Lys Pro Ile Asp Asn Trp His His Arg Ser Leu
610 615 620
Gly Tyr Leu Phe Gly Ile Ser Thr His Ser Leu Asp Asp His Ser Phe
625 630 635 640
Cys Leu Ala Ala Gly Gln Leu Leu Gly Lys Ser Ser Asp Ser Phe Ile
645 650 655
Thr Ser Thr Glu Thr Thr Ser Tyr Ile Ala Thr Val Gln Ala Gln Leu
660 665 670
Ala Thr Ser Leu Met Lys Ile Ser Ala Gln Ala Cys Tyr Asn Glu Ser
675 680 685
Ile His Glu Leu Lys Thr Lys Tyr Arg Ser Phe Ser Lys Glu Gly Phe
690 695 700
Gly Ser Trp His Ser Val Ala Val Ser Gly Glu Val Cys Ala Ser Ile
705 710 715 720
Pro Ile Val Ser Asn Gly Ser Gly Leu Phe Ser Ser Phe Ser Ile Phe
725 730 735
Ser Lys Leu Gln Gly Phe Ser Gly Thr Gln Asp Gly Phe Glu Glu Ser
740 745 750
Ser Gly Glu Ile Arg Ser Phe Ser Ala Ser Ser Phe Arg Asn Ile Ser
755 760 765
Leu Pro Ile Gly Ile Thr Phe Glu Lys Lys Ser Gln Lys Thr Arg Thr
770 775 780
Tyr Tyr Tyr Phe Leu Gly Ala Tyr Ile Gln Asp Leu Lys Arg Asp Val
785 790 795 800
Glu Ser Gly Pro Val Val Leu Leu Lys Asn Ala Val Ser Trp Asp Ala
805 810 815
Pro Met Ala Asn Leu Asp Ser Arg Ala Tyr Met Phe Arg Leu Thr Asn
820 825 830
Gln Arg Ala Leu His Arg Leu Gln Thr Leu Leu Asn Val Ser Cys Val
835 840 845
Leu Arg Gly Gln Ser His Ser Tyr Ser Leu Asp Leu Gly Thr Thr Tyr
850 855 860
Arg Phe
865
<210>190
<211>1006
<212>PRT
<213>Chlamydia
<400>190
Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu
1 5 10 15
Val Pro His His His His His His Met Ile Pro Gln Gly Ile Tyr Asp
20 25 30
Gly Glu Thr Leu Thr Val Ser Phe Pro Tyr Thr Val Ile Gly Asp Pro
35 40 45
Ser Gly Thr Thr Val Phe Ser Ala Gly Glu Leu Thr Leu Lys Asn Leu
50 55 60
Asp Asn Ser Ile Ala Ala Leu Pro Leu Ser Cys Phe Gly Asn Leu Leu
65 70 75 80
Gly Ser Phe Thr Val Leu Gly Arg Gly His Ser Leu Thr Phe Glu Asn
85 90 95
Ile Arg Thr Ser Thr Asn Gly Ala Ala Leu Ser Asn Ser Ala Ala Asp
100 105 110
Gly Leu Phe Thr Ile Glu Gly Phe Lys Glu Leu Ser Phe Ser Asn Cys
115 120 125
Asn Ser Leu Leu Ala Val Leu Pro Ala Ala Thr Thr Asn Lys Gly Ser
130 135 140
Gln Thr Pro Thr Thr Thr Ser Thr Pro Ser Asn Gly Thr Ile Tyr Ser
145 150 155 160
Lys Thr Asp Leu Leu Leu Leu Asn Asn Glu Lys Phe Ser Phe Tyr Ser
165 170 175
Asn Leu Val Ser Gly Asp Gly Gly Ala Ile Asp Ala Lys Ser Leu Thr
180 185 190
Val Gln Gly Ile Ser Lys Leu Cys Val Phe Gln Glu Asn Thr Ala Gln
195 200 205
Ala Asp Gly Gly Ala Cys Gln Val Val Thr Ser Phe Ser Ala Met Ala
210 215 220
Asn Glu Ala Pro Ile Ala Phe Val Ala Asn Val Ala Gly Val Arg Gly
225 230 235 240
Gly Gly Ile Ala Ala Val Gln Asp Gly Gln Gln Gly Val Ser Ser Ser
245 250 255
Thr Ser Thr Glu Asp Pro Val Val Ser Phe Ser Arg Asn Thr Ala Val
260 265 270
Glu Phe Asp Gly Asn Val Ala Arg Val Gly Gly Gly Ile Tyr Ser Tyr
275 280 285
Gly Asn Val Ala Phe Leu Asn Asn Gly Lys Thr Leu Phe Leu Asn Asn
290 295 300
Val Ala Ser Pro Val Tyr Ile Ala Ala Lys Gln Pro Thr Ser Gly Gln
305 310 315 320
Ala Ser Asn Thr Ser Asn Asn Tyr Gly Asp Gly Gly Ala Ile Phe Cys
325 330 335
Lys Asn Gly Ala Gln Ala Gly Ser Asn Asn Ser Gly Ser Val Ser Phe
340 345 350
Asp Gly Glu Gly Val Val Phe Phe Ser Ser Asn Val Ala Ala Gly Lys
355 360 365
Gly Gly Ala Ile Tyr Ala Lys Lys Leu Ser Val Ala Asn Cys Gly Pro
370 375 380
Val Gln Phe Leu Arg Asn Ile Ala Asn Asp Gly Gly Ala Ile Tyr Leu
385 390 395 400
Gly Glu Ser Gly Glu Leu Ser Leu Ser Ala Asp Tyr Gly Asp Ile Ile
405 410 415
Phe Asp Gly Asn Leu Lys Arg Thr Ala Lys Glu Asn Ala Ala Asp Val
420 425 430
Asn Gly Val Thr Val Ser Ser Gln Ala Ile Ser Met Gly Ser Gly Gly
435 440 445
Lys Ile Thr Thr Leu Arg Ala Lys Ala Gly His Gln Ile Leu Phe Asn
450 455 460
Asp Pro Ile Glu Met Ala Asn Gly Asn Asn Gln Pro Ala Gln Ser Ser
465 470 475 480
Lys Leu Leu Lys Ile Asn Asp Gly Glu Gly Tyr Thr Gly Asp Ile Val
485 490 495
Phe Ala Asn Gly Ser Ser Thr Leu Tyr Gln Asn Val Thr Ile Glu Gln
500 505 510
Gly Arg Ile Val Leu Arg Glu Lys Ala Lys Leu Ser Val Asn Ser Leu
515 520 525
Ser Gln Thr Gly Gly Ser Leu Tyr Met Glu Ala Gly Ser Thr Leu Asp
530 535 540
Phe Val Thr Pro Gln Pro Pro Gln Gln Pro Pro Ala Ala Asn Gln Leu
545 550 555 560
Ile Thr Leu Ser Asn Leu His Leu Ser Leu Ser Ser Leu Leu Ala Asn
565 570 575
Asn Ala Val Thr Asn Pro Pro Thr Asn Pro Pro Ala Gln Asp Ser His
580 585 590
Pro Ala Val Ile Gly Ser Thr Thr Ala Gly Ser Val Thr Ile Ser Gly
595 600 605
Pro Ile Phe Phe Glu Asp Leu Asp Asp Thr Ala Tyr Asp Arg Tyr Asp
610 615 620
Trp Leu Gly Ser Asn Gln Lys Ile Asn Val Leu Lys Leu Gln Leu Gly
625 630 635 640
Thr Lys Pro Pro Ala Asn Ala Pro Ser Asp Leu Thr Leu Gly Asn Glu
645 650 655
Met Pro Lys Tyr Gly Tyr Gln Gly Ser Trp Lys Leu Ala Trp Asp Pro
660 665 670
Asn Thr Ala Asn Asn Gly Pro Tyr Thr Leu Lys Ala Thr Trp Thr Lys
675 680 685
Thr Gly Tyr Asn Pro Gly Pro Glu Arg Val Ala Ser Leu Val Pro Asn
690 695 700
Ser Leu Trp Gly Ser Ile Leu Asp Ile Arg Ser Ala His Ser Ala Ile
705 710 715 720
Gln Ala Ser Val Asp Gly Arg Ser Tyr Cys Arg Gly Leu Trp Val Ser
725 730 735
Gly Val Ser Asn Phe Phe Tyr His Asp Arg Asp Ala Leu Gly Gln Gly
740 745 750
Tyr Arg Tyr Ile Ser Gly Gly Tyr Ser Leu Gly Ala Asn Ser Tyr Phe
755 760 765
Gly Ser Ser Met Phe Gly Leu Ala Phe Thr Glu Val Phe Gly Arg Ser
770 775 780
Lys Asp Tyr Val Val Cys Arg Ser Asn His His Ala Cys Ile Gly Ser
785 790 795 800
Val Tyr Leu Ser Thr Gln Gln Ala Leu Cys Gly Ser Tyr Leu Phe Gly
805 810 815
Asp Ala Phe Ile Arg Ala Ser Tyr Gly Phe Gly Asn Gln His Met Lys
820 825 830
Thr Ser Tyr Thr Phe Ala Glu Glu Ser Asp Val Arg Trp Asp Asn Asn
835 840 845
Cys Leu Ala Gly Glu Ile Gly Ala Gly Leu Pro Ile Val Ile Thr Pro
850 855 860
Ser Lys Leu Tyr Leu Asn Glu Leu Arg Pro Phe Val Gln Ala Glu Phe
865 870 875 880
Ser Tyr Ala Asp His Glu Ser Phe Thr Glu Glu Gly Asp Gln Ala Arg
885 890 895
Ala Phe Lys Ser Gly His Leu Leu Asn Leu Ser Val Pro Val Gly Val
900 905 910
Lys Phe Asp Arg Cys Ser Ser Thr His Pro Asn Lys Tyr Ser Phe Met
915 920 925
Ala Ala Tyr Ile Cys Asp Ala Tyr Arg Thr Ile Ser Gly Thr Glu Thr
930 935 940
Thr Leu Leu Ser His Gln Glu Thr Trp Thr Thr Asp Ala Phe His Leu
945 950 955 960
Ala Arg His Gly Val Val Val Arg Gly Ser Met Tyr Ala Ser Leu Thr
965 970 975
Ser Asn Ile Glu Val Tyr Gly His Gly Arg Tyr Glu Tyr Arg Asp Ala
980 985 990
Ser Arg Gly Tyr Gly Leu Ser Ala Gly Ser Lys Val Arg Phe
995 1000 1005
<210>191
<211>977
<212>PRT
<213>Chlamydia
<400>191
Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu
1 5 10 15
Val Pro Ser Ser Asp Pro His His His His His His Gly Leu Ala Arg
20 25 30
Glu Val Pro Ser Arg Ile Phe Leu Met Pro Asn Ser Val Pro Asp Pro
35 40 45
Thr Lys Glu Ser Leu Ser Asn Lys Ile Ser Leu Thr Gly Asp Thr His
50 55 60
Asn Leu Thr Asn Cys Tyr Leu Asp Asn Leu Arg Tyr Ile Leu Ala Ile
65 70 75 80
Leu Gln Lys Thr Pro Asn Glu Gly Ala Ala Val Thr Ile Thr Asp Tyr
85 90 95
Leu Ser Phe Phe Asp Thr Gln Lys Glu Gly Ile Tyr Phe Ala Lys Asn
100 105 110
Leu Thr Pro Glu Ser Gly Gly Ala Ile Gly Tyr Ala Ser Pro Ash Ser
115 120 125
Pro Thr Val Glu Ile arg Asp Thr Ile Gly Pro Val Ile Phe Glu Asn
130 135 140
Asn Thr Cys Cys Arg Leu Phe Thr Trp Arg Asn Pro Tyr Ala Ala Asp
145 150 155 160
Lys Ile Arg Glu Gly Gly Ala Ile His Ala Gln Asn Leu Tyr Ile Asn
165 170 175
His Asn His Asp Val Val Gly Phe Met Lys Asn Phe Ser Tyr Val Gln
180 185 190
Gly Gly Ala Ile Ser Thr Ala Asn Thr Phe Val Val Ser Glu Asn Gln
195 200 205
Ser Cys Phe Leu Phe Met Asp Asn Ile Cys Ile Gln Thr Asn Thr Ala
210 215 220
Gly Lys Gly Gly Ala Ile Tyr Ala Gly Thr Ser Asn Ser Phe Glu Ser
225 230 235 240
Asn Asn Cys Asp Leu Phe Phe Ile Asn Asn Ala Cys Cys Ala Gly Gly
245 250 255
Ala Ile Phe Ser Pro Ile Cys Ser Leu Thr Gly Asn Arg Gly Asn Ile
260 265 270
Val Phe Tyr Asn Asn Arg Cys Phe Lys Asn Val Glu Thr Ala Ser Ser
275 280 285
Glu Ala Ser Asp Gly Gly Ala Ile Lys Val Thr Thr Arg Leu Asp Val
290 295 300
Thr Gly Asn Arg Gly Arg Ile Phe Phe Ser Asp Asn Ile Thr Lys Asn
305 310 315 320
Tyr Gly Gly Ala Ile Tyr Ala Pro Val Val Thr Leu Val Asp Asn Gly
325 330 335
Pro Thr Tyr Phe Ile Asn Asn Ile Ala Asn Asn Lys Gly Gly Ala Ile
340 345 350
Tyr Ile Asp Gly Thr Ser Asn Ser Lys Ile Ser Ala Asp Arg His Ala
355 360 365
Ile Ile Phe Asn Glu Asn Ile Val Thr Asn Val Thr Asn Ala Asn Gly
370 375 380
Thr Ser Thr Ser Ala Asn Pro Pro Arg Arg Asn Ala Ile Thr Val Ala
385 390 395 400
Ser Ser Ser Gly Glu Ile Leu Leu Gly Ala Gly Ser Ser Gln Asn Leu
405 410 415
Ile Phe Tyr Asp Pro Ile Glu Val Ser Asn Ala Gly Val Ser Val Ser
420 425 430
Phe Asn Lys Glu Ala Asp Gln Thr Gly Ser Val Val Phe Ser Gly Ala
435 440 445
Thr Val Asn Ser Ala Asp Phe His Gln Arg Ash Leu Gln Thr Lys Thr
450 455 460
Pro Ala Pro Leu Thr Leu Ser Asn Gly Phe Leu Cys Ile Glu Asp His
465 470 475 480
Ala Gln Leu Thr Val Asn Arg Phe Thr Gln Thr Gly Gly Val Val Ser
485 490 495
Leu Gly Asn Gly Ala Val Leu Ser Cys Tyr Lys Asn Gly Thr Gly Asp
500 505 510
Ser Ala Ser Asn Ala Ser Ile Thr Leu Lys His Ile Gly Leu Asn Leu
515 520 525
Ser Ser Ile Leu Lys Ser Gly Ala Glu Ile Pro Leu Leu Trp Val Glu
530 535 540
Pro Thr Asn Asn Ser Asn Asn Tyr Thr Ala Asp Thr Ala Ala Thr Phe
545 550 555 560
Ser Leu Ser Asp Val Lys Leu Ser Leu Ile Asp Asp Tyr Gly Asn Ser
565 570 575
Pro Tyr Glu Ser Thr Asp Leu Thr His Ala Leu Ser Ser Gln Pro Met
580 585 590
Leu Ser Ile Ser Glu Ala Ser Asp Asn Gln Leu Gln Ser Glu Asn Ile
595 600 605
Asp Phe Ser Gly Leu Asn Val Pro His Tyr Gly Trp Gln Gly Leu Trp
610 615 620
Thr Trp Gly Trp Ala Lys Thr Gln Asp Pro Glu Pro Ala Ser Ser Ala
625 630 635 640
Thr Ile Thr Asp Pro Gln Lys Ala Asn Arg Phe His Arg Thr Leu Leu
645 650 655
Leu Thr Trp Leu Pro Ala Gly Tyr Val Pro Ser Pro Lys His Arg Ser
660 665 670
Pro Leu Ile Ala Asn Thr Leu Trp Gly Asn Met Leu Leu Ala Thr Glu
675 680 685
Ser Leu Lys Asn Ser Ala Glu Leu Thr Pro Ser Gly His Pro Phe Trp
690 695 700
Gly Ile Thr Gly Gly Gly Leu Gly Met Met Val Tyr Gln Asp Pro Arg
705 710 715 720
Glu Asn His Pro Gly Phe His Met Arg Ser Ser Gly Tyr Ser Ala Gly
725 730 735
Met Ile Ala Gly Gln Thr His Thr Phe Ser Leu Lys Phe Ser Gln Thr
740 745 750
Tyr Thr Lys Leu Asn Glu Arg Tyr Ala Lys Asn Asn Val Ser Ser Lys
755 760 765
Asn Tyr Ser Cys Gln Gly Glu Met Leu Phe Ser Leu Gln Glu Gly Phe
770 775 780
Leu Leu Thr Lys Leu Val Gly Leu Tyr Ser Tyr Gly Asp His Asn Cys
785 790 795 800
His His Phe Tyr Thr Gln Gly Glu Asn Leu Thr Ser Gln Gly Thr Phe
805 810 815
Arg Ser Gln Thr Met Gly Gly Ala Val Phe Phe Asp Leu Pro Met Lys
820 825 830
Pro Phe Gly Ser Thr His Ile Leu Thr Ala Pro Phe Leu Gly Ala Leu
835 840 845
Gly Ile Tyr Ser Ser Leu Ser His Phe Thr Glu Val Gly Ala Tyr Pro
850 855 860
Arg Ser Phe Ser Thr Lys Thr Pro Leu Ile Asn Val Leu Val Pro Ile
865 870 875 880
Gly Val Lys Gly Ser Phe Met Asn Ala Thr His Arg Pro Gln Ala Trp
885 890 895
Thr Val Glu Leu Ala Tyr Gln Pro Val Leu Tyr Arg Gln Glu Pro Gly
900 905 910
Ile Ala Thr Gln Leu Leu Ala Ser Lys Gly Ile Trp Phe Gly Ser Gly
915 920 925
Ser Pro Ser Ser Arg His Ala Met Ser Tyr Lys Ile Ser Gln Gln Thr
930 935 940
Gln Pro Leu Ser Trp Leu Thr Leu His Phe Gln Tyr His Gly Phe Tyr
945 950 955 960
Ser Ser Ser Thr Phe Cys Asn Tyr Leu Asn Gly Glu Ile Ala Leu Arg
965 970 975
Phe
<210>192
<211>848
<212>PRT
<213>Chlamydia
<400>192
Met Ala Ser His His His His His His Gly Ala Ile Ser Cys Leu Arg
1 5 10 15
Gly Asp Val Val Ile Ser Gly Asn Lys Gly Arg Val Glu Phe Lys Asp
20 25 30
Asn Ile Ala Thr Arg Leu Tyr Val Glu Glu Thr Val Glu Lys Val Glu
35 40 45
Glu Val Glu Pro Ala Pro Glu Gln Lys Asp Asn Asn Glu Leu Ser Phe
50 55 60
Leu Gly Ser Val Glu Gln Ser Phe Ile Thr Ala Ala Asn Gln Ala Leu
65 70 75 80
Phe Ala Ser Glu Asp Gly Asp Leu Ser Pro Glu Ser Ser Ile Ser Ser
85 90 95
Glu Glu Leu Ala Lys Arg Arg Glu Cys Ala Gly Gly Ala Ile Phe Ala
100 105 110
Lys Arg Val Arg Ile Val Asp Asn Gln Glu Ala Val Val Phe Ser Asn
115 120 125
Asn Phe Ser Asp Ile Tyr Gly Gly Ala Ile Phe Thr Gly Ser Leu Arg
130 135 140
Glu Glu Asp Lys Leu Asp Gly Gln Ile Pro Glu Val Leu Ile Ser Gly
145 150 155 160
Asn Ala Gly Asp Val Val Phe Ser Gly Asn Ser Ser Lys Arg Asp Glu
165 170 175
His Leu Pro His Thr Gly Gly Gly Ala Ile Cys Thr Gln Asn Leu Thr
180 185 190
Ile Ser Gln Asn Thr Gly Asn Val Leu Phe Tyr Asn Asn Val Ala Cys
195 200 205
Ser Gly Gly Ala Val Arg Ile Glu Asp His Gly Asn Val Leu Leu Glu
210 215 220
Ala Phe Gly Gly Asp Ile Val Phe Lys Gly Asn Ser Ser Phe Arg Ala
225 230 235 240
Gln Gly Ser Asp Ala Ile Tyr Phe Ala Gly Lys Glu Ser His Ile Thr
245 250 255
Ala Leu Asn Ala Thr Glu Gly His Ala Ile Val Phe His Asp Ala Leu
260 265 270
Val Phe Glu Asn Leu Lys Glu Arg Lys Ser Ala Glu Val Leu Leu Ile
275 280 285
Asn Ser Arg Glu Asn Pro Gly Tyr Thr Gly Ser Ile Arg Phe Leu Glu
290 295 300
Ala Glu Ser Lys Val Pro Gln Cys Ile His Val Gln Gln Gly Ser Leu
305 310 315 320
Glu Leu Leu Asn Gly Ala Thr Leu Cys Ser Tyr Gly Phe Lys Gln Asp
325 330 335
Ala Gly Ala Lys Leu Val Leu Ala Ala Gly Ser Lys Leu Lys Ile Leu
340 345 350
Asp Ser Gly Thr Pro Val Gln Gly His Ala Ile Ser Lys Pro Glu Ala
355 360 365
Glu Ile Glu Ser Ser Ser Glu Pro Glu Gly Ala His Ser Leu Trp Ile
370 375 380
Ala Lys Asn Ala Gln Thr Thr Val Pro Met Val Asp Ile His Thr Ile
385 390 395 400
Ser Val Asp Leu Ala Ser Phe Ser Ser Ser Gln Gln Glu Gly Thr Val
405 410 415
Glu Ala Pro Gln Val Ile Val Pro Gly Gly Ser Tyr Val Arg Ser Gly
420 425 430
Glu Leu Asn Leu Glu Leu Val Asn Thr Thr Gly Thr Gly Tyr Glu Asn
435 440 445
His Ala Leu Leu Lys Asn Glu Ala Lys Val Pro Leu Met Ser Phe Val
450 455 460
Ala Ser Ser Asp Glu Ala Ser Ala Glu Ile Ser Asn Leu Ser Val Ser
465 470 475 480
Asp Leu Gln Ile His Val Ala Thr Pro Glu Ile Glu Glu Asp Thr Tyr
485 490 495
Gly His Met Gly Asp Trp Ser Glu Ala Lys Ile Gln Asp Gly Thr Leu
500 505 510
Val Ile Asn Trp Asn Pro Thr Gly Tyr Arg Leu Asp Pro Gln Lys Ala
515 520 525
Gly Ala Leu Val Phe Asn Ala Leu Trp Glu Glu Gly Ala Val Leu Ser
530 535 540
Ala Leu Lys Asn Ala Arg Phe Ala His Asn Leu Thr Ala Gln Arg Met
545 550 555 560
Glu Phe Asp Tyr Ser Thr Asn Val Trp Gly Phe Ala Phe Gly Gly Phe
565 570 575
Arg Thr Leu Ser Ala Glu Asn Leu Val Ala Ile Asp Gly Tyr Lys Gly
580 585 590
Ala Tyr Gly Gly Ala Ser Ala Gly Val Asp Ile Gln Leu Met Glu Asp
595 600 605
Phe Val Leu Gly Val Ser Gly Ala Ala Phe Leu Gly Lys Met Asp Ser
610 615 620
Gln Lys Phe Asp Ala Glu Val Ser Arg Lys Gly Val Val Gly Ser Val
625 630 635 640
Tyr Thr Gly Phe Leu Ala Gly Ser Trp Phe Phe Lys Gly Gln Tyr Ser
645 650 655
Leu Gly Glu Thr Gln Asn Asp Met Lys Thr Arg Tyr Gly Val Leu Gly
660 665 670
Glu Ser Ser Ala Ser Trp Thr Ser Arg Gly Val Leu Ala Asp Ala Leu
675 680 685
Val Glu Tyr Arg Ser Leu Val Gly Pro Val Arg Pro Thr Phe Tyr Ala
690 695 700
Leu His Phe Asn Pro Tyr Val Glu Val Ser Tyr Ala Ser Met Lys Phe
705 710 715 720
Pro Gly Phe Thr Glu Gln Gly Arg Glu Ala Arg Ser Phe Glu Asp Ala
725 730 735
Ser Leu Thr Asn Ile Thr Ile Pro Leu Gly Met Lys Phe Glu Leu Ala
740 745 750
Phe Ile Lys Gly Gln Phe Ser Glu Val Asn Ser Leu Gly Ile Ser Tyr
755 760 765
Ala Trp Glu Ala Tyr Arg Lys Val Glu Gly Gly Ala Val Gln Leu Leu
770 775 780
Glu Ala Gly Phe Asp Trp Glu Gly Ala Pro Met Asp Leu Pro Arg Gln
785 790 795 800
Glu Leu Arg Val Ala Leu Glu Asn Asn Thr Glu Trp Ser Ser Tyr Phe
805 810 815
Ser Thr Val Leu Gly Leu Thr Ala Phe Cys Gly Gly Phe Thr Ser Thr
820 825 830
Asp Ser Lys Leu Gly Tyr Glu Ala Asn Thr Gly Leu Arg Leu Ile Phe
835 840 845
<210>193
<211>778
<212>PRT
<213>Chlamydia
<400>193
Met His His His His His His Gly Leu Ala Ser Cys Val Asp Leu His
1 5 10 15
Ala Gly Gly Gln Ser Val Asn Glu Leu Val Tyr Val Gly Pro Gln Ala
20 25 30
Val Leu Leu Leu Asp Gln Ile Arg Asp Leu Phe Val Gly Ser Lys Asp
35 40 45
Ser Gln Ala Glu Gly Gln Tyr Arg Leu Ile Val Gly Asp Pro Ser Ser
50 55 60
Phe Gln Glu Lys Asp Ala Asp Thr Leu Pro Gly Lys Val Glu Gln Ser
65 70 75 80
Thr Leu Phe Ser Val Thr Asn Pro Val Val Phe Gln Gly Val Asp Gln
85 90 95
Gln Asp Gln Val Ser Ser Gln Gly Leu Ile Cys Ser Phe Thr Ser Ser
100 105 110
Asn Leu Asp Ser Pro Arg Asp Gly Glu Ser Phe Leu Gly Ile Ala Phe
115 120 125
Val Gly Asp Ser Ser Lys Ala Gly Ile Thr Leu Thr Asp Val Lys Ala
130 135 140
Ser Leu Ser Gly Ala Ala Leu Tyr Ser Thr Glu Asp Leu Ile Phe Glu
145 150 155 160
Lys Ile Lys Gly Gly Leu Glu Phe Ala Ser Cys Ser Ser Leu Glu Gln
165 170 175
Gly Gly Ala Cys Ala Ala Gln Ser Ile Leu Ile His Asp Cys Gln Gly
180 185 190
Leu Gln Val Lys His Cys Thr Thr Ala Val Asn Ala Glu Gly Ser Ser
195 200 205
Ala Asn Asp His Leu Gly Phe Gly Gly Gly Ala Phe Phe Val Thr Gly
210 215 220
Ser Leu Ser Gly Glu Lys Ser Leu Tyr Met Pro Ala Gly Asp Met Val
225 230 235 240
Val Ala Asn Cys Asp Gly Ala Ile Ser Phe Glu Gly Ash Ser Ala Asn
245 250 255
Phe Ala Asn Gly Gly Ala Ile Ala Ala Ser Gly Lys Val Leu Phe Val
260 265 270
Ala Asn Asp Lys Lys Thr Ser Phe Ile Glu Asn Arg Ala Leu Ser Gly
275 280 285
Gly Ala Ile Ala Ala Ser Ser Asp Ile Ala Phe Gln Asn Cys Ala Glu
290 295 300
Leu Val Phe Lys Gly Asn Cys Ala Ile Gly Thr Glu Asp Lys Gly Ser
305 310 315 320
Leu Gly Gly Gly Ala Ile Ser Ser Leu Gly Thr Val Leu Leu Gln Gly
325 330 335
Asn His Gly Ile Thr Cys Asp Lys Asn Glu Ser Ala Ser Gln Gly Gly
340 345 350
Ala Ile Phe Gly Lys Asn Cys Gln Ile Ser Asp Asn Glu Gly Pro Val
355 360 365
Val Phe Arg Asp Ser Thr Ala Cys Leu Gly Gly Gly Ala Ile Ala Ala
370 375 380
Gln Glu Ile Val Ser Ile Gln Asn Asn Gln Ala Gly Ile Ser Phe Glu
385 390 395 400
Gly Gly Lys Ala Ser Phe Gly Gly Gly Ile Ala Cys Gly Ser Phe Ser
405 410 415
Ser Ala Gly Gly Ala Ser Val Leu Gly Thr Ile Asp Ile Ser Lys Asn
420 425 430
Leu Gly Ala Ile Ser Phe Ser Arg Thr Leu Cys Thr Thr Ser Asp Leu
435 440 445
Gly Gln Met Glu Tyr Gln Gly Gly Gly Ala Leu Phe Gly Glu Asn Ile
450 455 460
Ser Leu Ser Glu Asn Ala Gly Val Leu Thr Phe Lys Asp Asn Ile Val
465 470 475 480
Lys Thr Phe Ala Ser Asn Gly Lys Ile Leu Gly Gly Gly Ala Ile Leu
485 490 495
Ala Thr Gly Lys Val Glu Ile Thr Asn Asn Ser Gly Gly Ile Ser Phe
500 505 510
Thr Gly Asn Ala Arg Ala Pro Gln Ala Leu Pro Thr Gln Glu Glu Phe
515 520 525
Pro Leu Phe Ser Lys Lys Glu Gly Arg Pro Leu Ser Ser Gly Tyr Ser
530 535 540
Gly Gly Gly Ala Ile Leu Gly Arg Glu Val Ala Ile Leu His Asn Ala
545 550 555 560
Ala Val Val Phe Glu Gln Asn Arg Leu Gln Cys Ser Glu Glu Glu Ala
565 570 575
Thr Leu Leu Gly Cys Cys Gly Gly Gly Ala Val His Gly Met Asp Ser
580 585 590
Thr Ser Ile Val Gly Asn Ser Ser Val Arg Phe Gly Asn Asn Tyr Ala
595 600 605
Met Gly Gln Gly Val Ser Gly Gly Ala Leu Leu Ser Lys Thr Val Gln
610 615 620
Leu Ala Gly Asn Gly Ser Val Asp Phe Ser Arg Asn Ile Ala Ser Leu
625 630 635 640
Gly Gly Gly Ala Leu Gln Ala Ser Glu Gly Asn Cys Glu Leu Val Asp
645 650 655
Asn Gly Tyr Val Leu Phe Arg Asp Asn Arg Gly Arg Val Tyr Gly Gly
660 665 670
Ala Ile Ser Cys Leu Arg Gly Asp Val Val Ile Ser Gly Asn Lys Gly
675 680 685
Arg Val Glu Phe Lys Asp Asn Ile Ala Thr Arg Leu Tyr Val Glu Glu
690 695 700
Thr Val Glu Lys Val Glu Glu Val Glu Pro Ala Pro Glu Gln Lys Asp
705 710 715 720
Asn Asn Glu Leu Ser Phe Leu Gly Ser Val Glu Gln Ser Phe Ile Thr
725 730 735
Ala Ala Asn Gln Ala Leu Phe Ala Ser Glu Asp Gly Asp Leu Ser Pro
740 745 750
Glu Ser Ser Ile Ser Ser Glu Glu Leu Ala Lys Arg Arg Glu Cys Ala
755 760 765
Gly Gly Ala Asp Ser Ser Arg Ser Gly Cys
770 775
<210>194
<211>948
<212>PRT
<213>Chlamydia
<400>194
Met Ala Ser Met His His His His His His Val Lys Ile Glu Asn Phe
1 5 10 15
Ser Gly Gln Gly Ile Phe Ser Gly Asn Lys Ala Ile Asp Asn Thr Thr
20 25 30
Glu Gly Ser Ser Ser Lys Ser Asn Val Leu Gly Gly Ala Val Tyr Ala
35 40 45
Lys Thr Leu Phe Asn Leu Asp Ser Gly Ser Ser Arg Arg Thr Val Thr
50 55 60
Phe Ser Gly Asn Thr Val Ser Ser Gln Ser Thr Thr Gly Gln Val Ala
65 70 75 80
Gly Gly Ala Ile Tyr Ser Pro Thr Val Thr Ile Ala Thr Pro Val Val
85 90 95
Phe Ser Lys Asn Ser Ala Thr Asn Asn Ala Asn Asn Ala Thr Asp Thr
100 105 110
Gln Arg Lys Asp Thr Phe Gly Gly Ala Ile Gly Ala Thr Ser Ala Val
115 120 125
Ser Leu Ser Gly Gly Ala His Phe Leu Glu Asn Val Ala Asp Leu Gly
130 135 140
Ser Ala Ile Gly Leu Val Pro Asp Thr Gln Asn Thr Glu Thr Val Lys
145 150 155 160
Leu Glu Ser Gly Ser Tyr Tyr Phe Glu Lys Asn Lys Ala Leu Lys Arg
165 170 175
Ala Thr Ile Tyr Ala Pro Val Val Ser Ile Lys Ala Tyr Thr Ala Thr
180 185 190
Phe Asn Gln Asn Arg Ser Leu Glu Glu Gly Ser Ala Ile Tyr Phe Thr
195 200 205
Lys Glu Ala Ser Ile Glu Ser Leu Gly Ser Val Leu Phe Thr Gly Asn
210 215 220
Leu Val Thr Pro Thr Leu Ser Thr Thr Thr Glu Gly Thr Pro Ala Thr
225 230 235 240
Thr Ser Gly Asp Val Thr Lys Tyr Gly Ala Ala Ile Phe Gly Gln Ile
245 250 255
Ala Ser Ser Asn Gly Ser Gln Thr Asp Asn Leu Pro Leu Lys Leu Ile
260 265 270
Ala Ser Gly Gly Asn Ile Cys Phe Arg Asn Asn Glu Tyr Arg Pro Thr
275 280 285
Ser Ser Asp Thr Gly Thr Ser Thr Phe Cys Ser Ile Ala Gly Asp Val
290 295 300
Lys Leu Thr Met Gln Ala Ala Lys Gly Lys Thr Ile Ser Phe Phe Asp
305 310 315 320
Ala Ile Arg Thr Ser Thr Lys Lys Thr Gly Thr Gln Ala Thr Ala Tyr
325 330 335
Asp Thr Leu Asp Ile Asn Lys Ser Glu Asp Ser Glu Thr Val Asn Ser
340 345 350
Ala Phe Thr Gly Thr Ile Leu Phe Ser Ser Glu Leu His Glu Asn Lys
355 360 365
Ser Tyr Ile Pro Gln Asn Val Val Leu His Ser Gly Ser Leu Val Leu
370 375 380
Lys Pro Asn Thr Glu Leu His Val Ile Ser Phe Glu Gln Lys Glu Gly
385 390 395 400
Ser Ser Leu Val Met Thr Pro Gly Ser Val Leu Ser Asn Gln Thr Val
405 410 415
Ala Asp Gly Ala Leu Val Ile Asn Asn Met Thr Ile Asp Leu Ser Ser
420 425 430
Val Glu Lys Asn Gly Ile Ala Glu Gly Asn Ile Phe Thr Pro Pro Glu
435 440 445
Leu Arg Ile Ile Asp Thr Thr Thr Ser Gly Ser Gly Gly Thr Pro Ser
450 455 460
Thr Asp Ser Glu Ser Asn Gln Asn Ser Asp Asp Thr Lys Glu Gln Asn
465 470 475 480
Asn Asn Asp Ala Ser Asn Gln Gly Glu Ser Ala Asn Gly Ser Ser Ser
485 490 495
Pro Ala Val Ala Ala Ala His Thr Ser Arg Thr Arg Asn Phe Ala Ala
500 505 510
Ala Ala Thr Ala Thr Pro Thr Thr Thr Pro Thr Ala Thr Thr Thr Thr
515 520 525
Ser Asn Gln Val Ile Leu Gly Gly Glu Ile Lys Leu Ile Asp Pro Asn
530 535 540
Gly Thr Phe Phe Gln Asn Pro Ala Leu Arg Ser Asp Gln Gln Ile Ser
545 550 555 560
Leu Leu Val Leu Pro Thr Asp Ser Ser Lys Met Gln Ala Gln Lys Ile
565 570 575
Val Leu Thr Gly Asp Ile Ala Pro Gln Lys Gly Tyr Thr Gly Thr Leu
580 585 590
Thr Leu Asp Pro Asp Gln Leu Gln Asn Gly Thr Ile Ser Ala Leu Trp
595 600 605
Lys Phe Asp Ser Tyr Arg Gln Trp Ala Tyr Val Pro Arg Asp Asn His
610 615 620
Phe Tyr Ala Asn Ser Ile Leu Gly Ser Gln Met Ser Met Val Thr Val
625 630 635 640
Lys Gln Gly Leu Leu Asn Asp Lys Met Asn Leu Ala Arg Phe Asp Glu
645 650 655
Val Ser Tyr Asn Asn Leu Trp Ile Ser Gly Leu Gly Thr Met Leu Ser
660 665 670
Gln Val Gly Thr Pro Thr Ser Glu Glu Phe Thr Tyr Tyr Ser Arg Gly
675 680 685
Ala Ser Val Ala Leu Asp Ala Lys Pro Ala His Asp Val Ile Val Gly
690 695 700
Ala Ala Phe Ser Lys Met Ile Gly Lys Thr Lys Ser Leu Lys Arg Glu
705 710 715 720
Asn Asn Tyr Thr His Lys Gly Ser Glu Tyr Ser Tyr Gln Ala Ser Val
725 730 735
Tyr Gly Gly Lys Pro Phe His Phe Val Ile Asn Lys Lys Thr Glu Lys
740 745 750
Ser Leu Pro Leu Leu Leu Gln Gly Val Ile Ser Tyr Gly Tyr Ile Lys
755 760 765
His Asp Thr Val Thr His Tyr Pro Thr Ile Arg Glu Arg Asn Gln Gly
770 775 780
Glu Trp Glu Asp Leu Gly Trp Leu Thr Ala Leu Arg Val Ser Ser Val
785 790 795 800
Leu Arg Thr Pro Ala Gln Gly Asp Thr Lys Arg Ile Thr Val Tyr Gly
805 810 815
Glu Leu Glu Tyr Ser Ser Ile Arg Gln Lys Gln Phe Thr Glu Thr Glu
820 825 830
Tyr Asp Pro Arg Tyr Phe Asp Asn Cys Thr Tyr Arg Asn Leu Ala Ile
835 840 845
Pro Met Gly Leu Ala Phe Glu Gly Glu Leu Ser Gly Asn Asp Ile Leu
850 855 860
Met Tyr Asn Arg Phe Ser Val Ala Tyr Met Pro Ser Ile Tyr Arg Asn
865 870 875 880
Ser Pro Thr Cys Lys Tyr Gln Val Leu Ser Ser Gly Glu Gly Gly Glu
885 890 895
Ile Ile Cys Gly Val Pro Thr Arg Asn Ser Ala Arg Gly Glu Tyr Ser
900 905 910
Thr Gln Leu Tyr Pro Gly Pro Leu Trp Thr Leu Tyr Gly Ser Tyr Thr
915 920 925
Ile Glu Ala Asp Ala His Thr Leu Ala His Met Met Asn Cys Gly Ala
930 935 940
Arg Met Thr Phe
945
<210>195
<211>821
<212>PRT
<213>Chlamydia
<400>195
Met His His His His His His Glu Ala Ser Ser Ile Gln Asp Gln Ile
1 5 10 15
Lys Ash Thr Asp Cys Asn Val Ser Lys Val Gly Tyr Ser Thr Ser Gln
20 25 30
Ala Phe Thr Asp Met Met Leu Ala Asp Asn Thr Glu Tyr Arg Ala Ala
35 40 45
Asp Ser Val Ser Phe Tyr Asp Phe Ser Thr Ser Ser Gly Leu Pro Arg
50 55 60
Lys His Leu Ser Ser Ser Ser Glu Ala Ser Pro Thr Thr Glu Gly Val
65 70 75 80
Ser Ser Ser Ser Ser Gly Glu Asn Thr Glu Asn Ser Gln Asp Ser Ala
85 90 95
Pro Ser Ser Gly Glu Thr Asp Lys Lys Thr Glu Glu Glu Leu Asp Asn
100 105 110
Gly Gly Ile Ile Tyr Ala Arg Glu Lys Leu Thr Ile Ser Glu Ser Gln
115 120 125
Asp Ser Leu Ser Asn Pro Ser Ile Glu Leu His Asp Asn Ser Phe Phe
130 135 140
Phe Gly Glu Gly Glu Val Ile Phe Asp His Arg Val Ala Leu Lys Asn
145 150 155 160
Gly Gly Ala Ile Tyr Gly Glu Lys Glu Val Val Phe Glu Asn Ile Lys
165 170 175
Ser Leu Leu Val Glu Val Asn Ile Ser Val Glu Lys Gly Gly Ser Val
180 185 190
Tyr Ala Lys Glu Arg Val Ser Leu Glu Asn Val Thr Glu Ala Thr Phe
195 200 205
Ser Ser Asn Gly Gly Glu Gln Gly Gly Gly Gly Ile Tyr Ser Glu Gln
210 215 220
Asp Met Leu Ile Ser Asp Cys Asn Asn Val His Phe Gln Gly Asn Ala
225 230 235 240
Ala Gly Ala Thr Ala Val Lys Gln Cys Leu Asp Glu Glu Met Ile Val
245 250 255
Leu Leu Thr Glu Cys Val Asp Ser Leu Ser Glu Asp Thr Leu Asp Ser
260 265 270
Thr Pro Glu Thr Glu Gln Thr Lys Ser Asn Gly Asn Gln Asp Gly Ser
275 280 285
Ser Glu Thr Lys Asp Thr Gln Val Ser Glu Ser Pro Glu Ser Thr Pro
290 295 300
Ser Pro Asp Asp Val Leu Gly Lys Gly Gly Gly Ile Tyr Thr Glu Lys
305 310 315 320
Ser Leu Thr Ile Thr Gly Ile Thr Gly Thr Ile Asp Phe Val Ser Asn
325 330 335
Ile Ala Thr Asp Ser Gly Ala Gly Val Phe Thr Lys Glu Asn Leu Ser
340 345 350
Cys Thr Asn Thr Asn Ser Leu Gln Phe Leu Lys Asn Ser Ala Gly Gln
355 360 365
His Gly Gly Gly Ala Tyr Val Thr Gln Thr Met Ser Val Thr Asn Thr
370 375 380
Thr Ser Glu Ser Ile Thr Thr Pro Pro Leu Val Gly Glu Val Ile Phe
385 390 395 400
Ser Glu Asn Thr Ala Lys Gly His Gly Gly Gly Ile Cys Thr Asn Lys
405 410 415
Leu Ser Leu Ser Asn Leu Lys Thr Val Thr Leu Thr Lys Asn Ser Ala
420 425 430
Lys Glu Ser Gly Gly Ala Ile Phe Thr Asp Leu Ala Ser Ile Pro Thr
435 440 445
Thr Asp Thr Pro Glu Ser Ser Thr Pro Ser Ser Ser Ser Pro Ala Ser
450 455 460
Thr Pro Glu Val Val Ala Ser Ala Lys Ile Asn Arg Phe Phe Ala Ser
465 470 475 480
Thr Ala Glu Pro Ala Ala Pro Ser Leu Thr Glu Ala Glu Ser Asp Gln
485 490 495
Thr Asp Gln Thr Glu Thr Ser Asp Thr Asn Ser Asp Ile Asp Val Ser
500 505 510
Ile Glu Asn Ile Leu Asn Val Ala Ile Asn Gln Asn Thr Ser Ala Lys
515 520 525
Lys Gly Gly Ala Ile Tyr Gly Lys Lys Ala Lys Leu Ser Arg Ile Asn
530 535 540
Asn Leu Glu Leu Ser Gly Asn Ser Ser Gln Asp Val Gly Gly Gly Leu
545 550 555 560
Cys Leu Thr Glu Ser Val Glu Phe Asp Ala Ile Gly Ser Leu Leu Ser
565 570 575
His Tyr Asn Ser Ala Ala Lys Glu Gly Gly Val Ile His Ser Lys Thr
580 585 590
Val Thr Leu Ser Asn Leu Lys Ser Thr Phe Thr Phe Ala Asp Asn Thr
595 600 605
Val Lys Ala Ile Val Glu Ser Thr Pro Glu Ala Pro Glu Glu Ile Pro
610 615 620
Pro Val Glu Gly Glu Glu Ser Thr Ala Thr Glu Asn Pro Asn Ser Asn
625 630 635 640
Thr Glu Gly Ser Ser Ala Asn Thr Asn Leu Glu Gly Ser Gln Gly Asp
645 650 655
Thr Ala Asp Thr Gly Thr Gly Val Val Asn Asn Glu Ser Gln Asp Thr
660 665 670
Ser Asp Thr Gly Asn Ala Glu Ser Gly Glu Gln Leu Gln Asp Ser Thr
675 680 685
Gln Ser Asn Glu Glu Asn Thr Leu Pro Asn Ser Ser Ile Asp Gln Ser
690 695 700
Asn Glu Asn Thr Asp Glu Ser Ser Asp Ser His Thr Glu Glu Ile Thr
705 710 715 720
Asp Glu Ser Val Ser Ser Ser Ser Lys Ser Gly Ser Ser Thr Pro Gln
725 730 735
Asp Gly Gly Ala Ala Ser Ser Gly Ala Pro Ser Gly Asp Gln Ser Ile
740 745 750
Ser Ala Asn Ala Cys Leu Ala Lys Ser Tyr Ala Ala Ser Thr Asp Ser
755 760 765
Ser Pro Val Ser Asn Ser Ser Gly Ser Asp Val Thr Ala Ser Ser Asp
770 775 780
Asn Pro Asp Ser Ser Ser Ser Gly Asp Ser Ala Gly Asp Ser Glu Gly
785 790 795 800
Pro Thr Glu Pro Glu Ala Gly Ser Thr Thr Glu Thr Pro Thr Leu Ile
805 810 815
Gly Gly Gly Ala Ile
820
<210>196
<211>525
<212>PRT
<213>Chlamydia
<400>196
Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu
1 5 10 15
Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala
20 25 30
Ile Ala Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala
35 40 45
Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val
50 55 60
Gln Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr
65 70 75 80
Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr
85 90 95
Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser
100 105 110
Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr
115 120 125
Leu Ala Glu Gly Pro Pro Ala Glu Phe Pro Leu Val Pro Arg Gly Ser
130 135 140
Pro Leu Pro Val Gly Asn Pro Ala Glu Pro Ser Leu Leu Ile Asp Gly
145 150 155 160
Thr Met Trp Glu Gly Ala Ser Gly Asp Pro Cys Asp Pro Cys Ala Thr
165 170 175
Trp Cys Asp Ala Ile Ser Ile Arg Ala Gly Tyr Tyr Gly Asp Tyr Val
180 185 190
Phe Asp Arg Val Leu Lys Val Asp Val Asn Lys Thr Phe Ser Gly Met
195 200 205
Ala Ala Thr Pro Thr Gln Ala Ile Gly Asn Ala Ser Asn Thr Asn Gln
210 215 220
Pro Glu Ala Asn Gly Arg Pro Asn Ile Ala Tyr Gly Arg His Met Gln
225 230 235 240
Asp Ala Glu Trp Phe Ser Asn Ala Ala Phe Leu Ala Leu Asn Ile Trp
245 250 255
Asp Arg Phe Asp Ile Phe Cys Thr Leu Gly Ala Ser Asn Gly Tyr Phe
260 265 270
Lys Ala Ser Ser Ala Ala Phe Asn Leu Val Gly Leu Ile Gly Phe Ser
275 280 285
Ala Ala Ser Ser Ile Ser Thr Asp Leu Pro Met Gln Leu Pro Asn Val
290 295 300
Gly Ile Thr Gln Gly Val Val Glu Phe Tyr Thr Asp Thr Ser Phe Ser
305 310 315 320
Trp Ser Val Gly Ala Arg Gly Ala Leu Trp Glu Cys Gly Cys Ala Thr
325 330 335
Leu Gly Ala Glu Phe Gln Tyr Ala Gln Ser Asn Pro Lys Ile Glu Met
340 345 350
Leu Asn Val Thr Ser Ser Pro Ala Gln Phe Val Ile His Lys Pro Arg
355 360 365
Gly Tyr Lys Gly Ala Ser Ser Asn Phe Pro Leu Pro Ile Thr Ala Gly
370 375 380
Thr Thr Glu Ala Thr Asp Thr Lys Ser Ala Thr Ile Lys Tyr His Glu
385 390 395 400
Trp Gln Val Gly Leu Ala Leu Ser Tyr Arg Leu Asn Met Leu Val Pro
405 410 415
Tyr Ile Gly Val Asn Trp Ser Arg Ala Thr Phe Asp Ala Asp Thr Ile
420 425 430
Arg Ile Ala Gln Pro Lys Leu Lys Ser Glu Ile Leu Asn Ile Thr Thr
435 440 445
Trp Asn Pro Ser Leu Ile Gly Ser Thr Thr Ala Leu Pro Asn Asn Ser
450 455 460
Gly Lys Asp Val Leu Ser Asp Val Leu Gln Ile Ala Ser Ile Gln Ile
465 470 475 480
Asn Lys Met Lys Ser Arg Lys Ala Cys Gly Val Ala Val Gly Ala Thr
485 490 495
Leu Ile Asp Ala Asp Lys Trp Ser Ile Thr Gly Glu Ala Arg Leu Ile
500 505 510
Asn Glu Arg Ala Ala His Met Asn Ala Gln Phe Arg Phe
515 520 525
<210>197
<211>43
<212>DNA
<213>Chlamydia
<400>197
gataggcgcg ccgcaatcat gaaatttatg tcagctactg ctg 43
<210>198
<211>34
<212>DNA
<213>Chlamydia
<400>198
cagaacgcgt ttagaatgtc atacgagcac cgca 34
<210>199
<211>6
<212>DNA
<213>Chlamydia
<400>199
gcaatc 6
<210>200
<211>34
<212>DNA
<213>Chlamydia
<400>200
tgcaatcatg agttcgcaga aagatataaa aagc 34
<210>201
<211>38
<212>DNA
<213>Chlamydia
<400>201
cagagctagc ttaaaagatc aatcgcaatc cagtattc 38
<210>202
<211>5
<212>DNA
<213>Chlamydia
<400>202
caatc 5
<210>203
<211>31
<212>DNA
<213>Chlamydia
<400>203
tgcaatcatg aaaaaagcgt ttttcttttt c 31
<210>204
<211>31
<212>DNA
<213>Chlamydia
<400>204
cagaacgcgt ctagaatcgc agagcaattt c 31
<210>205
<211>30
<212>DNA
<213>Chlamydia
<400>205
gtgcaatcat gattcctcaa ggaatttacg 30
<210>206
<211>31
<212>DNA
<213>Chlamydia
<400>206
cagaacgcgt ttagaaccgg actttacttc c 31
<210>207
<211>50
<212>DNA
<213>Chlamydia
<400>207
cagacatatg catcaccatc accatcacga ggcgagctcg atccaagatc 50
<210>208
<211>40
<212>DNA
<213>Chlamydia
<400>208
cagaggtacc tcagatagca ctctctccta ttaaagtagg 40
<210>209
<211>55
<212>DNA
<213>Chlamydia
<400>209
cagagctagc atgcatcacc atcaccatca cgttaagatt gagaacttct ctggc 55
<210>210
<211>35
<212>DNA
<213>Chlamydia
<400>210
cagaggtacc ttagaatgtc atacgagcac cgcag 35
<210>211
<211>36
<212>DNA
<213>Chlamydia
<400>211
cagacatatg catcaccatc accatcacgg gttagc 36
<210>212
<211>35
<212>DNA
<213>Chlamydia
<400>212
cagaggtacc tcagctcctc cagcacactc tcttc 35
<210>213
<211>51
<212>DNA
<213>Chlamydia
<400>213
cagagctagc catcaccatc accatcacgg tgctatttct tgcttacgtg g 51
<210>214
<211>38
<212>DNA
<213>Chlamydia
<400>214
cagaggtact taaaagatca atcgcaatcc agtattcg 38
<210>215
<211>48
<212>DNA
<213>Chlamydia
<400>215
cagaggatcc acatcaccat caccatcacg gactagctag agaggttc 48
<210>216
<211>31
<212>DNA
<213>Chlamydia
<400>216
cagagaattc ctagaatcgc agagcaattt c 31
<210>217
<211>7
<212>DNA
<213>Chlamydia
<400>217
tgcaatc 7
<210>218
<211>22
<212>PRT
<213>Chlamydia
<400>218
Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Ser Ser Leu
1 5 10 15
Val Pro Ser Ser Asp Pro
20
<210>219
<211>51
<212>DNA
<213>Chlamydia
<400>219
cagaggtacc gcatcaccat caccatcaca tgattcctca aggaatttac g 51
<210>220
<211>33
<212>DNA
<213>Chlamydia
<400>220
cagagcggcc gcttagaacc ggactttact tcc 33
<210>221
<211>24
<212>PRT
<213>Chlamydia
<400>221
Met Ala Ser Met Thr Gly Gly Gln Gln Asn Gly Arg Asp Ser Ser Leu
1 5 10 15
Val Pro His His His His His His
20
<210>222
<211>46
<212>DNA
<213>Chlamydia
<400>222
cagagctagc catcaccatc accatcacct ctttggccag gatccc 46
<210>223
<211>30
<212>DNA
<213>Chlamydia
<400>223
cagaactagt ctagaacctg taagtggtcc 30
<210>224
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>224
Met Ser Gln Lys Asn Lys Asn Ser Ala Phe Met His Pro Val Asn Ile
1 5 10 15
Ser Thr Asp Leu
20
<210>225
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>225
Lys Asn Ser Ala Phe Met His Pro Val Asn Ile Ser Thr Asp Leu Ala
1 5 10 15
Val Ile Val Gly
20
<210>226
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>226
His Pro Val Asn Ile Ser Thr Asp Leu Ala Val Ile Val Gly Lys Gly
1 5 10 15
Pro Met Pro Arg
20
<210>227
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>227
Ser Thr Asp Leu Ala Val Ile Val Gly Lys Gly Pro Met Pro Arg Thr
1 5 10 15
Glu Ile Val Lys
20
<210>228
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>228
Val Ile Val Gly Lys Gly Pro Met Pro Arg Thr Glu Ile Val Lys Lys
1 5 10 15
Val Trp Glu Tyr
20
<210>229
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>229
Gly Pro Met Pro Arg Thr Glu Ile Val Lys Lys Val Trp Glu Tyr Ile
1 5 10 15
Lys Lys His Asn
20
<210>230
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>230
Ile Lys Lys His Asn Cys Gln Asp Gln Lys Asn Lys Arg Asn Ile Leu
1 5 10 15
Pro Asp Ala Asn
20
<210>231
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>231
Asn Cys Gln Asp Gln Lys Asn Lys Arg Asn Ile Leu Pro Asp Ala Asn
1 5 10 15
Leu Ala Lys Val
20
<210>232
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>232
Lys Asn Lys Arg Asn Ile Leu Pro Asp Ala Asn Leu Ala Lys Val Phe
1 5 10 15
Gly Ser Ser Asp
20
<210>233
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>233
Ile Leu Pro Asp Ala Asn Leu Ala Lys Val Phe Gly Ser Ser Asp Pro
1 5 10 15
Ile Asp Met Phe
20
<210>234
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>234
Asn Leu Ala Lys Val Phe Gly Ser Ser Asp Pro Ile Asp Met Phe Gln
1 5 10 15
Met Thr Lys Ala
20
<210>235
<211>22
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>235
Phe Gly Ser Ser Asp Pro Ile Asp Met Phe Gln Met Thr Lys Ala Leu
1 5 10 15
Ser Lys His Ile Val Lys
20
<210>236
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>236
Val Glu Ile Thr Gln Ala Val Pro Lys Tyr Ala Thr Val Gly Ser Pro
l 5 10 15
Tyr Pro Val Glu
20
<210>237
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>237
Ala Val Pro Lys Tyr Ala Thr Val Gly Ser Pro Tyr Pro Val Glu Ile
1 5 10 15
Thr Ala Thr Gly
20
<210>238
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>238
Ala Thr Val Gly Ser Pro Tyr Pro Val Glu Ile Thr Ala Thr Gly Lys
1 5 10 15
Arg Asp Cys Val
20
<210>239
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>239
Pro Tyr Pro Val Glu Ile Thr Ala Thr Gly Lys Arg Asp Cys Val Asp
1 5 10 15
Val Ile Ile Thr
20
<210>240
<211>21
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>240
Ile Thr Ala Thr Gly Lys Arg Asp Cys Val Asp Val Ile Ile Thr Gln
1 5 10 15
Gln Leu Pro Cys Glu
20
<210>241
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>241
Lys Arg Asp Cys Val Asp Val Ile Ile Thr Gln Gln Leu Pro Cys Glu
1 5 10 15
Ala Glu Phe Val
20
<210>242
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400> 242
Asp Val Ile Ile Thr Gln Gln Leu Pro Cys Glu Ala Glu Phe Val Arg
1 5 10 15
Ser Asp Pro Ala
20
<210>243
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>243
Thr Gln Gln Leu Pro Cys Glu Ala Glu Phe Val Arg Ser Asp Pro Ala
1 5 10 15
Thr Thr Pro Thr
20
<210>244
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>244
Cys Glu Ala Glu Phe Val Arg Ser Asp Pro Ala Thr Thr Pro Thr Ala
1 5 10 15
Asp Gly Lys Leu
20
<210>245
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>245
Val Arg Ser Asp Pro Ala Thr Thr Pro Thr Ala Asp Gly Lys Leu Val
1 5 10 15
Trp Lys Ile Asp
20
<210>246
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>246
Ala Thr Thr Pro Thr Ala Asp Gly Lys Leu Val Trp Lys Ile Asp Arg
1 5 10 15
Leu Gly Gln Gly
20
<210>247
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>247
Ala Asp Gly Lys Leu Val Trp Lys Ile Asp Arg Leu Gly Gln Gly Glu
1 5 10 15
Lys Ser Lys Ile
20
<210>248
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>248
Val Trp Lys Ile Asp Arg Leu Gly Gln Gly Glu Lys Ser Lys Ile Thr
1 5 10 15
Val Trp Val Lys
20
<210>249
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>249
Arg Leu Gly Gln Gly Glu Lys Ser Lys Ile Thr Val Trp Val Lys Pro
1 5 10 15
Leu Lys Glu Gly
20
<210>250
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>250
Gly Glu Lys Ser Lys Ile Thr Val Trp Val Lys Pro Leu Lys Glu Gly
1 5 10 15
Cys Cys Phe Thr
20
<210>251
<211>16
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>251
Gly Glu Lys Ser Lys Ile Thr Val Trp Val Lys Pro Leu Lys Glu Gly
1 5 10 15
<210>252
<211>12
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>252
Lys Ile Thr Val Trp Val Lys Pro Leu Lys Glu Gly
1 5 10
<210>253
<211>16
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>253
Gly Asp Lys Cys Lys Ile Thr Val Trp Val Lys Pro Leu Lys Glu Gly
1 5 10 15
<210>254
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>254
Thr Glu Tyr Pro Leu Leu Ala Asp Pro Ser Phe LysIle Ser Glu Ala
1 5 10 15
Phe Gly Val Leu
20
<210>255
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>255
Leu Ala Asp Pro Ser Phe Lys Ile Ser Glu Ala Phe Gly Val Leu Asn
1 5 10 15
Pro Glu Gly Ser
20
<210>256
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>256
Phe Lys Ile Ser Glu Ala Phe Gly Val Leu Asn Pro Glu Gly Ser Leu
1 5 10 15
Ala Leu arg Ala
20
<210>257
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>257
Ala Phe Gly Val Leu Asn Pro Glu Gly Ser Leu Ala Leu Arg Ala Thr
1 5 10 15
Phe Leu Ile Asp
20
<210>258
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>258
Asn Pro Glu Gly Ser Leu Ala Leu Arg Ala Thr Phe Leu Ile Asp Lys
1 5 10 15
His Gly Val Ile
20
<210>259
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>259
Leu Ala Leu Arg Ala Thr Phe Leu Ile Asp Lys His Gly Val Ile Arg
1 5 10 15
His Ala Val Ile
20
<210>260
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>260
Thr Phe Leu Ile Asp Lys His Gly Val Ile Arg His Ala Val Ile Asn
1 5 10 15
Asp Leu Pro Leu
20
<210>261
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>261
Lys His Gly Val Ile Arg His Ala Val Ile Asn Asp Leu Pro Leu Gly
1 5 10 15
Arg Ser Ile Asp
20
<210>262
<211>20
<212>PRT
<213>Artificial Sequence
<220>
<223>Made in a lab
<400>262
Arg His Ala Val Ile Asn Asp Leu Pro Leu Gly Arg Ser Ile Asp Glu
1 5 10 15
Glu Leu Arg Ile
20
<210>263
<211>897
<212>DNA
<213>Chlamydia
<220>
<221>misc_feature
<222>(1)...(897)
<223>n=A,T,C or G
<400>263
atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca acaataaaat ggcaagggta gtaaataaga cgaagggagt ggataagact 120
attaaggttg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240
actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctctcacat gaaagctgct agtcagaaaa cgcaagaaggggatgagggg 360
ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480
aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600
gcgnaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660
gaagtgccgg gagaggaaaa tgcttgcgag aagaaagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840
ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897
<210>264
<211>298
<212>PRT
<213>Chlamydia
<220>
<221>VARIANT
<222>(1)...(298)
<223>Xaa=Any Amino Acid
<400>264
Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Val Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
100 105 110
Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
180 185 190
Val Gly Ala Gly Leu Ala Ile Ser Ala Xaa Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Pro Gly
210 215 220
Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
275 280 285
Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
290 295
<210>265
<211>897
<212>DNA
<213>Chlamydia
<220>
<221>misc_feature
<222>(1)...(897)
<223>n=A,T,C or G
<400>265
atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60
acacagccca acaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120
attaaggttg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180
gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240
actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300
caaagcttct tctctcacat gaaagctgct agtcagaaaa cgcaagaagg ggatgagggg 360
ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatc 420
atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480
aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540
agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600
gcgnaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660
gaagtgccgg gagaggaaaa tgcttgcgag aagaaagtcg ctggagagaa agccaagacg 720
ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780
gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840
ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897
<210>266
<211>298
<212>PRT
<213>Chlamydia
<220>
<221>VARIANT
<222>(1)...(298)
<223>Xaa=Any Amino Acid
<400>266
Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu
1 5 10 15
Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn
20 25 30
Lys Thr Lys Gly Met Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala
35 40 45
Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser
50 55 60
Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg
65 70 75 80
Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr
85 90 95
Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln
100 105 110
Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser
115 120 125
His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile
130 135 140
Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn
145 150 155 160
Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met
165 170 175
Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val
180 185 190
Val Gly Ala Gly Leu Ala Ile Ser Ala Xaa Arg Ala Asp Cys Glu Ala
195 200 205
Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Pro Gly
210 215 220
Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr
225 230 235 240
Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu
245 250 255
Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met
260 265 270
Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile
275 280 285
Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala
290 295
<210>267
<211>680
<212>DNA
<213>Chlamydia
<400>267
tctatatcca tattgatagg aaaaaacgtc gcagaaagat tttagctatg acgtttatcc 60
gagctttagg atattcaaca gatgcagata ttattgaaga gttcttttct gtagaggagc 120
gttccttacg ttcagagaag gattttgtcg cgttagttgg taaagtttta gctgataacg 180
tagttgatgc ggattcttca ttagtttacg ggaaagctgg agagaagcta agtactgcta 240
tgctaaaacg catcttagat acgggagtcc aatctttgaa gattgctgtt ggcgcagatg 300
aaaatcaccc aattattaag atgctcgcaa aagatcctac ggattcttac gaagctgctc 360
ttaaagattt ttatcgcaga ttacgaccag gagagcctgc aactttagct aatgctcgat 420
ccacaattat gcgtttattc ttcgatgcta aacgttataa tttaggccgc gttggacgtt 480
ataaattaaa taaaaaatta ggcttcccat tagacgacga aacattatct caagtgactt 540
tgagaaaaga agatgttatc ggcgcgttga aatatttgat tcgtttgcga atgggcgatg 600
agaagacatc tatcgatgat attgaccatt tggcaaaccg acgagttcgc tctgttggag 660
aactaattca gaatcactgt 680
<210>268
<211>359
<212>DNA
<213>Chlamydia
<400>268
cttatgttct ggagaatgtt gcaacaacat attaatcgaa ccagctcctc ctagtaacat 60
agaaaccaag cccttttgag aaaaaacctg tacttcgcat cctttagcca tttgttgaat 120
agctcctaac aaagagctaa ttttttcctc ttccttgttt ttctgaggcg ctgtggactc 180
taaatatagc aagtgctctt ggaacacctc atcaacaatc gcttgtccta gattaggtat 240
agagactgtc tctccatcaa ttaaatggag tttcaaagta atatcccctt ccgtccctcc 300
atcacaagac tctatgaaag ctatctgatt ccatcgagca gaaatgtatg gggaaatac 359
<210>269
<211>124
<212>DNA
<213>Chlamydia
<400>269
gatcgaatca attgagggag ctcattaaca agaatagctg cagtttcttt gcgttcttct 60
ggaataacaa gaaataggta atcggtacca ttgatagaac gaacacgaca aatcgcagaa 120
ggtt 124
<210>270
<211>219
<212>DNA
<213>Chlamydia
<400>270
gatcctgttg ggcctagtaa taatacgttg gatttcccat aactcacttg tttatcctgc 60
ataagagcac ggatacgctt atagtggtta tagacggcaa ccgaaatcgt ttttttcgcg 120
cgctcttgtc caatgacata agagtcgatg tggcgtttga tttctttagg ggttaacact 180
ctcagacttg ttggagagct tgtggaagat gttgcgatc 219
<210>271
<211>511
<212>DNA
<213>Chlamydia
<220>
<221>misc_feature
<222>(1)...(511)
<223>n=A,T,C or G
<400>271
ggatccgaat tcggcacgag gagaaaatat aggaggttcc akcatcggaa gatctaatag 60
acaaagaggt tttggcatag atggctcctc cttgtacgtt caacgatgat tgggagggat 120
tgttatcgat agcttggttc ccagagaact gacaagtccc gctacattga gagaatgtaa 180
cctgttctcc atagatagct cctcctacta cacctgaata agttggtgtt gctggagatg 240
atggtgcggc tgctgcggct gcttgtaggg aagcagcagc tgcagcaggt gctgaagctg 300
ttgttgcgac tcctgtggat gaggagtttg ctttgttgtt cgagaaagag aagcctgatt 360
tcagattaga aatatttaca gttttagcat gtaagcctcc accttctttc ccaacaaggt 420
tctctgttac agataaggag actagangca tctagtttta aagatttttt acagcagata 480
cctccaccta tctctgtagc ggagttctca g 511
<210>272
<211>598
<212>DNA
<213>Chlamydia
<400>272
ctcttcctct cctcaatcta gttctggagc aactacagtc tccgactcag gagactctag 60
ctctggctca aactcggata cctcaaaaac agttccagtc acagctaaag gcggtgggct 120
ttatactgat aagaatcttt cgattactaa catcacagga attatcgaaa ttgcaaataa 180
caaagcgaca gatgttggag gtggtgctta cgtaaaattc cgggttaatt gtaaaaactc 240
tcaccgtcta caatttttga aaaactcttc cgataaacaa ggtggaggaa tctacggaga 300
agacaacatc accctatcta atttgacagg gaagactcta ttccaagaga atactgccaa 360
aaaagagggc ggtggactct tcataaaagg tacagataaa gctcttacaa tgacaggact 420
ggatagtttc tgtttaatta ataacacatc agaaaaacat ggtggtggga gcctttgtta 480
ccaaagaaat ctctcagact tacacctctt gatgtggaaa caattccagg aatcacgcct 540
gtacatggtg aaacagtcat tactggcaat aaatctacag gaggtaatgg tggagggc 598
<210>273
<211>126
<212>DNA
<213>Chlamydia
<400>273
ggatccgaat tcggcacgag atgagcctta tagtttaaca aaagcttctc acattccttc 60
gatagctttt tattagccgt ttttagcatc ctaatgagat ctcctcgttc gtaacaaata 120
cgagag 126
<210>274
<211>264
<212>DNA
<213>Chlamydia
<400>274
ggatccgaat tcggcacgag ctcttttaaa tcttaattac aaaaagacaa attaattcaa 60
tttttcaaaa aagaatttaa acattaattg ttgtaaaaaa acaatattta ttctaaaata 120
ataaccatag ttacggggga atctctttca tggtttattt tagagctcat caacctaggc 180
atacgcctaa aacatttcct ttgaaagttc accattcgtt ctccgataag catcctcaaa 240
ttgctaaagc tatgtggatt acgg 264
<210>275
<211>359
<212>DNA
<213>Chlamydia
<400>275
ggatccgaat tcggcacgag ataaaacctg aaccacaaca aagatctaaa acttcttgat 60
tttcagctgc aaattctttt agataaatat caaccatttc ttcagtttca tatcttggaa 120
ttaaaacttg ttctcttaaa ttaattctag tatttaagta ttcaacatag cccattatta 180
attgaattgg ataattttgc cttaataatt cacattcttt ttcagtaatt ttaggttcta 240
aaccgtaccg ctttttttct aaaattaatg tttcttcatt attcatttta taagccactt 300
tcctttattt tttgattttg ttcttctgtt agtaatgctt caataatagt taataattt 359
<210>276
<211>357
<212>DNA
<213>Chlamydia
<400>276
aaaacaattg atataatttt ttttttcata acttccagac tcctttctag aaaagtcttt 60
atgggtagta gtgactctaa cgttttttat tattaagacg atccccggag atccttttaa 120
tgatgaaaac ggaaacatcc tttcgccaga aactttagca ctattaaaga atcgttacgg 180
gttagataag cctttattca cccagtatct tatctatttg aaatgtctgc taacactaga 240
tttcggggaa tctcttatct acaaagatcg aaatctcagc attattgctg ccgctcttcc 300
atcttccgct attcttggac ttgaaagctt gtgtttactc gtgccgaatt cggatcc 357
<210>277
<211>505
<212>DNA
<213>Chlamydia
<400>277
ggatccgaat tcggcacgag ctcgtgccga ttgcttgctt cagtcacccc atcggtatag 60
agcactaaaa gagactcctc ttcaagaacg agagtgtaag cagggtgagg aggaacttca 120
ggtaaaaatc ctaaggccat accaggatgc gacaggaaag agatatctcc attaggagct 180
cggagacacg ctgggttgtg gccacaagaa tagtattcta gttctcgtgt tgcgtaatga 240
taacaataaa tgcatagtgt tacaaacatc ccagattcag ctgtctgttg atagaagaga 300
gcagctgttt gttgaacggc ttcttgaata gaggagagct cactcaaaaa ggtatgtaac 360
atgtttttca ggaataagga gtaggcgcac gcattgactc ctttcccgga agcatcagca 420
acgattagaa agagtttagc ttggggacct tcgcctataa caaagatatc aaagaaatct 480
cctcctaccg taactgcagg aatat 505
<210>278
<211>407
<212>DNA
<213>Chlamydia
<400>278
ggatccgaat tcggcacgag aactactgag caaattgggt atccaacttc ctctttacga 60
aagaaaaaca gaaggcattc tccataccaa gatttgttgc atcgacaata aaactccaat 120
ctttggctct gctaactgga gcggtgctgg tatgattaaa aactttgaag acctattcat 180
ccttcgccca attacagaga cacagcttca ggcctttatg gacgtctggt ctcttctaga 240
aacaaatagc tcctatctgt ccccagagag cgtgcttacg gcccctactc cttcaagtag 300
acctactcaa caagatacag attctgatga cgaacaaccg agtaccagcc agcaagctat 360
ccgtatgaga aaataggatt agggaaacaa aacgacagca aaccaca 407
<210>279
<211>351
<212>DNA
<213>Chlamydia
<400>279
ctcgtgccgc ttacaggagg cttgtatcct ttaaaataga gtttttctta tgaccccatg 60
tggcgatagg ccgggtctag cgccgatagt agaaatatcg gttggttttt gtccttgagg 120
ggatcgtata ctttttcaaa gtatggtccc cgtatcgatt atctggaggc tcttatgtct 180
ttttttcata ctagaaaata taagcttatc ctcagaggac tcttgtgttt agcaggctgt 240
ttcttaatga acagctgttc ctctagtcga ggaaatcaac ccgctgatga gagcatctat 300
gtcttgtcta tgaatcgcat gatttgtgat tctcgtgccg aattcggatc c 351
<210>280
<211>522
<212>DNA
<213>Chlamydia
<400>280
ggatccgaat tcggcacgag cagaggaaaa aggcgatact cctcttgaag atcgtttcac 60
agaagatctt tccgaagtct ctggagaaga ttttcgagga ttgaaaaatt cgttcgatga 120
tgattcttct tctgacgaaa ttctcgatgc gctcacaagt aaattttctg atcccacaat 180
aaaggatcta gctcttgatt atctaattca aatagctccc tctgatggga aacttaagtc 240
cgctctcatt caggcaaagc atcaactgat gagccagaat cctcaggcga ttgttggagg 300
acgcaatgtt ctgttagctt cagaaacctt tgcttccaga gcaaatacat ctccttcatc 360
gcttcgctcc ttatatttcc aagtaacctc atccccctct aattgcgcta atttacatca 420
aatgcttgct tcttactcgc catcagagaa aaccgctgtt atggagtttc tagtgaatgg 480
catggtagca gatttaaaat cggagggccc ttccattcct cc 522
<210>281
<211>577
<212>DNA
<213>Chlamydia
<400>281
ggatccgaat tcggcacgag atgcttctat tacaattggt ttggatgcgg aaaaagctta 60
ccagcttatt ctagaaaagt tgggagatca aattcttggt ggaattgctg atactattgt 120
tgatagtaca gtccaagata ttttagacaa aatcacaaca gacccttctc taggtttgtt 180
gaaagctttt aacaactttc caatcactaa taaaattcaa tgcaacgggt tattcactcc 240
caggaacatt gaaactttat taggaggaac tgaaatagga aaattcacag tcacacccaa 300
aagctctggg agcatgttct tagtctcagc agatattatt gcatcaagaa tggaaggcgg 360
cgttgttcta gctttggtac gagaaggtga ttctaagccc tacgcgatta gttatggata 420
ctcatcaggc gttcctaatt tatgtagtct aagaaccaga attattaata caggattgac 480
tccgacaacg tattcattac gtgtaggcgg tttagaaagc ggtgtggtat gggttaatgc 540
cctttctaat ggcaatgata ttttaggaat aacaaat 577
<210>282
<211>607
<212>DNA
<213>Chlamydia
<400>282
actmatcttc cccgggctcg agtgcggccg caagcttgtc gacggagctc gatacaaaaa 60
tgtgtgcgtg tgaaccgctt cttcaaaagc ttgtcttaaa agatattgtc tcgcttccgg 120
attagttaca tgtttaaaaa ttgctagaac aatattattc ccaaccaagc tctctgcggt 180
gctgaaaaaa cctaaattca aaagaatgac tcgccgctca tcttcagaaa gacgatccga 240
cttccataat tcgatgtctt tccccatggg gatctctgta gggagccagt tatttgcgca 300
gccattcaaa taatgttccc aagcccattt gtacttaata ggaacaagtt ggttgacatc 360
gacctggttg cagttcacta gacgcttgct atttagatta acgcgtttct gttttccatc 420
taaaatatct gcttgcataa gaaccgttaa ttttattgtt aatttatatg attaattact 480
gacatgcttc acacccttct tccaaagaac agacaggtgc tttcttcgct ctttcaacaa 540
taattcctgc cgaagcagac ttattcttca tccaacgagg ctgaattcct ctcttattaa 600
tatctac 607
<210>283
<211>1077
<212>DNA
<213>Chlamydia
<400>283
ggatccgaat tcggcacgag aagttaacga tgacgatttg ttcctttggt agagaaggag 60
caatcgaaac taaatgtgcg agagcatgtg aagactccaa tgcaggaata atcccctcat 120
ttctagtaag caggaaaaaa gctcgtaacg cctcttcatc ggtggctaat gtataaaagg 180
ctcgtcctga ctcatgcatt tcggcatgat ctggcccaac tgaaggataa tctaatccag 240
cggaaatgga gtgagtttgt aatacttgtc catcgtcatc ttgaagaaga tacgaataaa 300
atccgtggaa tactccaggt cgccctgttg caaaacgtgc tgcatgtttt cctgaagaaa 360
tgcccagtcc tcccccttcc actccaatta attggacttt tggattcggg ataaaatgat 420
ggaaaaatcc aatagcgttg gagccacctc cgatacatgc aatcagaata tcaggatctc 480
ttcctgcaac tgcatggatt tgctctttca cttcagcgct tataacagac tgaaaaaatc 540
gaacgatatc gggataaggt aaaggtccta aggccgatcc taagcaatag tgagtaaatg 600
agtgtgttgt tgcccaatct tgtagagctt gattaactgc atctttgagt ccacaagatc 660
cttttgttac agaaacgact tcagcaccta aaaagcgcat tttctctaca tttggtttct 720
gtcgttccac atcttttgct cccatgtata ctacacaatc taatcctaga taagcacacg 780
ctgttgctgt tgctactcca tgttgtcccg cacctgtttc agctacaaca cgtgttttcc 840
caagatattt agcaagcaaa cactgaccaa gagcattatt cagtttatgt gctcctgtat 900
gcaaaagatc ttcgcgttta agaaatactc tagggccatc aatagctcga gcaaaattct 960
taacttcagt cagaggagtt tgtctccccg catagttttt caaaatacaa tctagttcag 1020
ataaaaaact ttgctgagtt ttgagaatct cccattccgc ttttagattc tgtatag 1077
<210>284
<211>407
<212>DNA
<213>Chlamydia
<400>284
ggatccgaat tcggcacgag aactactgag caaattgggt atccaacttc ctctttacga 60
aagaaaaaca gaaggcattc tccataccaa gatttgttgc atcgacaata aaactccaat 120
ctttggctct gctaactgga gcggtgctgg tatgattaaa aactttgaag acctattcat 180
ccttcgccca attacagaga cacagcttca ggcctttatg gacgtctggt ctcttctaga 240
aacaaatagc tcctatctgt ccccagagag cgtgcttacg gcccctactc cttcaagtag 300
acctactcaa caagatacag attctgatga cgaacaaccg agtaccagcc agcaagctat 360
ccgtatgaga aaataggatt agggaaacaa aacgacagca aaccaca 407
<210>285
<211>802
<212>DNA
<213>Chlamydia
<400>285
ggatccgaat tcggcacgag ttagcttaat gtctttgtca tctctaccta catttgcagc 60
taattctaca ggcacaattg gaatcgttaa tttacgtcgc tgcctagaag agtctgctct 120
tgggaaaaaa gaatctgctg aattcgaaaa gatgaaaaac caattctcta acagcatggg 180
gaagatggag gaagaactgt cttctatcta ttccaagctc caagacgacgattacatgga 240
aggtctatcc gagaccgcag ctgccgaatt aagaaaaaaa ttcgaagatc tatctgcaga 300
atacaacaca gctcaagggc agtattacca aatattaaac caaagtaatc tcaagcgcat 360
gcaaaagatt atggaagaag tgaaaaaagc ttctgaaact gtgcgtattc aagaaggctt 420
gtcagtcctt cttaacgaag atattgtcttatctatcgat agttcggcag ataaaaccga 480
tgctgttatt aaagttcttg atgattcttt tcaaaataat taacatgcga agctagccga 540
ggagtgccgt atgtctcaat ccacttattc tcttgaacaa ttagctgatt ttttgaaagt 600
cgagtttcaa ggaaatggag ctactcttct ttccggagtt gaagagatcg aggaagcaaa 660
aacggcacac atcacattct tagataatga aaaatatgct aaacatttaa aatcatcgga 720
agctggcgct atcatcatat ctcgaacaca gtttcaaaaa tatcgagact tgaataaaaa 780
ctttcttatc acttctgagt ct 802
<210>286
<211>588
<212>DNA
<213>Chlamydia
<400>286
ggatccgaat tcggcacgag gcaatattta ctcccaacat tacggttcca aataagcgat 60
aaggtcttct aataaggaag ttaatgtaag aggctttttt attgcttttc gtaaggtagt 120
attgcaaccg cacgcgattg aatgatacgc aagccatttc catcatggaa aagaaccctt 180
ggacaaaaat acaaaggagg ttcactccta accagaaaaa gggagagtta gtttccatgg 240
gttttcctta tatacacccg tttcacacaa ttaggagccg cgtctagtat ttggaataca 300
aattgtcccc aagcgaattt tgttcctgtt tcagggattt ctcctaattg ttctgtcagc 360
catccgccta tggtaacgca attagctgta gtaggaagat caactccaaa caggtcatag 420
aaatcagaaa gctcataggt gcctgcagca ataacaacat tcttgtctga gtgagcgaat 480
tgtttaaaag atgggcgatt atgagctacc tcatcagaga ctattttaaa tagatcattt 540
tgggtaatca atccttctat agacccatat tcatcaatga taatctcg 588
<210>287
<211>489
<212>DNA
<213>Chlamydia
<220>
<221>misc_feature
<222>(1)...(489)
<223>n=A,T,C or G
<400>287
agtgcctatt gttttgcagg ctttgtctga tgatagcgat accgtacgtg agattgctgt 60
acaagtagct gttatgtatg gttctagttg cttactgcgc gccgtgggcg atttagcgaa 120
aaatgattct tctattcaag tacgcatcac tgcttatcgt gctgcagccg tgttggagat 180
acaagatctt gtgcctcatt tacgagttgt agtccaaaat acacaattag atggaacgga 240
aagaagagaa gcttggagat ctttatgtgt tcttactcgg cctcatagtg gtgtattaac 300
tggcatagat caagctttaa tgacctgtga gatgttaaag gaatatcctg aaaagtgtac 360
ggaagaacag attcgtacat tattggctgc agatcatcca gaagtgcagg tagctacttt 420
acagatcatt ctgagaggag gtagagtatt ccggtcatct tctataatgg aatcggttct 480
cgtgccgnt 489
<210>288
<211>191
<212>DNA
<213>Chlamydia
<400>288
ggatccgaat tcaggatatg ctgttgggtt atcaataaaa agggttttgc cattttttaa 60
gacgactttg tagataacgc taggagctgt agcaataata tcgagatcaa attctctaga 120
gattctctca aagatgattt ctaagtgcag cagtcctaaa aatccacagc ggaacccaaa 180
tccgagagag t 191
<210>289
<211>515
<212>DNA
<213>Chlamydia
<400>289
ggatccgaat tcggcacgag gagcgacgtg aaatagtgga atcttcccgt attcttatta 60
cttctgcgtt gccttacgca aatggtcctt tgcattttgg acatattacc ggtgcttatt 120
tgcctgcaga tgtttatgcg cgttttcaga gactacaagg caaagaggtt ttgtatattt 180
gtggttctga tgaatacgga atcgcaatta cccttaatgc agagttggca ggcatggggt 240
atcaagaata tgtcgacatg tatcataagc ttcataaaga taccttcaag aaattgggaa 300
tttctgtaga tttcttttcc agaactacga acgcttatca tcctgctatt gtgcaagatt 360
tctatcgaaa cttgcaggaa cgcggactgg tagagaatca ggtgaccgaa cagctgtatt 420
ctgaggaaga agggaagttt ttagcggacc gttatgttgt aggtacttgt cccaagtgtg 480
ggtttgatcg agctcgagga gatgagtgtc agcag 515
<210>290
<211>522
<212>DNA
<213>Chlamydia
<400>290
ggatccgaat tcggcacgag ggaggaatgg aagggccctc cgattktama tctgctacca 60
tgccattcac tagaaactcc ataacagcgg ttttctctga tggcgagtaa gaagcaagca 120
tttgatgtaa attagcgcaa ttagaggggg atgaggttac ttggaaatat aaggagcgaa 180
gcgatgaagg agatgtattt gctctggaag caaaggtttc tgaagctaac agaacattgc 240
gtcctccaac aatcgcctga ggattctggc tcatcagttg atgctttgcc tgaatgagag 300
cggacttaag tttcccatca gagggagcta tttgaattag ataatcaaga gctagatcct 360
ttattgtggg atcagaaaat ttacttgtga gcgcatcgag aatttcgtca gaagaagaat 420
catcatcgaa cgaatttttc aatcctcgaa aatcttctcc agagacttcg gaaagatctt 480
ctgtgaaacg atcttcaaga ggagtatcgc ctttttccyc tg 522
<210>291
<211>1002
<212>DNA
<213>Chlamydia
<400>291
atggcgacta acgcaattag atcggcagga agtgcagcaa gtaagatgct gctgccagtt 60
gccaaagaac cagcggctgt cagctccttt gctcagaaag ggatttattg tattcaacaa 120
ttttttacaa accctgggaa taagttagca aagtttgtag gggcaacaaa aagtttagat 180
aaatgcttta agctaagtaa ggcggtttct gactgtgtcg taggatcgct ggaagaggcg 240
ggatgcacag gggacgcatt gacctccgcg agaaacgccc agggtatgtt aaaaacaact 300
cgagaagttg ttgccttagc taatgtgctc aatggagctg ttccatctat cgttaactcg 360
actcagaggt gttaccaata cacacgtcaa gccttcgagt taggaagcaa gacaaaagaa 420
agaaaaacgc ctggggagta tagtaaaatg ctattaactc gaggtgatta cctattggca 480
gcttccaggg aagcttgtac ggcagtcggt gcaacgactt actcagcgac attcggtgtt 540
ttacgtccgt taatgttaat caataaactc acagcaaaac cattcttaga caaagcgact 600
gtaggcaatt ttggcacggc tgttgctgga attatgacca ttaatcatat ggcaggagtt 660
gctggtgctg ttggcggaat cgcattagaa caaaagctgt tcaaacgtgc gaaggaatcc 720
ctatacaatg agagatgtgc cttagaaaac caacaatctc agttgagtgg ggacgtgatt 780
ctaagcgcgg aaagggcatt acgtaaagaa cacgttgcta ctctaaaaag aaatgtttta 840
actcttcttg aaaaagcttt agagttggta gtggatggag tcaaactcat tcctttaccg 900
attacagtgg cttgctccgc tgcaatttct ggagccttga cggcagcatc cgcaggaatt 960
ggcttatata gcatatggca gaaaacaaag tctggcaaat aa 1002
<210>292
<211>333
<212>PRT
<213>Chlamydia
<400>292
Met Ala Thr Asn Ala Ile Arg Ser Ala Gly Ser Ala Ala Ser Lys Met
1 5 10 15
Leu Leu Pro Val Ala Lys Glu Pro Ala Ala Val Ser Ser Phe Ala Gln
20 25 30
Lys Gly Ile Tyr Cys Ile Gln Gln Phe Phe Thr Asn Pro Gly Asn Lys
35 0 45
Leu Ala Lys Phe Val Gly Ala Thr Lys Ser Leu Asp Lys Cys Phe Lys
50 55 60
Leu Ser Lys Ala Val Ser Asp Cys Val Val Gly Ser Leu Glu Glu Ala
65 70 75 80
Gly Cys Thr Gly Asp Ala Leu Thr Ser Ala Arg Asn Ala Gln Gly Met
85 90 95
Leu Lys Thr Thr Arg Glu Val Val Ala Leu Ala Asn Val Leu Asn Gly
100 105 110
Ala Val Pro Ser Ile Val Asn Ser Thr Gln Arg Cys Tyr Gln Tyr Thr
115 120 125
Arg Gln Ala Phe Glu Leu Gly Ser Lys Thr Lys Glu Arg Lys Thr Pro
130 135 140
Gly Glu Tyr Ser Lys Met Leu Leu Thr Arg Gly Asp Tyr Leu Leu Ala
145 150 155 160
Ala Ser Arg Glu Ala Cys Thr Ala Val Gly Ala Thr Thr Tyr Ser Ala
165 170 175
Thr Phe Gly Val Leu Arg Pro Leu Met Leu Ile Asn Lys Leu Thr Ala
180 185 190
Lys Pro Phe Leu Asp Lys Ala Thr Val Gly Asn Phe Gly Thr Ala Val
195 200 205
Ala Gly Ile Met Thr Ile Asn His Met Ala Gly Val Ala Gly Ala Val
210 215 220
Gly Gly Ile Ala Leu Glu Gln Lys Leu Phe Lys Arg Ala Lys Glu Ser
225 230 235 240
Leu Tyr Asn Glu Arg Cys Ala Leu Glu Asn Gln Gln Ser Gln Leu Ser
245 250 255
Gly Asp Val Ile Leu Ser Ala Glu Arg Ala Leu Arg Lys Glu His Val
260 265 270
Ala Thr Leu Lys Arg Asn Val Leu Thr Leu Leu Glu Lys Ala Leu Glu
275 280 285
Leu Val Val Asp Gly Val Lys Leu Ile Pro Leu Pro Ile Thr Val Ala
290 295 300
Cys Ser Ala Ala Ile Ser Gly Ala Leu Thr Ala Ala Ser Ala Gly Ile
305 310 315 320
Gly Leu Tyr Ser Ile Trp Gln Lys Thr Lys Ser Gly Lys
325 330
<210>293
<211>7
<212>DNA
<213>Chlamydia
<400>293
tgcaatc 7
<210>294
<211>196
<212>PRT
<213>Chlamydia
<400>294
Thr Met Gly Ser Leu Val Gly Arg Gln Ala Pro Asp Phe Ser Gly Lys
5 10 15
Ala Val Val Cys Gly Glu Glu Lys Glu Ile Ser Leu Ala Asp Phe Arg
20 25 30
Gly Lys Tyr Val Val Leu Phe Phe Tyr Pro Lys Asp Phe Thr Tyr Val
35 40 45
Cys Pro Thr Glu Leu His Ala Phe Gln Asp Arg Leu Val Asp Phe Glu
50 55 60
Glu His Gly Ala Val Val Leu Gly Cys Ser Val Asp Asp Ile Glu Thr
65 70 75 80
His Ser Arg Trp Leu Thr Val Ala Arg Asp Ala Gly Gly Ile Glu Gly
85 90 95
Thr Glu Tyr Pro Leu Leu Ala Asp Pro Ser Phe Lys Ile Ser Glu Ala
100 105 110
Phe Gly Val Leu Asn Pro Glu Gly Ser Leu Ala Leu Arg Ala Thr Phe
115 120 125
Leu Ile Asp Lys His Gly Val Ile Arg His Ala Val Ile Asn Asp Leu
130 135 140
Pro Leu Gly Arg Ser Ile Asp Glu Glu Leu Arg Ile Leu Asp Ser Leu
145 150 155 160
Ile Phe Phe Glu Asn His Gly Met Val Cys Pro Ala Asn Trp Arg Ser
165 170 175
Gly Glu Arg Gly Met Val Pro Ser Glu Glu Gly Leu Lys Glu Tyr Phe
180 185 190
Gln Thr Met Asp
195
<210>295
<211>181
<212>PRT
<213>Chlamydia
<400>295
Lys Gly Gly Lys Met Ser Thr Thr Ile Ser Gly Asp Ala Ser Ser Leu
5 10 15
Pro Leu Pro Thr Ala Ser Cys Val Glu Thr Lys Ser Thr Ser Ser Ser
20 25 30
Thr Lys Gly Ash Thr Cys Ser Lys Ile Leu Asp Ile Ala Leu Ala Ile
35 40 45
Val Gly Ala Leu Val Val Val Ala Gly Val Leu Ala Leu Val Leu Cys
50 55 60
Ala Ser Asn Val Ile Phe Thr Val Ile Gly Ile Pro Ala Leu Ile Ile
65 70 75 80
Gly Ser Ala Cys Val Gly Ala Gly Ile Ser Arg Leu Met Tyr Arg Ser
85 90 95
Ser Tyr Ala Ser Leu Glu Ala Lys Asn Val Leu Ala Glu Gln Arg Leu
100 105 110
Arg Asn Leu Ser Glu Glu Lys Asp Ala Leu Ala Ser Val Ser Phe Ile
115 120 125
Asn Lys Met Phe Leu Arg Gly Leu Thr Asp Asp Leu Gln Ala Leu Glu
130 135 140
Ala Lys Val Met Glu Phe Glu Ile Asp Cys Leu Asp Arg Leu Glu Lys
145 150 155 160
Asn Glu Gln Ala Leu Leu Ser Asp Val Arg Leu Val Leu Ser Ser Tyr
165 170 175
Thr Arg Trp Leu Asp
180
<210>296
<211>124
<212>PRT
<213>Chlamydia
<400>296
Ile Tyr Glu Val Met Asn Met Asp Leu Glu Thr Arg Arg Ser Phe Ala
5 10 15
Val Gln Gln Gly His Tyr Gln Asp Pro Arg Ala Ser Asp Tyr Asp Leu
20 25 30
Pro Arg Ala Ser Asp Tyr Asp Leu Pro Arg Ser Pro Tyr Pro Thr Pro
35 40 45
Pro Leu Pro Ser Arg Tyr Gln Leu Gln Asn Met Asp Val Glu Ala Gly
50 55 60
Phe Arg Glu Ala Val Tyr Ala Ser Phe Val Ala Gly Met Tyr Asn Tyr
65 70 75 80
Val Val Thr Gln Pro Gln Glu Arg Ile Pro Asn Ser Gln Gln Val Glu
85 90 95
Gly Ile Leu Arg Asp Met Leu Thr Asn Gly Ser Gln Thr Phe Ser Asn
100 105 110
Leu Met Gln Arg Trp Asp Arg Glu Val Asp Arg Glu
115 120
<210>297
<211>488
<212>PRT
<213>Chlamydia
<400>297
Lys Gly Ser Leu Pro Ile Leu Gly Pro Phe Leu Asn Gly Lys Met Gly
5 10 15
Phe Trp Arg Thr Ser Ile Met Lys Met Asn Arg Ile Trp Leu Leu Leu
20 25 30
Leu Thr Phe Ser Ser Ala Ile His Ser Pro Val Arg Gly Glu Ser Leu
35 40 45
Val Cys Lys Asn Ala Leu Gln Asp Leu Ser Phe Leu Glu His Leu Leu
50 55 60
Gln Val Lys Tyr Ala Pro Lys Thr Trp Lys Glu Gln Tyr Leu Gly Trp
65 70 75 80
Asp Leu Val Gln Ser Ser Val Ser Ala Gln Gln Lys Leu Arg Thr Gln
85 90 95
Glu Asn Pro Ser Thr Ser Phe Cys Gln Gln Val Leu Ala Asp Phe Ile
100 105 110
Gly Gly Leu Asn Asp Phe His Ala Gly Val Thr Phe Phe Ala Ile Glu
115 120 125
Ser Ala Tyr Leu Pro Tyr Thr Val Gln Lys Ser Ser Asp Gly Arg Phe
130 135 140
Tyr Phe Val Asp Ile Met Thr Phe Ser Ser Glu Ile Arg Val Gly Asp
145 150 155 160
Glu Leu Leu Glu Val Asp Gly Ala Pro Val Gln Asp Val Leu Ala Thr
165 170 175
Leu Tyr Gly Ser Asn His Lys Gly Thr Ala Ala Glu Glu Ser Ala Ala
180 185 190
Leu Arg Thr Leu Phe Ser Arg Met Ala Ser Leu Gly His Lys Val Pro
195 200 205
Ser Gly Arg Thr Thr Leu Lys Ile Arg Arg Pro Phe Gly Thr Thr Arg
210 215 220
Glu Val Arg Val Lys Trp Arg Tyr Val Pro Glu Gly Val Gly Asp Leu
225 230 235 240
Ala Thr Ile Ala Pro Ser Ile Arg Ala Pro Gln Leu Gln Lys Ser Met
245 250 255
Arg Ser Phe Phe Pro Lys Lys Asp Asp Ala Phe His Arg Ser Ser Ser
260 265 270
Leu Phe Tyr Ser Pro Met Val Pro His Phe Trp Ala Glu Leu Arg Asn
275 280 285
His Tyr Ala Thr Ser Gly Leu Lys Ser Gly Tyr Asn Ile Gly Ser Thr
290 295 300
Asp Gly Phe Leu Pro Val Ile Gly Pro Val Ile Trp Glu Ser Glu Gly
305 310 315 320
Leu Phe Arg Ala Tyr Ile Ser Ser Val Thr Asp Gly Asp Gly Lys Ser
325 330 335
His Lys Val Gly Phe Leu Arg Ile Pro Thr Tyr Ser Trp Gln Asp Met
340 345 350
Glu Asp Phe Asp Pro Ser Gly Pro Pro Pro Trp Glu Glu Phe Ala Lys
355 360 365
Ile Ile Gln Val Phe Ser Ser Asn Thr Glu Ala Leu Ile Ile Asp Gln
370 375 380
Thr Asn Asn Pro Gly Gly Ser Val Leu Tyr Leu Tyr Ala Leu Leu Ser
385 390 395 400
Met Leu Thr Asp Arg Pro Leu Glu Leu Pro Lys His Arg Met Ile Leu
405 410 415
Thr Gln Asp Glu Val Val Asp Ala Leu Asp Trp Leu Thr Leu Leu Glu
420 425 430
Asn Val Asp Thr Asn Val Glu Ser Arg Leu Ala Leu G1y Asp Asn Met
435 440 445
Glu Gly Tyr Thr Val Asp Leu Gln Val Ala Glu Tyr Leu Lys Ser Phe
450 455 460
Gly Arg Gln Val Leu Asn Cys Trp Ser Lys Gly Asp Ile Glu Leu Ser
465 470 475 480
Thr Pro Ile Pro Leu Phe Gly Phe
485
<210>298
<211>140
<212>PRT
<213>Chlamydia
<400>298
Arg Ile Asp Ile Ser Ser Val Thr Phe Phe Ile Gly Ile Leu Leu Ala
5 10 15
Val Asn Ala Leu Thr Tyr Ser His Val Leu Arg Asp Leu Ser Val Ser
20 25 30
Met Asp Ala Leu Phe Ser Arg Asn Thr Leu Ala Val Leu Leu Gly Leu
35 40 45
Val Ser Ser Val Leu Asp Asn Val Pro Leu Val Ala Ala Thr Ile Gly
50 55 60
Met Tyr Asp Leu Pro Met Asn Asp Pro Leu Trp Lys Leu Ile Ala Tyr
65 70 75 80
Thr Ala Gly Thr Gly Gly Ser Ile Leu Ile Ile Gly Ser Ala Ala Gly
85 90 95
Val Ala Tyr Met Gly Met Glu Lys Val Ser Phe Gly Trp Tyr Val Lys
100 105 110
His Ala Ser Trp Ile Ala Leu Ala Ser Tyr Phe Gly Gly Leu Ala Val
115 120 125
Tyr Phe Leu Met Glu Asn Cys Val Asn Leu Phe Val
130 135 140
<210>299
<211>361
<212>PRT
<213>Chlamydia
<400>299
His Gln Glu Ile Ala Asp Ser Pro Leu Val Lys Lys Ala Glu Glu Gln
5 10 15
Ile Asn Gln Ala Gln Gln Asp Ile Gln Thr Ile Thr Pro Ser Gly Leu
20 25 30
Asp Ile Pro Ile Val Gly Pro Ser Gly Ser Ala Ala Ser Ala Gly Ser
35 40 45
Ala Ala Gly Ala Leu Lys Ser Ser Asn Asn Ser Gly Arg Ile Ser Leu
50 55 60
Leu Leu Asp Asp Val Asp Asn Glu Met Ala Ala Ile Ala Met Gln Gly
65 70 75 80
Phe Arg Ser Met Ile Glu Gln Phe Asn Val Asn Asn Pro Ala Thr Ala
85 90 95
Lys Glu Leu Gln Ala Met Glu Ala Gln Leu Thr Ala Met Ser Asp Gln
100 105 110
Leu Val Gly Ala Asp Gly Glu Leu Pro Ala Glu Ile Gln Ala Ile Lys
115 120 125
Asp Ala Leu Ala Gln Ala Leu Lys Gln Pro Ser Ala Asp Gly Leu Ala
130 135 140
Thr Ala Met Gly Gln Val Ala Phe Ala Ala Ala Lys Val Gly Gly Gly
145 150 155 160
Ser Ala Gly Thr Ala Gly Thr Val Gln Met Asn Val Lys Gln Leu Tyr
165 170 175
Lys Thr Ala Phe Ser Ser Thr Ser Ser Ser Ser Tyr Ala Ala Ala Leu
180 185 190
Ser Asp Gly Tyr Ser Ala Tyr Lys Thr Leu Asn Ser Leu Tyr Ser Glu
195 200 205
Ser Arg Ser Gly Val Gln Ser Ala Ile Ser Gln Thr Ala Asn Pro Ala
210 215 220
Leu Ser Arg Ser Val Ser Arg Ser Gly Ile Glu Ser Gln Gly Arg Ser
225 230 235 240
Ala Asp Ala Ser Gln Arg Ala Ala Glu Thr Ile Val Arg Asp Ser Gln
245 250 255
Thr Leu Gly Asp Val Tyr Ser Arg Leu Gln Val Leu Asp Ser Leu Met
260 265 270
Ser Thr Ile Val Ser Asn Pro Gln Ala Asn Gln Glu Glu Ile Met Gln
275 280 285
Lys Leu Thr Ala Ser Ile Ser Lys Ala Pro Gln Phe Gly Tyr Pro Ala
290 295 300
Val Gln Asn Ser Val Asp Ser Leu Gln Lys Phe Ala Ala Gln Leu Glu
305 310 315 320
Arg Glu Phe Val Asp Gly Glu Arg Ser Leu Ala Glu Ser Gln Glu Asn
325 330 335
Ala Phe Arg Lys Gln Pro Ala Phe Ile Gln Gln Val Leu Val Asn Ile
340 345 350
Ala Ser Leu Phe Ser Gly Tyr Leu Ser
355 360
<210>300
<211>207
<212>PRT
<213>Chlamydia
<400>300
Ser Ser Lys Ile Val Ser Leu Cys Glu Gly Ala Val Ala Asp Ala Arg
5 10 15
Met Cys Lys Ala Glu Leu Ile Lys Lys Glu Ala Asp Ala Tyr Leu Phe
20 25 30
Cys Glu Lys Ser Gly Ile Tyr Leu Thr Lys Lys Glu Gly Ile Leu Ile
35 40 45
Pro Ser Ala Gly Ile Asp Glu Ser Asn Thr Asp Gln Pro Phe Val Leu
50 55 60
Tyr Pro Lys Asp Ile Leu Gly Ser Cys Asn Arg Ile Gly Glu Trp Leu
65 70 75 80
Arg Asn Tyr Phe Arg Val Lys Glu Leu Gly Val Ile Ile Thr Asp Ser
85 90 95
His Thr Thr Pro Met Arg Arg Gly Val Leu Gly Ile Gly Leu Cys Trp
100 105 110
Tyr Gly Phe Ser Pro Leu His Asn Tyr Ile Gly Ser Leu Asp Cys Phe
115 120 125
Gly Arg Pro Leu Gln Met Thr Gln Ser Asn Leu Val Asp Ala Leu Ala
130 135 140
Val Ala Ala Val Val Cys Met Gly Glu Gly Asn Glu Gln Thr Pro Leu
145 150 155 160
Ala Val Ile Glu Gln Ala Pro Asn Met Val Tyr His Ser Tyr Pro Thr
165 170 175
Ser Arg Glu Glu Tyr Cys Ser Leu Arg Ile Asp Glu Thr Glu Asp Leu
180 185 190
Tyr Gly Pro Phe Leu Gln Ala Val Thr Trp Ser Gln Glu Lys Lys
195 200 205
<210>301
<211>183
<212>PRT
<213>Chlamydia
<400>301
Ile Pro Pro Ala Pro Arg Gly His Pro Gln Ile Glu Val Thr Phe Asp
5 10 15
Ile Asp Ala Asn Gly Ile Leu His Val Ser Ala Lys Asp Ala Ala Ser
20 25 30
Gly Arg Glu Gln Lys Ile Arg Ile Glu Ala Ser Ser Gly Leu Lys Glu
35 40 45
Asp Glu Ile Gln Gln Met Ile Arg Asp Ala Glu Leu His Lys Glu Glu
50 55 60
Asp Lys Gln Arg Lys Glu Ala Ser Asp Val Lys Asn Glu Ala Asp Gly
65 70 75 80
Met Ile Phe Arg Ala Glu Lys Ala Val Lys Asp Tyr His Asp Lys Ile
85 90 95
Pro Ala Glu Leu Val Lys Glu Ile Glu Glu His Ile Glu Lys Val Arg
100 105 110
Gln Ala Ile Lys Glu Asp Ala Ser Thr Thr Ala Ile Lys Ala Ala Ser
115 120 125
Asp Glu Leu Ser Thr Arg Met Gln Lys Ile Gly Glu Ala Met Gln Ala
130 135 140
Gln Ser Ala Ser Ala Ala Ala Ser Ser Ala Ala Asn Ala Gln Gly Gly
145 150 155 160
Pro Asn Ile Asn Ser Glu Asp Leu Lys Lys His Ser Phe Ser Thr Arg
165 170 175
Pro Pro Ala Gly Gly Ser Ala
180
<210>302
<211>232
<212>PRT
<213>Chlamydia
<400>302
Met Thr Lys His Gly Lys Arg Ile Arg Gly Ile Gln Glu Thr Tyr Asp
5 10 15
Leu Ala Lys Ser Tyr Ser Leu Gly Glu Ala Ile Asp Ile Leu Lys Gln
20 25 30
Cys Pro Thr Val Arg Phe Asp Gln Thr Val Asp Val Ser Val Lys Leu
35 40 45
Gly Ile Asp Pro Arg Lys Ser Asp Gln Gln Ile Arg Gly Ser Val Ser
50 55 60
Leu Pro His Gly Thr Gly Lys Val Leu Arg Ile Leu Val Phe Ala Ala
65 70 75 80
Gly Asp Lys Ala Ala Glu Ala Ile Glu Ala Gly Ala Asp Phe Val Gly
85 90 95
Ser Asp Asp Leu Val Glu Lys Ile Lys Gly Gly Trp Val Asp Phe Asp
100 105 110
Val Ala Val Ala Thr Pro Asp Met Met Arg Glu Val Gly Lys Leu Gly
115 120 125
Lys Val Leu Gly Pro Arg Asn Leu Met Pro Thr Pro Lys Ala Gly Thr
130 135 140
Val Thr Thr Asp Val Val Lys Thr Ile Ala Glu Leu Arg Lys Gly Lys
145 150 155 160
Ile Glu Phe Lys Ala Asp Arg Ala Gly Val Cys Asn Val Gly Val Ala
165 170 175
Lys Leu Ser Phe Asp Ser Ala Gln Ile Lys Glu Asn Val Glu Ala Leu
180 185 190
Cys Ala Ala Leu Val Lys Ala Lys Pro Ala Thr Ala Lys Gly Gln Tyr
195 200 205
Leu Val Asn Phe Thr Ile Ser Ser Thr Met Gly Pro Gly Val Thr Val
210 215 220
Asp Thr Arg Glu Leu Ile Ala Leu
225 230
<210>303
<211>238
<212>PRT
<213>chlamydia
<400>303
Ile Asn Ser Lys Leu Glu Thr Lys Asn Leu Ile Tyr Leu Lys Leu Lys
5 10 15
Ile Lys Lys Ser Phe Lys Met Gly Asn Ser Gly Phe Tyr Leu Tyr Asn
20 25 30
Thr Gln Asn Cys Val Phe Ala Asp Asn Ile Lys Val Gly Gln Met Thr
35 40 45
Glu Pro Leu Lys Asp Gln Gln Ile Ile Leu Gly Thr Thr Ser Thr Pro
50 55 60
Val Ala Ala Lys Met Thr Ala Ser Asp Gly Ile Ser Leu Thr Val Ser
65 70 75 80
Asn Asn Pro Ser Thr Asn Ala Ser Ile Thr Ile Gly Leu Asp Ala Glu
85 90 95
Lys Ala Tyr Gln Leu Ile Leu Glu Lys Leu Gly Asp Gln Ile Leu Gly
100 105 110
Gly Ile Ala Asp Thr Ile Val Asp Ser Thr Val Gln Asp Ile Leu Asp
115 120 125
Lys Ile Thr Thr Asp Pro Ser Leu Gly Leu Leu Lys Ala Phe Asn Asn
130 135 140
Phe Pro Ile Thr Asn Lys Ile Gln Cys Asn Gly Leu Phe Thr Pro Arg
145 150 155 160
Asn Ile Glu Thr Leu Leu Gly Gly Thr Glu Ile Gly Lys Phe Thr Val
165 170 175
Thr Pro Lys Ser Ser Gly Ser Met Phe Leu Val Ser Ala Asp Ile Ile
180 185 190
Ala Ser Arg Met Glu Gly Gly Val Val Leu Ala Leu Val Arg Glu Gly
195 200 205
Asp Ser Lys Pro Tyr Ala Ile Ser Tyr Gly Tyr Ser Ser Gly Val Pro
210 215 220
Asn Leu Cys Ser Leu Arg Thr Arg Ile Ile Asn Thr Gly Leu
225 230 235
Claims (26)
1.药用组合物,其含有生理学可接受的载体和分离的
(a)多肽,其包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分;或
(b)编码(a)的多肽的多核苷酸。
2.权利要求1的药用组合物,含有生理学可接受的载体和分离的
(a)多肽,其包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少95%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分;或
(b)编码(a)的多肽的多核苷酸。
3.权利要求1的药用组合物,其含有生理学可接受的载体和分离的多肽,该多肽包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
4.权利要求3的药用组合物,其含有生理学可接受的载体和分离的多肽,该多肽包含SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列变体。
5.权利要求4的药用组合物,其含有生理学可接受的载体和分离的多肽,该多肽包含SEQ ID No:88所编码的氨基酸序列。
6.权利要求5的药用组合物,其含有生理学可接受的载体和分离的多肽,该多肽由SEQ ID No:88所编码的氨基酸序列组成。
7.权利要求3的药用组合物,其含有生理学可接受的载体和分离的多肽,该多肽包含SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
8.权利要求1的药用组合物,其含有生理学可接受的载体和融合蛋白,该融合蛋白包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
9.权利要求1的药用组合物,其含有生理学可接受的载体和编码多肽的分离的多核苷酸,该多肽包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
10.权利要求9的药用组合物,其含有生理学可接受的载体和编码多肽的分离的多核苷酸,该多肽包含SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体。
11.权利要求10的药用组合物,其含有生理学可接受的载体和编码多肽的分离的多核苷酸,该多肽包含SEQ ID No:88所编码的氨基酸序列。
12.权利要求9的药用组合物,其含有生理学可接受的载体和编码多肽的分离的多核苷酸,该多肽包含SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
13.疫苗,其含有免疫刺激剂和分离的
(a)多肽,其包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分;或
(b)编码(a)的多肽的多核苷酸。
14.权利要求13的疫苗,其含有免疫刺激剂和分离的
(a)多肽,其包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少95%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分;或
(b)编码(a)的多肽的多核苷酸。
15.权利要求13的疫苗,其含有免疫刺激剂和分离的多肽,该多肽包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
16.权利要求15的疫苗,其含有免疫刺激剂和分离的多肽,所述分离的多肽包含SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体。
17.权利要求16的疫苗,其含有免疫刺激剂和分离的多肽,所述分离的多肽包含SEQ ID No:88所编码的氨基酸序列。
18.权利要求15的疫苗,其含有免疫刺激剂和分离的多肽,所述分离的多肽包含SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
19.权利要求13的疫苗,其含有免疫刺激剂和融合蛋白,该融合蛋白包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
20.权利要求13的疫苗,其含有免疫刺激剂和编码多肽的分离的多核苷酸,该多肽包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
21.权利要求20的疫苗,其含有免疫刺激剂和编码多肽的分离的多核苷酸,所述多肽包含SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体。
22.权利要求21的疫苗,其含有免疫刺激剂和编码多肽的分离的多核苷酸,所述多肽包含SEQ ID No:88所编码的氨基酸序列。
23.权利要求20的疫苗,其含有免疫刺激剂和编码多肽的分离的多核苷酸,所述多肽包含SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
24.权利要求13-23中任一项的疫苗,其中所述免疫刺激剂是佐剂。
25.分离的多肽在制备用于治疗或预防沙眼衣原体感染的药物中的用途,该多肽包含:
(i)SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
26.编码多肽的分离的多核苷酸在制备用于治疗或预防沙眼衣原体感染的药物中的用途,该多肽包含:
((i)SEQ ID No:88所编码的氨基酸序列或与其具有至少90%同一性的所述氨基酸序列的变体;或
(ii)SEQ ID No:88所编码的氨基酸序列的免疫原性部分。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/208,277 | 1998-12-08 | ||
US09/208,277 US6166177A (en) | 1998-12-08 | 1998-12-08 | Compounds and methods for the treatment and diagnosis of chlamydial infection |
US09/288,594 | 1999-04-08 | ||
US09/410,568 | 1999-10-01 | ||
US09/426,571 | 1999-10-22 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998157236A Division CN100365120C (zh) | 1998-12-08 | 1999-12-08 | 用于治疗及诊断衣原体感染的化合物和方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101219215A true CN101219215A (zh) | 2008-07-16 |
Family
ID=22773985
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101933434A Pending CN101219205A (zh) | 1998-12-08 | 1999-12-08 | 用于治疗及诊断衣原体感染的化合物和方法 |
CNA2007101933449A Pending CN101219215A (zh) | 1998-12-08 | 1999-12-08 | 用于治疗及诊断衣原体感染的化合物和方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101933434A Pending CN101219205A (zh) | 1998-12-08 | 1999-12-08 | 用于治疗及诊断衣原体感染的化合物和方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US6166177A (zh) |
CN (2) | CN101219205A (zh) |
ZA (1) | ZA200104414B (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213264A1 (en) * | 1998-12-08 | 2008-09-04 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US6555115B1 (en) * | 1998-12-08 | 2003-04-29 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
US20010048927A1 (en) * | 2000-02-01 | 2001-12-06 | Richard Stephens | Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia |
ES2303525T3 (es) * | 2000-04-21 | 2008-08-16 | Corixa Corporation | Compuestos y metodos para el tratamiento y diagnostico de infeccion por chlamydia. |
US6919187B2 (en) * | 2000-04-21 | 2005-07-19 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US7731980B2 (en) * | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
US7537772B1 (en) * | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
EP1519745B1 (en) | 2002-07-05 | 2006-12-20 | Lipoxen Technologies Limited | Method to enhance an immune response of nucleic acid vaccination |
US8541007B2 (en) | 2005-03-31 | 2013-09-24 | Glaxosmithkline Biologicals S.A. | Vaccines against chlamydial infection |
WO2006104890A2 (en) | 2005-03-31 | 2006-10-05 | Glaxosmithkline Biologicals Sa | Vaccines against chlamydial infection |
WO2011063133A1 (en) * | 2009-11-18 | 2011-05-26 | Auburn University | LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE |
CN112779248B (zh) * | 2021-02-04 | 2022-12-02 | 杭州遂曾生物技术有限公司 | 一种沙眼衣原体一体化核酸检测卡盒 |
CN113801191B (zh) * | 2021-08-18 | 2022-05-17 | 南京大学 | 一种检测衣原体的多肽探针及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4118469A (en) * | 1976-04-27 | 1978-10-03 | Research Corporation | Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU) |
JP3018553B2 (ja) * | 1990-05-08 | 2000-03-13 | 日立化成工業株式会社 | クラミジア・トラコマティス抗体測定方法及びクラミジア・トラコマティス感染症診断用製剤 |
-
1998
- 1998-12-08 US US09/208,277 patent/US6166177A/en not_active Expired - Fee Related
-
1999
- 1999-12-08 CN CNA2007101933434A patent/CN101219205A/zh active Pending
- 1999-12-08 CN CNA2007101933449A patent/CN101219215A/zh active Pending
-
2001
- 2001-05-29 ZA ZA200104414A patent/ZA200104414B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200104414B (en) | 2002-08-29 |
US6166177A (en) | 2000-12-26 |
CN101219205A (zh) | 2008-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100365120C (zh) | 用于治疗及诊断衣原体感染的化合物和方法 | |
US6565856B1 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
CZ2001200A3 (en) | Herbicidal agents containing substituted phenylsulfonyl ureas compounds for controlling weed in rice, process of their preparation and use | |
US6448234B1 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
PL209107B1 (pl) | Kompozycje do zastosowania w leczeniu i diagnozowaniu infekcji Chlamydia | |
AU784193B2 (en) | Chlamydia antigens and corresponding DNA fragments and uses thereof | |
US6432916B1 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
CA2385325C (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
CN101219215A (zh) | 用于治疗及诊断衣原体感染的化合物和方法 | |
CA2408199A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
NZ529361A (en) | Chlamydia antigens and corresponding DNA fragments and uses thereof | |
US6555115B1 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
US20030206921A1 (en) | Chlamydia antigens and corresponding DNA fragments and uses thereof | |
US20040254130A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
US6660275B2 (en) | Chlamydia antigens and corresponding DNA fragments and uses thereof | |
CA2341637A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
US20030225017A1 (en) | Chlamydia antigens and corresponding DNA fragments and uses thereof | |
AU1540500A (en) | (chlamydia) antigens and corresponding dna fragments and uses thereof | |
AU4793199A (en) | (chlamydia) antigens and corresponding dna fragments and uses thereof | |
AU1851700A (en) | (Chlamydia) antigens and corresponding dna fragments and uses thereof | |
AU1254100A (en) | Chlamydia antigens and corresponding DNA fragments and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20080716 |